Original Article
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
N Engl J Med 2001; 345:861-869September 20, 2001
- Abstract
Background
Diabetic nephropathy is the leading cause of end-stage renal disease. Interruption of the renin–angiotensin system slows the progression of renal disease in patients with type 1 diabetes, but similar data are not available for patients with type 2, the most common form of diabetes. We assessed the role of the angiotensin-II–receptor antagonist losartan in patients with type 2 diabetes and nephropathy.
Methods
A total of 1513 patients were enrolled in this randomized, double-blind study comparing losartan (50 to 100 mg once daily) with placebo, both taken in addition to conventional antihypertensive treatment (calcium-channel antagonists, diuretics, alpha-blockers, beta-blockers, and centrally acting agents), for a mean of 3.4 years. The primary outcome was the composite of a doubling of the base-line serum creatinine concentration, end-stage renal disease, or death. Secondary end points included a composite of morbidity and mortality from cardiovascular causes, proteinuria, and the rate of progression of renal disease.
Results
A total of 327 patients in the losartan group reached the primary end point, as compared with 359 in the placebo group (risk reduction, 16 percent; P=0.02). Losartan reduced the incidence of a doubling of the serum creatinine concentration (risk reduction, 25 percent; P=0.006) and end-stage renal disease (risk reduction, 28 percent; P=0.002) but had no effect on the rate of death. The benefit exceeded that attributable to changes in blood pressure. The composite of morbidity and mortality from cardiovascular causes was similar in the two groups, although the rate of first hospitalization for heart failure was significantly lower with losartan (risk reduction, 32 percent; P=0.005). The level of proteinuria declined by 35 percent with losartan (P<0.001 for the comparison with placebo).
Conclusions
Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Media in This Article
Figure 3
Median Changes from Base Line in the Level of Proteinuria.Figure 1
Kaplan–Meier Curves of the Percentage of Patients with the Primary Composite End Point (Panel A) and Its Individual Components, a Doubling of the Serum Creatinine Concentration (Panel B), End-Stage Renal Disease (Panel C), and the Combined End Point of End-Stage Renal Disease or Death (Panel D).Article Activity
- Article
Interruption of the renin–angiotensin system with angiotensin-I–converting enzyme inhibitors slows the progression of renal disease both in patients with type 1 diabetes and in nondiabetic patients who have overt nephropathy.1-3 However, postponing end-stage renal disease in patients with type 2 diabetes, the leading cause of chronic renal failure in many countries, remains an elusive goal. We undertook a study in patients with type 2 diabetes and nephropathy in order to determine whether the angiotensin-II–receptor antagonist losartan, alone or in combination with conventional antihypertensive therapy, would increase the time to a doubling of the serum creatinine concentration, the onset of end-stage renal disease, or death. In addition, we assessed the effects of losartan and placebo on the following secondary end points: a composite of morbidity and mortality from cardiovascular causes, proteinuria, and the rate of progression of renal disease.
Methods
Study Design
The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan Study was an investigator-initiated, multinational, double-blind, randomized, placebo-controlled study designed to evaluate the renoprotective effects of losartan in 1513 patients with type 2 diabetes and nephropathy. The study design has been described previously.4 In brief, 250 centers in 28 countries in Asia, Europe, Central America, South America, and North America participated. The study protocol was approved by the institutional review board of each center, and all patients gave written informed consent. The study was overseen by steering and safety committees, each of which contained one nonvoting member who was an employee of the sponsoring pharmaceutical company. The steering committee oversaw the study design, the conduct of the trial, and the management and analysis of the data. A writing subcommittee of the steering committee prepared this report. An independent end-points committee whose members were unaware of the patients' treatment assignments reviewed the data to determine which patients had reached the end points.
We planned to complete the study 3.5 years after the last patient underwent randomization, which would have resulted in a mean follow-up time of 4.5 years. However, the study was discontinued early (February 10, 2001) by a unanimous vote of the steering committee, whose members were unaware of the treatment assignments. Their decision was based on new evidence suggesting that angiotensin-I–converting enzyme inhibitors, which were excluded by design from the study, may be effective in reducing the incidence of cardiovascular events in patients with renal impairment, including those with diabetes.5 Therefore, the results reported here represent a mean follow-up time of 3.4 years (range, 2.3 to 4.6).
Patients
The study involved male and female patients, ranging in age from 31 to 70 years, who had received diagnoses of type 2 diabetes and nephropathy. Nephropathy was defined by the presence on two occasions of a ratio of urinary albumin (measured in milligrams per liter) to urinary creatinine (measured in grams per liter) from a first morning specimen of at least 300 (or a rate of urinary protein excretion of at least 0.5 g per day) and serum creatinine values between 1.3 and 3.0 mg per deciliter (115 and 265 μmol per liter), with a lower limit of 1.5 mg per deciliter (133 μmol per liter) for male patients weighing more than 60 kg. Patients were excluded if they had received a diagnosis of type 1 diabetes or nondiabetic renal disease, including renal-artery stenosis. We also excluded patients who had had a myocardial infarction or had undergone coronary-artery bypass grafting within the previous month, who had had a cerebrovascular accident or had undergone percutaneous transluminal coronary angioplasty within the previous six months, who had had a transient ischemic attack within the previous year, or who had any history of heart failure before enrollment.4
Treatment
During the six-week screening phase, patients with hypertension continued to receive their standard antihypertensive therapy. If they had been taking angiotensin-I–converting enzyme inhibitors or angiotensin-II–receptor antagonists, however, these medications were discontinued and replaced by alternative open-label medications (diuretics, calcium-channel antagonists, alpha- or beta-blockers, centrally acting agents, or some combination of these types of medication). Patients were stratified according to their base-line level of proteinuria (a urinary albumin-to-creatinine ratio <2000 or ≥2000) and randomly assigned to receive either losartan (50 mg) or placebo once daily, along with conventional antihypertensive therapy. After four weeks, the dose of losartan or placebo was increased to 100 mg or the placebo equivalent once daily if the trough blood pressure with the patient sitting was above the target level of a systolic blood pressure of less than 140 mm Hg and a diastolic blood pressure of less than 90 mm Hg. After an additional eight weeks, antihypertensive agents of the types described above (but not angiotensin-I–converting enzyme inhibitors or angiotensin-II–receptor antagonists) were added or their doses increased to achieve the target blood pressure.
Throughout the study, patients received the standard of care for the treatment of diabetes, including measurements of glycosylated hemoglobin and fasting serum glucose concentrations. Visits were scheduled every three months, or more often if necessary, to monitor the blood pressure and laboratory measurements and to assess whether adverse events had occurred or end points had been reached. Patients who discontinued the study drugs early had follow-up visits every three months until the end of the study; at these visits, the primary and secondary end points reached were recorded, the blood pressure was measured, and laboratory measurements were performed. Those who could not return for clinic visits or a family member was contacted by telephone to determine whether they had reached the end points of the initiation of dialysis, renal transplantation, or death.
Outcome Measures
The primary efficacy measure was the time to the first event of the composite end point of a doubling of the serum creatinine concentration, end-stage renal disease, or death. The doubling of the serum creatinine concentration was defined as the first serum creatinine value that was twice the base-line value, as confirmed by a second serum creatinine value obtained at least four weeks after the initial doubling. End-stage renal disease was defined by the need for long-term dialysis or renal transplantation. The prespecified secondary end point, morbidity and mortality from cardiovascular causes, was a composite of myocardial infarction, stroke, first hospitalization for heart failure or unstable angina, coronary or peripheral revascularization, or death from cardiovascular causes. Analyses of the components of both the primary and secondary composite end points were also prespecified. Other secondary end points included the progression of renal disease6 and changes in the level of proteinuria.
Statistical Analysis
Analyses of the primary and secondary end points were performed according to the intention-to-treat principle; we included data from all randomized patients (with the exception of three patients who were lost to follow-up), from the time of randomization through the date of study termination. In a second, per-protocol analysis, we excluded patients who violated the criteria for inclusion and exclusion and censored patients' data 14 days after they permanently discontinued the study medication. A Cox regression model7 that included the base-line level of proteinuria as a stratification factor and the geographic region as a covariate was used to determine the hazard ratio for the primary end point and its 95 percent confidence interval. The risk reduction was calculated as 100 percent × (1 – hazard ratio). In analyses of nonfatal end points, data for the patients who had died were considered to have been censored. Event curves are based on Kaplan–Meier analysis.8 We examined the effect of differences between the groups in the control of blood pressure by adding the mean arterial pressure during treatment as a time-dependent covariate in the Cox model and comparing the effect of losartan estimated by this model with that estimated by the primary analysis.
The analyses of the progression of renal disease and changes in the level of proteinuria were based on an on-treatment approach. For the analysis of the progression of renal disease, we compared the slopes of the reciprocal of the serum creatinine concentration6 of the two treatment groups using a linear random-effects model. Changes in the level of proteinuria in the two groups were compared by means of a mixed-effects model9 whose terms included the treatment at each point and the base-line level of proteinuria.
Because one interim analysis used a stopping boundary that was based on an alpha spending function of the O'Brien–Fleming type,10 a critical P value of 0.048 was required for the primary hypothesis. For other outcomes, a P value of less than 0.05 was considered to indicate statistical significance. All statistical tests were two-sided.
Results
A total of 1513 patients were randomly assigned to receive losartan or placebo once daily, along with conventional antihypertensive therapy as needed but excluding angiotensin-I–converting enzyme inhibitors and angiotensin-II–receptor antagonists. The daily dose of losartan ranged from 50 to 100 mg, with 71 percent of the patients receiving 100 mg. The base-line characteristics were similar in the two groups (Table 1Table 1
Base-Line Characteristics of the Patients.). More patients discontinued the study treatment in the placebo group (53.5 percent) than in the losartan group (46.5 percent). Adverse clinical events resulted in discontinuation in 17.2 percent of the patients in the losartan group, as compared with 21.7 percent of those in the placebo group. Increased serum concentrations of creatinine or potassium led to the discontinuation of the study medication in 1.5 percent and 1.1 percent, respectively, of the patients in the losartan group, as compared with 1.2 percent and 0.5 percent of the patients in the placebo group. A total of 7.5 percent of the patients in the losartan group and 7.8 percent of those in the placebo group withdrew their consent. We were able to determine the status of all patients (except for three patients in the losartan group who could not be contacted) with respect to dialysis, transplantation, and death.Blood Pressure
At base line, 93.5 percent of the patients (92.3 percent in the losartan group and 94.6 percent in the placebo group) were receiving antihypertensive therapy. An additional 3 percent of the patients had hypertension but were not receiving antihypertensive therapy. The trough blood pressure declined progressively during the course of the study. The trough blood pressure at base line averaged 152/82 mm Hg in the losartan group and 153/82 mm Hg in the placebo group; the mean arterial pressure was 105.5 mm Hg in the losartan group and 106.0 mm Hg in the placebo group (P=0.38); and the pulse pressure was 69.4 mm Hg in the losartan group and 70.8 mm Hg in the placebo group (P=0.13). At one year, the values averaged 146/78 mm Hg in the losartan group and 150/80 mm Hg in the placebo group (mean arterial pressure, 100.9 mm Hg and 103.1 mm Hg, respectively [P<0.001]; pulse pressure, 67.8 mm Hg and 69.8 mm Hg, respectively [P=0.05]); at two years, the values were 143/77 mm Hg and 144/77 mm Hg, respectively (mean arterial pressure, 99.1 mm Hg and 99.7 mm Hg, respectively [P=0.38]; pulse pressure, 66.2 mm Hg and 67.1 mm Hg, respectively [P=0.37]); and at the end of the study they were 140/74 mm Hg and 142/74 mm Hg, respectively (mean arterial pressure, 95.9 mm Hg and 96.8 mm Hg, respectively [P=0.59]; pulse pressure, 66.7 mm Hg and 67.4 mm Hg, respectively [P=0.77]). The various classes of conventional antihypertensive drugs that were used before and during the study are listed in Table 2Table 2
Use of Conventional Antihypertensive Medications at Base Line and during Study Treatment..Primary Outcomes
According to the intention-to-treat analysis, the primary composite end point of a doubling of the serum creatinine concentration, end-stage renal disease, or death was reached in 327 patients in the losartan group (43.5 percent), as compared with 359 in the placebo group (47.1 percent) (Figure 1AFigure 1
Kaplan–Meier Curves of the Percentage of Patients with the Primary Composite End Point (Panel A) and Its Individual Components, a Doubling of the Serum Creatinine Concentration (Panel B), End-Stage Renal Disease (Panel C), and the Combined End Point of End-Stage Renal Disease or Death (Panel D).). Treatment with losartan resulted in a 16 percent reduction in the risk of the primary composite end point (P=0.02) (Table 3Table 3
Incidence of the Primary Composite End Point and Its Components.). The decrease in risk remained essentially unchanged (15 percent) after adjustment for blood pressure (P=0.03). Furthermore, according to the per-protocol analysis, among the patients who continued to receive their assigned study treatment, losartan conferred a 22 percent reduction in the risk of the primary composite end point (P=0.008).The intention-to-treat analyses of the individual components of the primary composite end point are also shown in Table 3. The risk of a doubling of the serum creatinine concentration was 25 percent lower in the losartan group than in the placebo group (P=0.006) (Figure 1B). Losartan also reduced the risk of end-stage renal disease by 28 percent (P=0.002) (Figure 1C). Approximately 20 percent of the patients died, but there was no significant difference in mortality between the two groups (P=0.88). The risk of the combined end point of end-stage renal disease or death was 20 percent lower in the losartan group than in the placebo group (P=0.01) (Figure 1D and Table 3). The reductions in the risk of end-stage renal disease and of end-stage renal disease or death changed little after correction for blood pressure (26 percent, P=0.007, and 19 percent, P=0.02, respectively).
Secondary Outcomes
There was no significant difference between the losartan group and the placebo group in the composite end point of morbidity and mortality from cardiovascular causes. Approximately one third of the patients had a fatal or nonfatal cardiovascular event (247 in the losartan group [32.9 percent] and 268 in the placebo group [35.2 percent]; risk reduction, 10 percent; P=0.26). There were no significant differences in the rates of most of the cardiovascular end points; the exception was the first hospitalization with heart failure (89 patients in the losartan group [11.9 percent], as compared with 127 in the placebo group [16.7 percent]), for which the risk was reduced by 32 percent (P=0.005) (Figure 2Figure 2
Kaplan–Meier Curves of the Percentage of Patients with a First Hospitalization for Heart Failure in the Losartan and Placebo Groups.). There was a difference between the number of myocardial infarctions in the losartan group (50 patients [6.7 percent]) and the number in the placebo group (68 patients [8.9 percent]; risk reduction, 28 percent), but this difference was not statistically significant (P=0.08).Losartan also led to an average reduction in the level of proteinuria (the urinary albumin-to-creatinine ratio) of 35 percent, whereas in the patients in the placebo group, the urinary albumin-to-creatinine ratio tended to increase (P<0.001 for the overall treatment effect) (Figure 3Figure 3
Median Changes from Base Line in the Level of Proteinuria.). Losartan reduced the rate of decline in renal function, as assessed by the reciprocal of the serum creatinine concentration, by 18 percent (median slope, –0.056 dl per milligram per year in the losartan group, as compared with –0.069 dl per milligram per year in the placebo group; P=0.01). Likewise, losartan was associated with a 15.2 percent reduction in the estimated decline in the glomerular filtration rate (median rate of decline, 4.4 ml per minute per 1.73 m2 of body-surface area per year in the losartan group, as compared with 5.2 ml per minute per 1.73 m2 per year in the placebo group; P=0.01).12,13 These reductions in the rate of decline are far smaller than those reported for captopril as compared with placebo in patients with type 1 diabetes nearly a decade ago.1 Discussion
Our study establishes that losartan, along with conventional antihypertensive treatment as needed, confers strong renal protection in patients with type 2 diabetes and nephropathy. The risk of the primary end point, a composite of a doubling of the serum creatinine concentration, end-stage renal disease, or death from any cause, was reduced by 16 percent with losartan. The primary benefit appeared to be the effect on the renal components of this composite end point. In particular, the risk of end-stage renal disease was reduced by 28 percent with losartan during an average follow-up of 3.4 years. Extrapolating from the observed data, we estimate that this reduction corresponds to an average delay of two years in the need for dialysis or transplantation. The risk of a doubling of the serum creatinine concentration was also reduced by 25 percent with losartan. The difference between the slopes of the reciprocals of the serum creatinine values and the lower level of proteinuria provide further evidence of global renal protection with losartan.
There was a small, time-averaged difference in the trough blood pressure between the losartan group and the placebo group. We cannot exclude the possibility that this small difference had a beneficial effect on the renal outcomes. However, statistical analysis that corrected for these small differences confirmed that the renal protection conferred by losartan exceeded that attributable to any small differences in blood pressure. This study extends our knowledge of the efficacy of antihypertensive therapy in patients with type 2 diabetes and nephropathy. Previous studies involving angiotensin-I–converting enzyme inhibitors have demonstrated beneficial effects on proteinuria but have not demonstrated the superiority of blockade of the renin–angiotensin system in slowing the progression to end-stage renal disease over nonblockade forms of therapy.14-20 Indeed, studies of the effects of angiotensin-I–converting enzyme inhibitors on the progression of renal disease and end-stage renal failure have yielded conflicting results.14,15,20-24 Therefore, in the absence of a direct comparison between angiotensin-I–converting enzyme inhibitors and angiotensin II antagonists, any extrapolation from the results obtained with different classes of drugs is speculative at best.
The benefits of losartan were observed among our patients, many of whom were already receiving other therapies, such as aspirin, beta-blockers, and lipid-lowering agents, as part of sound medical practice. Similarly, simultaneous therapy with calcium-channel antagonists did not detract from the beneficial effects of losartan, despite the recent controversy regarding the role of calcium-channel antagonists in the protection of the kidneys and the heart.25-27 In this regard, it should be noted that in related studies in patients with type 1 and type 2 diabetes,1,28,29 the benefits of captopril or irbesartan were not tested in the presence of concurrent calcium-channel–antagonist therapy. Furthermore, calcium-channel antagonists have been shown to augment the production of angiotensin II,30 a response that may be counteracted by concomitant angiotensin-II–receptor blockade.
There was no significant difference between the losartan group and the placebo group in the composite secondary end point of morbidity and mortality from cardiovascular causes. This similarity of incidence may have resulted in part from the relatively small sample and the strict criteria for enrollment that excluded patients at high risk for cardiovascular events including heart failure. We did find a significant difference in favor of losartan with regard to the rate of a first hospitalization for heart failure, a component of this secondary composite end point. This finding in patients without clinical heart failure at base line accords well with findings from the Studies of Left Ventricular Dysfunction Prevention study.31 That study, however, did not include patients with impaired renal function. The Heart Outcomes Prevention Evaluation (HOPE) Study32 and its substudy of patients with diabetes, MICRO-HOPE,20 showed benefits of angiotensin-I–converting enzyme inhibition in terms of the signs and symptoms of heart failure but failed to show significant differences in hospitalizations for heart failure. Furthermore, the evaluation of a subgroup of the HOPE population with renal insufficiency5 did not show a significant effect on this outcome. Our findings suggest that angiotensin II blockade in patients with renal disease decreases the risk of overt heart failure resulting in hospitalization.
In this population, losartan (plus conventional antihypertensive therapy) demonstrated excellent tolerability, similar to that of placebo (plus conventional antihypertensive therapy), as evidenced by the similar numbers of patients in the two groups in whom the study treatment was discontinued because of adverse events. The addition of losartan to a conventional antihypertensive treatment regimen did not increase the incidence of adverse events.
End-stage renal disease continues to be a worldwide public health concern. Recent estimates by the National Institutes of Health indicate that diabetes represents the single largest cause of end-stage renal disease, accounting for approximately 40 percent of all cases in the United States between 1994 and 1998.33 Furthermore, the incidence of end-stage renal disease in patients with type 2 diabetes is rising sharply in many regions of the world and is expected to double by 2010. The annual costs associated with end-stage renal disease in the United States reached $12 billion in 1998 and are expected to surpass $28 billion by 2010.34 Preventing or delaying the progression of diabetic nephropathy is therefore an essential management goal. We believe our findings go a long way toward achieving this goal and may also have an important economic effect.
In summary, losartan led to significant improvement in renal outcomes that was beyond that attributable to blood-pressure control in patients with type 2 diabetes and nephropathy.
Supported by Merck and Company.
Dr. Brenner has served as a consultant to Merck, Bayer, Bristol-Myers Squibb, Aventis, AstraZeneca, Glaxo, and King. He has received research grants from Merck, Bayer, Bristol-Myers Squibb, and Novartis. He has been a member of speakers' bureaus sponsored by Merck, AstraZeneca, Bristol-Myers Squibb, and Novartis.
Dr. Cooper has served as a consultant to Pfizer, Sanofi, and Alteon. He has received research grants from AstraZeneca, Bristol-Myers Squibb, Merck, and Servier. He has been a member of speakers' bureaus sponsored by AstraZeneca and Solvay.
Dr. de Zeeuw has served as a consultant to Boehringer Ingelheim, Dade Behring, Merck Sharp & Dohme, Pfizer, Takeda, and Yamanouchi. He has received research grants from Bristol-Myers Squibb, Boehringer Ingelheim, Dade Behring, Merck Sharp & Dohme, Sanofi, and Yamanouchi. He has been a member of speakers' bureaus sponsored by Bristol-Myers Squibb, Dade Behring, and Merck Sharp & Dohme.
Dr. Keane has served as a consultant to Bayer, Merck, AstraZeneca, and Monarch. He has received research grants from Bayer and Merck. He has been a member of speakers' bureaus sponsored by Bayer, Merck, AstraZeneca, and Monarch.
Dr. Mitch has served as a consultant to Merck and Biogen.
Dr. Parving has served as a consultant to Merck, Bristol-Myers Squibb, Sanofi, Pfizer, and BioStratum. He has received research grants from Merck, Bristol-Myers Squibb, Sanofi, and AstraZeneca. He has been a member of speakers' bureaus sponsored by Merck, Bristol-Myers Squibb, Sanofi, Pfizer, and AstraZeneca.
Dr. Remuzzi has received research grants from Aventis Pharma.
Drs. Snapinn, Zhang, and Shahinfar are employees of Merck and may own stock or hold stock options in Merck.
We are indebted to Roger L. Simpson, Denise R. Ramjit, Dr. Raymond P. Bain, and Dr. David J. van Dijk for their substantial contributions.
Source Information
From the Renal Division, Brigham and Women's Hospital, Boston (B.M.B.); the Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia (M.E.C.); the Department of Clinical Pharmacology, University of Groningen, Groningen, the Netherlands (D.Z.); the Department of Medicine, Hennepin County Medical Center, Minneapolis (W.F.K.); the Renal Division, Emory University, Atlanta (W.E.M.); Steno Diabetes Center, Gentofte, Denmark (H.-H.P.); Laboratori Negri Bergamo, Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy (G.R.); and Merck Research Laboratories, Blue Bell, Pa. (S.M.S., Z.Z., S.S.).
Address reprint requests to Dr. Brenner at the Renal Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at bbrenner@partners.org.
The investigators who participated in the RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) Study are listed in the Appendix.
Appendix
The following persons participated in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan Study: Independent Steering Committee: B.M. Brenner, M.E. Cooper, D. de Zeeuw, J.P. Grunfeld, W.F. Keane, K. Kurokawa, J. McGill, W.E. Mitch, H.-H. Parving, G. Remuzzi, A.B. Ribeiro, M. Schluchter; Independent Data Safety Monitoring Committee: C.E. Mogensen, M. Fifer, L. Fisher, P. Kowey, D. Schlondorff, G. Viberti, P. Whelton; Independent Endpoint Committee: S. Haffner, J. Carrozza, D. Kolansky, L. Raij, D. Sica, R. Toto; Primary Investigators (the numbers in parentheses are the numbers of patients in each country): Argentina (17) — F. Inserra, L. Juncos; Austria (15) — C. Gurdet, J.R. Patsch, H. Toplak; Brazil (58) — S. Silveiro, V. Woronik, T. Zanella; Canada (1) — E. Burgess, T.C. Monchesky; Chile (26) — F. González; Costa Rica (33) — M. Vinoccour; Czech Republic (33) — P. Boucek, R. Chlup, J. Olsovsky, P. Sifalda; Denmark (16) — P. Christensen; France (12) — T. Hannedouche, P. Passa, M. Rodier; Germany (12) — B. Boehm, H.-D. Bundschu, U. Leonhardt; Hong Kong, China (92) — J. Chan, J. Critchley, K. Lam; Hungary (10) — S. Sonkodi; Israel (37) — D.J. van Dijk; Italy (26) — G. Piras, G. Remuzzi, F. Santeusanio; Japan (96) — R. Abe, Y. Ando, T. Fujita, T. Hanafusa, M. Haneda, T. Haneda, Y. Hashimoto, T. Ida, Y. Iino, S. Ishibashi, S. Ito, H. Kakuta, M. Kanazawa, T. Kanda, M. Kasuga, M. Kato, T. Koike, H. Kurahachi, H. Kuzuya, K. Matoba, D. Nagasaku, K. Ohshiro, K. Okada, S. Owada, H. Sakai, J. Seino, C. Shigemasa, T. Shoji, Y. Tsubakihara, N. Ujihara, N. Ura, T. Watanabe, I. Yamaji, Y. Yamasaki, M. Yoshinari, N. Yoshioka; Malaysia (21) — C.T. Chua, Z. Morad; Mexico (67) — R. Correa, J. Herrera; the Netherlands (7) — J.-E. Heeg, R. Gansevoort, P.L. Rensma; New Zealand (3) — R. Scott; Peru (42) — R. Zavala; Portugal (10) — B. Carvalho; Russia (26) — M. Shestakova, G. Zalevskaya; Singapore (11) — K.S. Wong; Slovak Republic (2) — M. Pavlovic; Spain (67) — J.M. Bronsons, M.M. Campos Pastor, D. del Castillo-Caba, F. Diz-Lois, F. Escobar-Jiménez, M.T. Gonzalez-Alvarez, D. Lorenzo, A. Martínez-Castelao, J.M. Martínez García, A. Tejedor-Jorge, M. Valles-Prats; United Kingdom (56) — C. Fox, E. Hillhouse, M. MacLeod, M. MacMahon, J. Mclay, P. O'Hare, V. Patel, H. Tindall, J.P. Vora, J.U. Weaver; United States, including Puerto Rico (686) — S. Abramson, J.R. Allison III, J. Anderson, G. Appel, M. Avram, G. Bakris, Y. Barri, J. Beard, D. Bell, J. Benabe, R. Benedetti, W. Bennett, W.K. Bolton, J.P. Brennan, M. Broder, M. Cabezas-Mijuste, D. Calhoun, A. Carr, L. Chan, B. Chandler, Jr., G. Chao, D. Chapman, J. Chinn, J. Christensen, J. Chung, C. Clinkingbeard, G. Collins, C. Corder, D. Crittenden, P. Dandona, M. Davis, R. DeFronzo, V. DeQuattro, G. Dolson, J. Douglas, M. Doyle, M. Eckert-Norton, A. Edin, M. El Shahawy, D. Elson, J.G. Evans, G. Fain III, T. Ferguson, J. Fica, C. Fisher, D. Fitz-Patrick, D. Frid, R. Galagan, L. Gaudiani, J. Geohas, M. Goldberg, R. Goldberg, J. Gorkin, R. Goulah, R. Graf, M. Greenspan, A. Guasch, C. Guerin, N. Gupta, C.E. Guthrow, S. Haffner, J. Hamilton, L.L. Hamm, L. Hancock, J. Hawkins, K. Hershon, W. Herzog, J. Holtzman, J. Insel, G. Jilly, L. Jovanovic, L. Katz, G. Kaysen, G. Keightley III, D. Kereiakes, G. Kershaw, B. Kerzner, R. Khairi, C. Kilo, M. Kipnes, R. Kipperman, L.D. Knoll, W. Kraus, J. Lash, J. LeLevier, S. Lerman, F.M. Lester, B. Levine, R. Louard, K. Ma, R. Maddox, D. Mapel, S. Martin, R. Mayfield, J. McGill, J.F. McNeer, J. Miller, S. Miller, B. Miskin, M. Mohan, T. Mooney, B. Musa, P. Nachman, A. Nafziger, J. Nardandrea, Jr., M. Nunez, L. Olansky, P. Pagnozzi, J. Pappas, T. Parker, T. Patel, B. Phillipson, J. Pino, D. Pitts, P. Raskin, P. Reber, E. Reisin, J. Ringold, V. Roberts, D. Roh, J. Rosenstock, N. Rossi, E. Rubin, L. Rubin, D. Ruff, M. Salem, R. Santangelo, Y. Segal, K.S. Self, S. Sharma, J. Sloand, L.K. Smith, R. Solomon, C. Spellman, B. Spinowitz, D. Steward, W. Suki, S. Swan, A. Swislocki, M. Tonkon, R. Toto, N.D. Vaziri, S. Vicks, J. Villamizar, R. Vranian, T. Walden, F. Wei, M. Weinberg, M. Weir, C. Williamson, L. Wruble, W. Yeung, F. Ziel; Venezuela (31) — A. Perez, J. Weisinger; Coordinating Center, Merck Research Laboratories: Program Coordinators — R. Simpson, D. Ramjit, S. Thompson-Bell, B. McVan, D. Fong, R. Poston, G. Drucker, M. McFadden-Neyer, M. Hinz, C. Assang, D. Brown, S. Mereminsky, C. Curry, G. McPeters, B. Bertino, International Liaisons — J. Lorfing, B. Koslowski, C. Wagner, C. Arena; Statisticians — S. Snapinn, H. Zhang, C. White, A. Carides, D. Snavely; Data Coordinators — D. Wolf, J. Sickel, C. Shanahan, K. Morgan, S. Plourde; Clinical Supply Coordinator — B. Vanslembrouck.
- References
References
1
Lewis EJ ,Hunsicker LG ,Bain RP ,Rohde RD . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462
Full Text | Web of Science | Medline2
Maschio G ,Alberti D ,Janin G , et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-945
Full Text | Web of Science | Medline3
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy: the GISEN Group. Lancet 1997;349:1857-1863
CrossRef | Web of Science | Medline4
Brenner BM ,Cooper ME ,de Zeeuw D , et al. The Losartan Renal Protection Study: rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000;1:328-335
CrossRef | Medline5
Mann JFE ,Gerstein HC ,Pogue J ,Bosch J ,Yusuf S . Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-636
Web of Science | Medline6
Mitch WE ,Walser M ,Buffington GA ,Lemann J Jr . A simple method of estimating progression of chronic renal failure. Lancet 1976;2:1326-1328
CrossRef | Web of Science | Medline7
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-2208
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science9
The mixed procedure. In: SAS Institute. SAS/STAT software: changes and enhancements through release 6.12. Cary, N.C.: SAS Institute, 1977:573-701.
10
O'Brien PC ,Fleming TR . A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
CrossRef | Web of Science | Medline11
Black HR ,Kuller LH ,O'Rourke MF , et al. The first report of the Systolic and Pulse Pressure (SYPP) working group. J Hypertens 1999;17:Suppl 5:S3-S14
Web of Science12
Levey AS ,Bosch JP ,Lewis JB ,Greene T ,Rogers N ,Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470
Web of Science | Medline13
Levey AS ,Greene T ,Kusek JW ,Beck GJ . A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:155A-155A abstract.14
Walker WG ,Hermann J ,Anderson J ,Zachary J ,Russell RP . Blood pressure (BP) control slows decline of glomerular filtration rate (GFR) in hypertensive NIDDM patients. J Am Soc Nephrol 1992;3:339-339 abstract.15
Lebovitz HE ,Wiegmann TB ,Cnaan A , et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994;45:S150-S155
CrossRef | Medline16
Bakris GL ,Copley JB ,Vicknair N ,Sadler R ,Leurgans S . Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-1650
CrossRef | Web of Science | Medline17
Nielsen FS ,Rossing P ,Gall MA ,Skott P ,Smidt UM ,Parving HH . Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997;46:1182-1188
CrossRef | Web of Science | Medline18
Fogari R ,Zoppi A ,Corradi L , et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999;13:47-53
CrossRef | Web of Science | Medline19
Estacio RO ,Jeffers BW ,Gifford N ,Schrier RW . Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23:Suppl 2:B54-B64
Web of Science | Medline20
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators
CrossRef | Web of Science | Medline21
Ravid M ,Savin H ,Jutrin I ,Bental T ,Katz B ,Lishner M . Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-581
Web of Science | Medline22
Ahmad J ,Siddiqui MA ,Ahmad H . Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997;20:1576-1581
CrossRef | Web of Science | Medline23
Ruggenenti P ,Perna A ,Gherardi G ,Benini R ,Remuzzi G . Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000;35:1155-1165
CrossRef | Web of Science | Medline24
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39: U.K. Prospective Diabetes Study Group. BMJ 1998;317:713-720
CrossRef | Web of Science25
Agodoa LY ,Appel L ,Bakris GL , et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719-2728
CrossRef | Web of Science | Medline26
Estacio RO ,Jeffers BW ,Hiatt WR ,Biggerstaff SL ,Gifford N ,Schrier RW . The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-652
Full Text | Web of Science | Medline27
Tatti P ,Pahor M ,Byington RP , et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603
CrossRef | Web of Science | Medline28
Lewis EJ ,Hunsicker LG ,Clarke WR , et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860
Full Text | Web of Science | Medline29
Parving H-H ,Lehnert H ,Brochner-Mortensen J ,Gomis R ,Andersen S ,Arner P . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878
Full Text | Web of Science | Medline30
Bauer JH, Reams GP. Antihypertensive drugs. In: Brenner BM, ed. The kidney. 6th ed. Philadelphia: W.B. Saunders, 2000:2253-97.
31
The SOLVD Investigators
Full Text | Web of Science | Medline32
The Heart Outcomes Prevention Evaluation Study Investigators
Full Text | Web of Science | Medline33
National Institutes of Health 34
National Institutes of Health
- Citing Articles (1761)
Citing Articles
1
Hirofumi Tomita, Ryan B Sanford, Oliver Smithies, Masao Kakoki. (2012) The kallikrein–kinin system in diabetic nephropathy. Kidney International
CrossRef2
Shinji Hagiwara, Phillip Kantharidis, Mark E. Cooper. (2012) What Are New Avenues for Renal Protection, in Addition to RAAS Inhibition?. Current Hypertension Reports
CrossRef3
Abdul Ali Abdellatif. (2012) The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence. Expert Review of Cardiovascular Therapy 10:2, 251-263
CrossRef4
Hiromi Rakugi, Kazuaki Enya, Kenkichi Sugiura, Yoshinori Ikeda. (2012) Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study. Hypertension Research
CrossRef5
T. Eisen, C. N. Sternberg, C. Robert, P. Mulders, L. Pyle, S. Zbinden, H. Izzedine, B. Escudier. (2012) Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies. JNCI Journal of the National Cancer Institute 104:2, 93-113
CrossRef6
S. Kücükköylü, L.C. Rump. (2012) Arterielle Hypertonie als Progressionsfaktor der chronischen Niereninsuffizienz. Der Nephrologe
CrossRef7
Sripal Bangalore, Ludwin Ley. (2012) Improving treatment adherence to antihypertensive therapy: the role of single-pill combinations. Expert Opinion on Pharmacotherapy1-11
CrossRef8
Kouichi Utsumi, Fumihiko Yasuda, Yoko Watanabe, Seiichiro Higo, Akio Hirama, Emiko Fujita, Kae Ueda, Akiko Mii, Tomohiro Kaneko, Masahiro Mishina, Yasuhiko Iino, Yasuo Katayama. (2012) Effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of diabetic nephropathy patients. Clinica Chimica Acta 413:1-2, 348-349
CrossRef9
Jose Luis Gorriz, Alberto Martinez-Castelao. (2012) Proteinuria: detection and role in native renal disease progression. Transplantation Reviews 26:1, 3-13
CrossRef10
Cesar Cerezo, Luis M. Ruilope, Julian Segura, Jose A. Garcia-Donaire, Juan J. de la Cruz, Jose R. Banegas, Bernard Waeber, Ton J. Rabelink, Franz H. Messerli. (2012) Microalbuminuria breakthrough under chronic renin–angiotensin–aldosterone system suppression. Journal of Hypertension 30:1, 204-209
CrossRef11
Arun Prasath Lakshmanan, Rajarajan A. Thandavarayan, Kenichi Watanabe, Flori R. Sari, Harima Meilei, Vijayasree V. Giridharan, Vijayakumar Sukumaran, Vivian Soetikno, Somasundaram Arumugam, Kenji Suzuki, Makoto Kodama. (2012) Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice. Molecular and Cellular Endocrinology 348:1, 104-111
CrossRef12
Gerald Schulman. (2012) A Nexus of Progression of Chronic Kidney Disease: Tryptophan, Profibrotic Cytokines, and Charcoal. Journal of Renal Nutrition 22:1, 107-113
CrossRef13
Allison B. Dart, Elizabeth A. Sellers, Heather J. Dean. (2012) Kidney Disease and Youth Onset Type 2 Diabetes: Considerations for the General Practitioner. International Journal of Pediatrics 2012, 1-8
CrossRef14
A. M. Villani, P. M. Clifton, J. B. Keogh. (2012) Sodium intake and excretion in individuals with type 2 diabetes mellitus: a cross-sectional analysis of overweight and obese males and females in Australia. Journal of Human Nutrition and Dieteticsno-no
CrossRef15
Chang-Gyu Park, Ho-Joong Youn, Shung-Chull Chae, Joo-Young Yang, Moo-Hyun Kim, Taek-Jong Hong, Cheol Ho Kim, Jae Joong Kim, Bum-Kee Hong, Jin-Won Jeong, Si-Hoon Park, Jun Kwan, Young-Jin Choi, Seung-Yun Cho. (2012) Evaluation of the Dose-Response Relationship of Amlodipine and Losartan Combination in Patients with Essential Hypertension. American Journal Cardiovascular Drugs1
CrossRef16
Liang Li, Brad C. Astor, Julia Lewis, Bo Hu, Lawrence J. Appel, Michael S. Lipkowitz, Robert D. Toto, Xuelei Wang, Jackson T. Wright, Tom H. Greene. (2012) Longitudinal Progression Trajectory of GFR Among Patients With CKD. American Journal of Kidney Diseases
CrossRef17
Patrick H. Pun, John P. Middleton. (2012) Sudden Cardiac Death in Hemodialysis Patients: A Comprehensive Care Approach to Reduce Risk. Blood Purification 33:1-3, 183-189
CrossRef18
The DCCT/EDIC Research Group. (2011) Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes. New England Journal of Medicine 365:25, 2366-2376
Full Text19
P. Vejakama, A. Thakkinstian, D. Lertrattananon, A. Ingsathit, C. Ngarmukos, J. Attia. (2011) Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia
CrossRef20
Domenic A. Sica. (2011) Diuretic use in renal disease. Nature Reviews Nephrology
CrossRef21
Elizabeth J. Brant, Albert Q. Lam, Julian L. Seifter. 2011. Pharmacology of Vasopressin and the Renin-Angiotensin-Aldosterone System. .
CrossRef22
2011. Complications Associated with Diabetes. , 201-249.
CrossRef23
M. Evans, S. C. Bain, S. Hogan, R. W. Bilous, . (2011) Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. Nephrology Dialysis Transplantation
CrossRef24
Jeffrey M Turner, Carolyn Bauer, Matthew K Abramowitz, Michal L Melamed, Thomas H Hostetter. (2011) Treatment of chronic kidney disease. Kidney International
CrossRef25
Gianpaolo Reboldi, Giorgio Gentile, Valeria Maria Manfreda, Fabio Angeli, Paolo Verdecchia. (2011) Tight Blood Pressure Control in Diabetes: Evidence-Based Review of Treatment Targets in Patients with Diabetes. Current Cardiology Reports
CrossRef26
Shadi Karabsheh, Divya Ratan Verma, Mohit Jain, Greg Stoddard, Kim Brunisholz, Josef Stehlik, Abdallah Kfoury, Edward Gilbert, Feras Bader. (2011) Clinical and Hemodynamic Effects of Renin–Angiotensin System Blockade in Cardiac Transplant Recipients. The American Journal of Cardiology 108:12, 1836-1839
CrossRef27
, E. Imai, J. C. N. Chan, S. Ito, T. Yamasaki, F. Kobayashi, M. Haneda, H. Makino. (2011) Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 54:12, 2978-2986
CrossRef28
Colleen Flynn, George L. Bakris. (2011) Blood Pressure Targets for Patients with Diabetes or Kidney Disease. Current Hypertension Reports 13:6, 452-455
CrossRef29
J. A. García-Donaire, J. Segura, C. Cerezo, L. M. Ruilope. (2011) A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients. Blood Pressure 20:6, 322-334
CrossRef30
Maurizio Destro, Francesca Cagnoni, Giuseppina Patrizia Dognini, Vincenzo Galimberti, Carlo Taietti, Chiara Cavalleri, Emilio Galli. (2011) Telmisartan: just an antihypertensive agent? A literature review. Expert Opinion on Pharmacotherapy 12:17, 2719-2735
CrossRef31
A. de la Sierra, J.A. Divisón, P. Garrido, A. Barbón, R. Arístegui. (2011) Determinación de la excreción urinaria de albúmina en la hipertensión arterial. Revista Clínica Española
CrossRef32
Seok-Min Kang, Jong-Chan Youn, Shung Chull Chae, Chang Gyu Park, Joo Young Yang, Moo Hyun Kim, Taek Jong Hong, Cheol Ho Kim, Jae Joong Kim, Dong Gu Shin, Jin Won Jung, Jung Han Yoon, Si Hoon Park, Jun Kwon, Seung Yun Cho. (2011) Comparative Efficacy and Safety Profile of Amlodipine 5 mg/Losartan 50 mg Fixed-Dose Combination and Amlodipine 10 mg Monotherapy in Hypertensive Patients Who Respond Poorly to Amlodipine 5 mg Monotherapy: An 8-Week, Multicenter, Randomized, Double-Blind Phase III Noninferiority Study. Clinical Therapeutics
CrossRef33
Yoko M. Nakao, Satoshi Teramukai, Sachiko Tanaka, Shinji Yasuno, Akira Fujimoto, Masato Kasahara, Kenji Ueshima, Kazuhiro Nakao, Shiro Hinotsu, Kazuwa Nakao, Koji Kawakami. (2011) Effects of renin–angiotensin system blockades on cardiovascular outcomes in patients with diabetes mellitus: A systematic review and meta-analysis. Diabetes Research and Clinical Practice
CrossRef34
Ronald Pyram, Abhishek Kansara, Mary Ann Banerji, Lisel Loney-Hutchinson. (2011) Chronic kidney disease and diabetes. Maturitas
CrossRef35
Michelle M. Estrella, Gregory D. Kirk, Shruti H. Mehta, Todd T. Brown, Derek M. Fine, Mohamed G. Atta, Gregory M. Lucas. (2011) Vitamin D deficiency and persistent proteinuria among HIV-infected and uninfected injection drug users. AIDS1
CrossRef36
Pinaki Sengupta, Utpal Nandi, Tapan Kumar Pal. (2011) Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats. Regulatory Toxicology and Pharmacology
CrossRef37
Tsukasa Nakamura, Eiichi Sato, Mayuko Amaha, Yasuhiro Kawagoe, Sayaka Maeda, Sho-ichi Yamagishi. (2011) Addition of aliskiren to angiotensin II receptor blockers ameliorates renal tubular injury and reduces intima media thickness of carotid artery in patients with diabetic nephropathy. International Journal of Cardiology
CrossRef38
Tatsuo Hosoya, Satoru Kuriyama, Iwao Ohno, Tetsuya Kawamura, Makoto Ogura, Masato Ikeda, Masahiro Ishikawa, Fumihiro Hayashi, Tatsuya Kanai, Haruo Tomonari, Michimasa Soejima, Kiyoaki Akaba, Goro Tokudome. (2011) Antihypertensive effect of a fixed-dose combination of losartan /hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study. Clinical and Experimental Nephrology
CrossRef39
, T. Kwok, J. Leung, Y. F. Zhang, D. Bauer, K. E. Ensrud, E. Barrett-Connor, P. C. Leung. (2011) Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men?. Osteoporosis International
CrossRef40
Thierry Krummel, Anne-Laure Faller, Dorothée Bazin, Thierry Hannedouche. (2011) Les promesses de la néphroprotection à l’épreuve des faits. La Presse Médicale 40:11, 1037-1042
CrossRef41
S. S. Roscioni, Y. Miao, D. Zeeuw, H. J. Lambers Heerspink. (2011) High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]. Diabetologia 54:11, 2965-2967
CrossRef42
Angela Brown, Becky Captain. (2011) 50 Years of Thiazides: Should Thiazide Diuretics Be Considered Third-Line Hypertension Treatment?. American Journal of Therapeutics 18:6, e244-e254
CrossRef43
A. R. Gonçalves, A. M. Nahas. (2011) High serum potassium levels after using losartan can reflect more severe renal disease. Diabetologia 54:11, 2963-2964
CrossRef44
Jean-Jacques Boffa, Sophie Chauvet, Fabrice Mihout. (2011) Ralentir la progression de l’insuffisance rénale chronique : espoirs et déceptions. La réparation vasculaire du rein chronique. La Presse Médicale 40:11, 1065-1073
CrossRef45
Sum Lam. (2011) Azilsartan. Cardiology in Review 19:6, 300-304
CrossRef46
John J. Sim, Jiaxiao Shi, Federico Calara, Scott Rasgon, Steven Jacobsen, Kamyar Kalantar-Zadeh. (2011) Association of plasma renin activity and aldosterone–renin ratio with prevalence of chronic kidney disease. Journal of Hypertension 29:11, 2226-2235
CrossRef47
Savina Nodari, Alberto Palazzuoli. (2011) Current treatment in acute and chronic cardio-renal syndrome. Heart Failure Reviews 16:6, 583-594
CrossRef48
Akshay S. Desai, Robert Toto, Petr Jarolim, Hajime Uno, Kai-Uwe Eckardt, Reshma Kewalramani, Andrew S. Levey, Eldrin F. Lewis, John J.V. McMurray, Hans-Henrik Parving, Scott D. Solomon, Marc A. Pfeffer. (2011) Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD. American Journal of Kidney Diseases 58:5, 717-728
CrossRef49
Keiji Kusumoto, Hideki Igata, Mami Ojima, Ayako Tsuboi, Mitsuaki Imanishi, Fuminari Yamaguchi, Hiroki Sakamoto, Takanobu Kuroita, Naohiro Kawaguchi, Nobuhiro Nishigaki, Hideaki Nagaya. (2011) Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. European Journal of Pharmacology 669:1-3, 84-93
CrossRef50
D. Fliser, F. Dellanna, M. Koch, J. Seufert, O. Witzke, I.A. Hauser. (2011) The PRIMAVERA study protocol design: Evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease. Contemporary Clinical Trials 32:6, 786-792
CrossRef51
Makoto Sawaguchi, Shin-ichi Araki, Hiroyuki Kobori, Maki Urushihara, Masakazu Haneda, Daisuke Koya, Atsunori Kashiwagi, Takashi Uzu, Hiroshi Maegawa. (2011) Association between urinary angiotensinogen levels and renal and cardiovascular prognoses in patients with type 2 diabetes mellitus. Journal of Diabetes Investigationno-no
CrossRef52
Raymond R. Townsend, Alan D. Forker, Vaishali Bhosekar, Anthony Yadao, Deborah L. Keefe. (2011) Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy and Amlodipine Monotherapy in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus. The Journal of Clinical Hypertensionno-no
CrossRef53
Tadashi Konoshita, Yasukazu Makino, Tomoko Kimura, Miki Fujii, Norihiro Morikawa, Shigeyuki Wakahara, Kenichiro Arakawa, Isao Inoki, Hiroyuki Nakamura, Isamu Miyamori. (2011) A crossover comparison of urinary albumin excretion as a new surrogate marker for cardiovascular disease among 4 types of calcium channel blockers. International Journal of Cardiology
CrossRef54
Yong-Chiat Wong, Meng-Kwoon Sim, Kok-Onn Lee. (2011) Des-aspartate-angiotensin-I and angiotensin IV improve glucose tolerance and insulin signalling in diet-induced hyperglycaemic mice. Biochemical Pharmacology 82:9, 1198-1208
CrossRef55
Jamie P. Dwyer, Julia B. Lewis. (2011) Olmesartan to Prevent the Development of Microalbuminuria: Is It New? Is It True? Is It Important?. American Journal of Kidney Diseases 58:5, 700-703
CrossRef56
Sadayoshi Ito. (2011) Cardiorenal connection in chronic kidney disease. Clinical and Experimental Nephrology
CrossRef57
Maria Elena Manni, Elisabetta Bigagli, Maura Lodovici, Marina Zazzeri, Laura Raimondi. (2011) The protective effect of losartan in the nephropathy of the diabetic rat includes the control of monoamine oxidase type A activity. Pharmacological Research
CrossRef58
David K. Packham, Tahira P. Alves, Jamie P. Dwyer, Robert Atkins, Dick de Zeeuw, Mark Cooper, Shahnaz Shahinfar, Julia B. Lewis, Hiddo J. Lambers Heerspink. (2011) Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results From the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) Database. American Journal of Kidney Diseases
CrossRef59
L. Engelen, F. Persson, I. Ferreira, P. Rossing, P. Hovind, T. Teerlink, C. D. Stehouwer, H.-H. Parving, C. G. Schalkwijk. (2011) Irbesartan treatment does not influence plasma levels of the advanced glycation end products N (1-carboxymethyl)lysine and N (1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. Nephrology Dialysis Transplantation 26:11, 3573-3577
CrossRef60
S. H. Han, E. W. Kang, S.-J. Yoon, H. S. Yoon, H. C. Lee, T. H. Yoo, K. H. Choi, D.-S. Han, S.-W. Kang. (2011) Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis. Nephrology Dialysis Transplantation 26:11, 3722-3728
CrossRef61
F. A. McAlister, . (2011) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. European Heart Journal
CrossRef62
Peng-Bin Lai, Lei Zhang, Li-Yong Yang. (2011) Quercetin Ameliorates Diabetic Nephropathy by Reducing the Expressions of Transforming Growth Factor-β1 and Connective Tissue Growth Factor in Streptozotocin-Induced Diabetic Rats. Renal Failure1-5
CrossRef63
M. Volpe. (2011) Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?. QJM
CrossRef64
P. E. Ronksley, M. Tonelli, H. Quan, B. J. Manns, M. T. James, F. M. Clement, S. Samuel, R. R. Quinn, P. Ravani, S. S. Brar, B. R. Hemmelgarn, . (2011) Validating a case definition for chronic kidney disease using administrative data. Nephrology Dialysis Transplantation
CrossRef65
Emaad M. Abdel-Rahman, Lawand Saadulla, W. Brian Reeves, Alaa S. Awad. (2011) Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches. Journal of General Internal Medicine
CrossRef66
P. Ruggenenti, G. Remuzzi. (2011) Worsening kidney function in decompensated heart failure: treat the heart, don't mind the kidney. European Heart Journal 32:20, 2476-2478
CrossRef67
Tamaki Wakamatsu-Yamanaka, Michio Fukuda, Ryo Sato, Takehiro Naito, Hiroyuki Togawa, Tatsuya Tomonari, Yoko Kato, Toshiyuki Miura, Masashi Mizuno, Tadashi Ichikawa, Sota Miyagi, Yuichi Shirasawa, Akinori Ito, Atsuhiro Yoshida, Genjiro Kimura. (2011) Geographic differences in the increasing ESRD rate have disappeared in Japan. Clinical and Experimental Nephrology 15:5, 708-713
CrossRef68
W. Drummond, Y.M. Sirenko, E. Ramos, I. Baek, D.L. Keefe. (2011) Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination. American Journal Cardiovascular Drugs 11:5, 327-333
CrossRef69
, Tadashi Konoshita. (2011) Do Genetic Variants of the Renin-Angiotensin System Predict Blood Pressure Response to Renin-Angiotensin System–Blocking Drugs? A Systematic Review of Pharmacogenomics in the Renin-Angiotensin System. Current Hypertension Reports 13:5, 356-361
CrossRef70
Samir Parikh, Lee Hebert, Brad Rovin. (2011) Protecting the kidneys in lupus nephritis. International Journal of Clinical Rheumatology 6:5, 529-546
CrossRef71
Michael Resl, Martin Clodi. (2011) Diabetische Nephropathie. Wiener klinische Wochenschrift Education 6:3, 67-77
CrossRef72
Naoki Nakagawa, Takayuki Fujino, Maki Kabara, Motoki Matsuki, Junko Chinda, Kenjiro Kikuchi, Naoyuki Hasebe. (2011) Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate. Hypertension Research 34:10, 1121-1126
CrossRef73
Haroon-Ur Rashid, Christian Mende. (2011) The Role of Direct Renin Inhibition in Clinical Practice. American Journal Cardiovascular Drugs 11:5, 303-315
CrossRef74
Rachel S. Meyers, Anita Siu. (2011) Pharmacotherapy Review of Chronic Pediatric Hypertension. Clinical Therapeutics 33:10, 1331-1356
CrossRef75
Rupal Mehta, Paul E. Drawz. (2011) Is Nocturnal Blood Pressure Reduction the Secret to Reducing the Rate of Progression of Hypertensive Chronic Kidney Disease?. Current Hypertension Reports 13:5, 378-385
CrossRef76
Takahiro Kuwashiro, Masahiro Kamouchi, Tetsuro Ago, Jun Hata, Hiroshi Sugimori, Takanari Kitazono. (2011) The factors associated with a functional outcome after ischemic stroke in diabetic patients: The Fukuoka Stroke Registry. Journal of the Neurological Sciences
CrossRef77
C.-W. Yang, J. T. Park, Y. S. Kim, Y. L. Kim, Y.-S. Lee, Y.-S. Oh, S.-W. Kang. (2011) Prevalence of diabetic nephropathy in primary care type 2 diabetic patients with hypertension: data from the Korean Epidemiology Study on Hypertension III (KEY III study). Nephrology Dialysis Transplantation 26:10, 3249-3255
CrossRef78
Wayne G. Fisher, Jessica E. Lucas, Uzma F. Mehdi, Danna W. Qunibi, Harold R. Garner, Kevin P. Rosenblatt, Robert D. Toto. (2011) A Method for Isolation and Identification of Urinary Biomarkers in Patients with Diabetic Nephropathy. PROTEOMICS - Clinical Applicationsn/a-n/a
CrossRef79
B. R. Johns, A. C. Pao, S. H. Kim. (2011) Metabolic syndrome, insulin resistance and kidney function in non-diabetic individuals. Nephrology Dialysis Transplantation
CrossRef80
Jun-Ren Zhu, Ning-Ling Sun, Kan Yang, Jian Hu, Geng Xu, Huashan Hong, Ruonan Wang, Ying-Mei Tu, Shannon Ritter, Deborah Keefe. (2011) Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertension Research
CrossRef81
M. K. Rutter, R. W. Nesto. (2011) Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. European Heart Journal 32:18, 2247-2255
CrossRef82
Robert Petrella, Paul Michailidis. (2011) Retrospective Analysis of Real-World Efficacy of Angiotensin Receptor Blockers Versus Other Classes of Antihypertensive Agents in Blood Pressure Management. Clinical Therapeutics 33:9, 1190-1203
CrossRef83
Kevin Damman, Adriaan A. Voors, Gerjan Navis, Dirk J. van Veldhuisen, Hans L. Hillege. (2011) The Cardiorenal Syndrome in Heart Failure. Progress in Cardiovascular Diseases 54:2, 144-153
CrossRef84
Risa Ozaki, Kitty K.T. Cheung, Enoch Wu, Alice Kong, Xilin Yang, Eric Lau, Philippe Brunswick, Jean-Henri Calvet, Jean-Paul Deslypere, Juliana C.N. Chan. (2011) A New Tool to Detect Kidney Disease in Chinese Type 2 Diabetes Patients: Comparison of EZSCAN with Standard Screening Methods. Diabetes Technology & Therapeutics 13:9, 937-943
CrossRef85
Addison A. Taylor, Helmy Siragy, Shawna Nesbitt. (2011) Angiotensin Receptor Blockers: Pharmacology, Efficacy, and Safety. The Journal of Clinical Hypertension 13:9, 677-686
CrossRef86
Philippe Gatault, Azmi Al-Najjar, Christelle Barbet, Mélanie Roland, Inass Laouad, Matthias Buchler, Jean-Frédéric Marlière, Pierre Emmanuel Métais, Alice Clément, Hubert Nivet, Yvon Lebranchu, Jean-Michel Halimi. (2011) Doubling of Serum Creatinine in Clinical Trials, Cost-Effectiveness Studies, and Individual Patients: Adequate Use in Renal Transplantation. Transplantation1
CrossRef87
Juan F. Navarro-González, Mercedes Muros, Carmen Mora-Fernández, Haridian Herrera, Beatriz Meneses, Javier García. (2011) Pentoxifylline for Renoprotection in Diabetic Nephropathy: the PREDIAN study. Rationale and basal results. Journal of Diabetes and its Complications 25:5, 314-319
CrossRef88
Massimo Volpe, Roberto Pontremoli, Claudio Borghi. (2011) Direct Renin Inhibition. High Blood Pressure & Cardiovascular Prevention 18:3, 93-105
CrossRef89
Diana I. Jalal, David M. Maahs, Peter Hovind, Takahiko Nakagawa. (2011) Uric Acid as a Mediator of Diabetic Nephropathy. Seminars in Nephrology 31:5, 459-465
CrossRef90
Alejandro Sierra, Jorge Salazar. (2011) What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?. Advances in Therapy 28:9, 716-727
CrossRef91
J. J. V. McMurray. (2011) CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. European Journal of Heart Failure 13:9, 929-936
CrossRef92
Hugo P Baglivo, Ramiro A Sánchez. (2011) Secondary Arterial Hypertension: Improvements in Diagnosis and Management in the Last 10 Years. American Journal of Therapeutics 18:5, 403-415
CrossRef93
E. Nerpin, E. Ingelsson, U. Riserus, J. Sundstrom, A. Larsson, E. Jobs, M. Jobs, S. Hallan, B. Zethelius, L. Berglund, S. Basu, J. Arnlov. (2011) The combined contribution of albuminuria and glomerular filtration rate to the prediction of cardiovascular mortality in elderly men. Nephrology Dialysis Transplantation 26:9, 2820-2827
CrossRef94
A. Maione, S. D. Navaneethan, G. Graziano, R. Mitchell, D. Johnson, J. F. E. Mann, P. Gao, J. C. Craig, G. Tognoni, V. Perkovic, A. Nicolucci, S. De Cosmo, A. Sasso, O. Lamacchia, M. Cignarelli, V. Maria Manfreda, G. Gentile, G. F. M. Strippoli. (2011) Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrology Dialysis Transplantation 26:9, 2827-2847
CrossRef95
John Cijiang He, Peter Y Chuang, Avi Ma'Ayan, Ravi Iyengar. (2011) Systems biology of kidney diseases. Kidney International
CrossRef96
Merlin C. Thomas, Mark E. Cooper. (2011) Diabetes: Bardoxolone improves kidney function in type 2 diabetes. Nature Reviews Nephrology 7:10, 552-553
CrossRef97
M. C. J. Slagman, F. Waanders, L. Vogt, K. Damman, M. Hemmelder, G. Navis, G. D. Laverman. (2011) Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients. Nephrology Dialysis Transplantation
CrossRef98
James Matthew Luther, Nancy J. Brown. (2011) The renin–angiotensin–aldosterone system and glucose homeostasis. Trends in Pharmacological Sciences
CrossRef99
Ralph A. DeFronzo, Muhammad Abdul-Ghani. (2011) Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose. The American Journal of Cardiology 108:3, 3B-24B
CrossRef100
Masanori Abe, Noriaki Maruyama, Kazuyoshi Okada, Shiro Matsumoto, Koichi Matsumoto, Masayoshi Soma. (2011) Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertension Research 34:8, 935-941
CrossRef101
Taishi Nakamura, Keiichiro Kataoka, Yoshiko Tokutomi, Hisato Nako, Kensuke Toyama, Yi-Fei Dong, Nobutaka Koibuchi, Eiichiro Yamamoto, Osamu Yasuda, Hisao Ogawa, Shokei Kim-Mitsuyama. (2011) Novel mechanism of salt-induced glomerular injury. Journal of Hypertension 29:8, 1528-1535
CrossRef102
Frank A Holtkamp, Dick de Zeeuw, Merlin C Thomas, Mark E Cooper, Pieter A de Graeff, Hans J L Hillege, Hans-Henrik Parving, Barry M Brenner, Shahnaz Shahinfar, Hiddo J Lambers Heerspink. (2011) An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney International 80:3, 282-287
CrossRef103
Matthew R Weir. (2011) Acute fall in glomerular filtration rate with renin–angiotensin system inhibition: a biomeasure of therapeutic success?. Kidney International 80:3, 235-237
CrossRef104
Katsuyuki Ando, Masakazu Haneda, Sadayoshi Ito, Naoki Kashihara, Koichi Node, Masaomi Nangaku, Tatsuo Shimosawa, Junji Kishimoto, Toshiro Fujita. (2011) Design and Rationale of Japanese Evaluation Between Formula of Azelnidipine and Amlodipine Add on Olmesartan to Get Antialbuminuric Effect Study (J-FLAG). Cardiovascular Drugs and Therapy 25:4, 341-347
CrossRef105
N. J. A. Webb, C. Lam, S. Shahinfar, J. Strehlau, T. G. Wells, G. W. Gleim, C. Le Bailly De Tilleghem. (2011) Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. Nephrology Dialysis Transplantation 26:8, 2521-2526
CrossRef106
Michael J. Fischer, Alan S. Go, Claudia M. Lora, Lynn Ackerson, Janet Cohan, John W. Kusek, Alejandro Mercado, Akinlolu Ojo, Ana C. Ricardo, Leigh K. Rosen, Kaixiang Tao, Dawei Xie, Harold I. Feldman, James P. Lash. (2011) CKD in Hispanics: Baseline Characteristics From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies. American Journal of Kidney Diseases 58:2, 214-227
CrossRef107
Luciano Consuegra-Sánchez, Juan Sanchis, Julio Núñez, José Domingo Cascón, Manuel Villegas, Francisco Picó. (2011) Aumento de mortalidad asociado a olmesartán en pacientes diabéticos para la prevención o retraso de microalbuminuria: ¿es una causa de preocupación?. Revista Española de Cardiología
CrossRef108
Ehud Grossman, Franz H. Messerli. (2011) Management of Blood Pressure in Patients With Diabetes. American Journal of Hypertension 24:8, 863-875
CrossRef109
Michelle W Krause, Vivian A Fonseca, Sudhir V Shah. (2011) Combination inhibition of the renin–angiotensin system: is more better?. Kidney International 80:3, 245-255
CrossRef110
William R Colyer, Christopher J Cooper. (2011) Medical therapy for renal artery stenosis. Clinical Investigation 1:8, 1167-1174
CrossRef111
Luciano Consuegra-Sánchez, Juan Sanchis, Julio Núñez, José Domingo Cascón, Manuel Villegas, Francisco Picó. (2011) Increased Mortality in Patients With Diabetes Associated With Olmesartan for the Prevention/Delay of Microalbuminuria Onset: a Matter of Concern?. Revista Española de Cardiología (English Edition)
CrossRef112
Daisuke Koya, Shin-ichi Araki, Masakazu Haneda. (2011) Therapeutic management of diabetic kidney disease. Journal of Diabetes Investigation 2:4, 248-254
CrossRef113
Massimo Volpe, Francesco Cosentino, Giuliano Tocci, Francesca Palano, Francesco Paneni. (2011) Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade. Current Hypertension Reports 13:4, 318-324
CrossRef114
Domenic Sica, William B. White, Michael A. Weber, George L. Bakris, Alfonso Perez, Charlie Cao, Alison Handley, Stuart Kupfer. (2011) Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. The Journal of Clinical Hypertension 13:7, 467-472
CrossRef115
Wilbert S. Aronow, Jerome L. Fleg, Carl J. Pepine, Nancy T. Artinian, George Bakris, Alan S. Brown, Keith C. Ferdinand, Mary Ann Forciea, William H. Frishman, Cheryl Jaigobin, John B. Kostis, Giuseppi Mancia, Suzanne Oparil, Eduardo Ortiz, Efrain Reisin, Michael W. Rich, Douglas D. Schocken, Michael A. Weber, Deborah J. Wesley, Robert A. Harrington, Eric R. Bates, Deepak L. Bhatt, Charles R. Bridges, Mark J. Eisenberg, Victor A. Ferrari, John D. Fisher, Timothy J. Gardner, Federico Gentile, Michael F. Gilson, Mark A. Hlatky, Alice K. Jacobs, Sanjay Kaul, David J. Moliterno, Debabrata Mukherjee, Robert S. Rosenson, James H. Stein, Howard H. Weitz, Deborah J. Wesley. (2011) ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American Society of Hypertension 5:4, 259-352
CrossRef116
Emmanuel Villar, Michel Lièvre, Michèle Kessler, Vincent Lemaître, Eric Alamartine, Michel Rodier, Maud François, Philippe Zaoui, Olivier Moranne, Gabriel Choukroun, Abdallah Guerraoui, Anne Jolivot, Gérard Janin, Bernard Branger, Anne-Elisabeth Heng, Catherine Boudray, Alvine Bissery, Muriel Rabilloud, Claire Pouteil-Noble. (2011) Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial. Journal of Diabetes and its Complications 25:4, 237-243
CrossRef117
Kazuhiro Sugimoto, Keiya Kojima, Masayuki Baba, Minoru Yasujima. (2011) Olmesartan ameliorates peripheral nerve dysfunction in Zucker diabetic fatty rats. Journal of Hypertension 29:7, 1337-1346
CrossRef118
James B. Wetmore, Jonathan D. Mahnken, Purna Mukhopadhyay, Qingjiang Hou, Edward F. Ellerbeck, Sally K. Rigler, John A. Spertus, Theresa I. Shireman. (2011) Geographic Variation in Cardioprotective Antihypertensive Medication Usage in Dialysis Patients. American Journal of Kidney Diseases 58:1, 73-83
CrossRef119
Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli, Giuseppe Ambrosio, Giuseppe Mancia, Paolo Verdecchia. (2011) Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. Journal of Hypertension 29:7, 1253-1269
CrossRef120
Paul Laflam, Kristen E. Schmitt, Christine F. Edie, Loretta A. Simbartl, Charuhas V. Thakar. (2011) Factors Affecting Conformity to Renin-Angiotensin System Inhibitor Usage in Chronic Kidney Disease and Diabetes Mellitus. The Journal of Clinical Hypertension 13:7, 473-478
CrossRef121
Volker Vallon, Radko Komers. 2011. Pathophysiology of the Diabetic Kidney. .
CrossRef122
Mark J. Sarnak, Brad C. Astor. (2011) Implications of Proteinuria: CKD Progression and Cardiovascular Outcomes. Advances in Chronic Kidney Disease 18:4, 258-266
CrossRef123
Tamara Isakova, Orlando M. Gutiérrez, Neha M. Patel, Dennis L. Andress, Myles Wolf, Adeera Levin. (2011) Vitamin D Deficiency, Inflammation, and Albuminuria in Chronic Kidney Disease: Complex Interactions. Journal of Renal Nutrition 21:4, 295-302
CrossRef124
P. G. Fegan, W. A. Davis, N. Kamber, S. Sivakumar, J. Beilby, T. M. E. Davis. (2011) Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: The Fremantle Diabetes Study. Diabetic Medicine 28:7, 849-855
CrossRef125
Andrew S Bomback, Adam Whaley-Connell. (2011) Ask the Experts: How can the National Kidney Foundation’s Kidney Early Evaluation Program help to prevent/manage kidney disease in diabetic patients?. Diabetes Management 1:4, 365-368
CrossRef126
M. Li. (2011) Careful re-evaluation of the impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrology Dialysis Transplantation 26:7, 2413-2413
CrossRef127
Hiddo J. Lambers Heerspink. (2011) Therapeutic Approaches in Lowering Albuminuria: Travels Along the Renin-Angiotensin-Aldosterone-System Pathway. Advances in Chronic Kidney Disease 18:4, 290-299
CrossRef128
Yuichiro Yamada, Koji Tsuboi, Takuya Hattori, Tamayo Murase, Masafumi Ohtake, Mayuko Furukawa, Jun Ueyama, Akira Nishiyama, Toyoaki Murohara, Kohzo Nagata. (2011) Mechanism underlying the efficacy of combination therapy with losartan and hydrochlorothiazide in rats with salt-sensitive hypertension. Hypertension Research 34:7, 809-816
CrossRef129
Elke Wühl, Franz Schaefer. (2011) Managing kidney disease with blood-pressure control. Nature Reviews Nephrology 7:8, 434-444
CrossRef130
S. C. W. Tang, M. Lin, S. Tam, W. S. Au, M. K. M. Ma, D. Y. H. Yap, Y. W. Ho, K. N. Lai. (2011) Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrology Dialysis Transplantation
CrossRef131
F. A. Holtkamp, D. de Zeeuw, P. A. de Graeff, G. D. Laverman, T. Berl, G. Remuzzi, D. Packham, J. B. Lewis, H.-H. Parving, H. J. Lambers Heerspink. (2011) Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. European Heart Journal 32:12, 1493-1499
CrossRef132
Brad C Astor, Kunihiro Matsushita, Ron T Gansevoort, Marije van der Velde, Mark Woodward, Andrew S Levey, Paul E de Jong, Josef Coresh, Brad C Astor, Kunihiro Matsushita, Ron T Gansevoort, Marije van der Velde, Mark Woodward, Andrew S Levey, Paul E de Jong, Josef Coresh, Meguid El-Nahas, Kai-Uwe Eckardt, Bertram L Kasiske, Jackson Wright, Larry Appel, Tom Greene, Adeera Levin, Ognjenka Djurdjev, David C Wheeler, Martin J Landray, John N Townend, Jonathan Emberson, Laura E Clark, Alison Macleod, Angharad Marks, Tariq Ali, Nicholas Fluck, Gordon Prescott, David H Smith, Jessica R Weinstein, Eric S Johnson, Micah L Thorp, Jack F Wetzels, P J Blankestijn, A D van Zuilen, Vandana Menon, Mark Sarnak, Gerald Beck, Florian Kronenberg, Barbara Kollerits, Marc Froissart, Benedicte Stengel, Marie Metzger, Giuseppe Remuzzi, Piero Ruggenenti, Annalisa Perna, H.J. Lambers Heerspink, Barry Brenner, Dick de Zeeuw, Peter Rossing, Hans-Henrik Parving, Priscilla Auguste, Kasper Veldhuis, Yaping Wang, Laura Camarata, Beverly Thomas, Tom Manley. (2011) Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney International 79:12, 1331-1340
CrossRef133
Shunichi Takiguchi, Makoto Ayaori, Harumi Uto-Kondo, Maki Iizuka, Makoto Sasaki, Tomohiro Komatsu, Bonpei Takase, Tetsuo Adachi, Fumitaka Ohsuzu, Katsunori Ikewaki. (2011) Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase. Hypertension Research 34:6, 686-692
CrossRef134
Raj Thuraisingham. (2011) Management of hypertension in renal disease. Medicine 39:6, 362-363
CrossRef135
Juliana C. N. Chan, Wingyee So, Ronald C. W. Ma, Peter C. Y. Tong, Rebecca Wong, Xilin Yang. (2011) The Complexity of Vascular and Non-Vascular Complications of Diabetes: The Hong Kong Diabetes Registry. Current Cardiovascular Risk Reports 5:3, 230-239
CrossRef136
Pascal Meier, Marc P Maillard, Jacqueline R Meier, Sylvie Tremblay, Thierry Gauthier, Michel Burnier. (2011) Combining blockers of the renin-angiotensin system or increasing the dose of an angiotensin II receptor antagonist in proteinuric patients: a randomized triple-crossover study. Journal of Hypertension 29:6, 1228-1235
CrossRef137
Hiroko Furukawa, Kazuaki Mawatari, Kei Koyama, Sonoko Yasui, Ran Morizumi, Takaaki Shimohata, Nagakatsu Harada, Akira Takahashi, Yutaka Nakaya. (2011) Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes. European Journal of Pharmacology 660:2-3, 485-491
CrossRef138
Miguel Camafort-Babkowski, Vivencio Barrios, Antonio Coca. (2011) Management of hypertension in diabetic patients: outstanding issues. Expert Review of Cardiovascular Therapy 9:6, 721-728
CrossRef139
Niloofar Nobakht, Mohammad Kamgar, Anjay Rastogi, Robert W. Schrier. (2011) Limitations of angiotensin inhibition. Nature Reviews Nephrology 7:6, 356-359
CrossRef140
Shusuke Yagi, Masashi Akaike, Ken-Ichi Aihara, Takashi Iwase, Kazue Ishikawa, Sumiko Yoshida, Yuka Sumitomo-Ueda, Kenya Kusunose, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Toshio Matsumoto, Masataka Sata. (2011) Effect of Low-Dose (1 mg/day) Pitavastatin on Left Ventricular Diastolic Function and Albuminuria in Patients With Hyperlipidemia. The American Journal of Cardiology 107:11, 1644-1649
CrossRef141
Chih-Kang Chiang, Meei-Ling Sheu, Yi-Wei Lin, Cheng-Tien Wu, Chin-Ching Yang, Min-Wei Chen, Kuan-Yu Hung, Kuan-Dun Wu, Shing-Hwa Liu. (2011) Honokiol ameliorates renal fibrosis by inhibiting extracellular matrix and pro-inflammatory factors in vivo and in vitro. British Journal of Pharmacology 163:3, 586-597
CrossRef142
Hideki Shimizu, Toshiro Fujita. (2011) New short interfering RNA-based therapies for glomerulonephritis. Nature Reviews Nephrology 7:7, 407-415
CrossRef143
Lal B. Rawal, Robyn J. Tapp, Emily D. Williams, Carina Chan, Shajahan Yasin, Brian Oldenburg. (2011) Prevention of Type 2 Diabetes and Its Complications in Developing Countries: A Review. International Journal of Behavioral Medicine
CrossRef144
Yuansheng Xie, Songmin Huang, Li Wang, Lining Miao, Aiping Zhang, Ying Li, Xiongfei Wu, Lining Wang, Shuxin Liu, Caihua Lie, Pu Chen, Xiangmei Chen. (2011) Efficacy and Safety of Mizoribine Combined With Losartan in the Treatment of IgA Nephropathy: A Multicenter, Randomized, Controlled Study. The American Journal of the Medical Sciences 341:5, 367-372
CrossRef145
Simona de Portu, Anna Citarella, Simona Cammarota, Enrica Menditto, Lorenzo G. Mantovani. (2011) Pharmaco-Economic Consequences of Losartan Therapy in Patients Undergoing Diabetic End Stage Renal Disease in EU and USA. Clinical and Experimental Hypertension 33:3, 174-178
CrossRef146
Anna Möllsten, Nathalie Vionnet, Carol Forsblom, Maija Parkkonen, Lise Tarnow, Samy Hadjadj, Michel Marre, Hans-Henrik Parving, Per-Henrik Groop. (2011) A polymorphism in the angiotensin II type 1 receptor gene has different effects on the risk of diabetic nephropathy in men and women. Molecular Genetics and Metabolism 103:1, 66-70
CrossRef147
, S. Katayama, T. Moriya, S. Tanaka, S. Tanaka, Y. Yajima, H. Sone, S. Iimuro, Y. Ohashi, Y. Akanuma, N. Yamada. (2011) Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS). Diabetologia 54:5, 1025-1031
CrossRef148
E. P. McQuarrie, L. Shakerdi, A. G. Jardine, J. G. Fox, B. Mackinnon. (2011) Fractional excretions of albumin and IgG are the best predictors of progression in primary glomerulonephritis. Nephrology Dialysis Transplantation 26:5, 1563-1569
CrossRef149
Amparo B. Gonzalez, Daniela Salas, Guillermo E. Umpierrez. (2011) Special considerations on the management of Latino patients with type 2 diabetes mellitus. Current Medical Research and Opinion 27:5, 969-979
CrossRef150
Michel Burnier, Grégoire Wuerzner. (2011) Pharmacokinetic evaluation of losartan. Expert Opinion on Drug Metabolism & Toxicology 7:5, 643-649
CrossRef151
Wilbert S. Aronow, Jerome L. Fleg, Carl J. Pepine, Nancy T. Artinian, George Bakris, Alan S. Brown, Keith C. Ferdinand, Mary Ann Forciea, William H. Frishman, Cheryl Jaigobin, John B. Kostis, Giuseppi Mancia, Suzanne Oparil, Eduardo Ortiz, Efrain Reisin, Michael W. Rich, Douglas D. Schocken, Michael A. Weber, Deborah J. Wesley. (2011) ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American College of Cardiology 57:20, 2037-2114
CrossRef152
M. Azizi, M. Frank, O. Steichen, A. Blanchard. (2011) Intérêts et limites de l’inhibition de la rénine par l’aliskiren. Annales Pharmaceutiques Françaises 69:3, 142-150
CrossRef153
Sunil V. Badve, Fiona Brown, Carmel M. Hawley, David W. Johnson, John Kanellis, Gopala K. Rangan, Vlado Perkovic. (2011) Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nature Reviews Nephrology 7:5, 295-300
CrossRef154
Paolo Cravedi, Giuseppe Remuzzi, Piero Ruggenenti. (2011) Targeting the Renin Angiotensin System in Dialysis Patients. Seminars in Dialysis 24:3, 290-297
CrossRef155
Giuliano Tocci, Massimo Volpe. (2011) End-Organ Protection in Patients with Hypertension. Drugs 71:8, 1003-1017
CrossRef156
S. H. Han, E. W. Kang, J. K. Park, J. H. Kie, D. S. Han, S.-W. Kang. (2011) Spontaneous remission of nephrotic syndrome in patients with IgA nephropathy. Nephrology Dialysis Transplantation 26:5, 1570-1575
CrossRef157
G. L. Bakris. (2011) Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus. Mayo Clinic Proceedings 86:5, 444-456
CrossRef158
H. Afghahi, J. Cederholm, B. Eliasson, B. Zethelius, S. Gudbjornsdottir, H. Hadimeri, M. K. Svensson. (2011) Risk factors for the development of albuminuria and renal impairment in type 2 diabetes--the Swedish National Diabetes Register (NDR). Nephrology Dialysis Transplantation 26:4, 1236-1243
CrossRef159
Gang Liu, Hirofumi Hitomi, Naohisa Hosomi, Yuki Shibayama, Daisuke Nakano, Hideyasu Kiyomoto, Hong Ma, Yasuyoshi Yamaji, Masakazu Kohno, Atsuhiro Ichihara, Hiroshi Itoh, Akira Nishiyama. (2011) Prorenin induces vascular smooth muscle cell proliferation and hypertrophy via epidermal growth factor receptor-mediated extracellular signal-regulated kinase and Akt activation pathway. Journal of Hypertension 29:4, 696-705
CrossRef160
Susan B. Gurley, Anne D.M. Riquier-Brison, Jurgen Schnermann, Matthew A. Sparks, Andrew M. Allen, Volker H. Haase, John N. Snouwaert, Thu H. Le, Alicia A. McDonough, Beverley H. Koller, Thomas M. Coffman. (2011) AT1A Angiotensin Receptors in the Renal Proximal Tubule Regulate Blood Pressure. Cell Metabolism 13:4, 469-475
CrossRef161
Domenic Sica. (2011) Are There Pleiotropic Effects of Antihypertensive Medications or Is It All About the Blood Pressure in the Patient With Diabetes and Hypertension?. The Journal of Clinical Hypertension 13:4, 301-304
CrossRef162
Hiroe Toba, Mamiko Yoshida, Chisato Tojo, Arisa Nakano, Yuko Oshima, Yushi Kojima, Kazuki Noda, Jiahong Wang, Miyuki Kobara, Tetsuo Nakata. (2011) L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin–angiotensin–aldosterone system in deoxycorticosterone acetate-salt hypertensive rats. Hypertension Research 34:4, 521-529
CrossRef163
William G. Couser, Miguel C. Riella. (2011) World Kidney Day 2011: Protect Your Kidneys, Save Your Heart. Hong Kong Journal of Nephrology 13:1, 1-4
CrossRef164
Anna Solini, Ele Ferrannini. (2011) Pathophysiology, Prevention and Management of Chronic Kidney Disease in the Hypertensive Patient With Diabetes Mellitus. The Journal of Clinical Hypertension 13:4, 252-257
CrossRef165
Willa A. Hsueh, Kathleen Wyne. (2011) Renin-Angiotensin-Aldosterone System in Diabetes and Hypertension. The Journal of Clinical Hypertension 13:4, 224-237
CrossRef166
José Butori Lopes de Faria, Kamila Cristina Silva, Jacqueline Mendonça Lopes de Faria. (2011) The contribution of hypertension to diabetic nephropathy and retinopathy: the role of inflammation and oxidative stress. Hypertension Research 34:4, 413-422
CrossRef167
Joseph L. Izzo Jr, Adrienne S. Zion. (2011) Value of Angiotensin Receptor Blocker Therapy in Diabetes. The Journal of Clinical Hypertension 13:4, 290-295
CrossRef168
Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli, Paolo Verdecchia. (2011) Optimal Therapy in Hypertensive Subjects with Diabetes Mellitus. Current Atherosclerosis Reports 13:2, 176-185
CrossRef169
T Okura, M Kojima, H Machida, M Sugiyama, T Kato, T Komada, T Miyazaki, T Ninomiya, T Ichikawa, K Nakatani, Y Watanabe, Y Dohi, M Ito, G Kimura. (2011) Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. Journal of Human Hypertension
CrossRef170
Ingelfinger, Julie R., . (2011) Preemptive Olmesartan for the Delay or Prevention of Microalbuminuria in Diabetes. New England Journal of Medicine 364:10, 970-971
Full Text171
Haller, Hermann, Ito, Sadayoshi, Izzo, Joseph L. Jr., Januszewicz, Andrzej, Katayama, Shigehiro, Menne, Jan, Mimran, Albert, Rabelink, Ton J., Ritz, Eberhard, Ruilope, Luis M., Rump, Lars C., Viberti, Giancarlo, . (2011) Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine 364:10, 907-917
Full Text172
Peter Rossing, Dick de Zeeuw. (2011) Need for better diabetes treatment for improved renal outcome. Kidney International 79, S28-S32
CrossRef173
Suneel M. Udani, George L. Bakris. (2011) Chronic kidney disease: Do fibrates truly preserve kidney function?. Nature Reviews Endocrinology 7:3, 130-131
CrossRef174
, William G. Couser, Miguel C. Riella. (2011) World Kidney Day 2011: Protect your kidneys, save your heart. Pediatric Nephrology 26:3, 329-332
CrossRef175
, M. Nishimura, M. Kato, F. Shimada, Y. Kato, R. Todo, Y. Ando, K. Hida, I. Iseda, A. Tone, N. Nagase, H. Yoshizumi, K. Higashi, Y. Hoshiyama. (2011) Prognostic importance of home blood pressure measurement in patients with diabetic nephropathy. Diabetology International 2:1, 10-18
CrossRef176
William G. Couser, Miguel C. Riella, Sara Martin. (2011) World Kidney Day 2011: Protect Your Kidneys, Save Your Heart. Advances in Chronic Kidney Disease 18:2, 57-60
CrossRef177
E. P. McQuarrie, R. K. Patel, P. B. Mark, C. Delles, J. Connell, H. J. Dargie, T. Steedman, A. G. Jardine. (2011) Association between proteinuria and left ventricular mass index: a cardiac MRI study in patients with chronic kidney disease. Nephrology Dialysis Transplantation 26:3, 933-938
CrossRef178
Howard S. Weintraub, Henry Tran, Arthur Schwartzbard. (2011) Potential Benefits of Aliskiren Beyond Blood Pressure Reduction. Cardiology in Review 19:2, 90-94
CrossRef179
N. Stoycheff, K. Pandya, A. Okparavero, A. Schiff, A. S. Levey, T. Greene, L. A. Stevens. (2011) Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrology Dialysis Transplantation 26:3, 848-857
CrossRef180
J.M. Galcerán. (2011) ¿Es posible prevenir la nefropatía diabética? El estudio ROADMAP. Hipertensión y Riesgo Vascular 28, 24-29
CrossRef181
Johji Kato, Naoto Yokota, Noboru Tamaki, Sumito Kariya, Toshihiro Kita, Takao Ayabe, Tanenao Eto, Kazuo Kitamura. (2011) Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension. Hypertension Research 34:3, 331-335
CrossRef182
Oliver Gross, Rainer Girgert, Diana Rubel, Johanna Temme, Stephanie Theissen, Gerhard-Anton Müller. (2011) Renal Protective Effects of Aliskiren Beyond Its Antihypertensive Property in a Mouse Model of Progressive Fibrosis. American Journal of Hypertension 24:3, 355-361
CrossRef183
M. Khaled Shamseddin, Patrick S. Parfrey. (2011) Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nature Reviews Nephrology 7:3, 145-154
CrossRef184
William G. Couser, Miguel C. Riella. (2011) World Kidney Day 2011: Protect Your Kidneys, Save Your Heart. American Journal of Kidney Diseases 57:3, 371-374
CrossRef185
Hou-Yong Dai, Min Zheng, Ri-Ning Tang, Jie Ni, Kun-Ling Ma, Qing Li, Bi-Cheng Liu. (2011) Effects of Angiotensin Receptor Blocker on Phenotypic Alterations of Podocytes in Early Diabetic Nephropathy. The American Journal of the Medical Sciences 341:3, 207-214
CrossRef186
Toshihiro Sugiura, Akira Wada. (2011) Resistive index predicts renal prognosis in chronic kidney disease: results of a 4-year follow-up. Clinical and Experimental Nephrology 15:1, 114-120
CrossRef187
Radko Komers, Terry T Oyama, Douglas R Beard, Chris Tikellis, Bei Xu, Daniel F Lotspeich, Sharon Anderson. (2011) Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. Kidney International 79:4, 432-442
CrossRef188
Juliana CN Chan. (2011) What can we learn from the recent blood glucose lowering megatrials?. Journal of Diabetes Investigation 2:1, 1-5
CrossRef189
Noriko Takeuchi, Emi Takenoshita, Fumino Kato, Tomoko Terajima, Makoto Ogawa, Satoshi Suzuki, Takayuki Fujii, Eriko Kobayashi, Tomoya Sakurada, Nobunori Satoh, Shiro Ueda. (2011) Doubling of serum creatinine: is it appropriate as the endpoint for CKD? Proposal of a new surrogate endpoint based on the reciprocal of serum creatinine. Clinical and Experimental Nephrology 15:1, 100-107
CrossRef190
Davoud Mohtat, Rosemary Thomas, Zangfang Du, Yaa Boakye, Thomas Moulton, Catherine Driscoll, Robert Woroniecki. (2011) Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease. Pediatric Nephrology 26:2, 275-280
CrossRef191
George L. Bakris, Domenic Sica, Michael Weber, William B. White, Andrew Roberts, Alfonso Perez, Charlie Cao, Stuart Kupfer. (2011) The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure. The Journal of Clinical Hypertension 13:2, 81-88
CrossRef192
Piero Ruggenenti, Anna Fassi, Aneliya Parvanova Ilieva, Ilian Petrov Iliev, Carlos Chiurchiu, Nadia Rubis, Giulia Gherardi, Bogdan Ene-Iordache, Flavio Gaspari, Annalisa Perna, Paolo Cravedi, Antonio Bossi, Roberto Trevisan, Nicola Motterlini, Giuseppe Remuzzi. (2011) Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. Journal of Hypertension 29:2, 207-216
CrossRef193
W. G. Couser, M. C. Riella. (2011) World Kidney Day 2011: protect your kidneys, save your heart. Internal Medicine Journal 41:2, 140-143
CrossRef194
Helmy M. Siragy. (2011) Rationale for Combining a Direct Renin Inhibitor with other Renin- Angiotensin System Blockers. Focus on Aliskiren and Combinations. Cardiovascular Drugs and Therapy 25:1, 87-97
CrossRef195
Kazuki Ohno, Yasushi Amano, Hirotoshi Kakuta, Tatsuya Niimi, Shoji Takakura, Masaya Orita, Keiji Miyata, Hitoshi Sakashita, Makoto Takeuchi, Issei Komuro, Jitsuo Higaki, Masatsugu Horiuchi, Shokei Kim-Mitsuyama, Yutaka Mori, Ryuichi Morishita, Sho-ichi Yamagishi. (2011) Unique “delta lock” structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor. Biochemical and Biophysical Research Communications 404:1, 434-437
CrossRef196
Christiane Rüster, Sybille Franke, Ulrich Wenzel, Robin Schmidthaupt, Christoph Fraune, Christian Krebs, Gunter Wolf. (2011) Podocytes of AT2 Receptor Knockout Mice Are Protected from Angiotensin II-Mediated RAGE Induction. American Journal of Nephrology 34:4, 309-317
CrossRef197
Ikko Ohara, Mitsuo Tanimoto, Tomohito Gohda, Takahiko Yamazaki, Shinji Hagiwara, Maki Murakoshi, Tatsuya Aoki, Hitoe Toyoda, Yuji Ishikawa, Kazuhiko Funabiki, Satoshi Horikoshi, Yasuhiko Tomino. (2011) Effect of Combination Therapy with Angiotensin Receptor Blocker and 1,25-Dihydroxyvitamin D3 in Type 2 Diabetic Nephropathy in KK-Ay/Ta Mice. Nephron Experimental Nephrology 117:4, 124-132
CrossRef198
Yayoi Nishida, Yasuo Takahashi, Tomohiro Nakayama, Masayoshi Soma, Satoshi Asai. (2011) Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study. Cardiovascular Diabetology 10:1, 74
CrossRef199
Ayaka Sumi, Natsuko Yamanaka-Hanada, Fan Bai, Toshiaki Makino, Hajime Mizukami, Takahiko Ono. (2011) Roles of Coagulation Pathway and Factor Xa in the Progression of Diabetic Nephropathy in db/db Mice. Biological & Pharmaceutical Bulletin 34:6, 824-830
CrossRef200
F. M. Tedla, A. Brar, R. Browne, C. Brown. (2011) Hypertension in Chronic Kidney Disease: Navigating the Evidence. International Journal of Hypertension 2011, 1-9
CrossRef201
Sébastien Czernichow, Alberto Zanchetti, Fiona Turnbull, Federica Barzi, Toshiaru Ninomiya, André-Pascal Kengne, Hiddo J Lambers Heerspink, Vlado Perkovic, Rachel Huxley, Hisatomi Arima, Anushka Patel, John Chalmers, Mark Woodward, Stephen MacMahon, Bruce Neal. (2011) The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. Journal of Hypertension 29:1, 4-16
CrossRef202
Takahiko Nakagawa, Katsuyuki Tanabe, Byron P. Croker, Richard J. Johnson, Maria B. Grant, Tomoki Kosugi, Qiuhong Li. (2011) Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nature Reviews Nephrology 7:1, 36-44
CrossRef203
Domenic A. Sica. (2011) Pharmacologic Issues in Treating Hypertension in CKD. Advances in Chronic Kidney Disease 18:1, 42-47
CrossRef204
Hajime Nagasu, Minoru Satoh, Daisuke Yorimitsu, Naruya Tomita, Tamaki Sasaki, Naoki Kashihara. (2011) Comparison of Combination Therapy of Olmesartan plus Azelnidipine or Hydrochlorothiazide on Renal and Vascular Damage in SHR/NDmcr-cp Rats. Kidney and Blood Pressure Research 34:2, 87-96
CrossRef205
Jian-Zhong Sun, Long-Hui Cao, Hong Liu. (2011) ACE inhibitors in cardiac surgery: current studies and controversies. Hypertension Research 34:1, 15-22
CrossRef206
Diana Rucker, Brenda R Hemmelgarn, Meng Lin, Braden J Manns, Scott W Klarenbach, Bharati Ayyalasomayajula, Matthew T James, Aminu Bello, Deb Gordon, Kailash K Jindal, Marcello Tonelli. (2011) Quality of care and mortality are worse in chronic kidney disease patients living in remote areas. Kidney International 79:2, 210-217
CrossRef207
H.J. Lambers Heerspink, V. Perkovic, D. de Zeeuw. (2011) Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials. Nephron Clinical Practice 119:3, 195-199
CrossRef208
Marsha A. Raebel. (2011) Hyperkalemia Associated with Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Cardiovascular Therapeuticsno-no
CrossRef209
Sripal Bangalore, Sunil Kumar, Sverre E Kjeldsen, Harikrishna Makani, Ehud Grossman, Jørn Wetterslev, Ajay K Gupta, Peter S Sever, Christian Gluud, Franz H Messerli. (2011) Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. The Lancet Oncology 12:1, 65-82
CrossRef210
Mario F. Rubin. (2011) Hypertension Following Kidney Transplantation. Advances in Chronic Kidney Disease 18:1, 17-22
CrossRef211
Fusakazu Jo, Satoshi Morimoto, Mitsutaka Nakahigashi, Makiko Kusabe, Kazunori Someya, Tatsuyori Morita, Hiromi Jo, Takanobu Imada, Atsushi Kosaki, Nagaoki Toyoda, Mitsushige Nishikawa, Toshiji Iwasaka. (2011) Olmesartan Induces Renoprotective Effects by Stimulating Angiotensin Type 2 Receptors and Reducing Oxidative Stress in Diabetic Nephropathy. Kidney and Blood Pressure Research 34:6, 418-423
CrossRef212
Yoko Ozawa, Toshihide Kurihara, Kazuo Tsubota, Hideyuki Okano. (2011) Regulation of Posttranscriptional Modification as a Possible Therapeutic Approach for Retinal Neuroprotection. Journal of Ophthalmology 2011, 1-8
CrossRef213
Anadil Faqah, Tazeen H. Jafar. (2011) Control of Blood Pressure in Chronic Kidney Disease: How Low to Go. Nephron Clinical Practice 119:4, c324-c332
CrossRef214
José A. García-Donaire, Luis M. Ruilope. (2011) Cardiovascular and Renal Links along the Cardiorenal Continuum. International Journal of Nephrology 2011, 1-8
CrossRef215
Peter P. Toth. (2011) Pleiotropic Effects of Angiotensin Receptor Blockers: Addressing Comorbidities by Optimizing Hypertension Therapy. The Journal of Clinical Hypertension 13:1, 42-51
CrossRef216
Mark S. MacGregor, Maarten W. Taal. (2011) Renal Association Clinical Practice Guideline on Detection, Monitoring and Management of Patients with CKD. Nephron Clinical Practice 118:s1, c71-c100
CrossRef217
Sung H Kim, Kyu H Ryu, Nam-Ho Lee, Jin-Ho Kang, Woo-Shik Kim, Sang-Weon Park, Hae-Young Lee, Jae-Joong Kim, Young-Keun Ahn, Soon Y Suh. (2011) Efficacy of fixed-dose amlodipine and losartan combination compared with amlodipine monotherapy in stage 2 hypertension: a randomized, double blind, multicenter study. BMC Research Notes 4:1, 461
CrossRef218
Y. Miao, D. Dobre, H. J. Lambers Heerspink, B. M. Brenner, M. E. Cooper, H-H. Parving, S. Shahinfar, D. Grobbee, D. Zeeuw. (2011) Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 54:1, 44-50
CrossRef219
Natasha J. McIntyre, Richard J. Fluck, Christopher W. McIntyre, Maarten W. Taal. (2011) Risk Profile in Chronic Kidney Disease Stage 3: Older versus Younger Patients. Nephron Clinical Practice 119:4, c269-c276
CrossRef220
David K. Packham, Sara E. Ivory, Anne T. Reutens, Rory Wolfe, Richard Rohde, Hiddo Lambers Heerspink, Jamie P. Dwyer, Robert C. Atkins, Julia Lewis. (2011) Proteinuria in Type 2 Diabetic Patients with Renal Impairment: The Changing Face of Diabetic Nephropathy. Nephron Clinical Practice 118:4, c331-c338
CrossRef221
Johannes Stegbauer, Thomas M Coffman. (2011) New insights into angiotensin receptor actions: from blood pressure to aging. Current Opinion in Nephrology and Hypertension 20:1, 84-88
CrossRef222
Peter N. Van Buren, Robert Toto. (2011) Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and Management. Advances in Chronic Kidney Disease 18:1, 28-41
CrossRef223
A. Nishiyama, Y. Konishi, N. Ohashi, T. Morikawa, M. Urushihara, I. Maeda, M. Hamada, M. Kishida, H. Hitomi, N. Shirahashi, H. Kobori, M. Imanishi. (2011) Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrology Dialysis Transplantation 26:1, 170-177
CrossRef224
Suneel Udani, Ivana Lazich, George L. Bakris. (2011) Epidemiology of hypertensive kidney disease. Nature Reviews Nephrology 7:1, 11-21
CrossRef225
Jithendra B Somaratne, Gillian A Whalley, Katrina K Poppe, Mariska M ter Bals, Gina Wadams, Ann Pearl, Warwick Bagg, Rob N Doughty. (2011) Screening for left ventricular hypertrophy in patients with type 2 diabetes mellitus in the community. Cardiovascular Diabetology 10:1, 29
CrossRef226
Mi Young Lee, Myoung Sook Shim, Bo Hwan Kim, Soon Won Hong, Ran Choi, Eun Young Lee, Soo Min Nam, Gun Woo Kim, Jang Yel Shin, Young Goo Shin, Choon Hee Chung. (2011) Effects of Spironolactone and Losartan on Diabetic Nephropathy in a Type 2 Diabetic Rat Model. Diabetes & Metabolism Journal 35:2, 130
CrossRef227
Sally Hull, Gavin Dreyer, Ellena Badrick, Alistair Chesser, Muhammad Yaqoob. (2011) The relationship of ethnicity to the prevalence and management of hypertension and associated chronic kidney disease. BMC Nephrology 12:1, 41
CrossRef228
William G. Couser, Miguel C. Riella. (2011) World Kidney Day 2011: Protect Your Kidneys, Save Your Heart. Transplantation1
CrossRef229
Moon-Jae Kim. (2011) Current Controversies over the Management of Elderly Hypertension with Impaired Renal Function. Journal of the Korean Society of Hypertension 17:4, 148
CrossRef230
Brad H. Rovin, Isaac E. Stillman. 2011. Kidney. , 769-814.
CrossRef231
Yan Chun Li. 2011. Vitamin D and the Renin-Angiotensin System. , 707-723.
CrossRef232
Mustafa Emre, Servet Kavak, Hakki Unlugenc. (2010) The effects of telmisartan on mechanical responses of left ventricular papillary muscle in rats with streptozotocin-induced diabetes mellitus. Acta Diabetologica 47:S1, 153-159
CrossRef233
H. M. James Hung, Sue-Jane Wang. (2010) Challenges to multiple testing in clinical trials. Biometrical Journal 52:6, 747-756
CrossRef234
Vivencio Barrios, Carlos Escobar. (2010) Antihypertensive and organ-protective effects of benazepril. Expert Review of Cardiovascular Therapy 8:12, 1653-1671
CrossRef235
Valentina Forni, Grégoire Wuerzner, Menno Pruijm, Michel Burnier. (2010) Treating high blood pressure: Is reaching the target more important than the means? No, the means are important. European Journal of Internal Medicine 21:6, 478-483
CrossRef236
János Peti-Peterdi. (2010) High glucose and renin release: the role of succinate and GPR91. Kidney International 78:12, 1214-1217
CrossRef237
Pierre Nantel, Paul René de Cotret. (2010) The evolution of angiotensin blockade in the management of cardiovascular disease. Canadian Journal of Cardiology 26, 7E-13E
CrossRef238
K. C. Sourris, A. L. Morley, A. Koitka, P. Samuel, M. T. Coughlan, S. A. Penfold, M. C. Thomas, A. Bierhaus, P. P. Nawroth, H. Yamamoto, T. J. Allen, T. Walther, T. Hussain, M. E. Cooper, J. M. Forbes. (2010) Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia 53:11, 2442-2451
CrossRef239
SHARP Collaborative Group. (2010) Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal 160:5, 785-794.e10
CrossRef240
Yasuaki Hayashino, Shunichi Fukuhara, Tadao Akizawa, Yasushi Asano, Takafumi Wakita, Yoshihiro Onishi, Kiyoshi Kurokawa. (2010) Cost-effectiveness of administering oral adsorbent AST-120 to patients with diabetes and advance-stage chronic kidney disease. Diabetes Research and Clinical Practice 90:2, 154-159
CrossRef241
Sabha Bhatti, Abdul Hakeem, Kathryn S. Dillie, Jeffery R. Cook, Su Min Chang. (2010) Prevalence, Prognosis, and Therapeutic Implications of Unrecognized Left Ventricular Systolic Dysfunction in Patients With Anemia and Chronic Kidney Disease. Congestive Heart Failure 16:6, 271-277
CrossRef242
Naro Ohashi, Maki Urushihara, Ryousuke Satou, Hiroyuki Kobori. (2010) Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen species—ERK/JNK pathways. Hypertension Research 33:11, 1174-1181
CrossRef243
Genei Ihara, Hideyasu Kiyomoto, Hiroyuki Kobori, Yukiko Nagai, Naro Ohashi, Hirofumi Hitomi, Daisuke Nakano, Nicolas Pelisch, Taiga Hara, Takefumi Mori, Sadayoshi Ito, Masakazu Kohno, Akira Nishiyama. (2010) Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade. Journal of Hypertension 28:11, 2289-2298
CrossRef244
Mitsuru Ohishi, Yasushi Takeya, Yuji Tatara, Koichi Yamamoto, Miyuki Onishi, Yoshihiro Maekawa, Kei Kamide, Hiromi Rakugi. (2010) Strong suppression of the renin–angiotensin system has a renal-protective effect in hypertensive patients: High-dose ARB with ACE inhibitor (Hawaii) study. Hypertension Research 33:11, 1150-1154
CrossRef245
Antonis S. Manolis, Spyridon Koulouris, Kostas Triantafyllou, Dimitris Sakellariou, Sokratis Pastromas, Helen Melita. 2010. Anemia and Cardiovascular Disease. , 229-251.
CrossRef246
Josephine M. Forbes, Mark E. Cooper. (2010) Glycation in diabetic nephropathy. Amino Acids
CrossRef247
Vijay U. Rao, John R. Teerlink. 2010. Treating Systolic Heart Failure. , 287-326.
CrossRef248
Kevin V. Lemley. (2010) When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes. Pediatric Nephrology 25:10, 2021-2034
CrossRef249
C. Hotu, W. Bagg, J. Collins, L. Harwood, G. Whalley, R. Doughty, G. Gamble, G. Braatvedt, . (2010) A community-based model of care improves blood pressure control and delays progression of proteinuria, left ventricular hypertrophy and diastolic dysfunction in Maori and Pacific patients with type 2 diabetes and chronic kidney disease: a randomized controlled trial. Nephrology Dialysis Transplantation 25:10, 3260-3266
CrossRef250
Takashi Uzu, Masayoshi Sakaguchi, Atsuko Tsuda, Aya Kadota, Yukiyo Yokomaku, Shinji Kume, Masami Kanasaki, Keiji Isshiki, Shin-ichi Araki, Toshiro Sugiomoto, Hiroshi Maegawa, Atsunori Kashiwagi. (2010) Effects of blood pressure and the renin-angiotensin system on platelet activation in type 2 diabetes. Journal of Diabetes Investigation 1:5, 196-201
CrossRef251
M. C. J. Slagman, S. J. Sinkeler, M. H. Hemmelder, F. Waanders, L. Vogt, H. C. Kluin-Nelemans, G. Navis, G. D. Laverman. (2010) Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function. Nephrology Dialysis Transplantation 25:10, 3256-3260
CrossRef252
Yoshikazu Miwa, Takuya Tsuchihashi, Yuko Ohta, Mitsuhiro Tominaga, Yuhei Kawano, Toshiyuki Sasaguri, Michio Ueno, Hiroaki Matsuoka. (2010) Antiproteinuric Effect of Cilnidipine in Hypertensive Japanese Treated with Renin-Angiotensin-System Inhibitors - A Multicenter, Open, Randomized Trial Using 24-Hour Urine Collection. Clinical and Experimental Hypertension 32:6, 400-405
CrossRef253
Giovanna Leoncini, Francesca Viazzi, Roberto Pontremoli. (2010) Chronic Kidney Disease and Albuminuria in Arterial Hypertension. Current Hypertension Reports 12:5, 335-341
CrossRef254
Robert G. Fassett, Glenda C. Gobe, Jonathan M. Peake, Jeff S. Coombes. (2010) Omega-3 Polyunsaturated Fatty Acids in the Treatment of Kidney Disease. American Journal of Kidney Diseases 56:4, 728-742
CrossRef255
Michael R. Lattanzio, Matthew R. Weir. (2010) Does Blockade of the Renin-Angiotensin-Aldosterone System Slow Progression of All Forms of Kidney Disease?. Current Hypertension Reports 12:5, 369-377
CrossRef256
Gianfranco Parati, Roland Asmar, Grzegorz Bilo, Albert Kandra, Robert Di Giovanni, Thomas Mengden. (2010) Effectiveness and safety of high-dose valsartan monotherapy in hypertension treatment: the ValTop study. Hypertension Research 33:10, 986-994
CrossRef257
Macaulay A.C. Onuigbo. (2010) Syndrome of rapid-onset end-stage renal disease: a new unrecognized pattern of CKD progression to ESRD. Renal Failure 32:8, 954-958
CrossRef258
Lalitha De Silva, Matthew R Weir. (2010) Renin inhibition and microalbuminuria development: meaningful predictor of kidney disease progression. Current Opinion in Nephrology and Hypertension 19:5, 437-443
CrossRef259
P. A. Swift, P. A. Andrews. (2010) Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence required. International Journal of Clinical Practice 64:10, 1331-1333
CrossRef260
M. Gorostidi, A. de la Sierra. (2010) Antagonistas de los receptores de la angiotensina II en combinación con antagonistas del calcio. Focus en la asociación de olmesartán con amlodipino. Hipertensión y Riesgo Vascular 27, 16-21
CrossRef261
Jean-Jacques Mourad, Sylvain Le Jeune, Anthony Pirollo, Clarisse Mourad, Yann Gaudouen, Marilucy Lopez-Sublet. (2010) Combinations of inhibitors of the renin–angiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine. Current Medical Research and Opinion 26:9, 2263-2276
CrossRef262
Giovanni Cerasola, Santina Cottone, Giuseppe Mulè. (2010) The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor. Journal of Hypertension1
CrossRef263
Gianluca EM Boari, Damiano Rizzoni, Carolina De Ciuceis, Enzo Porteri, Daniele Avanzi, Caterina Platto, Monica Mazza, Alida Brignani, Claudia Agabiti Rosei, Doris Ricotta, Luigi Caimi, Enrico Agabiti Rosei. (2010) Structural alterations in subcutaneous small resistance arteries predict changes in the renal function of hypertensive patients. Journal of Hypertension 28:9, 1951-1958
CrossRef264
J. Rojas-Rivera, C. De La Piedra, A. Ramos, A. Ortiz, J. Egido. (2010) The expanding spectrum of biological actions of vitamin D. Nephrology Dialysis Transplantation 25:9, 2850-2865
CrossRef265
Sharon Adler. (2010) Novel Kidney Injury Biomarkers. Journal of Renal Nutrition 20:5, S15-S18
CrossRef266
S. Hirsch. (2010) Dual renin-angiotensin-aldosterone system inhibition: boon or bust?. International Journal of Clinical Practice 64:10, 1337-1340
CrossRef267
M. A. C. Onuigbo. (2010) Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far?. International Journal of Clinical Practice 64:10, 1341-1346
CrossRef268
Jessica W Weiss, Micah L Thorp, Ann M OʼHare. (2010) Renin–angiotensin system blockade in older adults with chronic kidney disease: a review of the literature. Current Opinion in Nephrology and Hypertension 19:5, 413-419
CrossRef269
Tetsunori Saikawa, Jun Sasaki, Sadayoshi Biro, Suminori Kono, Takatoshi Otonari, Yoshiyuki Ikeda. (2010) Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day−1. Hypertension Research 33:9, 886-891
CrossRef270
Robert D Toto. (2010) Aldosterone blockade in chronic kidney disease: can it improve outcome?. Current Opinion in Nephrology and Hypertension 19:5, 444-449
CrossRef271
Hari Krishan Aggarwal, Deepak Jain, Paulomi Talapatra, Raj Kumar Yadav, Tarana Gupta, Kashmiri Lal Kathuria. (2010) Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy. Renal Failure 32:8, 941-946
CrossRef272
Nathalie Thilly, Stéphanie Boini, Carole Loos-Ayav, Michèle Kessler, Serge Briançon, Luc Frimat. (2010) Impact of Predialysis Therapeutic Practices on Patient Outcomes During the First Year of Dialysis. Medical Care1
CrossRef273
M. Nagata, T. Ninomiya, Y. Doi, K. Yonemoto, M. Kubo, J. Hata, K. Tsuruya, M. Iida, Y. Kiyohara. (2010) Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: The Hisayama Study. Nephrology Dialysis Transplantation 25:8, 2557-2564
CrossRef274
Yu-Jen Su, Chien-Te Lee, Feng-Rong Chuang, Chih-Hsiung Lee, Yi-Chun Wang, Ben-Chung Cheng, Kuo-Tai Hsu, Jin-Bor Chen. (2010) Comparison of clinical characteristics between automated peritoneal dialysis and continuous ambulatory peritoneal dialysis: a 2-year single-center observational study. Renal Failure 32:7, 817-824
CrossRef275
F. Persson, P. Rossing, H. Reinhard, T. Juhl, C. D. A. Stehouwer, C. Schalkwijk, A. H. J. Danser, F. Boomsma, E. Frandsen, H.-H. Parving. (2010) Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia 53:8, 1576-1580
CrossRef276
José D. Méndez, Jianling Xie, Montserrat Aguilar-Hernández, Verna Méndez-Valenzuela. (2010) Trends in advanced glycation end products research in diabetes mellitus and its complications. Molecular and Cellular Biochemistry 341:1-2, 33-41
CrossRef277
Miki Nagase. (2010) Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clinical and Experimental Nephrology 14:4, 303-314
CrossRef278
Raimund H. Pichler, Ian H. de Boer. (2010) Dual Renin-Angiotensin-Aldosterone System Blockade for Diabetic Kidney Disease. Current Diabetes Reports 10:4, 297-305
CrossRef279
2010. Hypertension in Diabetes. , 142-151.
CrossRef280
Riccardo Candido, Mark E. Cooper, Karin A. M. Jandeleit-Dahm. 2010. The Pathogenesis of Macrovascular Complications Including Atherosclerosis in Diabetes. , 635-656.
CrossRef281
Sally M. Marshall, Allan Flyvbjerg. 2010. Diabetic Nephropathy. , 599-614.
CrossRef282
Maria Kamper, Olia Tsimpoukidi, Antonios Chatzigeorgiou, Maria Lymberi, Elli F. Kamper. (2010) The antioxidant effect of angiotensin II receptor blocker, losartan, in streptozotocin-induced diabetic rats. Translational Research 156:1, 26-36
CrossRef283
Paula T Einhorn, Barry R Davis, Jackson T Wright, Mahboob Rahman, Paul K Whelton, Sara L Pressel. (2010) ALLHAT: still providing correct answers after 7 years. Current Opinion in Cardiology 25:4, 355-365
CrossRef284
Gen Yasuda, Daisaku Ando, Nobuhito Hirawa, Satoshi Umemura. (2010) Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy. Renal Failure 32:6, 680-686
CrossRef285
Yuki Ando, Toshimitsu Hamasaki. (2010) Practical issues and lessons learned from multi-regional clinical trials via case examples: a Japanese perspective. Pharmaceutical Statistics 9:3, 190-200
CrossRef286
Yi-Fei Dong, Lei Liu, Zhong-Fang Lai, Eiichiro Yamamoto, Keiichiro Kataoka, Taishi Nakamura, Masaya Fukuda, Yoshiko Tokutomi, Hisato Nako, Hisao Ogawa, Shokei Kim-Mitsuyama. (2010) Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. Journal of Hypertension 28:7, 1554-1565
CrossRef287
Yi Yang, Vennela Thumula, Patrick F. Pace, Benjamin F. Banahan, Noel E. Wilkin, William B. Lobb. (2010) Nonadherence to angiotensinconverting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs. Journal of the American Pharmacists Association 50:4, 527-531
CrossRef288
Yan Chun Li. (2010) Renoprotective effects of vitamin D analogs. Kidney International 78:2, 134-139
CrossRef289
Ilke Sipahi, Sara M Debanne, Douglas Y Rowland, Daniel I Simon, James C Fang. (2010) Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. The Lancet Oncology 11:7, 627-636
CrossRef290
Josep Galceran, Jaume Plana, Angela Felip, Gabriel Pou, Joaquim Vila, Javier Sobrino. (2010) Manidipine treatment in patients with albuminuria not sufficiently reduced with renin–angiotensin system blockers. Expert Review of Cardiovascular Therapy 8:6, 751-757
CrossRef291
Andrea O. Luk, Xilin Yang, Ronald C. Ma, Vanessa W. Ng, Linda W. Yu, Winnie W. Lau, Risa Ozaki, Francis C. Chow, Alice P. Kong, Peter C. Tong, Juliana C. Chan, Wingyee So. (2010) Association of statin use and development of renal dysfunction in type 2 diabetes—The Hong Kong Diabetes Registry. Diabetes Research and Clinical Practice 88:3, 227-233
CrossRef292
Kum Hyun Han, Sang Youb Han, Han Seong Kim, Young Sun Kang, Dae Ryong Cha. (2010) Prolonged Administration Enhances the Renoprotective Effect of Pentoxifylline via Anti-Inflammatory Activity in Streptozotocin-Induced Diabetic Nephropathy. Inflammation 33:3, 137-143
CrossRef293
A. A. Hernandez, F. Moreso, B. Bayes, R. Lauzurica, D. Sanz-Guajardo, E. Gomez-Huertas, P. Pereira, J. Paul, J. Crespo, J. J. Amenabar, J. Oliver, D. Seron. (2010) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain. NDT Plus 3:Supplement 2, ii21-ii25
CrossRef294
Piero Ruggenenti, Paolo Cravedi, Giuseppe Remuzzi. (2010) The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nature Reviews Nephrology 6:6, 319-330
CrossRef295
Nobuaki Ozaki, Yoshio Nomura, Hiroshi Sobajima, Kunikazu Kondo, Yutaka Oiso. (2010) Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. European Journal of Internal Medicine 21:3, 236-239
CrossRef296
Dilip K Deb, Tao Sun, Kari E Wong, Zhongyi Zhang, Gang Ning, Yan Zhang, Juan Kong, Helen Shi, Anthony Chang, Yan Chun Li. (2010) Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney International 77:11, 1000-1009
CrossRef297
Cornelis Boersma, Ron T. Gansevoort, Petros Pechlivanoglou, Sipke T. Visser, Flip F.J. van Toly, Lolkje T.W. de Jong-van den Berg, Paul E. de Jong, Maarten J. Postma. (2010) Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: Cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands. Clinical Therapeutics 32:6, 1103-1121
CrossRef298
Heart Failure Society of America. (2010) Section 3: Prevention of Ventricular Remodeling, Cardiac Dysfunction, and Heart Failure. Journal of Cardiac Failure 16:6, e38-e43
CrossRef299
Lesley-Ann Miller, Rolin Wade, Dingwei Dai, Mark J. Cziraky, Krishnan Ramaswamy, Sumeet Panjabi. (2010) Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension. Current Medical Research and Opinion 26:6, 1307-1320
CrossRef300
Michael A. Weber, George L. Bakris, Kenneth Jamerson, Matthew Weir, Sverre E. Kjeldsen, Richard B. Devereux, Eric J. Velazquez, Björn Dahlöf, Roxzana Y. Kelly, Tsushung A. Hua, Allen Hester, Bertram Pitt. (2010) Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. Journal of the American College of Cardiology 56:1, 77-85
CrossRef301
Massimo Volpe, Claudio Borghi, Paolo Cavallo Perin, Massimo Chiariello, Enzo Manzato, Roberto Miccoli, Maria Grazia Modena, Gabriele Riccardi, Giorgio Sesti, Antonio Tiengo, Bruno Trimarco, Diego Vanuzzo, Paolo Verdecchia, Augusto Zaninelli, Stefano Del Prato. (2010) Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. High Blood Pressure & Cardiovascular Prevention 17:2, 73-102
CrossRef302
Han Wang, Jue Lin Deng, Jirong Yue, Jun Li, Yan Bin Hou, Jue Lin Deng. 2010. Prostaglandin E1 for preventing the progression of diabetic kidney disease. .
CrossRef303
Hariprasad Trivedi. (2010) Cost Implications of Caring for Chronic Kidney Disease: Are Interventions Cost-effective?. Advances in Chronic Kidney Disease 17:3, 265-270
CrossRef304
Helmy M. Siragy. (2010) Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Advances in Therapy 27:5, 257-284
CrossRef305
Karen Jenkins, Mary Kirk. (2010) HEART FAILURE AND CHRONIC KIDNEY DISEASE: AN INTEGRATED CARE APPROACH. Journal of Renal Care 36, 127-135
CrossRef306
Faruk Turgut, Warren Kline Bolton. (2010) Potential New Therapeutic Agents for Diabetic Kidney Disease. American Journal of Kidney Diseases 55:5, 928-940
CrossRef307
David Benavente, Colin D. Chue, Charles J. Ferro. (2010) THE IMPORTANCE OF RENIN-ANGIOTENSIN BLOCKADE IN PATIENTS WITH CARDIO-RENAL DISEASE. Journal of Renal Care 36, 97-105
CrossRef308
John P Middleton, Patrick H Pun. (2010) Hypertension, chronic kidney disease, and the development of cardiovascular risk: a joint primacy. Kidney International 77:9, 753-755
CrossRef309
Vahakn B. Shahinian, Rajiv Saran. (2010) The Role of Primary Care in the Management of the Chronic Kidney Disease Population. Advances in Chronic Kidney Disease 17:3, 246-253
CrossRef310
Helga Frank, Stefan Pscherer, Danilo Fliser, Uwe Heemann. (2010) Effect of experimental hyperglycaemia on renal haemodynamics in prediabetic patients with and without AT1 receptor blockade. European Journal of Clinical Investigation 40:5, 414-421
CrossRef311
Marie Briet, Ernesto L. Schiffrin. (2010) Aldosterone: effects on the kidney and cardiovascular system. Nature Reviews Nephrology 6:5, 261-273
CrossRef312
S.F. Ige, R.E. Akhigbe, A.O. Akinsanya. (2010) The Role of Hyperglycemia in Skin Wrinkle Formation: Mediation of Advanced Glycation End-Products. Research Journal of Medical Sciences 4:5, 324-329
CrossRef313
Irene M. Van Der Meer, Piero Ruggenenti, Giuseppe Remuzzi. (2010) THE DIABETIC CKD PATIENT-A MAJOR CARDIOVASCULAR CHALLENGE. Journal of Renal Care 36, 34-46
CrossRef314
Julián Segura de La Morena, José Antonio García Donaire, Luis Miguel Ruilope Urioste. (2010) Nuevas estrategias terapéuticas para mejorar el control de la hipertensión arterial y simplificar la pauta de tratamiento farmacológico. Medicina Clínica 134:14, 635-642
CrossRef315
Oliver Faust, Rajendra Acharya U., E. Y. K. Ng, Kwan-Hoong Ng, Jasjit S. Suri. (2010) Algorithms for the Automated Detection of Diabetic Retinopathy Using Digital Fundus Images: A Review. Journal of Medical Systems
CrossRef316
Matthew T James, Brenda R Hemmelgarn, Marcello Tonelli. (2010) Early recognition and prevention of chronic kidney disease. The Lancet 375:9722, 1296-1309
CrossRef317
Stefano Bianchi, Roberto Bigazzi, Vito M. Campese. (2010) Intensive Versus Conventional Therapy to Slow the Progression of Idiopathic Glomerular Diseases. American Journal of Kidney Diseases 55:4, 671-681
CrossRef318
Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A, Campbell D, Nicholls K, Tong A, Mangos G, Stack A, MacIsaac RJ, Girgis S, Colagiuri R, Colagiuri S, Craig J. (2010) Prevention and management of chronic kidney disease in type 2 diabetes. Nephrology 15, S162-S194
CrossRef319
Toshihiro Kita, Naoto Yokota, Yoshinari Ichiki, Takao Ayabe, Takuma Etoh, Noboru Tamaki, Johji Kato, Tanenao Eto, Kazuo Kitamura. (2010) One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. Hypertension Research 33:4, 320-325
CrossRef320
George L Bakris, Pantelis A Sarafidis, Matthew R Weir, Björn Dahlöf, Bertram Pitt, Kenneth Jamerson, Eric J Velazquez, Linda Staikos-Byrne, Roxzana Y Kelly, Victor Shi, Yann-Tong Chiang, Michael A Weber. (2010) Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. The Lancet 375:9721, 1173-1181
CrossRef321
Michael A. Weber, Barry J. Materson. (2010) Hypertension Guidelines: A Major Reappraisal Critically Examines the Available Evidence. The Journal of Clinical Hypertension 12:4, 229-236
CrossRef322
Takahiko Nakagawa. (2010) Diabetic nephropathy: Aldosterone breakthrough in patients on an ACEI. Nature Reviews Nephrology 6:4, 194-196
CrossRef323
Christian W. Mende. (2010) Application of Direct Renin Inhibition to Chronic Kidney Disease. Cardiovascular Drugs and Therapy 24:2, 139-149
CrossRef324
Domenic A. Sica. (2010) The Evolution of Renin-Angiotensin Blockade: Angiotensin-Converting Enzyme Inhibitors as the Starting Point. Current Hypertension Reports 12:2, 67-73
CrossRef325
, Kunihiro Yamagata, Hirofumi Makino, Tadao Akizawa, Kunitoshi Iseki, Sadayoshi Itoh, Kenjiro Kimura, Daisuke Koya, Ichiei Narita, Tetsuya Mitarai, Masanobu Miyazaki, Yoshiharu Tsubakihara, Tsuyoshi Watanabe, Takashi Wada, Osamu Sakai. (2010) Design and methods of a strategic outcome study for chronic kidney disease: Frontier of Renal Outcome Modifications in Japan. Clinical and Experimental Nephrology 14:2, 144-151
CrossRef326
Marsha A. Raebel, Colleen Ross, Stanley Xu, Douglas W. Roblin, Craig Cheetham, Christopher M. Blanchette, Gwyn Saylor, David H. Smith. (2010) Diabetes and Drug-Associated Hyperkalemia: Effect of Potassium Monitoring. Journal of General Internal Medicine 25:4, 326-333
CrossRef327
Peter Mount. (2010) Inhibition of the renin-angiotensin system. Nephrology 15, S234-S243
CrossRef328
Yi Yang, Vennela Thumula, Patrick F. Pace, Benjamin F. Banahan, Noel E. Wilkin, William B. Lobb. (2010) High-risk Diabetic Patients in Medicare Part D Programs: Are They Getting the Recommended ACEI/ARB Therapy?. Journal of General Internal Medicine 25:4, 298-304
CrossRef329
John Chalmers, Hisatomi Arima. (2010) Importance of Blood Pressure Lowering in Type 2 Diabetes: Focus on ADVANCE. Journal of Cardiovascular Pharmacology 55:4, 340-347
CrossRef330
KEISHI HIGASHI, TAKASHI ODA, TAKETOSHI KUSHIYAMA, TOSHITAKE HYODO, MUNEHARU YAMADA, SHIGENOBU SUZUKI, YUTAKA SAKURAI, SOICHIRO MIURA, HIROO KUMAGAI. (2010) Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. Nephrology 15:3, 327-335
CrossRef331
David L Feldman. (2010) New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease. Hypertension Research 33:4, 279-287
CrossRef332
Atsushi Shiota, Koichi Yamamoto, Mitsuru Ohishi, Yuji Tatara, Miyuki Ohnishi, Yoshihiro Maekawa, Yoshihiro Iwamoto, Masao Takeda, Hiromi Rakugi. (2010) Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice. Hypertension Research 33:4, 298-307
CrossRef333
Albert Lam, Siddharth Shah, James Paparello. (2010) Outpatient Management of Chronic Kidney Disease: Proteinuria, Anemia and Bone Disease as Therapeutic Targets. Disease-a-Month 56:4, 215-232
CrossRef334
M. Komajda, J. J.V. McMurray, H. Beck-Nielsen, R. Gomis, M. Hanefeld, S. J. Pocock, P. S. Curtis, N. P. Jones, P. D. Home. (2010) Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal 31:7, 824-831
CrossRef335
Hiddo Lambers Heerspink, Dick de Zeeuw. (2010) Composite renal endpoints: was ACCOMPLISH accomplished?. The Lancet 375:9721, 1140-1142
CrossRef336
Kirsten Howard, Sarah White, Glenn Salkeld, Stephen McDonald, Jonathan C. Craig, Steven Chadban, Alan Cass. (2010) Cost-Effectiveness of Screening and Optimal Management for Diabetes, Hypertension, and Chronic Kidney Disease: A Modeled Analysis. Value in Health 13:2, 196-208
CrossRef337
Fu L. Luan, Millie Samaniego. (2010) Transplantation in Diabetic Kidney Failure Patients: Modalities, Outcomes, and Clinical Management. Seminars in Dialysis 23:2, 198-205
CrossRef338
Mark E. Williams. (2010) Diabetic CKD/ESRD 2010: A Progress Report?. Seminars in Dialysis 23:2, 129-133
CrossRef339
A. Koïtka, Z. Cao, P. Koh, A. M. D. Watson, K. C. Sourris, L. Loufrani, A. Soro-Paavonen, T. Walther, K. J. Woollard, K. A. M. Jandeleit-Dahm, M. E. Cooper, T. J. Allen. (2010) Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes. Diabetologia 53:3, 584-592
CrossRef340
Jon Bergset, Eugene Storozynsky, John D Bisognano. (2010) Renin Inhibition for Hypertension: Selecting the Right Role for a New Class of Drug. American Journal of Therapeutics 17:2, 182-187
CrossRef341
Luis C Matavelli, Jiqian Huang, Helmy M Siragy. (2010) (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clinical and Experimental Pharmacology and Physiology 37:3, 277-282
CrossRef342
Sihem Boudina, Evan Dale Abel. (2010) Diabetic cardiomyopathy, causes and effects. Reviews in Endocrine and Metabolic Disorders 11:1, 31-39
CrossRef343
Maartje CJ Slagman, Gerjan Navis, Gozewijn D Laverman. (2010) Dual blockade of the renin–angiotensin–aldosterone system in cardiac and renal disease. Current Opinion in Nephrology and Hypertension 19:2, 140-152
CrossRef344
T. Philipp, F. Martinez, H. Geiger, B. Moulin, G. Mourad, R. Schmieder, M. Lievre, U. Heemann, C. Legendre. (2010) Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrology Dialysis Transplantation 25:3, 967-976
CrossRef345
Cho-Kai Wu, Chung-Yi Yang, Chia-Ti Tsai, Fu-Chun Chiu, Yin-Tsen Huang, Jen-Kuang Lee, Chia-Ling Cheng, Lian-Yu Lin, Jou-Wei Lin, Juey-Jen Hwang, Fu-Tien Chiang. (2010) Association of low glomerular filtration rate and albuminuria with peripheral arterial disease: The National Health and Nutrition Examination Survey, 1999–2004. Atherosclerosis 209:1, 230-234
CrossRef346
Peter Bramlage, Christoph Schindler. (2010) Differences in pharmacology and their translation into differences in clinical efficacy – a comparison of the renin angiotensin blocking agents irbesartan and losartan. Expert Opinion on Pharmacotherapy 11:4, 521-535
CrossRef347
Joel M. Neutel, Dean J. Kereiakes, William F. Waverczak, Kathy A. Stoakes, Jianbo Xu, Ali Shojaee. (2010) Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Current Medical Research and Opinion 26:3, 721-728
CrossRef348
, Axel Müller, Johannes Schweizer, Wilhelm Kirch, Christoph Schindler. (2010) Status der Behandlung der arteriellen Hypertonie unter Praxisbedingungen in deutschen Arztpraxen zum Zeitpunkt der Einführung des Renininhibitors Aliskiren. Medizinische Klinik 105:3, 155-162
CrossRef349
Toshio Miyata, Charles van Ypersele de Strihou. (2010) Diabetic nephropathy: a disorder of oxygen metabolism?. Nature Reviews Nephrology 6:2, 83-95
CrossRef350
Fiona Turnbull, Mark Woodward, Vibeke Anna. (2010) Effectiveness of blood pressure lowering: evidence-based comparisons between men and women. Expert Review of Cardiovascular Therapy 8:2, 199-209
CrossRef351
Carlos Escobar, Vivencio Barrios. (2010) Combined therapy in the treatment of hypertension. Fundamental & Clinical Pharmacology 24:1, 3-8
CrossRef352
Lamioko Shika Pappoe, Wolfgang C. Winkelmayer. (2010) ACE Inhibitor and Angiotensin II Type 1 Receptor Antagonist Therapies in Elderly Patients with Diabetes Mellitus. Drugs & Aging 27:2, 87-94
CrossRef353
J. J.V. McMurray, K. Swedberg. (2010) HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure--lessons learnt from a decade of trials. European Journal of Heart Failure 12:2, 99-103
CrossRef354
Carly Skamra, Rosalind Ramsey-Goldman. (2010) Management of cardiovascular complications in systemic lupus erythematosus. International Journal of Clinical Rheumatology 5:1, 75-100
CrossRef355
Fernando Martinez, Maria Luisa Mansego, Felipe Javier Chaves, Josep Redon. (2010) Genetic bases of urinary albumin excretion and related traits in hypertension. Journal of Hypertension 28:2, 213-225
CrossRef356
Haisam Ismail, Rena Mitchell, Samy I. McFarlane, Amgad N. Makaryus. (2010) Pleiotropic Effects of Inhibitors of the RAAS in the Diabetic Population: Above and Beyond Blood Pressure Lowering. Current Diabetes Reports 10:1, 32-36
CrossRef357
Kenichi Shikata, Masakazu Haneda, Daisuke Koya, Yoshiki Suzuki, Yasuhiko Tomino, Kenichi Yamada, Shiro Maeda, Norito Kawakami, Takashi Uzu, Motonobu Nishimura, Chikage Sato, Daisuke Ogawa, Hirofumi Makino. (2010) Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design. Diabetes Research and Clinical Practice 87:2, 228-232
CrossRef358
Tomoki Kosugi, Marcelo Heinig, Takahiro Nakayama, Seiichi Matsuo, Takahiko Nakagawa. (2010) eNOS Knockout Mice with Advanced Diabetic Nephropathy Have Less Benefit from Renin-Angiotensin Blockade than from Aldosterone Receptor Antagonists. The American Journal of Pathology 176:2, 619-629
CrossRef359
K. Ishizawa, Y. Izawa-Ishizawa, N. Dorjsuren, E. Miki, Y. Kihira, Y. Ikeda, S. Hamano, K. Kawazoe, K. Minakuchi, S. Tomita, K. Tsuchiya, T. Tamaki. (2010) Angiotensin II receptor blocker attenuates PDGF-induced mesangial cell migration in a receptor-independent manner. Nephrology Dialysis Transplantation 25:2, 364-372
CrossRef360
Gang Zhao, Hong Zhao, Ling Tu, Xizhen Xu, Changlong Zheng, Meihua Jiang, Peihua Wang, Daowen Wang. (2010) Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats. Journal of Huazhong University of Science and Technology [Medical Sciences] 30:1, 48-54
CrossRef361
Jijun Wang, Ichiro M Omori, Mark Fenton, Bernardo Soares, Jijun Wang. 2010. Sulpiride augmentation for schizophrenia. .
CrossRef362
Abboud, Hanna, Henrich, William L., . (2010) Stage IV Chronic Kidney Disease. New England Journal of Medicine 362:1, 56-65
Full Text363
T. Sawada, H. Matsubara. (2010) Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study: reply. European Heart Journal 31:2, 262-262
CrossRef364
Sadayoshi Ito. (2010) Proteinuria: Usefulness of RAS inhibition depends on baseline albuminuria. Nature Reviews Nephrology 6:1, 10-11
CrossRef365
Marsha A. Raebel, Colleen Ross, Craig Cheetham, Hans Petersen, Gwyn Saylor, David H. Smith, Leslie A. Wright, Douglas W. Roblin, Stanley Xu. (2010) Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates. Pharmacoepidemiology and Drug Safety 19:1, 19-25
CrossRef366
Gurch Randhawa. (2010) Renal Health Disparities in the United Kingdom: A Focus on Ethnicity. Seminars in Nephrology 30:1, 8-11
CrossRef367
R. F. Mapanga, C. T. Musabayane. (2010) The Renal Effects of Blood Glucose-Lowering Plant-Derived Extracts in Diabetes Mellitus—an Overview. Renal Failure 32:1, 132-138
CrossRef368
Tamara B. Horwich, Gregg C. Fonarow. (2010) Glucose, Obesity, Metabolic Syndrome, and Diabetes. Journal of the American College of Cardiology 55:4, 283-293
CrossRef369
Yoshihiro Kiya, Shin-Ichiro Miura, Masahiro Fujino, Satoshi Imaizumi, Sadashiva S. Karnik, Keijiro Saku. (2010) Clinical and Pharmacotherapeutic Relevance of the Double-Chain Domain of the Angiotensin II Type 1 Receptor Blocker Olmesartan. Clinical and Experimental Hypertension 32:2, 129-136
CrossRef370
Steven A Yarows. (2010) Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases. Expert Review of Cardiovascular Therapy 8:1, 19-33
CrossRef371
Parminder Singh, Wilbert S Aronow, William Michael Mellana, Andrew H Gutwein. (2010) Prevalence of Appropriate Management of Diabetes Mellitus in an Academic General Medicine Clinic. American Journal of Therapeutics 17:1, 42-45
CrossRef372
W B White, G Davidai, H Schumacher. (2009) Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1–2 hypertension. Journal of Human Hypertension 23:12, 817-825
CrossRef373
T. Unger. (2009) The rationale for choosing telmisartan and ramipril in the ONTARGET programme. European Heart Journal Supplements 11:Suppl F, F3-F8
CrossRef374
Kenichiro Kinouchi, Atsuhiro Ichihara, Mariyo Sakoda, Asako Kurauchi-Mito, Hiroshi Itoh. (2009) Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. Hypertension Research 32:12, 1143-1147
CrossRef375
D. Dobre, H. J. Lambers Heerspink, D. de Zeeuw. (2009) Reducing cardiovascular risk: protecting the kidney. European Heart Journal Supplements 11:Suppl F, F39-F46
CrossRef376
F. Lühder, D.H. Lee, R. Gold, J. Stegbauer, R.A. Linker. (2009) Small but powerful: Short peptide hormones and their role in autoimmune inflammation. Journal of Neuroimmunology 217:1-2, 1-7
CrossRef377
(2009) Evidence-based Practice Guideline for the Treatment of CKD. Clinical and Experimental Nephrology 13:6, 537-566
CrossRef378
K. K. Teo. (2009) Clinical evidence from ONTARGET: proven cardio- and vascular protection. European Heart Journal Supplements 11:Suppl F, F9-F15
CrossRef379
S. Fujimoto, M. Satoh, H. Nagasu, H. Horike, T. Sasaki, N. Kashihara. (2009) Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats. Nephrology Dialysis Transplantation 24:12, 3651-3658
CrossRef380
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J. Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Antony Heagerty, Sverre E. Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H. Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E. Schmieder, Harry A.J. Struijker-Boudier, Pieter A. Van Zwieten, Margus Viigimaa, Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure 18:6, 308-347
CrossRef381
Xiaoyue Tan, Weichun He, Youhua Liu. (2009) Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney International 76:12, 1248-1257
CrossRef382
Francesco Locatelli, Biff F. Palmer, Naoki Kashihara, Tevfik Ecder. (2009) Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan. Current Medical Research and Opinion 25:12, 2933-2949
CrossRef383
Martin A. Alpert, Gurushankar Govindarajan, Marc L.E. Del Rosario, Efrain Reisin. (2009) The Role of the Renin-Angiotensin System in the Pathophysiology, Prevention, and Treatment of Renal Impairment in Patients With the Cardiometabolic Syndrome or Its Components. Journal of the CardioMetabolic Syndrome 4:1, 57-62
CrossRef384
Elaine Ku, Vito M. Campese. (2009) Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children. Pediatric Nephrology 24:12, 2301-2307
CrossRef385
R. Haynes, P. Mason, K. Rahimi, M. J. Landray. (2009) Dual blockade of the renin-angiotensin system: are two better than one?. Nephrology Dialysis Transplantation 24:12, 3602-3607
CrossRef386
Toshio Ogihara, Takao Saruta, Kazuyuki Shimada, Kizuku Kuramoto. (2009) A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study. Hypertension Research 32:12, 1148-1154
CrossRef387
Julia M. Steinke. (2009) The natural progression of kidney injury in young type 1 diabetic patients. Current Diabetes Reports 9:6, 473-479
CrossRef388
Tayebeh Hadizad, Sheryn A. Kirkpatrick, Samantha Mason, Kevin Burns, Rob. S. Beanlands, Jean N. DaSilva. (2009) Novel O-[11C]methylated derivatives of candesartan as angiotensin II AT1 receptor imaging ligands: Radiosynthesis and ex vivo evaluation in rats. Bioorganic & Medicinal Chemistry 17:23, 7971-7977
CrossRef389
Pfeffer, Marc A., Burdmann, Emmanuel A., Chen, Chao-Yin, Cooper, Mark E., de Zeeuw, Dick, Eckardt, Kai-Uwe, Feyzi, Jan M., Ivanovich, Peter, Kewalramani, Reshma, Levey, Andrew S., Lewis, Eldrin F., McGill, Janet B., McMurray, John J.V., Parfrey, Patrick, Parving, Hans-Henrik, Remuzzi, Giuseppe, Singh, Ajay K., Solomon, Scott D., Toto, Robert, . (2009) A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. New England Journal of Medicine 361:21, 2019-2032
Full Text390
Suzanne Oparil, James Lee, Sulekha Karki, Michael Melino. (2009) Subgroup Analyses of an Efficacy and Safety Study of Concomitant Administration of Amlodipine Besylate and Olmesartan Medoxomil: Evaluation by Baseline Hypertension Stage and Prior Antihypertensive Medication Use. Journal of Cardiovascular Pharmacology 54:5, 427-436
CrossRef391
Riccardo Candido, Stella Bernardi, Terri J Allen. (2009) Linking diabetes and atherosclerosis. Expert Review of Endocrinology & Metabolism 4:6, 603-624
CrossRef392
Wilbert S. Aronow. (2009) Hypertension in the Elderly. Clinics in Geriatric Medicine 25:4, 579-590
CrossRef393
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Anthony Heagerty, Sverre E Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E Schmieder, Harry AJ Struijker-Boudier, Pieter A van Zwieten, Margus Viigimaa, Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension 27:11, 2121-2158
CrossRef394
Benjamin J Epstein, Mary Ellen Roberts. (2009) Managing Peripheral Edema in Patients With Arterial Hypertension. American Journal of Therapeutics 16:6, 543-553
CrossRef395
Uta Hillebrand, Barbara M. Suwelack, Karsten Loley, Detlef Lang, Stefan Reuter, Susanne Amler, Hermann Pavenstädt, Martin Hausberg, Eckhart Büssemaker. (2009) Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients. Transplant International 22:11, 1073-1080
CrossRef396
Marvin A Konstam, James D Neaton, Kenneth Dickstein, Helmut Drexler, Michel Komajda, Felipe A Martinez, Gunter AJ Riegger, William Malbecq, Ronald D Smith, Soneil Guptha, Philip A Poole-Wilson. (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. The Lancet 374:9704, 1840-1848
CrossRef397
Christine T. Cigolle, Caroline S. Blaum, Jeffrey B. Halter. (2009) Diabetes and Cardiovascular Disease Prevention in Older Adults. Clinics in Geriatric Medicine 25:4, 607-641
CrossRef398
D E Weiner. (2009) Public Health Consequences of Chronic Kidney Disease. Clinical Pharmacology & Therapeutics 86:5, 566-569
CrossRef399
Teemu L Ahola, Antti M Jula, Ilkka M Kantola, Juhani Mäki, Timo Klaukka, Antti Reunanen. (2009) Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult diabetics in Finland. Results from large national database between 2000 and 2006. Journal of Hypertension 27:11, 2283-2293
CrossRef400
Benjamin J Epstein, Steven M Smith, Rushab Choksi. (2009) Recent changes in the landscape of combination RAS blockade. Expert Review of Cardiovascular Therapy 7:11, 1373-1384
CrossRef401
Jan A Krikken, Gozewijn D Laverman, Gerjan Navis. (2009) Benefits of dietary sodium restriction in the management of chronic kidney disease. Current Opinion in Nephrology and Hypertension 18:6, 531-538
CrossRef402
Nisha I. Parikh, Michelle J. Keyes, Martin G. Larson, Karla M. Pou, Naomi M. Hamburg, Joseph A. Vita, Christopher J. O'Donnell, Ramachandran S. Vasan, Gary F. Mitchell, Udo Hoffmann, Caroline S. Fox, Emelia J. Benjamin. (2009) Visceral and Subcutaneous Adiposity and Brachial Artery Vasodilator Function. Obesity 17:11, 2054-2059
CrossRef403
Henry Krum. (2009) Optimising management of chronic heart failure. The Lancet 374:9704, 1808-1809
CrossRef404
Rigas Kalaitzidis, George Bakris. (2009) Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead. The Journal of Clinical Hypertension 11:11, 636-643
CrossRef405
Rigas G. Kalaitzidis, George L. Bakris. (2009) The current state of RAAS blockade in the treatment of hypertension and proteinuria. Current Cardiology Reports 11:6, 436-442
CrossRef406
Wenlu Tang, Gavin WK Wong, Marco I Perez, James M Wright, Wenlu Tang. 2009. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. .
CrossRef407
F. H. Messerli, S. Bangalore, F. Ruschitzka. (2009) Angiotensin receptor blockers: baseline therapy in hypertension?. European Heart Journal 30:20, 2427-2430
CrossRef408
Sheldon W. Tobe, Monica O. Dai. (2009) Outcomes of antiproteinuric RAAS blockade: High-dose compared with dual therapy. Current Hypertension Reports 11:5, 345-353
CrossRef409
Naohiro Yano, Daisuke Suzuki, Masayuki Endoh, Tram N. Cao, John R. Dahdah, Andy Tseng, Joan P. Stabila, Bethany G. McGonnigal, James F. Padbury, Yi
Tang Tseng. (2009) High ambient glucose induces angiotensin-independent AT-1 receptor activation, leading to increases in proliferation and extracellular matrix accumulation in MES-13 mesangial cells. Biochemical Journal 423:1, 129-143
CrossRef410
Tamara Isakova, Orlando M Gutiérrez, Myles Wolf. (2009) A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney International 76:7, 705-716
CrossRef411
Yoshie Sasatomi, Hidetoshi Kaneoka, Yasuhiro Abe, Atunori Ishimura, Satoru Ogahara, Toshiaki Murata, Noriko Uesugi, Shigeo Takebayashi, Hiroshi Iwasaki, Takao Saito. (2009) Anemia and hypertension are risk factors for both renal prognosis and survival in patients with diabetes mellitus. Clinical and Experimental Nephrology 13:5, 473-479
CrossRef412
Jan Basile, Peter P. Toth. (2009) Angiotensin Receptor Blockers: Role in Hypertension Management, Cardiovascular Risk Reduction, and Nephropathy. Southern Medical Journal 102, S1-S12
CrossRef413
Eddie Vos, Colin P. Rose, Pierre Biron. (2009) Blood pressure drugs have no mortality benefit in diabetic patients. Canadian Journal of Cardiology 25:10, 594
CrossRef414
Andrew S. Bomback, Robert Toto. (2009) Dual Blockade of the Renin–Angiotensin–Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. American Journal of Hypertension 22:10, 1032-1040
CrossRef415
Kunal Chaudhary, Ravi Nistala, Adam Whaley-Connell. (2009) Dual renin-angiotensin system blockade in the ONTARGET study: Clinically relevant risk for the kidney?. Current Hypertension Reports 11:5, 375-381
CrossRef416
Suneel M. Udani, Jay L. Koyner. (2009) Effect of blood pressure lowering on markers of kidney disease progression. Current Hypertension Reports 11:5, 368-374
CrossRef417
Mark E Williams. (2009) Diabetic kidney disease in the older adult: an update. Aging Health 5:5, 625-633
CrossRef418
Radica Z. Alicic, Sandeep A. Saha, Robert A. Short, Katherine R. Tuttle. (2009) Should albuminuria be a focus of antihypertensive therapy goals?. Current Hypertension Reports 11:5, 354-362
CrossRef419
M. J. Postma, D. de Zeeuw. (2009) The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus. Nephrology Dialysis Transplantation 24:10, 2975-2983
CrossRef420
Steven Fishbane, Harini Chittineni, Michal Packman, Paula Dutka, Nicole Ali, Nicole Durie. (2009) Oral Paricalcitol in the Treatment of Patients With CKD and Proteinuria: A Randomized Trial. American Journal of Kidney Diseases 54:4, 647-652
CrossRef421
Bernard Waeber, Alejandro de la Sierra, Luis M. Ruilope. (2009) The ADVANCE Trial. American Journal Cardiovascular Drugs 9:5, 283-291
CrossRef422
Bassam G. Abu Jawdeh, Mahboob Rahman. (2009) Blood pressure level and kidney disease progression: Do we really need to go to 130/80 mm Hg?. Current Hypertension Reports 11:5, 363-367
CrossRef423
, D. Koya, M. Haneda, S. Inomata, Y. Suzuki, D. Suzuki, H. Makino, K. Shikata, Y. Murakami, Y. Tomino, K. Yamada, S. I. Araki, A. Kashiwagi, R. Kikkawa. (2009) Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial. Diabetologia 52:10, 2037-2045
CrossRef424
Tadashi Sofue, Hideyasu Kiyomoto. (2009) Angiotensin II receptor blocker is a renoprotective remedy for metabolic syndrome. Hypertension Research 32:9, 735-737
CrossRef425
Lawrence A. Notaro, Mohammed H. Usman, James F. Burke, Aqeel Siddiqui, Keith R. Superdock, Michael D. Ezekowitz. (2009) Secondary Prevention in Concurrent Coronary Artery, Cerebrovascular, and Chronic Kidney Disease: Focus on Pharmacological Therapy. Cardiovascular Therapeutics 27:3, 199-215
CrossRef426
Masanori Abe, Kazuyoshi Okada, Takashi Maruyama, Koichi Matsumoto. (2009) Antiproteinuric and Blood Pressure–Lowering Effects of a Fixed-Dose Combination of Losartan and Hydrochlorothiazide in Hypertensive Patients with Stage 3 Chronic Kidney Disease. Pharmacotherapy 29:9, 1061-1072
CrossRef427
T. Sugiura, A. Wada. (2009) Resistive index predicts renal prognosis in chronic kidney disease. Nephrology Dialysis Transplantation 24:9, 2780-2785
CrossRef428
J. Díez. (2009) Enfoque nefrológico del bloqueo del sistema renina-angiotensina para el tratamiento de la hipertensión. Revista Clínica Española 209, 3-8
CrossRef429
C Venkata S Ram. (2009) Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease. Future Cardiology 5:5, 453-465
CrossRef430
Daisuke Watanabe, Akiyo Tanabe, Mitsuhide Naruse, Shunichi Morikawa, Taichi Ezaki, Kazue Takano. (2009) Renoprotective effects of an angiotensin II receptor blocker in experimental model rats with hypertension and metabolic disorders. Hypertension Research 32:9, 807-815
CrossRef431
NAOTO TOMINAGA, ANNIE ROBERT, YUKO IZUHARA, SHUICHI OHTOMO, TAKASHI DAN, KAZUO CHIHARA, KIYOSHI KUROKAWA, CHARLES VAN YPERSELE DE STRIHOU, TOSHIO MIYATA. (2009) Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model. Nephrology 14:6, 581-587
CrossRef432
Luis M Ruilope, Julian Segura, Toshiro Fujita, Eberhard Ritz. (2009) Renal and cardiovascular events: do they deserve the same consideration in clinical trials?. Journal of Hypertension 27:9, 1743-1745
CrossRef433
Dong-Churl Suh, Chul-Min Kim, In-Sun Choi, Craig A Plauschinat, Joseph A Barone. (2009) Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988–2004. Journal of Hypertension 27:9, 1908-1916
CrossRef434
Sarina van der Zee, Usman Baber, Sammy Elmariah, Jonathan Winston, Valentin Fuster. (2009) Cardiovascular risk factors in patients with chronic kidney disease. Nature Reviews Cardiology 6:9, 580-589
CrossRef435
Rainer Düsing, Felicity Sellers. (2009) ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Current Medical Research and Opinion 25:9, 2287-2301
CrossRef436
Alan H. Gradman. (2009) Role of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Hypertension in Patients Aged ≥65 Years. Drugs & Aging 26:9, 751-767
CrossRef437
Rigas G Kalaitzidis, George L Bakris. (2009) Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?. Current Opinion in Nephrology and Hypertension 18:5, 386-391
CrossRef438
(2009) Journal Club. Kidney International 76:5, 473-474
CrossRef439
Yoshio N. Hall, Rudolph A. Rodriguez, Edward J. Boyko, Glenn M. Chertow, Ann M. O’Hare. (2009) Characteristics of Uninsured Americans with Chronic Kidney Disease. Journal of General Internal Medicine 24:8, 917-922
CrossRef440
C. Venkata S. Ram, Andrew Z. Fenves. (2009) Management of hypertension in hemodialysis patients. Current Hypertension Reports 11:4, 292-298
CrossRef441
Alan S. Maisel. (2009) Cardiovascular and Renal Surrogate Markers in the Clinical Management of Hypertension. Cardiovascular Drugs and Therapy 23:4, 317-326
CrossRef442
Santiago Tofé Povedano, Bernardo García De La Villa. (2009) 24-Hour and Nighttime Blood Pressures in Type 2 Diabetic Hypertensive Patients Following Morning or Evening Administration of Olmesartan. The Journal of Clinical Hypertension 11:8, 426-431
CrossRef443
Andrew S. Levey, Daniel Cattran, Aaron Friedman, W. Greg Miller, John Sedor, Katherine Tuttle, Bertram Kasiske, Thomas Hostetter. (2009) Proteinuria as a Surrogate Outcome in CKD: Report of a Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration. American Journal of Kidney Diseases 54:2, 205-226
CrossRef444
Satoshi Hagiwara, Hideo Iwasaka, Seigo Hidaka, Akira Hasegawa, Hironori Koga, Takayuki Noguchi. (2009) Antagonist of the Type-1 ANG II receptor prevents against LPS-induced septic shock in rats. Intensive Care Medicine 35:8, 1471-1478
CrossRef445
Rigas Kalaitzidis, George Bakris. (2009) Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. Diabetes, Obesity and Metabolism 11:8, 757-769
CrossRef446
Samir N. Shah, Matthew Abramowitz, Thomas H. Hostetter, Michal L. Melamed. (2009) Serum Bicarbonate Levels and the Progression of Kidney Disease: A Cohort Study. American Journal of Kidney Diseases 54:2, 270-277
CrossRef447
Takashi Uzu, Masayoshi Sakaguchi, Yukiyo Yokomaku, Shinji Kume, Masami Kanasaki, Keiji Isshiki, Shin-ichi Araki, Toshiro Sugiomoto, Daisuke Koya, Masakazu Haneda, Atsunori Kashiwagi. (2009) Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker. Clinical and Experimental Nephrology 13:4, 300-306
CrossRef448
Hiroshi Kawachi, Koichi Suzuki, Naoko Miyauchi, Taeko Hashimoto, Yasuhiro Otaki, Fujio Shimizu. (2009) Slit diaphragm dysfunction in proteinuric states: identification of novel therapeutic targets for nephrotic syndrome. Clinical and Experimental Nephrology 13:4, 275-280
CrossRef449
Anthony J. Joseph, Eli A. Friedman. (2009) Diabetic Nephropathy in the Elderly. Clinics in Geriatric Medicine 25:3, 373-389
CrossRef450
Mauer, Michael, Zinman, Bernard, Gardiner, Robert, Suissa, Samy, Sinaiko, Alan, Strand, Trudy, Drummond, Keith, Donnelly, Sandra, Goodyer, Paul, Gubler, Marie Claire, Klein, Ronald, . (2009) Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes. New England Journal of Medicine 361:1, 40-51
Full Text451
Charlotta Ljungman, Lena Mortensen, Thomas Kahan, Karin Manhem. (2009) Treatment of Mild to Moderate Hypertension by Gender Perspective: A Systematic Review. Journal of Women's Health 18:7, 1049-1062
CrossRef452
J M Flack, D A Calhoun, L Satlin, M Barbier, R Hilkert, P Brunel. (2009) Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. Journal of Human Hypertension 23:7, 479-489
CrossRef453
Kathryn J Wiggins, Darren J Kelly. (2009) Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?. Kidney International 76:1, 23-31
CrossRef454
Hans-Henrik Parving, Barry M. Brenner, John J.V. McMurray, Dick de Zeeuw, Steven M. Haffner, Scott D. Solomon, Nish Chaturvedi, Marc A. Pfeffer. (2009) Dual Renin-Angiotensin System Blockade and Kidney Disease. Journal of the American College of Cardiology 54:3, 278-279
CrossRef455
George Jerums, Sianna Panagiotopoulos, Erosha Premaratne, Richard J. MacIsaac. (2009) Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nature Reviews Nephrology 5:7, 397-406
CrossRef456
Siobhan HM Brown, Ahmed H Abdelhafiz. (2009) Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction. Therapy 6:4, 515-529
CrossRef457
Marc A. Pfeffer, Emmanuel A. Burdmann, Chao-Yin Chen, Mark E. Cooper, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Reshma Kewalramani, Andrew S. Levey, Eldrin F. Lewis, Janet McGill, John J.V. McMurray, Patrick Parfrey, Hans-Henrik Parving, Giuseppe Remuzzi, Ajay K. Singh, Scott D. Solomon, Robert Toto, Hajime Uno. (2009) Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases 54:1, 59-69
CrossRef458
Eswari Vilayur, David C. H. Harris. (2009) Emerging therapies for chronic kidney disease: what is their role?. Nature Reviews Nephrology 5:7, 375-383
CrossRef459
R. Schiffmann, D. G. Warnock, M. Banikazemi, J. Bultas, G. E. Linthorst, S. Packman, S. A. Sorensen, W. R. Wilcox, R. J. Desnick. (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrology Dialysis Transplantation 24:7, 2102-2111
CrossRef460
Hisao Ogawa, Shokei Kim-Mitsuyama, Tomio Jinnouchi, Kunihiko Matsui, Kikuo Arakawa. (2009) Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Hypertension Research 32:7, 575-580
CrossRef461
Manikkam Suthanthiran, Linda M Gerber, Joseph E Schwartz, Vijay K Sharma, Mara Medeiros, RoseMerie Marion, Thomas G Pickering, Phyllis August. (2009) Circulating transforming growth factor-β1 levels and the risk for kidney disease in African Americans. Kidney International 76:1, 72-80
CrossRef462
Rigas Kalaitzidis, George L Bakris. (2009) Effects of angiotensin II receptor blockers on diabetic nephropathy. Journal of Hypertension 27:Suppl 5, S15-S21
CrossRef463
Amgad N Makaryus, Samy I McFarlane. (2009) Treatment of hypertension in the diabetic patient. Therapy 6:4, 497-505
CrossRef464
Matthew R. Weir, Raymond Townsend. (2009) Gauging adequacy of cardiovascular disease treatment: importance of estimating glomerular filtration rate and time-varying albuminuria. Journal of the American Society of Hypertension 3:4, 277-285
CrossRef465
J. Susie Woo, Jeffrey L. Probstfield. (2009) The role of ACE inhibitors and angiotensin receptor blockers in the treatment of hypertension and cardiovascular disease. Current Cardiovascular Risk Reports 3:4, 255-263
CrossRef466
Francine Salinitri, Helen Berlie, Neha Desai. (2009) Pharmacotherapeutic Blood Pressure Management in a Chronic Kidney Disease Patient. AACN Advanced Critical Care 20:3, 205-213
CrossRef467
L. L. Guo, Y. Pan, H. M. Jin. (2009) Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrology Dialysis Transplantation 24:6, 1876-1883
CrossRef468
Amir Ravandi, Koon K Teo. (2009) Blocking the renin–angiotensin system: dual- versus mono-therapy. Expert Review of Cardiovascular Therapy 7:6, 667-674
CrossRef469
Gillian M. Keating. (2009) Losartan/Hydrochlorothiazide. Drugs 69:9, 1239-1265
CrossRef470
Amgad N. Makaryus, Philippe Akhrass, Samy I. McFarlane. (2009) Treatment of hypertension in metabolic syndrome: Implications of recent clinical trials. Current Diabetes Reports 9:3, 229-237
CrossRef471
Yu Wang, Luxia Zhang, Xiaomei Li, Yulan Xu, Min Yang, Jiaqi Qian, Lining Wang, Nan Chen, Yong Gu, Mangmang Chen, Changying Xing, Xiangmei Chen, Fanfan Hou, Xueqing Yu, Xiaomiao Cheng, Lanzhong Guo, Chongyi Wei, Guodong Huang, Qing Zhang, Rong Wang, Li Wang, Changlin Mei, Youyun Li, Zhihong Liu, Liancheng Zhao, Yangfeng Wu, Hai Yan Wang. (2009) Improvement of awareness, treatment and control of hypertension among chronic kidney disease patients in China from 1999 to 2005. Hypertension Research 32:6, 444-449
CrossRef472
Hiroyuki Shimizu, Yutaka Uehara, Aya Ohsaki, Shuichi Okada, Masatomo Mori. (2009) Administration time difference of candesartin effect on albuminuria in type 2 diabetic patients. Hypertension Research 32:6, 527-528
CrossRef473
Takao Saruta, Koichi Hayashi, Toshio Ogihara, Kazuwa Nakao, Tsuguya Fukui, Kohshiro Fukiyama. (2009) Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study. Hypertension Research 32:6, 505-512
CrossRef474
Christine Perret-Guillaume, Laure Joly, Piotr Jankowski, Athanase Benetos. (2009) Benefits of the RAS blockade: clinical evidence before the ONTARGET study. Journal of Hypertension 27:Suppl 2, S3-S7
CrossRef475
Massimo Volpe. (2009) The Myth of Janus. High Blood Pressure & Cardiovascular Prevention 16:2, 35-37
CrossRef476
Jan Basile. (2009) New Therapeutic Options in Patients Prone to Hypertension: A Focus on Direct Renin Inhibition and Aldosterone Blockade. The American Journal of the Medical Sciences 337:6, 438-444
CrossRef477
Flávio Danni Fuchs. (2009) Diuretics: still essential drugs for the management of hypertension. Expert Review of Cardiovascular Therapy 7:6, 591-598
CrossRef478
Alejandro de la Sierra. (2009) Main results and clinical interpretations from the TRANSCEND study. Journal of Hypertension 27:Suppl 2, S22-S25
CrossRef479
Kee-Sik Kim, Wei Hu Fan, Young-Dae Kim, Wenling Zhu, Yen Yew Ngau, Peter Tong, Byung-Soo Kim, Maureen Santos, Wei-Hsiang Lin, Peera Buranakitjaroen, Rachid Massaad, Ronald D Smith. (2009) Effectiveness of open-label losartan/hydrochlorothiazide combination therapy in Asian patients with hypertension not controlled with ACE inhibitor or ARB monotherapy. Hypertension Research 32:6, 520-526
CrossRef480
M Mazerska, M Myśliwiec. (2009) Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors. Advances in Medical Sciences 54:1, 37-40
CrossRef481
Onovughakpo-Sakpa O. Ejuogha, Onyeneke E. Chukwu, Olumese E. Fidelis. (2009) Incidence of Diabetic Nephropathy in Southern Nigeria. Journal of Medical Sciences(Faisalabad) 9:6, 264-269
CrossRef482
Keita Inanaga, Toshihiro Ichiki, Hirohide Matsuura, Ryohei Miyazaki, Toru Hashimoto, Kotaro Takeda, Kenji Sunagawa. (2009) Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis. Hypertension Research 32:6, 466-471
CrossRef483
Sai Prasad Sahoo, Sandeep Mandal, Sanjiv Jasuja. (2009) Diabetic Nephropathy: Prevention and Management. Apollo Medicine 6:2, 105-108
CrossRef484
Norman R.C. Campbell, Lawrence A. Leiter, Pierre Larochelle, Sheldon Tobe, Arun Chockalingam, Richard Ward, Dorothy Morris, Ross Tsuyuki. (2009) Hypertension in diabetes: A call to action. Canadian Journal of Cardiology 25:5, 299-302
CrossRef485
H.-H. Parving, B. M. Brenner, John. J. V. McMurray, D. de Zeeuw, S. M. Haffner, S. D. Solomon, N. Chaturvedi, M. Ghadanfar, N. Weissbach, Z. Xiang, J. Armbrecht, M. A. Pfeffer. (2009) Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology Dialysis Transplantation 24:5, 1663-1671
CrossRef486
D. Goldsmith. (2009) Tratamiento de la dislipemia y la diabetes mellitus en pacientes con enfermedad renal crónica. Evidencias e implicaciones. Medicina Clínica 132, 27-32
CrossRef487
Xiaoling Hu, Yuanting Zheng, Jianguo Sun, Lili Shang, Guangji Wang, Haitao Zhang. (2009) Simultaneous Quantification of Benazepril, Gliclazide and Valsartan in Human Plasma by LC–MS–MS and Application for Rapidly Measuring Protein Binding Interaction between Rhein and These Three Drugs. Chromatographia 69:9-10, 843-852
CrossRef488
Eugene A. Magee, James P. Lash. (2009) Aliskiren: An Overview of the First Direct Renin Inhibitor. Kidney 18:3, 117-120
CrossRef489
Nigel A. Calcutt, Mark E. Cooper, Tim S. Kern, Ann Marie Schmidt. (2009) Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nature Reviews Drug Discovery 8:5, 417-430
CrossRef490
Massimo Volpe, Giuliano Tocci, Sebastiano Sciarretta, Paolo Verdecchia, Bruno Trimarco, Giuseppe Mancia. (2009) Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. Journal of Hypertension 27:5, 941-946
CrossRef491
Norman R.C. Campbell, Nadia A. Khan, Michael D. Hill, Guy Tremblay, Marcel Lebel, Janusz Kaczorowski, Finlay A. McAlister, Richard Z. Lewanczuk, Sheldon Tobe. (2009) 2009 Canadian Hypertension Education Program recommendations: The scientific summary – an annual update. Canadian Journal of Cardiology 25:5, 271-277
CrossRef492
Maura Ravera, Michela Re, Ursula Weiss, Rossella Cannavoʼ, Luca Deferrari, Giacomo Deferrari. (2009) Cardiovascular Risk in Hypertensive Patients with Renal Dysfunction. High Blood Pressure & Cardiovascular Prevention 16:1, 13-20
CrossRef493
Alberto Zanchetti, Guido Grassi, Giuseppe Mancia. (2009) When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. Journal of Hypertension 27:5, 923-934
CrossRef494
R. Marín, M. Gorostidi, R. Álvarez-Navascués, S. García-Melendreras. (2009) Tratamiento de la hipertensión arterial en pacientes con enfermedad renal crónica. Evidencias e implicaciones. Medicina Clínica 132, 20-26
CrossRef495
Antonio Hormigo Pozo, María Ángeles Viciana López, Leonor Gómez Jiménez, María Dolores Gallego Parrilla, Javier Orellana Lozano, José Miguel Morales Asencio. (2009) Mejora de la efectividad en el manejo del riesgo cardiovascular de pacientes diabéticos tipo 2 en atención primaria. Atención Primaria 41:5, 240-245
CrossRef496
Diana Rucker, Marcello Tonelli. (2009) Cardiovascular risk and management in chronic kidney disease. Nature Reviews Nephrology 5:5, 287-296
CrossRef497
Maha A. Mohamed, Matthew R. Weir. (2009) Renin Angiotensin System Inhibition in the Older Person: A Review. Clinics in Geriatric Medicine 25:2, 245-257
CrossRef498
Pedro Armario, Raquel Hernández Del Rey, Anna Oliveras. (2009) Papel actual de los antagonistas de los receptores de la angiotensina II y de sus combinaciones en el tratamiento de la hipertensión arterial. Medicina Clínica 132:20, 792-796
CrossRef499
G. Y. Oudit, Y. Imai, K. Kuba, J. W. Scholey, J. M. Penninger. (2009) The role of ACE2 in pulmonary diseases--relevance for the nephrologist. Nephrology Dialysis Transplantation 24:5, 1362-1365
CrossRef500
Luis M Ruilope, Julian Segura. (2009) Kidney protection: a key target in the management of patients with diabetes. Journal of Hypertension 27:Suppl 1, S15-S18
CrossRef501
Pablo Lapuerta, Stanley Franklin. (2009) The Risks and Benefits of Initial Irbesartan/Hydrochlorothiazide Combination Therapy in Patients With Severe Hypertension. The Journal of Clinical Hypertension 11:5, 277-283
CrossRef502
Jean-Jacques Mourad, Sylvain Le Jeune. (2009) Heart protection: a key target in the management of patients with diabetes. Journal of Hypertension 27:Suppl 1, S9-S13
CrossRef503
Giuseppe Mancia, Guido Grassi. (2009) Protection of patients with diabetes, with or without hypertension: implications of ADVANCE for clinical practice. Journal of Hypertension 27:Suppl 1, S19-S23
CrossRef504
Nitin Khosla, Rigas Kalaitzidis, George L. Bakris. (2009) The Kidney, Hypertension, and Remaining Challenges. Medical Clinics of North America 93:3, 697-715
CrossRef505
Ramiro A Sanchez, Miryam Ayala, Hugo Baglivo, Carlos Velazquez, Guillermo Burlando, Oswaldo Kohlmann, Jorge Jimenez, Patricio López Jaramillo, Ayrton Brandao, Gloria Valdes, Luis Alcocer, Mario Bendersky, Agustín José Ramirez, Alberto Zanchetti. (2009) Latin American guidelines on hypertension*. Journal of Hypertension 27:5, 905-922
CrossRef506
Yong Jian Yang, Cheng Cheng Li, Yan Yang, Jin Hui Tian, Ke Hu Yang, Yong Jian Yang. 2009. Probucol for type 2 diabetes mellitus. .
CrossRef507
Sankar D Navaneethan, Francesca Pansini, Vlado Perkovic, Carlo Manno, Fabio Pellegrini, David W Johnson, Jonathan C Craig, Giovanni FM Strippoli, Sankar D Navaneethan. 2009. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. .
CrossRef508
Jun Iwanami, Masaki Mogi, Masaru Iwai, Masatsugu Horiuchi. (2009) Inhibition of the renin–angiotensin system and target organ protection. Hypertension Research 32:4, 229-237
CrossRef509
S. T. Knudsen, E. Laugesen, K. W. Hansen, T. Bek, C. E. Mogensen, P. L. Poulsen. (2009) Ambulatory pulse pressure, decreased nocturnal blood pressure reduction and progression of nephropathy in type 2 diabetic patients. Diabetologia 52:4, 698-704
CrossRef510
K.H. Rahn. (2009) Leitliniengerechte Differenzialtherapie der Hypertonie. Der Internist 50:4, 433-441
CrossRef511
Paolo Cravedi, Piero Ruggenenti, Giuseppe Remuzzi. (2009) Intensified inhibition of renin-angiotensin system: A way to improve renal protection?. Current Hypertension Reports 11:2, 118-124
CrossRef512
G. Bönner, W. Smolka, C. Jung, K. Bestehorn. (2009) Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: obser-vational, prospective study in primary care. Current Medical Research and Opinion 25:4, 981-990
CrossRef513
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, e1-e90
CrossRef514
Robert M. Perkins, Matthew C. Aboudara, Alice L. Uy, Stephen W. Olson, Howard M. Cushner, Christina M. Yuan. (2009) Effect of Pentoxifylline on GFR Decline in CKD: A Pilot, Double-Blind, Randomized, Placebo-Controlled Trial. American Journal of Kidney Diseases 53:4, 606-616
CrossRef515
I. Quack, L.C. Rump. (2009) Niere und Hypertonie. Der Internist 50:4, 410-422
CrossRef516
Varun Agrawal, Victor Marinescu, Mohit Agarwal, Peter A. McCullough. (2009) Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. Nature Reviews Cardiology 6:4, 301-311
CrossRef517
Steven D. Crowley, Matthew P. Vasievich, Phillip Ruiz, Samantha K. Gould, Kelly K. Parsons, A. Kathy Pazmino, Carie Facemire, Benny J. Chen, Hyung-Suk Kim, Trinh T. Tran, David S. Pisetsky, Laura Barisoni, Minolfa C. Prieto-Carrasquero, Marie Jeansson, Mary H. Foster, Thomas M. Coffman. (2009) Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. Journal of Clinical Investigation
CrossRef518
M. Dalla Vestra, N. Simioni, A. Masiero. (2009) Renal effects of dual renin–angiotensin–aldosterone system blockade in patients with diabetic nephropathy. International Urology and Nephrology 41:1, 119-126
CrossRef519
Carla Sueta Dupree. (2009) Primary prevention of heart failure: what is the evidence?. Current Opinion in Cardiology 24:2, 142-147
CrossRef520
Betina T. Blak, C. Daniel Mullins, Fadia T. Shaya, Linda Simoni-Wastila, Catherine E. Cooke, Matthew R. Weir. (2009) Prescribing Trends and Drug Budget Impact of the ARBs in the UK. Value in Health 12:2, 302-308
CrossRef521
Allan J. Collins, Joseph A. Vassalotti, Changchun Wang, Suying Li, David T. Gilbertson, Jiannong Liu, Robert N. Foley, Shu-Cheng Chen, Thomas J. Arneson. (2009) Who Should Be Targeted for CKD Screening? Impact of Diabetes, Hypertension, and Cardiovascular Disease. American Journal of Kidney Diseases 53:3, S71-S77
CrossRef522
Shivaram Hegde, Malcolm G. Coulthard. (2009) Renal agenesis and unilateral nephrectomy: what are the risks of living with a single kidney?. Pediatric Nephrology 24:3, 439-446
CrossRef523
Ravi Nistala, Yongzhong Wei, James R. Sowers, Adam Whaley-Connell. (2009) Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease. Translational Research 153:3, 102-113
CrossRef524
Michael Rudnicki, Gert Mayer. (2009) Significance of genetic polymorphisms of the renin–angiotensin–aldosterone system in cardiovascular and renal disease. Pharmacogenomics 10:3, 463-476
CrossRef525
Hae-Young Lee, Byung-Hee Oh. (2009) Cardio–renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program. Expert Review of Cardiovascular Therapy 7:3, 251-257
CrossRef526
Apurv Khanna, William B. White. (2009) The Management of Hyperkalemia in Patients with Cardiovascular Disease. The American Journal of Medicine 122:3, 215-221
CrossRef527
Ann Albright, Nilka Ríos Burrows, Regina Jordan, Desmond E. Williams. (2009) The Kidney Disease Initiative and the Division of Diabetes Translation at the Centers for Disease Control and Prevention. American Journal of Kidney Diseases 53:3, S121-S125
CrossRef528
G. Dreyer, S. Hull, Z. Aitken, A. Chesser, M.M. Yaqoob. (2009) The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease. QJM 102:4, 261-269
CrossRef529
Takashige Kuwabara, Kiyoshi Mori, Masashi Mukoyama, Masato Kasahara, Hideki Yokoi, Yoko Saito, Tetsuro Yoshioka, Yoshihisa Ogawa, Hirotaka Imamaki, Toru Kusakabe, Ken Ebihara, Mitsugu Omata, Noriko Satoh, Akira Sugawara, Jonathan Barasch, Kazuwa Nakao. (2009) Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney International 75:3, 285-294
CrossRef530
S. Charriere, N. Rognant, F. Chiche, A. Cremer, G. Deray, M. Priou. (2009) Insuffisance rénale chronique et maladie cardiovasculaire. Annales de Cardiologie et d'Angéiologie 58:1, 40-52
CrossRef531
Murray Epstein. (2009) Hyperkalemia as a Constraint to Therapy With Combination Renin-Angiotensin System Blockade: The Elephant in the Room. The Journal of Clinical Hypertension 11:2, 55-60
CrossRef532
Ryuzo Kawamori, Toshiro Fujita, Hiroaki Matsuoka, Satoshi Umemura, Yasushi Saito. (2009) Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study. Diabetes Research and Clinical Practice 83:2, 241-248
CrossRef533
Daniel M. Riche, Deborah S. Minor, Amber S. Holdiness, Honey E. East. (2009) An Issue of Dependence: Implications From the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) Trial. The Journal of Clinical Hypertension 11:2, 89-93
CrossRef534
Duncan J. Campbell. (2009) Angiotensin vaccination: What is the prospect of success?. Current Hypertension Reports 11:1, 63-68
CrossRef535
Qi Jiang. (2009) Nonproportional Hazards and the Power of Sequential Trials. Statistics in Biopharmaceutical Research 1:1, 66-73
CrossRef536
Juan Carlos Q Velez. (2009) The importance of the intrarenal renin–angiotensin system. Nature Clinical Practice Nephrology 5:2, 89-100
CrossRef537
Erkan Sengul, Tayfun Sahin, Erce Sevin, Ahmet Yilmaz. (2009) Effect of Spironolactone on Urinary Protein Excretion in Patients with Chronic Kidney Disease. Renal Failure 31:10, 928-932
CrossRef538
Katherine R Tuttle. (2009) Could renin inhibition be the next step forward in the treatment of diabetic kidney disease?. Nature Clinical Practice Endocrinology & Metabolism 5:1, 20-21
CrossRef539
Kihito TAKAHASHI. (2009) Multi-National Clinical Trial in Circulatory Disorders. YAKUGAKU ZASSHI 129:2, 237-240
CrossRef540
Shu Meguro, Toshikatsu Shigihara, Yusuke Kabeya, Masuomi Tomita, Yoshihito Atsumi. (2009) Increased Risk of Renal Deterioration Associated with Low e-GFR in Type 2 Diabetes Mellitus Only in Albuminuric Subjects. Internal Medicine 48:9, 657-663
CrossRef541
Gautham Ravipati, Wilbert S Aronow, Chul Ahn, Rose M Alappat, John A McClung, Melvin B Weiss. (2009) Incidence of New Stroke or New Myocardial Infarction or Death at 39-Month Follow Up in Patients With Diabetes Mellitus, Hypertension, or Both Treated With and Without Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. American Journal of Therapeutics 16:1, 2-4
CrossRef542
H. F. McIntyre. (2009) Hypertension strategies in the third millennium: conservatism, evidence and the folly of speculation. International Journal of Clinical Practice 63:1, 7-14
CrossRef543
Leo Deelman, Kumar Sharma. (2009) Mechanisms of kidney fibrosis and the role of antifibrotic therapies. Current Opinion in Nephrology and Hypertension 18:1, 85-90
CrossRef544
Kathy Berra, Nancy Houston Miller. (2009) Inhibiting the renin-angiotensin system: Why and in which patients. Journal of the American Academy of Nurse Practitioners 21:1, 66-75
CrossRef545
Hiroki Ikeda, Yoshiyuki Hamamoto, Sachiko Honjo, Koichiro Nabe, Yoshiharu Wada, Hiroyuki Koshiyama. (2009) Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes Research and Clinical Practice 83:1, 117-118
CrossRef546
Aihua Deng, Tong Tang, Prabhleen Singh, Chen Wang, Joe Satriano, Scott C Thomson, Roland C Blantz. (2009) Regulation of oxygen utilization by angiotensin II in chronic kidney disease. Kidney International 75:2, 197-204
CrossRef547
Kensuke Asaba, Akihiro Tojo, Maristela Lika Onozato, Satoshi Kinugasa, Hiroki Miyazaki, Kazuhisa Miyashita, Yoshio Uehara, Yasunobu Hirata, Kenjiro Kimura, Atsuo Goto, Masao Omata, Toshiro Fujita. (2009) Long-term Renal Prognosis of IgA Nephropathy with Therapeutic Trend Shifts. Internal Medicine 48:11, 883-890
CrossRef548
Tae-Sun Ha. (2009) Diabetic Nephropathy in Childhood and Adolescence (II) ; Pathology and Pathophysiology. Journal of the Korean Society of Pediatric Nephrology 13:2, 99
CrossRef549
Shin-ichiro Miura, Keijiro Saku. (2009) Do Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Have Similar Effects in the Improvement of Left Ventricular Dysfunction after Myocardial Infarction in Japanese?. Internal Medicine 48:22, 1929-1930
CrossRef550
Wilbert S. Aronow. (2009) Treating Hypertension in Older Adults. Drug Safety 32:2, 111-118
CrossRef551
Yong Kyun Kim, Jung Eun Lee, Yoon Goo Kim, Dae Joong Kim, Ha-Young Oh, Chul Woo Yang, Kwang-Won Kim, Wooseong Huh. (2009) Cardiac Autonomic Neuropathy as a Predictor of Deterioration of the Renal Function in Normoalbuminuric, Normotensive Patients with Type 2 Diabetes Mellitus. Journal of Korean Medical Science 24:Suppl 1, S69
CrossRef552
Tsuyoshi Tsujimura, Jun Nagamine, Eiji Sugaru, Michiko Ono-Kishino, Teruhisa Tokunaga, Makoto Kitoh, Ryu Nagata, Tsutomu Nakagawa, Mutsuo Taiji. (2009) Combination Therapy with SMP-534 and an Angiotensin-Converting Enzyme Inhibitor Provides Additional Renoprotection in 5/6 Nephrectomized Rats. Biological & Pharmaceutical Bulletin 32:12, 1991-1996
CrossRef553
L. Michael PrisantMD. (2009) Target-organ protection with combination renin-angiotensin-system blockade. Clinical Cardiology 32:1, 4-12
CrossRef554
Markus Flesch, Stephan Knipp, Gerhard Kessler, Hans-Joachim Geissler, Parwis Massoudy, Hans Wilhelm, Thomas Philipp, Erland Erdmann. (2009) ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting. Clinical Research in Cardiology 98:1, 33-43
CrossRef555
S S Franklin, J M Neutel. (2009) Initial combination therapy for rapid and effective control of moderate and severe hypertension. Journal of Human Hypertension 23:1, 4-11
CrossRef556
Philip R. Liebson, Ezra A. Amsterdam. (2009) Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): Implications for Reduced Cardiovascular Risk. Preventive Cardiology 12:1, 43-50
CrossRef557
Mohamed G. Atta, Kesha Baptiste-Roberts, Frederick L. Brancati, Tiffany L. Gary. (2009) The Natural Course of Microalbuminuria among African Americans with Type 2 Diabetes: A 3-Year Study. The American Journal of Medicine 122:1, 62-72
CrossRef558
Domenic A. Sica. 2009. Renin–Angiotensin Blockade: Therapeutic Agents. , 189-201.
CrossRef559
John C. Alexander, Daniel E. Salazar. 2009. Modern Drug Discovery and Development. , 361-380.
CrossRef560
Jason G. Umans, Edgardo J. Abalos, Marshall D. Lindheimer. 2009. Antihypertensive Treatment. , 369-387.
CrossRef561
Roberto Ferrari. (2008) Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. Current Medical Research and Opinion 24:12, 3543-3557
CrossRef562
Emma S. Jones, Antony Vinh, Claudia A. McCarthy, Tracey A. Gaspari, Robert E. Widdop. (2008) AT2 receptors: Functional relevance in cardiovascular disease. Pharmacology & Therapeutics 120:3, 292-316
CrossRef563
Heather N Reich, Gavin Y Oudit, Josef M Penninger, James W Scholey, Andrew M Herzenberg. (2008) Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney International 74:12, 1610-1616
CrossRef564
Kostas C. Siamopoulos, Rigas G. Kalaitzidis. (2008) Inhibition of the renin–angiotensin system and chronic kidney disease. International Urology and Nephrology 40:4, 1015-1025
CrossRef565
Christopher D. Lang, Rohit R. Arora, Sandeep A. Saha, Janos Molnar. (2008) Bayesian Meta-Analysis of Tissue Angiotensin-Converting Enzyme Inhibitors for Reduction of Adverse Cardiovascular Events in Patients with Diabetes Mellitus and Preserved Left Ventricular Function. Journal of the CardioMetabolic Syndrome 3:1, 45-52
CrossRef566
Christopher S. Vaccari, Syed T. Rahman, Qamar A. Khan, Faiz A. Cheema, Bobby V. Khan. (2008) Effects of Angiotensin-Converting Enzyme Inhibitor Therapy on Levels of Inflammatory Markers in Response to Exercise-Induced Stress: Studies in the Metabolic Syndrome. Journal of the CardioMetabolic Syndrome 3:1, 12-17
CrossRef567
Ravi Nistala, Adam Whaley-Connell, James R. Sowers. (2008) Redox Control of Renal Function and Hypertension. Antioxidants & Redox Signaling 10:12, 2047-2089
CrossRef568
Meda E. Pavkov, William C. Knowler, Robert L. Hanson, Robert G. Nelson. (2008) Diabetic nephropathy in American Indians, with a special emphasis on the pima Indians. Current Diabetes Reports 8:6, 486-493
CrossRef569
Jose A. Silva. (2008) Evaluation and approach to treatment of renal artery stenosis in patients with diabetic nephropathy. Current Diabetes Reports 8:6, 494-498
CrossRef570
B. Radbill, B. Murphy, D. LeRoith. (2008) Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease. Mayo Clinic Proceedings 83:12, 1373-1381
CrossRef571
Zainab Samad, Tracy Y. Wang, Camille G. Frazier, Svati H. Shah, Rowena J. Dolor, L Kristin Newby. (2008) Closing the Gap. Cardiology in Review 16:6, 305-313
CrossRef572
James E Novak, Jula K Inrig, Uptal D Patel, Robert M Califf, Lynda A Szczech. (2008) Negative trials in nephrology: what can we learn?. Kidney International 74:9, 1121-1127
CrossRef573
Robert G. Nelson, Meda E. Pavkov, Robert L. Hanson, William C. Knowler. (2008) Changing course of diabetic nephropathy in the Pima Indians. Diabetes Research and Clinical Practice 82, S10-S14
CrossRef574
William J. Elliott, Richard H. Grimm Jr. (2008) Using Diuretics in Practice-One Opinion. The Journal of Clinical Hypertension 10:11, 856-862
CrossRef575
Katherine R. Tuttle. (2008) Protein kinase C-β inhibition for diabetic kidney disease. Diabetes Research and Clinical Practice 82, S70-S74
CrossRef576
G. Jerums, E. Premaratne, S. Panagiotopoulos, S. Clarke, D.A. Power, R.J. MacIsaac. (2008) New and old markers of progression of diabetic nephropathy. Diabetes Research and Clinical Practice 82, S30-S37
CrossRef577
Natasha J McIntyre, Maarten W Taal. (2008) How to measure proteinuria?. Current Opinion in Nephrology and Hypertension 17:6, 600-603
CrossRef578
Karen A. Griffin, Anil K. Bidani. (2008) Potential risks of calcium channel blockers in chronic kidney disease. Current Cardiology Reports 10:6, 448-455
CrossRef579
Norberto Perico, Ariela Benigni, Giuseppe Remuzzi. (2008) Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nature Reviews Drug Discovery 7:11, 936-953
CrossRef580
Steven D. Crowley, Thomas M. Coffman. (2008) In hypertension, the kidney breaks your heart. Current Cardiology Reports 10:6, 470-476
CrossRef581
Henry R. Black, Drew Griffin Levy, Nora Crikelair, Ricardo Rocha. (2008) Predicting age- and dose-related responses to antihypertensive therapy: pooled analysis of two randomized clinical trials of valsartan alone and combined with hydrochlorothiazide. Journal of the American Society of Hypertension 2:6, 476-483
CrossRef582
José R. González-Juanatey, Lilian Grigorian-Shamagian, María A. Juiz-Crespo, Manuel Sánchez-Loureiro, Esperanza Rodríguez-Moldes, Jaime Dopico-Pita, Genaro Gutiérrez-Fernández, Jorge Torres-Colomer, Rubén Blanco-Rodríguez, Fernando Otero-Raviña. (2008) Impacto pronóstico de la localización de la enfermedad aterosclerosa previa en pacientes diabéticos. Estudio Barbanza-diabetes. Revista Española de Cardiología 61:11, 1168-1177
CrossRef583
Andrea Luk, Juliana C.N. Chan. (2008) Diabetic nephropathy—What are the unmet needs?. Diabetes Research and Clinical Practice 82, S15-S20
CrossRef584
Z. Zhang, Y. Zhang, G. Ning, D. K. Deb, J. Kong, Y. C. Li. (2008) Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase. Proceedings of the National Academy of Sciences 105:41, 15896-15901
CrossRef585
N. Thilly, S. Boini, M. Kessler, S. Briancon, L. Frimat. (2008) Management and control of hypertension and proteinuria in patients with advanced chronic kidney disease under nephrologist care or not: data from the AVENIR study (AVantagE de la Nephroprotection dans l'Insuffisance Renale). Nephrology Dialysis Transplantation 24:3, 934-939
CrossRef586
Adeera Levin, Ognjenka Djurdjev, Monica Beaulieu, Lee Er. (2008) Variability and Risk Factors for Kidney Disease Progression and Death Following Attainment of Stage 4 CKD in a Referred Cohort. American Journal of Kidney Diseases 52:4, 661-671
CrossRef587
Teresa M Seccia, Carmen Maniero, Anna S Belloni, Diego Guidolin, Pothen Poulose, Achille C Pessina, Gian Paolo Rossi. (2008) Role of angiotensin II, endothelin-1 and L-type calcium channel in the development of glomerular, tubulointerstitial and perivascular fibrosis. Journal of Hypertension 26:10, 2022-2029
CrossRef588
Anne Katrin Sjølie, Ronald Klein, Massimo Porta, Trevor Orchard, John Fuller, Hans Henrik Parving, Rudy Bilous, Nish Chaturvedi. (2008) Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. The Lancet 372:9647, 1385-1393
CrossRef589
Monica Cortinovis, Dario Cattaneo, Norberto Perico, Giuseppe Remuzzi. (2008) Investigational drugs for diabetic nephropathy. Expert Opinion on Investigational Drugs 17:10, 1487-1500
CrossRef590
Takuo Hirota, Eiji Suzuki, Isamu Ito, Masami Ishiyama, Shinobu Goto, Yukio Horikawa, Takahiko Asano, Masayuki Kanematsu, Hiroaki Hoshi, Jun Takeda. (2008) Coronary artery calcification, arterial stiffness and renal insufficiency associate with serum levels of tumor necrosis factor-alpha in Japanese type 2 diabetic patients. Diabetes Research and Clinical Practice 82:1, 58-65
CrossRef591
Keith C Norris, Naureen Tareen, David Martins, Nosratola D Vaziri. (2008) Implications of ethnicity for the treatment of hypertensive kidney disease, with an emphasis on African Americans. Nature Clinical Practice Nephrology 4:10, 538-549
CrossRef592
Domenic A. Sica. (2008) Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure?. Current Hypertension Reports 10:5, 415-420
CrossRef593
M. Angelyn Bethel, Rury Holman, Steven M. Haffner, Robert M. Califf, Alice Huntsman-Labed, Tsushung A. Hua, John McMurray. (2008) Determining the most appropriate components for a composite clinical trial outcome. American Heart Journal 156:4, 633-640
CrossRef594
M. Sánchez Ledesma, I. Cruz González, M.L. Pérez García, A.J. Plata Izquierdo, Á. Sánchez Rodríguez. (2008) Complicaciones macrovasculares del paciente diabético. Pie diabético. Medicine - Programa de Formación Médica Continuada Acreditado 10:17, 1110-1124
CrossRef595
Toshio Ogihara, Akira Fujimoto, Kazuwa Nakao, Takao Saruta. (2008) ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Review of Cardiovascular Therapy 6:9, 1195-1201
CrossRef596
Ning-L. Sun, Jun-R. Zhu, Yanxing Zhao, Ying-M. Tu. (2008) Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension. Current Medical Research and Opinion 24:10, 2863-2871
CrossRef597
SUPRIYA MADDIRALA, AKRAM KHAN, ANDREA VINCENT, KAI LAU. (2008) Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Serum Potassium Levels and Renal Function in Ambulatory Outpatients: Risk Factors Analysis. The American Journal of the Medical Sciences 336:4, 330-335
CrossRef598
Robert D. Toto, Min Tian, Kaffa Fakouhi, Annette Champion, Peter Bacher. (2008) Effects of Calcium Channel Blockers on Proteinuria in Patients With Diabetic Nephropathy. The Journal of Clinical Hypertension 10:10, 761-769
CrossRef599
M.A.C. Onuigbo. (2008) Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ontarget--a call for more circumspection. QJM 102:3, 155-167
CrossRef600
Yukari Kamijima, Nobuhiro Ooba, Mitsunori Yagame, Kazuo Samizo, Yoshihiro Shimodozono, Shigeru Kageyama, Shingo Horiguchi, Ryozo Nagai, Tadashi Kusunoki, Kiyoshi Kubota. (2008) Hypertension management in diabetic patients: prescribing trends from 1999 to 2005 in three Japanese university hospitals. Pharmacoepidemiology and Drug Safety 17:9, 904-911
CrossRef601
Philip R. Liebson. (2008) Diabetes Control and Cardiovascular Risk: ACCORD, ADVANCE, AVOID, and SANDS. Preventive Cardiology 11:4, 230-236
CrossRef602
Mark Greathouse. (2008) Olmesartan medoxomil-based therapy for the management of hypertension. Expert Review of Clinical Pharmacology 1:5, 593-604
CrossRef603
Robert D. Toto. (2008) Improving Outcomes in Hemodialysis Patients: The Need for Well-Designed Clinical Trials. American Journal of Kidney Diseases 52:3, 400-402
CrossRef604
Thai Nguyen, Robert D. Toto. (2008) Slowing chronic kidney disease progression: results of prospective clinical trials in adults. Pediatric Nephrology 23:9, 1409-1422
CrossRef605
Daniel Sacristán, María Marques, José J Zamorano-León, Manuel Luque, Juan Armengol, Juan del Castillo, Javier Martín, Eva Delpón, Priscila Ramos-Mozo, Teresa P de Prada, Juan Tamargo, Alberto Barrientos, Carlos Macaya, Antonio López-Farré. (2008) Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients. PROTEOMICS - CLINICAL APPLICATIONS 2:9, 1300-1312
CrossRef606
Helmy Siragy, Jiqian Huang, David C Lieb. (2008) The development of the direct renin inhibitor aliskiren: treating hypertension and beyond. Expert Opinion on Emerging Drugs 13:3, 417-430
CrossRef607
Hiroyuki Kobori, Naro Ohashi, Akemi Katsurada, Kayoko Miyata, Ryousuke Satou, Toshie Saito, Tatsuo Yamamoto. (2008) Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. Journal of the American Society of Hypertension 2:5, 349-354
CrossRef608
M. Volpe, G. Tocci. (2008) Managing hypertension in cardiology practice according to risk profile. International Journal of Clinical Practice 62:9, 1403-1412
CrossRef609
Fasika M. Tedla, Eli A. Friedman. (2008) The Trend Toward Geriatric Nephrology. Primary Care: Clinics in Office Practice 35:3, 515-530
CrossRef610
Wilbert S. Aronow. (2008) Hypertension in the Nursing Home. Journal of the American Medical Directors Association 9:7, 486-490
CrossRef611
Brendan B. McCormick, Amy Sydor, Ayub Akbari, Dean Fergusson, Steve Doucette, Greg Knoll. (2008) The Effect of Pentoxifylline on Proteinuria in Diabetic Kidney Disease: A Meta-analysis. American Journal of Kidney Diseases 52:3, 454-463
CrossRef612
Irena Duka, George Bakris. (2008) Influence of microalbuminuria in achieving blood pressure goals. Current Opinion in Nephrology and Hypertension 17:5, 457-463
CrossRef613
Su-Yen Goh, Mariusz Jasik, Mark E Cooper. (2008) Agents in development for the treatment of diabetic nephropathy. Expert Opinion on Emerging Drugs 13:3, 447-463
CrossRef614
Faiez Zannad. (2008) Applications de lʼétude ADVANCE en pratique clinique. Journal of Hypertension 26:Suppl 3, S31-S34
CrossRef615
Caroline Sirois, Paul Poirier, Jocelyne Moisan, Jean-Pierre Grégoire. (2008) The benefit of aspirin therapy in type 2 diabetes: What is the evidence?. International Journal of Cardiology 129:2, 172-179
CrossRef616
Alain Cohen-Solal, Florence Beauvais, Damien Logeart. (2008) Heart Failure and Diabetes Mellitus: Epidemiology and Management of an Alarming Association. Journal of Cardiac Failure 14:7, 615-625
CrossRef617
Shuei-Liong Lin, Yung-Ming Chen, Wen-Chih Chiang, Kwan-Dun Wu, Tun-Jun Tsai. (2008) Effect of Pentoxifylline in Addition to Losartan on Proteinuria and GFR in CKD: A 12-Month Randomized Trial. American Journal of Kidney Diseases 52:3, 464-474
CrossRef618
SHUICHI OHTOMO, MASAKI ITO, YUKO IZUHARA, CHARLES VAN YPERSELE DE STRIHOU, TOSHIO MIYATA. (2008) Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: Evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model. Nephrology 13:6, 517-521
CrossRef619
John Chalmers, Rohina Joshi, Andre Pascal Kengne, Toshiharu Ninomiya, Yufang Bi, Severine Bompoint, Laurent Billot, Anushka Patel. (2008) Efficacité et tolérance de lʼassociation fixe perindopril / indapamide dans le diabète de type 2: résultats de lʼétude ADVANCE. Journal of Hypertension 26:Suppl 3, S23-S30
CrossRef620
P. Verdecchia, F. Angeli, C. Cavallini, R. Gattobigio, G. Gentile, J. A. Staessen, G. Reboldi. (2008) Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. European Heart Journal 30:6, 679-688
CrossRef621
I. Kolesnyk, M. Noordzij, F. W. Dekker, E. W. Boeschoten, R. T. Krediet. (2008) A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrology Dialysis Transplantation 24:1, 272-277
CrossRef622
Helmy M. Siragy. (2008) ADVANCE in management of vascular complications of diabetes. Current Hypertension Reports 10:4, 255-257
CrossRef623
Yoshifuru Tamura, Masahiro Kosuga, Masahiro Yamashita, Satoru Tomioka, Michiko Sasaki, Tomoyuki Hikita, Hideaki Nakajima, Kenichiro Kojima, Shunya Uchida. (2008) Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4–5 chronic kidney disease. Clinical and Experimental Nephrology 12:4, 256-263
CrossRef624
Pantelis A. Sarafidis, Panagiotis C. Stafylas, Aggeliki I. Kanaki, Anastasios N. Lasaridis. (2008) Effects of Renin–Angiotensin System Blockers on Renal Outcomes and All-cause Mortality in Patients With Diabetic Nephropathy: An Updated Meta-analysis. American Journal of Hypertension 21:8, 922-929
CrossRef625
Helmy M. Siragy. (2008) Evidence for benefits of angiotensin receptor blockade beyond blood pressure control. Current Hypertension Reports 10:4, 261-267
CrossRef626
Kellie Hunter Campbell, Ann M OʼHare. (2008) Kidney disease in the elderly: update on recent literature. Current Opinion in Internal Medicine 7:4, 356-361
CrossRef627
P. Fioretto, M. L. Caramori, M. Mauer. (2008) The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia 51:8, 1347-1355
CrossRef628
Gert Jan van der Wilt, Gerhard A Zielhuis. (2008) Merging evidence-based and mechanism-based medicine. The Lancet 372:9638, 519-520
CrossRef629
Johannes FE Mann, Roland E Schmieder, Matthew McQueen, Leanne Dyal, Helmut Schumacher, Janice Pogue, Xingyu Wang, Aldo Maggioni, Andrzej Budaj, Suphachai Chaithiraphan, Kenneth Dickstein, Matyas Keltai, Kaj Metsärinne, Ali Oto, Alexander Parkhomenko, Leopoldo S Piegas, Tage L Svendsen, Koon K Teo, Salim Yusuf. (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. The Lancet 372:9638, 547-553
CrossRef630
W B White, J M Cleveland, R L Rolleri. (2008) Utility of semiautomatic clinic and 24-h ambulatory blood pressure measurements to evaluate combination therapy: the Ramipril–Hydrochlorothiazide Hypertension Trial. Journal of Human Hypertension 22:8, 559-568
CrossRef631
TOMOHIKO TAKAHASHI, SHELBY D REED, KEVIN A SCHULMAN. (2008) Cost-effectiveness of the oral adsorbent AST-120 versus placebo for chronic kidney disease. Nephrology 13:5, 419-427
CrossRef632
Norman K Hollenberg. (2008) Influencing the natural history of hypertension: is it the blood pressure achieved, the drug, or the drug dose?. Journal of Hypertension 26:8, 1527-1532
CrossRef633
Kayoko Miyata, Naro Ohashi, Yuki Suzaki, Akemi Katsurada, Hiroyuki Kobori. (2008) SEQUENTIAL ACTIVATION OF THE REACTIVE OXYGEN SPECIES/ANGIOTENSINOGEN/RENINANGIOTENSIN SYSTEM AXIS IN RENAL INJURY OF TYPE 2 DIABETIC RATS. Clinical and Experimental Pharmacology and Physiology 35:8, 922-927
CrossRef634
B. Williams. (2008) The Hypertension in Diabetes Study (HDS): a catalyst for change. Diabetic Medicine 25, 13-19
CrossRef635
George Bakris, Ellen Burgess, Matthew Weir, Giora Davidai, Stephen Koval. (2008) Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney International 74:3, 364-369
CrossRef636
C. Venkata S. Ram. (2008) Angiotensin Receptor Blockers: Current Status and Future Prospects. The American Journal of Medicine 121:8, 656-663
CrossRef637
Amy K. Mottl, David A. Shoham, Kari E. North. (2008) Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: A HuGE review. Genetics in Medicine 10:8, 560-574
CrossRef638
M. Satoh, S. Fujimoto, S. Arakawa, T. Yada, T. Namikoshi, Y. Haruna, H. Horike, T. Sasaki, N. Kashihara. (2008) Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrology Dialysis Transplantation 23:12, 3806-3813
CrossRef639
Nathalie Thilly, Sahar Bayat, François Alla, Michèle Kessler, Serge Briançon, Luc Frimat. (2008) Determinants and patterns of renin-angiotensin system inhibitors’ prescription in the first year following kidney transplantation. Clinical Transplantation 22:4, 439-446
CrossRef640
Masateru Taira, Hiroe Toba, Masafumi Murakami, Ikumi Iga, Ryoko Serizawa, Shoko Murata, Miyuki Kobara, Tetsuo Nakata. (2008) Spironolactone exhibits direct renoprotective effects and inhibits renal renin–angiotensin–aldosterone system in diabetic rats. European Journal of Pharmacology 589:1-3, 264-271
CrossRef641
Dick de Zeeuw. (2008) Renal disease: a common and a silent killer. Nature Clinical Practice Cardiovascular Medicine 5, S27-S35
CrossRef642
Y Hong, J Dingemanse, DE Mager. (2008) Pharmacokinetic/Pharmacodynamic Modeling of Renin Biomarkers in Subjects Treated With the Renin Inhibitor Aliskiren. Clinical Pharmacology & Therapeutics 84:1, 136-143
CrossRef643
Ying SHAO, Ming HE, Li ZHOU, Tai YAO, Yu HUANG, Li-min LU. (2008) Chronic angiotensin (17) injection accelerates STZ-induced diabetic renal injury 1. Acta Pharmacologica Sinica 29:7, 829-837
CrossRef644
Katharina Hohenstein, Bruno Watschinger. (2008) Hypertonie und Niere. Wiener Medizinische Wochenschrift 158:13-14, 359-364
CrossRef645
Tomoko Kakehi, Chihiro Yabe-Nishimura. (2008) NOX enzymes and diabetic complications. Seminars in Immunopathology 30:3, 301-314
CrossRef646
Ellen Burgess. (2008) Slowing the progression of kidney disease in patients with diabetes. Journal of the American Society of Hypertension 2:4, S30-S37
CrossRef647
Varun Agrawal, Sani Haider Kizilbash, Peter A McCullough. (2008) New therapeutic agents for diabetic kidney disease. Therapy 5:4, 553-575
CrossRef648
Gregory M. Singer, John F. Setaro. (2008) Secondary Hypertension: Obesity and the Metabolic Syndrome. The Journal of Clinical Hypertension 10:7, 567-574
CrossRef649
Jan Galle. (2008) Reduction of proteinuria with angiotensin receptor blockers. Nature Clinical Practice Cardiovascular Medicine 5, S36-S43
CrossRef650
Giuliano Tocci, Sebastiano Sciarretta, Massimo Volpe. (2008) Development of heart failure in recent hypertension trials. Journal of Hypertension 26:7, 1477-1486
CrossRef651
Eberhard Ritz, Björn Dahlöf. (2008) Introduction. Journal of the American Society of Hypertension 2:4, S1-S2
CrossRef652
Christian Werner, Magnus Baumhäkel, Koon K. Teo, Roland Schmieder, Johannes Mann, Thomas Unger, Salim Yusuf, Michael Böhm. (2008) RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clinical Research in Cardiology 97:7, 418-431
CrossRef653
J. Peti-Peterdi, J. J. Kang, I. Toma. (2008) Activation of the renal renin-angiotensin system in diabetes--new concepts. Nephrology Dialysis Transplantation 23:10, 3047-3049
CrossRef654
J. Galle, E. Schwedhelm, S. Pinnetti, R. H. Boger, C. Wanner, . (2008) Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrology Dialysis Transplantation 23:10, 3174-3183
CrossRef655
Parving, Hans-Henrik, Persson, Frederik, Lewis, Julia B., Lewis, Edmund J., Hollenberg, Norman K., . (2008) Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. New England Journal of Medicine 358:23, 2433-2446
Full Text656
Jamal Ahmad. (2008) Renin–angiotensin system blockade in diabetic nephropathy. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 2:2, 135-158
CrossRef657
Toru Yoshimura, Eiji Suzuki, Isamu Ito, Masayoshi Sakaguchi, Takashi Uzu, Yoshihiko Nishio, Hiroshi Maegawa, Shigehiro Morikawa, Toshiro Inubushi, Akitaka Hisatomi, Kazuma Fujimoto, Jun Takeda, Atsunori Kashiwagi. (2008) Impaired peripheral circulation in lower-leg arteries caused by higher arterial stiffness and greater vascular resistance associates with nephropathy in type 2 diabetic patients with normal ankle–brachial indices. Diabetes Research and Clinical Practice 80:3, 416-423
CrossRef658
Samina Khan, Chester A. Amedia. (2008) Economic burden of chronic kidney disease. Journal of Evaluation in Clinical Practice 14:3, 422-434
CrossRef659
(2008) Journal Club. Kidney International 73:12, 1343-1344
CrossRef660
Asha Rajashekar, Mark A. Perazella, Susan Crowley. (2008) Systemic Diseases with Renal Manifestations. Primary Care: Clinics in Office Practice 35:2, 297-328
CrossRef661
William J. Bommer. (2008) Use of Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy to Reduce Cardiovascular Events in High-Risk Patients: Part 1. Preventive Cardiology 11:3, 148-154
CrossRef662
Nina E. S. S. Perrin, Georg A. Jaremko, Ulla B. Berg. (2008) The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial. Pediatric Nephrology 23:6, 947-954
CrossRef663
William B. White, David A. Calhoun, Rita Samuel, Addison A. Taylor, Dion H. Zappe, Das Purkayastha. (2008) Improving Blood Pressure Control: Increase the Dose of Diuretic or Switch to a Fixed-Dose Angiotensin Receptor Blocker/Diuretic? The Valsartan Hydrochlorothiazide Diuretic for Initial Control and Titration to Achieve Optimal Therapeutic Effect (Val-DICTAT. The Journal of Clinical Hypertension 10:6, 450-458
CrossRef664
F Persson, P Rossing, K J Schjoedt, T Juhl, L Tarnow, C D A Stehouwer, C Schalkwijk, F Boomsma, E Frandsen, H-H Parving. (2008) Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney International 73:12, 1419-1425
CrossRef665
Ivonne Hernandez Schulman, Leopoldo Raij. (2008) The angiotensin II type 2 receptor: What is its clinical significance?. Current Hypertension Reports 10:3, 188-193
CrossRef666
F. Turnbull, M. Woodward, B. Neal, F. Barzi, T. Ninomiya, J. Chalmers, V. Perkovic, N. Li, S. MacMahon, . (2008) Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. European Heart Journal 29:21, 2669-2680
CrossRef667
Hussam Abuissa, James O’Keefe. (2008) The role of renin–angiotensin–aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Diabetes, Obesity and Metabolism 0:0, 080520205432340-???
CrossRef668
Dick de Zeeuw. (2008) Targeting Proteinuria as a Valid Surrogate for Individualized Kidney Protective Therapy. American Journal of Kidney Diseases 51:5, 713-716
CrossRef669
Saravanan Balamuthusamy, Lavanya Srinivasan, Meenakshi Verma, Sasikanth Adigopula, Nishant Jalandara, Suresh Hathiwala, Earl Smith. (2008) Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: A meta-analysis. American Heart Journal 155:5, 791-805
CrossRef670
Elke Wühl, Franz Schaefer. (2008) Therapeutic strategies to slow chronic kidney disease progression. Pediatric Nephrology 23:5, 705-716
CrossRef671
H. Haller. (2008) Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. International Journal of Clinical Practice 62:5, 781-790
CrossRef672
Luis M. Ruilope. (2008) Angiotensin receptor blockers: RAAS blockade and renoprotection. Current Medical Research and Opinion 24:5, 1285-1293
CrossRef673
Laura Cortés-Sanabria, Carlos E. Cabrera-Pivaral, Alfonso M. Cueto-Manzano, Enrique Rojas-Campos, Graciela Barragán, Moisés Hernández-Anaya, Héctor R. Martínez-Ramírez. (2008) Improving Care of Patients With Diabetes and CKD: A Pilot Study for a Cluster-Randomized Trial. American Journal of Kidney Diseases 51:5, 777-788
CrossRef674
Albert Lam, Siddharth Shah, James Paparello. (2008) Outpatient Management of Chronic Kidney Disease: Proteinuria, Anemia and Bone Disease as Therapeutic Targets. American Journal of Therapeutics 15:3, 278-286
CrossRef675
Kwok Leung Ong, Louisa Y.F. Wong, Bernard M.Y. Cheung. (2008) The role of urotensin II in the metabolic syndrome. Peptides 29:5, 859-867
CrossRef676
Keith C. Ferdinand. (2008) Cardiovascular Disease in Blacks: Can We Stop the Clock?. The Journal of Clinical Hypertension 10:5, 382-389
CrossRef677
Chris Jensen, Peter Herold, Hans Rudolf Brunner. (2008) Aliskiren: the first renin inhibitor for clinical treatment. Nature Reviews Drug Discovery 7:5, 399-410
CrossRef678
Ronald D. Smith, Hiroshi Yokoyama, David B. Averill, Ernesto L. Schiffrin, Carlos M. Ferrario. (2008) Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. Journal of the American Society of Hypertension 2:3, 165-172
CrossRef679
Kellie Hunter Campbell, Ann M OʼHare. (2008) Kidney disease in the elderly: update on recent literature. Current Opinion in Nephrology and Hypertension 17:3, 298-303
CrossRef680
Swarna Varma, Laura L. Boyle, Manu R. Varma, Gretchen A. Piatt. (2008) Controlling the ABCs of diabetes in clinical practice: A community-based endocrinology practice experience. Diabetes Research and Clinical Practice 80:1, 89-95
CrossRef681
Larry A. Weinrauch, Julie Lin, Scott D. Solomon. (2008) Mapping Directions for the Cardiorenal Conundrum. Journal of the American College of Cardiology 51:13, 1275-1276
CrossRef682
Nagesh S. Anavekar, Scott D. Solomon, John J.V. McMurray, Aldo Maggioni, Jean Lucien Rouleau, Robert Califf, Harvey White, Lars Kober, Eric Velazquez, Marc A. Pfeffer. (2008) Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. The American Journal of Cardiology 101:7, 925-929
CrossRef683
Roberto B. Vargas, Loretta Jones, Chrystene Terry, Suzanne B. Nicholas, Joel Kopple, Nell Forge, Anne Griffin, Margo Louis, Lilly Barba, Linda Small, Keith C. Norris. (2008) Community-Partnered Approaches to Enhance Chronic Kidney Disease Awareness, Prevention, and Early Intervention. Advances in Chronic Kidney Disease 15:2, 153-161
CrossRef684
Craig I Coleman, William L Baker, Jeffrey Kluger, C Michael White. (2008) Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. Journal of Hypertension 26:4, 622-629
CrossRef685
KANTIMA PHISITKUL, KHALED HEGAZY, TEMDUANG CHUAHIRUN, CATHY HUDSON, JAN SIMONI, HASAN RAJAB, DONALD E. WESSON. (2008) Continued Smoking Exacerbates but Cessation Ameliorates Progression of Early Type 2 Diabetic Nephropathy. The American Journal of the Medical Sciences 335:4, 284-291
CrossRef686
Steven G. Chrysant, Michael Melino, Sulekha Karki, James Lee, Reinilde Heyrman. (2008) The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clinical Therapeutics 30:4, 587-604
CrossRef687
Claudio Ferri, Giuseppe Croce, Giovambattista Desideri. (2008) Role of combination therapy in the treatment of hypertension: Focus on valsartan plus amlodipine. Advances in Therapy 25:4, 300-320
CrossRef688
David J. Leehey, Ashok K. Singh, Joseph P. Bast, Periannan Sethupathi, Rekha Singh. (2008) Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats. Translational Research 151:4, 208-216
CrossRef689
Norihiko Sakai, Takashi Wada, Kouji Matsushima, Richard Bucala, Masaru Iwai, Masatsugu Horiuchi, Shuichi Kaneko. (2008) The renin–angiotensin system contributes to renal fibrosis through regulation of fibrocytes. Journal of Hypertension 26:4, 780-790
CrossRef690
Radovan Bogdanović. (2008) Diabetic nephropathy in children and adolescents. Pediatric Nephrology 23:4, 507-525
CrossRef691
Karly C. Sourris, Josephine M. Forbes, Mark E. Cooper. (2008) Therapeutic Interruption of Advanced Glycation in Diabetic Nephropathy. Annals of the New York Academy of Sciences 1126:1, 101-106
CrossRef692
Moiz M. Shafiq, Dileep V. Menon, Ronald G. Victor. (2008) Oral Direct Renin Inhibition: Premise, Promise, and Potential Limitations of a New Antihypertensive Drug. The American Journal of Medicine 121:4, 265-271
CrossRef693
M.A.C. Onuigbo, N.T.C. Onuigbo. (2008) Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis. QJM 101:7, 519-527
CrossRef694
Aiko Inoue, Tetsuya Babazono, Yasuhiko Iwamoto. (2008) Effects of the Renin–Angiotensin System Blockade on Hemoglobin Levels in Type 2 Diabetic Patients With Chronic Kidney Disease. American Journal of Hypertension 21:3, 317-322
CrossRef695
Jay N. Cohn, Jesse M. Goldman. (2008) Establishing A New Option for Target-organ Protection: Rationale for ARB Plus ACE Inhibitor Combination Therapy. American Journal of Hypertension 21:3, 248-256
CrossRef696
Macaulay A. C. Onuigbo, Nnonyelum T. C. Onuigbo. (2008) Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. International Urology and Nephrology 40:1, 233-239
CrossRef697
Juan M. Aranda, Rafael Calderon, Juan M. Aranda. (2008) Clinical Characteristics and Outcomes in Hypertensive Patients of Hispanic Descent. Preventive Cardiology 11:2, 116-120
CrossRef698
A Mohanram, Z Zhang, S Shahinfar, P A Lyle, R D Toto. (2008) The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney International 73:5, 630-636
CrossRef699
Emilio A Francischetti, Bruno MJ Celoria, Aloisio Francischetti, Virginia A Genelhu. (2008) Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan. Expert Review of Cardiovascular Therapy 6:3, 289-303
CrossRef700
Susanne H Meeuwisse-Pasterkamp, Melanie M van der Klauw, Bruce HR Wolffenbuttel. (2008) Type 2 diabetes mellitus: prevention of macrovascular complications. Expert Review of Cardiovascular Therapy 6:3, 323-341
CrossRef701
M. Shargorodsky, E. Hass, M. Boaz, D. Gavish, R. Zimlichman. (2008) High dose treatment with angiotensin II receptor blocker in patients with hypertension: Differential effect of tissue protection versus blood pressure lowering. Atherosclerosis 197:1, 303-310
CrossRef702
Hyun-Jung Kim, Hyun-Syuk Yoo, Chan-Wha Kim. (2008) Proteomics in diabetic nephropathy. PROTEOMICS – CLINICAL APPLICATIONS 2:3, 301-311
CrossRef703
William B. White, Debra Murwin, Steven G. Chrysant, Stephen E. Koval, Giora Davidai, Robert Guthrie. (2008) Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Pressure Monitoring 13:1, 21-27
CrossRef704
Stephen Tonna, Savita V. Dandapani, Andrea Uscinski, Gerald B. Appel, Johannes S. Schlöndorff, Kang Zhang, Bradley M. Denker, Martin R. Pollak. (2008) Functional genetic variation in aminopeptidase A (ENPEP): Lack of clear association with focal and segmental glomerulosclerosis (FSGS). Gene 410:1, 44-52
CrossRef705
Andreia Tufescu, Masayuki Kanazawa, Atsuko Ishida, Hongmei Lu, Yuko Sasaki, Tetsuya Ootaka, Toshinobu Sato, Masahiro Kohzuki. (2008) Combination of exercise and losartan enhances renoprotective and peripheral effects in spontaneously type 2 diabetes mellitus rats with nephropathy. Journal of Hypertension 26:2, 312-321
CrossRef706
Kunihiro Yamagata, Kunitoshi Iseki, Kousaku Nitta, Hirokazu Imai, Yasuhiko Iino, Seiichi Matsuo, Hirofumi Makino, Akira Hishida. (2008) Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clinical and Experimental Nephrology 12:1, 1-8
CrossRef707
William H Frishman, Wilbert S Aronow, Angela Cheng-Lai. 2008. Cardiovascular Drug Therapy in the Elderly. , 99-136.
CrossRef708
Christine K Choy, Jo E Rodgers, Jean M Nappi, Stuart T Haines. (2008) Type 2 Diabetes Mellitus and Heart Failure. Pharmacotherapy 28:2, 170-192
CrossRef709
Alan H. Gradman, Rishi Kad. (2008) Renin Inhibition in Hypertension. Journal of the American College of Cardiology 51:5, 519-528
CrossRef710
Wilbert S. Aronow. 2008. Management of the Older Patient After Myocardial Infarction. , 327-350.
CrossRef711
Han Wang, Jue Lin Deng, Jirong Yue, Jun Li, Yan Bin Hou, Jue Lin Deng. 2008. Prostaglandin E1 for preventing the progression of diabetic kidney disease. .
CrossRef712
Sankar D Navaneethan, Sagar U Nigwekar, Giovanni FM Strippoli, Sankar D Navaneethan. 2008. Aldosterone antagonists for preventing the progression of chronic kidney disease. .
CrossRef713
Prabhleen Singh, Aihua Deng, Matthew R Weir, Roland C Blantz. (2008) The balance of angiotensin II and nitric oxide in kidney diseases. Current Opinion in Nephrology and Hypertension 17:1, 51-56
CrossRef714
Se Jun Park, Dae Jung Kim, Hae Jin Kim, Soo Yeon Park, Ji A Seo, Nan Hee Kim, Sung Hee Choi, Soo Lim, Hak Chul Jang, Seung Hyun Ko, Ki Ho Song, Yu Bae Ahn, Soo Kyoung Kim, Yong Wook Cho, Jun Goo Kang, Sung Hee Ihm, Cheol Young Park, Sung Woo Park, Dong Hyun Shin, Yong Hyun Kim, Kwan Woo Lee. (2008) Effect of Valsartan on Blood Pressure and Urinary Albumin Excretion in Hypertensive Type 2 Diabetic Patients: An Open-Label, Multicenter Study. Korean Diabetes Journal 32:6, 513
CrossRef715
Biff F Palmer. (2008) Improving BP Control with Combined Renin-Angiotensin System Blockade and Thiazide Diuretics in Hypertensive Patients with Diabetes Mellitus or Kidney Disease. American Journal of Cardiovascular Drugs 8:1, 9-14
CrossRef716
Norman K. Hollenberg. 2008. ACE Inhibitors, Angiotensin Receptor Blockers, Mineralocorticoid Receptor Antagonists, and Renin Antagonists. , 601-609.
CrossRef717
Enrico Agabiti Rosei. (2008) Reduction of Cardiovascular Risk through Angiotensin II Type 1 Receptor Antagonism. High Blood Pressure & Cardiovascular Prevention 15:4, 231-243
CrossRef718
Norman M. Kaplan. 2008. Individualization of Pharmacologic Therapy. , 620-623.
CrossRef719
Ki Chul Sung, Byung Jin Kim, Seungho Ryu. (2008) An association of a variety of cardiovascular risk factors with low grade albuminuria in Korean men. Atherosclerosis 196:1, 320-326
CrossRef720
Akshay Desai, James C. Fang. (2008) Heart Failure with Preserved Ejection Fraction: Hypertension, Diabetes, Obesity/Sleep Apnea, and Hypertrophic and Infiltrative Cardiomyopathy. Heart Failure Clinics 4:1, 87-97
CrossRef721
Shakil Aslam. (2008) Cardiovascular disease in dialysis patients: do some antihypertensive drugs have specific antioxidant effects or is it just blood pressure reduction? Does antioxidant treatment reduce the risk for cardiovascular disease?. Current Opinion in Nephrology and Hypertension 17:1, 99-105
CrossRef722
Tatsuyuki Inoue, Hitoshi Sugiyama, Hirofumi Makino. (2008) Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 120:2, 215-218
CrossRef723
Hideaki Sawaki, Jungo Terasaki, Atsushi Fujita, Seiko Nakagawa, Norio Kanatsuna, Katsuhiko Sadahiro, Haruhiko Isotani, Akihisa Imagawa, Toshiaki Hanafusa. (2008) A renoprotective effect of low dose losartan in patients with type 2 diabetes. Diabetes Research and Clinical Practice 79:1, 86-90
CrossRef724
T Mimura, T Takenaka, Y Kanno, K Moriwaki, H Okada, H Suzuki. (2008) Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases. Journal of Human Hypertension 22:1, 38-47
CrossRef725
Macaulay A. C. Onuigbo, Nnonyelum T. C. Onuigbo. (2008) Renal Failure and Concurrent RAAS Blockade in Older CKD Patients with Renal Artery Stenosis: An Extended Mayo Clinic Prospective 63-Month Experience. Renal Failure 30:4, 363-371
CrossRef726
William L. Whittier, Julia B. Lewis, Edmund J. Lewis. 2008. Therapy for Diabetic Nephropathy. , 323-333.
CrossRef727
David H G Smith. (2008) Comparison of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Essential Hypertension. Drugs 68:9, 1207-1225
CrossRef728
Christos Chatziantoniou, Jean-Claude Dussaule. (2008) Is kidney injury a reversible process?. Current Opinion in Nephrology and Hypertension 17:1, 76-81
CrossRef729
Katherine F Croom, Greg L Plosker. (2008) Irbesartan. Drugs 68:11, 1543-1569
CrossRef730
Antonio Coca. (2008) Economic Benefits of Treating High-Risk Hypertension with Angiotensin II Receptor Antagonists (Blockers). Clinical Drug Investigation 28:4, 211-220
CrossRef731
Macaulay A.C. Onuigbo, Nnonyelum T.C. Onuigbo. (2008) Late Onset Azotemia from RAAS Blockade in CKD Patients with Normal Renal Arteries and No Precipitating Risk Factors. Renal Failure 30:1, 73-80
CrossRef732
Tomoya Umezono, Masao Toyoda, Makiko Abe, Keiko Kobayashi, Mayuko Kato, Masaaki Miyauchi, Takako Kobayashi, Naoyuki Yamamoto, Moritsugu Kimura, Mitsunori Yagame, Daisuke Suzuki. (2008) Long-Term Intensive Insulin Therapy for Japanese Patients with Type 2 Diabetes Mellitus. Internal Medicine 47:24, 2109-2115
CrossRef733
Giuseppe Mancia. (2008) Dihydropiridinic Calcium-Channel Antagonists in the 2007 ESH/ESC Hypertension Guidelines. High Blood Pressure & Cardiovascular Prevention 15:2, 85-90
CrossRef734
Z Zhang, L Sun, Y Wang, G Ning, A W Minto, J Kong, R J Quigg, Y C Li. (2008) Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney International 73:2, 163-171
CrossRef735
Guido Grassi. (2008) The Clinical Significance of Blood Pressure Lowering Treatment: Is First-Line Drug Choice Important?. High Blood Pressure & Cardiovascular Prevention 15:3, 117-119
CrossRef736
Kaheita Kakinoki, Shuichi Kaneko. (2008) Management of the Liver Transplant Recipients in the Stable-Phase. Kanzo 49:8, 339-351
CrossRef737
Matthew R. Weir. (2008) Risk-Based Classification of Hypertension and the Role of Combination Therapy. The Journal of Clinical Hypertension 10:s1, 4-12
CrossRef738
Maarten W. Taal. 2008. Prevention of Progressive Renal Failure. , 699-714.
CrossRef739
Motofumi Sasaki, Kenichi Shikata, Hirofumi Makino. (2008) Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 119:3, 311-313
CrossRef740
Ramnath Dukkipati, Sharon Adler, Rajnish Mehrotra. (2008) Cardiovascular Implications of Chronic Kidney Disease in Older Adults. Drugs & Aging 25:3, 241-253
CrossRef741
(2008) Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida. Revista Española de Cardiología 61:1, 82.e1-82.e49
CrossRef742
Michael Böhm, Jan-Christian Reil, Nicolas Danchin, Martin Thoenes, Peter Bramlage, Massimo Volpe. (2008) Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. Journal of Hypertension 26:1, 18-25
CrossRef743
Shoichi Maruyama. (2008) Current and future medical therapies for CKD (chronic kidney disease). Folia Pharmacologica Japonica 132:3, 166-172
CrossRef744
Thomas F. Mueller, Juliane Raeder, Karl Oettl, Sabine Zitta, Gert Klausmann, Willibald Estelberger, Valerie A. Luyckx, Gilbert Reibnegger. (2008) Cystatin C Does Not Detect Acute Changes in Glomerular Filtration Rate in Early Diabetic Nephropathy. Renal Failure 30:1, 21-29
CrossRef745
Douglas G. Shemin, Lance D. Dworkin. 2008. Calcium Channel Blockers. , 610-619.
CrossRef746
Voa Ratsimbazafy, Claude Cassat, Roger Leverge, Rémy Contreras. 2008. Traitement de l'hypertension artérielle. , 41-71.
CrossRef747
Benjamin Ko, George Bakris. 2008. The Renin–Angiotensin–Aldosterone System and the Kidney. , 167-180.
CrossRef748
T Fujita, K Ando, H Nishimura, T Ideura, G Yasuda, M Isshiki, K Takahashi. (2007) Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney International 72:12, 1543-1549
CrossRef749
N Perico, G Remuzzi. (2007) Inhibition of TGF-β expression: A novel role for thiazolidinediones to implement renoprotection in diabetes. Kidney International 72:12, 1419-1421
CrossRef750
Rajiv Agarwal. (2007) Antihypertensive agents and arterial stiffness: relevance to reducing cardiovascular risk in the chronic kidney disease patient. Current Opinion in Internal Medicine 6:6, 618-624
CrossRef751
Seema Basi, Julia B. Lewis. (2007) Microalbuminuria as a target to improve cardiovascular and renal outcomes in diabetic patients. Current Diabetes Reports 7:6, 439-442
CrossRef752
Piero Ruggenenti, Paolo Cravedi, Giuseppe Remuzzi. (2007) Latest treatment strategies for membranous nephropathy. Expert Opinion on Pharmacotherapy 8:18, 3159-3171
CrossRef753
Ulrich O. Wenzel, Christian Krebs. (2007) Management of arterial hypertension in obese patients. Current Hypertension Reports 9:6, 491-497
CrossRef754
J. M. Flack. (2007) Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide. International Journal of Clinical Practice 61:12, 2093-2102
CrossRef755
T. Ohmura, I. Tsunenari, R. Seidler, M. Chachin, T. Hayashi, A. Konomi, T. Matsumaru, T. Sumida, N. Hayashi, Y. Horie. (2007) Renoprotective effects of telmisartan on renal injury in obese Zucker rats. Acta Diabetologica
CrossRef756
G. Mathur, J. G. F. Cleland, E. Rodrigues, G. K. Davis. (2007) Role of angiotensin receptor blockers in the prevention and management of ischaemic stroke. European Journal of Neurology 14:11, 1201-1209
CrossRef757
Lawrence Agodoa, Paul Eggers. (2007) CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Racial and Ethnic Disparities in End-Stage Kidney Failure-Survival Paradoxes in African-Americans. Seminars in Dialysis 20:6, 577-585
CrossRef758
Robert D. Toto. (2007) Reducing Cardiovascular Events in High-Risk Patients: The Challenge of Managing Hypertension in Patients With Diabetic Renal Disease. The Journal of Clinical Hypertension 9, 16-25
CrossRef759
H. J. Lambers Heerspink, M. J. Fowler, J. Volgi, A. T. Reutens, I. Klein, T. A. Herskovits, D. K. Packham, I. R. Fraser, S. L. Schwartz, C. Abaterusso, J. Lewis, . (2007) Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. Diabetic Medicine 24:11, 1290-1295
CrossRef760
Guilherme Figueiredo Marquezine, Bernardo Leo Wajchenberg. (2007) Molecular Activity of Insulin and Selective Insulin Resistance. The Endocrinologist 17:6, 351-356
CrossRef761
Disaya Chavalitdhamrong, Gabriel M. Danovitch, Suphamai Bunnapradist. (2007) CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Is There a Reversal of Reverse Epidemiology in Renal Transplant Recipients?. Seminars in Dialysis 20:6, 544-548
CrossRef762
PING LI, JING YAN, YU SUN, FRANK J BURCZYNSKI, YUEWEN GONG. (2007) Chinese herbal formula Qilong-Lishui granule improves puromycin aminonucleoside-induced renal injury through regulation of bone morphogenetic proteins. Nephrology 12:5, 466-473
CrossRef763
Rashida Blake, Leopoldo Raij, Ivonne Hernandez Schulman. (2007) Renal protection: Are all antihypertensive drugs comparable?. Current Hypertension Reports 9:5, 373-379
CrossRef764
Lillian C. Min, Rajnish Mehrotra, Constance H. Fung. (2007) Quality Indicators for the Care of Hypertension in Vulnerable Elders. Journal of the American Geriatrics Society 55, S359-S365
CrossRef765
M R Weir. (2007) Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin–angiotensin system blockade. Journal of Human Hypertension 21:10, 770-779
CrossRef766
Paolo Cravedi, Piero Ruggenenti, Giuseppe Remuzzi. (2007) Intensified inhibition of renin-angiotensin system: A way to improve renal protection?. Current Hypertension Reports 9:5, 430-436
CrossRef767
A. J. Palmer, W. J. Valentine, J. A. Ray. (2007) Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis. International Journal of Clinical Practice 61:10, 1626-1633
CrossRef768
Eberhard Ritz, Lars Christian Rump. (2007) Do β-blockers combined with RAS inhibitors make sense after all to protect against renal injury?. Current Hypertension Reports 9:5, 409-414
CrossRef769
Wilbert S. Aronow. (2007) Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Heart Failure Clinics 3:4, 423-436
CrossRef770
Matthias Weck. (2007) Treatment of hypertension in patients with diabetes mellitus. Clinical Research in Cardiology 96:10, 707-718
CrossRef771
Roland E. Schmieder. (2007) Renin inhibitors: Optimal strategy for renal protection. Current Hypertension Reports 9:5, 415-421
CrossRef772
D. J. Kelly, Y. Zhang, G. Moe, G. Naik, R. E. Gilbert. (2007) Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 50:11, 2398-2404
CrossRef773
Jochen Reiser, Peter Mundel. (2007) Dual effects of RAS blockade on blood pressure and podocyte function. Current Hypertension Reports 9:5, 403-408
CrossRef774
V. R. Sørensen, E. R. Mathiesen, T. Watt, J. B. Bjorner, M. V. N. Andersen, B. Feldt-Rasmussen. (2007) Diabetic patients treated with dialysis: complications and quality of life. Diabetologia 50:11, 2254-2262
CrossRef775
S. Hiremath, D. Fergusson, S. Doucette, A. V. Mulay, G. A. Knoll. (2007) Renin Angiotensin System Blockade in Kidney Transplantation: A Systematic Review of the Evidence. American Journal of Transplantation 7:10, 2350-2360
CrossRef776
Panagiotis C. Stafylas, Pantelis A. Sarafidis, Dimitrios M. Grekas, Anastasios N. Lasaridis. (2007) A Cost-Effectiveness Analysis of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Diabetic Nephropathy. The Journal of Clinical Hypertension 9:10, 751-759
CrossRef777
G. Mathur, B. Noronha, E. Rodrigues, G. Davis. (2007) The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus. Diabetes, Obesity and Metabolism 9:5, 617-629
CrossRef778
Benjamin J Epstein, Shawn Anderson. (2007) Discordant Effects of β-Blockade on Central Aortic Systolic and Brachial Systolic Blood Pressure: Considerations Beyond the Cuff. Pharmacotherapy 27:9, 1322-1333
CrossRef779
Yoshiharu Horie, Jitsuo Higaki, Masahiro Takeuchi. (2007) Design, statistical analysis and sample size calculation of dose response study of telmisartan and hydrochlorothiazide. Contemporary Clinical Trials 28:5, 647-653
CrossRef780
S G Chrysant, B Dimas, M Shiraz. (2007) Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update. Journal of Human Hypertension 21:9, 699-708
CrossRef781
Matthew R Weir. (2007) Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering?. Current Opinion in Nephrology and Hypertension 16:5, 416-421
CrossRef782
(2007) Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007. Revista Española de Cardiología 60:9, 968.e1-968.e94
CrossRef783
Sheldon Hirsch. (2007) Prerenal Success in Chronic Kidney Disease. The American Journal of Medicine 120:9, 754-759
CrossRef784
Jing Chen, Raymond R Townsend. (2007) Preventing cardiovascular and renal complications in the management of hypertension and metabolic syndrome. Expert Opinion on Pharmacotherapy 8:13, 2001-2009
CrossRef785
C. Hasslacher. (2007) Antihyperglykämische Therapie bei diabetischer Nephropathie. Der Nephrologe 2:5, 333-339
CrossRef786
Pamela W Anderson, Janet B McGill, Katherine R Tuttle. (2007) Protein kinase C ?? inhibition: the promise for treatment of diabetic nephropathy. Current Opinion in Nephrology and Hypertension 16:5, 397-402
CrossRef787
&NA;. (2007) FULL TEXT Chapter 1: Introduction. European Journal of Cardiovascular Prevention & Rehabilitation 14:Supplement 2, S2-S113
CrossRef788
Ian Graham. (2007) European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis 194:1, 1-45
CrossRef789
Michel Azizi, Grégoire Wuerzner. (2007) Rationale for Combining Blockers of the Renin-Angiotensin System. Seminars in Nephrology 27:5, 544-554
CrossRef790
Chobanian, Aram V., . (2007) Isolated Systolic Hypertension in the Elderly. New England Journal of Medicine 357:8, 789-796
Full Text791
Richard Grimm. (2007) Diuretics Are Preferred Over Angiotensin II-Converting Enzyme Inhibitors For Initial Therapy of Uncomplicated Hypertension. American Journal of Kidney Diseases 50:2, 188-196
CrossRef792
Denise W. Wong, Gavin Y. Oudit, Heather Reich, Zamaneh Kassiri, Joyce Zhou, Qiao C. Liu, Peter H. Backx, Josef M. Penninger, Andrew M. Herzenberg, James W. Scholey. (2007) Loss of Angiotensin-Converting Enzyme-2 (Ace2) Accelerates Diabetic Kidney Injury. The American Journal of Pathology 171:2, 438-451
CrossRef793
P de Pablos-Velasco, O Gonzalez-Albarran, V Estopiñan, A Khanbhai. (2007) Blood pressure, antihypertensive treatment and factors associated with good blood pressure control in hypertensive diabetics: the Tarmidas study. Journal of Human Hypertension 21:8, 664-672
CrossRef794
McWilliams, J. Michael, Meara, Ellen, Zaslavsky, Alan M., Ayanian, John Z., . (2007) Use of Health Services by Previously Uninsured Medicare Beneficiaries. New England Journal of Medicine 357:2, 143-153
Full Text795
Hanna Tinel. (2007) Beneficial Effects of the Combination of Nifedipine and Losartan in Hypertensive Dahl Salt-Sensitive Rats. Journal of Cardiovascular Pharmacology 50:1, 75-82
CrossRef796
Jan A Staessen, Lutgarde Thijs, Yan Li, Tatiana Kuznetsova, Tom Richart, Jiguang Wang, Willem H Birkenh??ger. (2007) ???Beyond blood pressure??? means multiple risk factor intervention, not pleiotropic antihypertensive drugs. Current Opinion in Cardiology 22:4, 335-343
CrossRef797
Roland E Schmieder. (2007) The potential role of prorenin in diabetic nephropathy. Journal of Hypertension 25:7, 1323-1326
CrossRef798
Domenic A. Sica. (2007) Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure?. Current Cardiovascular Risk Reports 1:3, 198-203
CrossRef799
Peter A. Meredith. (2007) Candesartan cilexetil – a review of effects on cardiovascular complications in hypertension and chronic heart failure. Current Medical Research and Opinion 23:7, 1693-1705
CrossRef800
J-C Dussaule, C Chatziantoniou. (2007) Reversal of renal disease: is it enough to inhibit the action of angiotensin II?. Cell Death and Differentiation 14:7, 1343-1349
CrossRef801
S.-C. Lim, A. F. Y. Koh, S. K. Goh, C.-L. Chua, B.-L. Heng, T. Subramaniam, C.-F. Sum. (2007) Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria ? a randomized crossover study. Diabetes, Obesity and Metabolism 9:4, 477-482
CrossRef802
Giuliano Tocci, Francesco Paneni, Beatrice Ponziani, Massimo Volpe. (2007) Use of predictive markers to improve cardiovascular protection. Future Cardiology 3:4, 447-456
CrossRef803
Giuliano Tocci, Sebastiano Sciarretta, Caterina Facciolo, Massimo Volpe. (2007) Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Review of Cardiovascular Therapy 5:4, 767-776
CrossRef804
Folkert W Asselbergs, Wiek H van Gilst. (2007) Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most. Current Opinion in Cardiology 22:4, 267-272
CrossRef805
Wilbert S. Aronow, William H. Frishman, Angela Cheng-Lai. (2007) Cardiovascular Drug Therapy in the Elderly. Cardiology in Review 15:4, 195-215
CrossRef806
Phuong-Thu T. Pham, Phuong-Chi T. Pham, Gabriel M. Danovitch. (2007) Cardiovascular Disease Posttransplant. Seminars in Nephrology 27:4, 430-444
CrossRef807
Mohammed Sika, Julia Lewis, Janice Douglas, Thomas Erlinger, Donna Dowie, Michael Lipkowitz, James Lash, Denise Cornish-Zirker, Gail Peterson, Robert Toto, John Kusek, Lawrence Appel, Cynthia Kendrick, Jennifer Gassman. (2007) Baseline Characteristics of Participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study. American Journal of Kidney Diseases 50:1, 78-89.e1
CrossRef808
Masayuki Tanemoto, Michiaki Abe, Fumitoshi Satoh, Takaaki Abe, Hiroshi Satoh, Sadayoshi Ito. (2007) Mesangial proliferative glomerulonephritis with aldosterone-producing adenoma. Clinical and Experimental Nephrology 11:2, 164-167
CrossRef809
C.E. Mogensen. (2007) Microalbuminuria, renal disease, metabolic syndrome and risks in diabetes. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 1:2, 127-133
CrossRef810
TOSHIHIKO ISHIMITSU, AKIRA AKASHIBA, TOMOKO KAMEDA, TOSHIAKI TAKAHASHI, SATOSHI OHTA, MASAYOSHI YOSHII, JUNICHI MINAMI, HIDEHIKO ONO, ATSUSHI NUMABE, HIROAKI MATSUOKA. (2007) Benazepril slows progression of renal dysfunction in patients with non-diabetic renal disease. Nephrology 12:3, 294-298
CrossRef811
Sudha Ganne, Surender K. Arora, Olena Dotsenko, Samy I. McFarlane, Adam Whaley-Connell. (2007) Hypertension in people with diabetes and the metabolic syndrome: Pathophysiologic insights and therapeutic update. Current Diabetes Reports 7:3, 208-217
CrossRef812
Rebecca S. Grubbs, Domenic A. Sica. (2007) Taking the Pressure off Type 2 Diabetes Mellitus: Implementing Hypertension Guidelines. Progress in Cardiovascular Nursing 22:3, 159-165
CrossRef813
Giuseppe Mancia. (2007) Optimal control of blood pressure in patients with diabetes reduces the incidence of macro and microvascular events. Journal of Hypertension 25:Suppl 1, S7-S12
CrossRef814
Alan H. Gradman. (2007) Treating Patients for Cardiovascular Protection: Combination Therapy to Achieve Complete Renin-Angiotensin System Blockade. Preventive Cardiology 10:3, 147-155
CrossRef815
Andrew J. Palmer, William J. Valentine, Joshua A. Ray, Stephane Roze, Noemi Muszbek. (2007) Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis. The European Journal of Health Economics 8:2, 161-168
CrossRef816
Koichi Suzuki, Gi Dong Han, Naoko Miyauchi, Taeko Hashimoto, Takeshi Nakatsue, Yumiko Fujioka, Hiroko Koike, Fujio Shimizu, Hiroshi Kawachi. (2007) Angiotensin II Type 1 and Type 2 Receptors Play Opposite Roles in Regulating the Barrier Function of Kidney Glomerular Capillary Wall. The American Journal of Pathology 170:6, 1841-1853
CrossRef817
G. Fernández Fresnedo, C. Gómez Alamillo, E. Rodrigo Calabia, M. Arias Rodríguez. (2007) Tratamiento de la hipertensión arterial. Medicine - Programa de Formación Médica Continuada Acreditado 9:82, 5272-5282
CrossRef818
Philip A. McFarlane, Sheldon W. Tobe, Bruce Culleton. (2007) Improving outcomes in diabetes and chronic kidney disease: The basis for Canadian guidelines. Canadian Journal of Cardiology 23:7, 585-590
CrossRef819
Preethi Yerram, Poorna R. Karuparthi, Laura Hesemann, Jennifer Horst, Adam Whaley-Connell. (2007) Chronic kidney disease and cardiovascular risk. Journal of the American Society of Hypertension 1:3, 178-184
CrossRef820
T-H Yoo, J-J Li, J-J Kim, D-S Jung, S-J Kwak, D-R Ryu, H Y Choi, J S Kim, H J Kim, S H Han, J E Lee, D S Han, S-W Kang. (2007) Activation of the renin–angiotensin system within podocytes in diabetes. Kidney International 71:10, 1019-1027
CrossRef821
Ali S Alzahrani. (2007) Management of hypertension in diabetes mellitus. Expert Review of Endocrinology & Metabolism 2:3, 341-357
CrossRef822
J.C. Ruiz San Millán, G. Fernández, M. Arias. (2007) Insuficiencia renal crónica (II). Medicine - Programa de Formación Médica Continuada Acreditado 9:79, 5077-5086
CrossRef823
Christina Wyatt, Vinaya Konduri, John Eng, Rajeev Rohatgi. (2007) Reporting of Estimated GFR in the Primary Care Clinic. American Journal of Kidney Diseases 49:5, 634-641
CrossRef824
(2007) Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system. Journal of Hypertension 25:5, 951-958
CrossRef825
Arnljot Flaa, Tonje Amb Aksnes, Arne Strand, Sverre Erik Kjeldsen. (2007) Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials. Expert Review of Cardiovascular Therapy 5:3, 451-461
CrossRef826
Paolo Cravedi, Piero Ruggenenti, Giuseppe Remuzzi. (2007) Does remission of renal disease associated with antihypertensive treatment exist?. Current Hypertension Reports 9:2, 160-165
CrossRef827
Roland E. Schmieder, Joachim Schrader, Walter Zidek, Ulrich Tebbe, W. Dieter Paar, Peter Bramlage, D. Pittrow, Michael Böhm. (2007) Low-grade albuminuria and cardiovascular risk. Clinical Research in Cardiology 96:5, 247-257
CrossRef828
Steven D. Crowley, Thomas M. Coffman. (2007) In hypertension, the kidney rules. Current Hypertension Reports 9:2, 148-153
CrossRef829
D. L. Jennings, J. S. Kalus, C. I. Coleman, C. Manierski, J. Yee. (2007) Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabetic Medicine 24:5, 486-493
CrossRef830
Marcel Ruzicka, Kevin D. Burns, Bruce Culleton, Sheldon Tobe. (2007) Treatment of hypertension in patients with nondiabetic chronic kidney disease. Canadian Journal of Cardiology 23:7, 595-601
CrossRef831
José A. García Donaire, Luis M. Ruilope. (2007) Angiotensin receptor blockade in diabetic renal disease—Focus on candesartan. Diabetes Research and Clinical Practice 76:3, S22-S30
CrossRef832
A. Martínez Castelao, F. de Álvaro Moreno, J.L. Gorriz. (2007) Glomerulopatías secundarias y enfermedades renales asociadas a enfermedades metabólicas. Diabetes mellitus. Medicine - Programa de Formación Médica Continuada Acreditado 9:80, 5157-5163
CrossRef833
V. R. Sørensen, E. R. Mathiesen, J. Heaf, B. Feldt-Rasmussen. (2007) Improved survival rate in patients with diabetes and end-stage renal disease in Denmark. Diabetologia 50:5, 922-929
CrossRef834
Anne Merete Boas Soja, Ann-Dorthe Olsen Zwisler, Marianne Frederiksen, Thomas Melchior, Eva Hommel, Christian Torp-Pedersen, Mette Madsen. (2007) Use of intensified comprehensive cardiac rehabilitation to improve risk factor control in patients with type 2 diabetes mellitus or impaired glucose tolerance—the randomized DANish StUdy of impaired glucose metabolism in the settings of cardiac rehabilitation (DANSUK) study. American Heart Journal 153:4, 621-628
CrossRef835
Julie Schmittdiel, Sandeep Vijan, Bruce Fireman, Jennifer Elston Lafata, Nina Oestreicher, Joe V. Selby. (2007) Predicted Quality-Adjusted Life Years as a Composite Measure of the Clinical Value of Diabetes Risk Factor Control. Medical Care 45:4, 315-321
CrossRef836
David T. Nash. (2007) Rationale for Combination Therapy in Hypertension Management: Focus on Angiotensin Receptor Blockers and Thiazide Diuretics. Southern Medical Journal 100:4, 386-392
CrossRef837
Roland E Schmieder, Karl F Hilgers, Markus P Schlaich, Bernhard MW Schmidt. (2007) Renin-angiotensin system and cardiovascular risk. The Lancet 369:9568, 1208-1219
CrossRef838
Andreas J Flammer, Frank Hermann, Peter Wiesli, Beat Schwegler, Rémy Chenevard, David Hürlimann, Isabella Sudano, Steffen Gay, Michel Neidhart, Walter Riesen, Frank Ruschitzka, Thomas F Lüscher, Georg Noll, Roger Lehmann. (2007) Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. Journal of Hypertension 25:4, 785-791
CrossRef839
J.F. Blicklé, J. Doucet, T. Krummel, T. Hannedouche. (2007) Diabetic nephropathy in the elderly. Diabetes & Metabolism 33, S40-S55
CrossRef840
Alejandro de la Sierra, Juan Antonio Divisón. (2007) Valor pronóstico de la presión arterial en el paciente diabético. Medicina Clínica 128:13, 495-497
CrossRef841
William J. Elliott. (2007) Systemic Hypertension. Current Problems in Cardiology 32:4, 201-259
CrossRef842
Chi-Wen Chiang, Chi-Yu Chen, Hui-Fen Chiu, Hsin-Lung Wu, Chun-Yuh Yang. (2007) Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997–2003. Pharmacoepidemiology and Drug Safety 16:4, 412-421
CrossRef843
Gary Owens, Matthew F. Emons, Jennifer Christian-Herman, Grant Lawless. (2007) Current Trends in Pharmacy Benefit Designs: A Threat to Disease Management in Chronic Complex Diseases. Disease Management 10:2, 74-82
CrossRef844
Wouter BA Eijkelkamp, Zhongxin Zhang, Barry M Brenner, Mark E Cooper, Richard B Devereux, Björn Dahlöf, Hans Ibsen, William F Keane, Lars H Lindholm, Michael H Olsen, Hans-Henrik Parving, Giuseppe Remuzzi, Shahnaz Shahinfar, Steven M Snapinn, Kristian Wachtell, Dick de Zeeuw. (2007) Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. Journal of Hypertension 25:4, 871-876
CrossRef845
Toshio MIYATA, Shunya TAKIZAWA. (2007) Toward better renoprotection: Lessons from angiotensin receptor blockers. Hemodialysis International 11:2, 164-168
CrossRef846
Yuko Okazaki, Yasushi Yamasaki, Haruhito A. Uchida, Kazunori Okamoto, Minoru Satoh, Keisuke Maruyama, Yohei Maeshima, Hitoshi Sugiyama, Takeshi Sugaya, Naoki Kashihara, Hirofumi Makino. (2007) Enhanced TGF-b/Smad signaling in the early stage of diabetic nephropathy is independent of the AT1a receptor. Clinical and Experimental Nephrology 11:1, 77-87
CrossRef847
Dick de Zeeuw. (2007) Albuminuria: A Target for Treatment of Type 2 Diabetic Nephropathy. Seminars in Nephrology 27:2, 172-181
CrossRef848
Masahiko Igarashi, Akihiko Hirata, Hisae Nozaki, Yuko Kadomoto-Antsuki, Makoto Tominaga. (2007) Role of angiotensin II type-1 and type-2 receptors on vascular smooth muscle cell growth and glucose metabolism in diabetic rats. Diabetes Research and Clinical Practice 75:3, 267-277
CrossRef849
Kevin D Burns. (2007) The emerging role of angiotensin-converting enzyme-2 in the kidney. Current Opinion in Nephrology and Hypertension 16:2, 116-121
CrossRef850
Susan B. Gurley, Thomas M. Coffman. (2007) The Renin-Angiotensin System and Diabetic Nephropathy. Seminars in Nephrology 27:2, 144-152
CrossRef851
Jacoba P Greving, Petra Denig, Dick de Zeeuw, Flora M Haaijer-Ruskamp. (2007) Claims in advertisements for antihypertensive drugs in a Dutch medical journal. Journal of Hypertension 25:3, 713-722
CrossRef852
Edmund J. Lewis. (2007) Treating Hypertension in the Patient With Overt Diabetic Nephropathy. Seminars in Nephrology 27:2, 182-194
CrossRef853
Paola Fioretto, Michael Mauer. (2007) Histopathology of Diabetic Nephropathy. Seminars in Nephrology 27:2, 195-207
CrossRef854
Jose A Garcia-Donaire, Julian Segura, Luis M Ruilope. (2007) Clinical trials in nephrology: success or failure. Current Opinion in Nephrology and Hypertension 16:2, 59-63
CrossRef855
G Y H Lip, A H Barnett, A Bradbury, F P Cappuccio, P S Gill, E Hughes, C Imray, K Jolly, K Patel. (2007) Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. Journal of Human Hypertension 21:3, 183-211
CrossRef856
Atsuhiro Ichihara, Yuki Kaneshiro, Mariyo Sakoda, Tomoko Takemitsu, Hiroshi Itoh. (2007) Add-on Amlodipine Improves Arterial Function and Structure in Hypertensive Patients Treated With an Angiotensin Receptor Blocker. Journal of Cardiovascular Pharmacology 49:3, 161-166
CrossRef857
Elena Gagliardini, Ariela Benigni. (2007) Therapeutic potential of TGF-β inhibition in chronic renal failure. Expert Opinion on Biological Therapy 7:3, 293-304
CrossRef858
Sudha Ganne, Surender Arora, Jocelyne Karam, Samy I McFarlane. (2007) Therapeutic interventions for hypertension in metabolic syndrome: a comprehensive approach. Expert Review of Cardiovascular Therapy 5:2, 201-211
CrossRef859
Zhenqi Liu. (2007) The renin-angiotensin system and insulin resistance. Current Diabetes Reports 7:1, 34-42
CrossRef860
Michiyo Hase, Tetsuya Babazono, Sachiko Karibe, Naohide Kinae, Yasuhiko Iwamoto. (2007) Renoprotective effects of tea catechin in streptozotocin- induced diabetic rats. International Urology and Nephrology 38:3-4, 693-699
CrossRef861
George S. Stergiou. (2007) Combination pharmacotherapy in hypertension. International Urology and Nephrology 38:3-4, 673-682
CrossRef862
Wilbert S. Aronow. (2007) Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Clinics in Geriatric Medicine 23:1, 61-81
CrossRef863
Thomas G. Pickering, Kazuomi Kario. (2007) Why Is Blood Pressure So Hard to Control in Patients With Type 2 Diabetes?. Journal of the CardioMetabolic Syndrome 2:2, 114-118
CrossRef864
Colin Berry, Jean-Claude Tardif, Martial G. Bourassa. (2007) Coronary Heart Disease in Patients With Diabetes. Journal of the American College of Cardiology 49:6, 631-642
CrossRef865
E. A. Francischetti, V. A. Genelhu. (2007) Obesity-hypertension: an ongoing pandemic. International Journal of Clinical Practice 61:2, 269-280
CrossRef866
(2007) References. American Journal of Kidney Diseases 49:2, S160-S179
CrossRef867
Tsuneo Takenaka, Yoshihiko Kanno, Yoichi Ohno, Hiromichi Suzuki. (2007) Key role of insulin resistance in vascular injury among hemodialysis patients. Metabolism 56:2, 153-159
CrossRef868
Athanase D Protogerou, Theodore G Papaioannou, Jacques Blacher, Christos M Papamichael, John P Lekakis, Michel E Safar. (2007) Central blood pressures: do we need them in the management of cardiovascular disease? Is it a feasible therapeutic target?. Journal of Hypertension 25:2, 265-272
CrossRef869
Asterios Karagiannis, Dimitri P Mikhailidis, Vasilios G Athyros, Anna I Kakafika, Konstantinos Tziomalos, Evangelos N Liberopoulos, Matilda Florentin, Moses Elisaf. (2007) The role of renin–angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. Expert Opinion on Therapeutic Targets 11:2, 191-205
CrossRef870
B. Lu, J. Wen, X.Y. Song, X.H. Dong, Y.H. Yang, Z.Y. Zhang, N.Q. Zhao, H.Y. Ye, B. Mou, F.L. Chen, Y. Liu, Y. Shen, X.C. Wang, L.N. Zhou, Y.M. Li, X.X. Zhu, R.M. Hu. (2007) High prevalence of albuminuria in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown. Diabetes Research and Clinical Practice 75:2, 184-192
CrossRef871
PAOLO FERRARI. (2007) Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease (Review Article). Nephrology 12:1, 81-89
CrossRef872
György Jermendy, Piero Ruggenenti. (2007) Preventing microalbuminuria in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews 23:2, 100-110
CrossRef873
Farahnak Assadi. (2007) Effect of Microalbuminuria Lowering on Regression of Left Ventricular Hypertrophy in Children and Adolescents with Essential Hypertension. Pediatric Cardiology 28:1, 27-33
CrossRef874
Norihisa Osawa, Daisuke Koya, Shin-ichi Araki, Takashi Uzu, Tatsuhiko Tsunoda, Atsunori Kashiwagi, Yusuke Nakamura, Shiro Maeda. (2007) Combinational effect of genes for the renin–angiotensin system in conferring susceptibility to diabetic nephropathy. Journal of Human Genetics 52:2, 143-151
CrossRef875
D. G. Brillante, A. J. O'Sullivan, M. T. Johnstone, L. G. Howes. (2007) Evidence for functional expression of vascular angiotensin II type 2 receptors in patients with insulin resistance. Diabetes, Obesity and Metabolism 0:0, 070116065049006
CrossRef876
S. A. Saha, J. Molnar, R. R. Arora. (2007) Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials. Diabetes, Obesity and Metabolism 0:0, 070116065049004
CrossRef877
Hsin-Wei Kuo, Shang-Shyue Tsai, Mao-Meng Tiao, Chun-Yuh Yang. (2007) Epidemiological Features of CKD in Taiwan. American Journal of Kidney Diseases 49:1, 46-55
CrossRef878
Roberto Bleuel Amazonas, Rodrigo de Almeida Sanita, Hiroshi Kawachi, José B. Lopes de Faria. (2007) Prevention of Hypertension with or without Renin-Angiotensin System Inhibition Precludes Nephrin Loss in the Early Stage of Experimental Diabetes Mellitus. Nephron Physiology 107:2, p57-p64
CrossRef879
Benjamin J Epstein, Katherine Vogel, Biff F Palmer. (2007) Dihydropyridine Calcium Channel Antagonists in the Management of Hypertension. Drugs 67:9, 1309-1327
CrossRef880
Tatsuya Shoji, Akira Wada, Kazunori Inoue, Daisuke Hayashi, Kodo Tomida, Yoshiyuki Furumatsu, Tetsuya Kaneko, Noriyuki Okada, Yoshifumi Fukuhara, Enyu Imai, Yoshiharu Tsubakihara. (2007) Prospective Randomized Study Evaluating the Efficacy of the Spherical Adsorptive Carbon AST-120 in Chronic Kidney Disease Patients with Moderate Decrease in Renal Function. Nephron Clinical Practice 105:3, c99-c107
CrossRef881
R. Garrick. (2007) Combination Therapy With an Angiotensin Receptor Blocker and an ACE Inhibitor in Proteinuric Renal Disease: A Systematic Review of the Efficacy and Safety Data. Yearbook of Medicine 2007, 197-198
CrossRef882
H. Frank, S. Pscherer. (2007) Diabetische Nephropathie. Der Nephrologe 2:1, 53-59
CrossRef883
Kenmei Takaichi, Fumi Takemoto, Yoshifumi Ubara, Yasumichi Mori. (2007) Analysis of Factors Causing Hyperkalemia. Internal Medicine 46:12, 823-829
CrossRef884
Hui Min Jin, Yu Pan. (2007) Renoprotection Provided by Losartan in Combination with Pioglitazone Is Superior to Renoprotection Provided by Losartan Alone in Patients with Type 2 Diabetic Nephropathy. Kidney and Blood Pressure Research 30:4, 203-211
CrossRef885
Domenic A Sica. (2007) Combination ACE Inhibitor and Angiotensin Receptor Blocker Therapy-Future Considerations. The Journal of Clinical Hypertension 9:1, 78-86
CrossRef886
R. Garrick. (2007) Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: A Post Hoc Analysis of the BENEDICT Trial. Yearbook of Medicine 2007, 198-200
CrossRef887
Murray Epstein. (2007) Resistant Hypertension: Prevalence and Evolving Concepts. The Journal of Clinical Hypertension 9, 2-6
CrossRef888
Toshiaki Takahashi, Hidehiko Ono, Yuko Ono, Toshihiko Ishimitsu, Hiroaki Matsuoka. (2007) Combination Therapy With Telmisartan and Spironolactone Alleviates L-NAME Exacerbated Nephrosclerosis With an Increase in PPAR-γ and Decrease in TGF-β1. International Heart Journal 48:5, 637-647
CrossRef889
David H G Smith. (2007) Fixed-Dose Combination Antihypertensives and Reduction in Target Organ Damage. American Journal of Cardiovascular Drugs 7:6, 413-422
CrossRef890
Marsha A. Raebel, David L. McClure, Steven R. Simon, K. Arnold Chan, Adrianne Feldstein, Susan E. Andrade, Jennifer Elston Lafata, Douglas Roblin, Robert L. Davis, Margaret J. Gunter, Richard Platt. (2007) Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiology and Drug Safety 16:1, 55-64
CrossRef891
D Lyons, S H D Jackson, C G Swift. (2007) Selective AT1 Receptor Antagonism Enhances Sympathetically Mediated Vasoconstriction in Man. Clinical Pharmacology & Therapeutics 81:1, 83-87
CrossRef892
W.J. Elliott. (2007) Long-Term Renoprotective Effects of Standard Versus High Doses of Telmisartan in Hypertensive Nondiabetic Nephropathies. Yearbook of Cardiology 2007, 99-101
CrossRef893
Eiji Sugaru, Tsutomu Nakagawa, Michiko Ono-Kishino, Jun Nagamine, Teruhisa Tokunaga, Makoto Kitoh, W. Ewan Hume, Ryu Nagata, Mutsuo Taiji. (2007) Amelioration of Established Diabetic Nephropathy by Combined Treatment with SMP-534 (Antifibrotic Agent) and Losartan in <i>db/db</i> Mice. Nephron Experimental Nephrology 105:2, e45-e52
CrossRef894
George S Stergiou. (2007) Flaws in Dose-Finding of Antihypertensive Drugs. American Journal of Cardiovascular Drugs 7:5, 357-359
CrossRef895
Steven D. Crowley, Susan B. Gurley, Thomas M. Coffman. (2007) AT1 Receptors and Control of Blood Pressure: The Kidney and More…. Trends in Cardiovascular Medicine 17:1, 30-34
CrossRef896
W.J. Elliott. (2007) Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration Rate. Yearbook of Cardiology 2007, 94-96
CrossRef897
Bruce Ovbiagele, Sandeep Sachdeva. (2007) Preventing another event: Role of the hospitalist in discharge stroke prevention. Journal of Hospital Medicine 2:1, 31-38
CrossRef898
Genjiro Kimura. (2007) Clinical Pathology and Treatment of Renin-Angiotensin System 2. Chronic Kidney Disease and the Renin-Angiotensin System. Internal Medicine 46:16, 1295-1298
CrossRef899
Stavroula Ziakka, Nikolaos Kaperonis, Eleftheria Ferentinou, Filippos Karakasis, George Ntatsis, Christine Kourvelou, Nikolaos Papagalanis. (2007) Calcium Channels Blockers and Progression of Kidney Disease. Renal Failure 29:8, 1003-1012
CrossRef900
Alberto Zanchetti. (2007) Clinical practice and guidelines in Europe for the treatment of hypertension, with a focus on patients with diabetes mellitus. Clinical Therapeutics 29, S44-S53
CrossRef901
(2007) Traitement médicamenteux du diabète de type 2recommandation de bonne pratique. Diabetes & Metabolism 33:1, S26-S105
CrossRef902
Andres Serrano, Jie Huang, Cybele Ghossein, Laura Nishi, Anupama Gangavathi, Vijayachitra Madhan, Paramesh Ramadugu, Shubhada N. Ahya, James Paparello, Neenoo Khosla, William Schlueter, Daniel Batlle. (2007) Stabilization of Glomerular Filtration Rate in Advanced Chronic Kidney Disease: A Two-Year Follow-up of a Cohort of Chronic Kidney Disease Patients Stages 4 and 5. Advances in Chronic Kidney Disease 14:1, 105-112
CrossRef903
Serdar Kahvecioglu, Ibrahim Akdag, Mustafa Gullulu, Mahmut Arabul, Alpaslan Ersoy, Kamil Dilek, Mahmut Yavuz, Mustafa Yurtkuran. (2007) Comparison of Higher Dose of Losartan Treatment with Losartan Plus Carvedilol and Losartan Plus Ramipril in Patients with Glomerulonephritis and Proteinuria*. Renal Failure 29:2, 169-175
CrossRef904
Lucia Del Vecchio, Mirella Procaccio, Sara Viganò, Daniele Cusi. (2007) Mechanisms of Disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nature Clinical Practice Nephrology 3:1, 42-49
CrossRef905
Mitsushige SUGIMOTO, Takahisa FURUTA, Naohito SHIRAI, Chise KODAIRA, Masahumi NISHINO, Mihoko YAMADE, Mutsuhiro IKUMA, Akira HISHIDA. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:4, 205-212
CrossRef906
Vivencio Barrios, Alessandro Boccanelli, Silke Ewald, Xavier Girerd, Anthony Heagerty, Jean-Marie Krzesinski, Robert Lins, Jos?? Rodicio, Thomas Stefenelli, Arend Woittiez, Michael B??hm. (2007) Efficacy and Tolerability of Olmesartan Medoxomil in Patients??with Mild to Moderate Essential Hypertension. Clinical Drug Investigation 27:8, 545-558
CrossRef907
Kihito Takahashi. (2007) Drug Development in Japan. International Journal of Pharmaceutical Medicine 21:5, 331-338
CrossRef908
Giuseppe Remuzzi. (2007) Clinical perspectives in the prevention and treatment of chronic nephropathy, including an overview of the DEMAND Study. Clinical Therapeutics 29, S64-S72
CrossRef909
Geng Zhang, He Wang, Fuli Wang, Lei Yu, Xiaojian Yang, Junhua Meng, Weijun Qin, Guojun Wu, Jianhua Li, Angang Yang, Yu Zhou, Rui Zhang. (2007) Gene Polymorphisms of the Renin-Angiotensin-Aldosterone System and Angiotensin II Type 1-Receptor Activating Antibodies in Renal Rejection. The Tohoku Journal of Experimental Medicine 213:3, 203-214
CrossRef910
Pantelis A. Sarafidis, Nitin Khosla, George L. Bakris. (2007) Antihypertensive Therapy in the Presence of Proteinuria. American Journal of Kidney Diseases 49:1, 12-26
CrossRef911
C. J. F. Holubarsch. (2007) Kardiovaskuläre Erkrankungen bei Patienten mit Nierenerkrankungen. Clinical Research in Cardiology Supplements 2:S1, S9-S14
CrossRef912
Philip R Liebson. (2006) Calcium channel blockers in the spectrum of antihypertensive agents. Expert Opinion on Pharmacotherapy 7:17, 2385-2401
CrossRef913
Atsuko Kamijo-Ikemori, Takeshi Sugaya, Kenjiro Kimura. (2006) Urinary fatty acid binding protein in renal disease. Clinica Chimica Acta 374:1-2, 1-7
CrossRef914
Darpan Bansal, Georges Chahoud, Eugene S Smith, Jawahar L Mehta. (2006) Prevention of heart failure. Current Opinion in Internal Medicine 5:6, 537-543
CrossRef915
Andrew S. Levey, Tom Greene, Mark J. Sarnak, Xuelei Wang, Gerald J. Beck, John W. Kusek, Allan J. Collins, Joel D. Kopple. (2006) Effect of Dietary Protein Restriction on the Progression of Kidney Disease: Long-Term Follow-Up of the Modification of Diet in Renal Disease (MDRD) Study. American Journal of Kidney Diseases 48:6, 879-888
CrossRef916
Hans R Brunner. (2006) Olmesartan medoxomil: current status of its use in monotherapy. Vascular Health and Risk Management 2:4, 327-340
CrossRef917
Georg Heinze, Sean Collins, Michael A. Benedict, Louis L. Nguyen, Reinhard Kramar, Wolfgang C. Winkelmayer, Martin Haas, Alexander Kainz, Rainer Oberbauer. (2006) The Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use During Postischemic Acute Transplant Failure and Renal Allograft Survival. Transplantation 82:11, 1441-1448
CrossRef918
William C. Cushman, Jan Basile. (2006) Achieving Blood Pressure Goals: Why Aren't We?. The Journal of Clinical Hypertension 8:12, 865-871
CrossRef919
R MA Van de Wal, A A Voors, R T Gansevoort. (2006) Urinary albumin excretion and the renin–angiotensin system in cardiovascular risk management. Expert Opinion on Pharmacotherapy 7:18, 2505-2520
CrossRef920
Sheldon Hirsch. (2006) Preventing end-stage renal disease: flexible strategies to overcome obstacles. Current Opinion in Internal Medicine 5:6, 609-616
CrossRef921
, G. Breithardt. (2006) Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz. Clinical Research in Cardiology Supplements 1:2, 103-117
CrossRef922
Keith Norris, Jacque Bourgoigne, Jennifer Gassman, Lee Hebert, John Middleton, Robert A. Phillips, Otelio Randall, Stephen Rostand, Susan Sherer, Robert D. Toto, Jackson T. Wright, Xuelei Wang, Tom Greene, Lawrence J. Appel, Julia Lewis. (2006) Cardiovascular Outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases 48:5, 739-751
CrossRef923
Georgia Soldatos, Mark Emmanuel Cooper. (2006) Advanced glycation end products and vascular structure and function. Current Hypertension Reports 8:6, 472-478
CrossRef924
A. GIRACH, D. MANNER, M. PORTA. (2006) Diabetic microvascular complications: can patients at risk be identified? A review. International Journal of Clinical Practice 60:11, 1471-1483
CrossRef925
M E Pavkov, W C Knowler, P H Bennett, H C Looker, J Krakoff, R G Nelson. (2006) Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians. Kidney International 70:10, 1840-1846
CrossRef926
Anton H van den Meiracker, Rini GA Baggen, Sacha Pauli, Anouk Lindemans, Arnold G Vulto, Don Poldermans, Frans Boomsma. (2006) Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. Journal of Hypertension 24:11, 2285-2292
CrossRef927
Andrew J. Palmer, William J. Valentine, Daniel M. D. Tucker, Joshua A. Ray, Stéphane Roze, Lieven Annemans, Pablo Lapuerta, Roland Chen, Sylvie Gabriel, Paulo Carita, Roger A. Rodby, Dick de Zeeuw, Hans-Henrik Parving, Maurice Laville. (2006) A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. Current Medical Research and Opinion 22:11, 2095-2100
CrossRef928
Vito M Campese, Jeanie Park. (2006) Use of antagonists of aldosterone in patients with chronic kidney disease: potential advantages and risks. Journal of Hypertension 24:11, 2157-2159
CrossRef929
Claudio Borghi, Sibel Ertek, Arrigo FG Cicero. (2006) Irbesartan: a review of its use alone and in combination with hydrochlorothiazide. Therapy 3:6, 733-749
CrossRef930
A Heagerty. (2006) Optimizing hypertension management in clinical practice. Journal of Human Hypertension 20:11, 841-849
CrossRef931
J Mahmood, F Khan, S Okada, N Kumagai, T Morioka, T Oite. (2006) Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis. Kidney International 70:9, 1591-1598
CrossRef932
Daniel C Cattran. (2006) Is valsartan renoprotective in patients with IgA nephropathy?. Nature Clinical Practice Nephrology 2:11, 610-611
CrossRef933
G. R. Hetzel. (2006) Progressionsverlangsamung am Beispiel der diabetischen Nephropathie. Der Nephrologe 1:4, 217-224
CrossRef934
Hiddo J Lambers Heerspink, Jacoline W Brinkman, Stephan JL Bakker, Ron T Gansevoort, Dick de Zeeuw. (2006) Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Current Opinion in Nephrology and Hypertension 15:6, 631-636
CrossRef935
Matthew C. Leinung. (2006) The Role of Calcium Antagonists in the Treatment of Hypertension in Patients With Diabetes. The Endocrinologist 16:6, 349-357
CrossRef936
Lawrence Blonde, Judith Dempster, Joanne M. Gallivan, Elizabeth Warren-Boulton. (2006) Reducing cardiovascular disease risk in patients with diabetes: A message from the National Diabetes Education Program. Journal of the American Academy of Nurse Practitioners 18:11, 524-533
CrossRef937
Pasquale Zamboli, Luca Nicola, Roberto Minutolo, Valerio Bertino, Fausta Catapano, Giuseppe Conte. (2006) Management of hypertension in chronic kidney disease. Current Hypertension Reports 8:6, 497-501
CrossRef938
Peter Rossing. (2006) Diabetic Nephropathy: Worldwide epidemic and effects of current treatment on natural history. Current Diabetes Reports 6:6, 479-483
CrossRef939
Giovanni FM Strippoli, Carmen Bonifati, Maria E Craig, Sankar D Navaneethan, Jonathan C Craig, Giovanni FM Strippoli. 2006. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. .
CrossRef940
Giovanni FM Strippoli, Allison Tong, Suetonia C Palmer, Grahame J Elder, Jonathan C Craig, Giovanni FM Strippoli. 2006. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. .
CrossRef941
2006. Hypertension. .
CrossRef942
S Bianchi, R Bigazzi, V M Campese. (2006) Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International
CrossRef943
Robert E. Heinig. (2006) The patient with diabetes: Preventing cardiovascular complications. Clinical Cardiology 29:S2, 13-20
CrossRef944
Atsuhiro Ichihara, Yuki Kaneshiro, Fumiaki Suzuki. (2006) Prorenin receptor blockers: effects on cardiovascular complications of diabetes and hypertension. Expert Opinion on Investigational Drugs 15:10, 1137-1139
CrossRef945
P Ruggenenti, G Remuzzi. (2006) Time to abandon microalbuminuria?. Kidney International 70:7, 1214-1222
CrossRef946
Ronald Goldberg. 2006. Type 2 Diabetes. , 187-254.
CrossRef947
Nelson Kopyt. 2006. Chronic Kidney Disease. , 463-500.
CrossRef948
YOSHIO HORITA, KOUICHI TAURA, TAKASHI TAGUCHI, AKIRA FURUSU, SHIGERU KOHNO. (2006) Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology 11:5, 462-466
CrossRef949
Graham J Macdonald. (2006) Mechanics or mediators: arterial damage from high blood pressure. Journal of Hypertension 24:10, 1921-1923
CrossRef950
Sanae Watanabe, Takafumi Okura, Mie Kurata, Jun Irita, Seiko Manabe, Ken-ichi Miyoshi, Tomikazu Fukuoka, Kazuo Murakami, Jitsuo Higaki. (2006) The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Clinical Therapeutics 28:10, 1677-1685
CrossRef951
Eberhard Ritz, Ralf Dikow. (2006) Hypertension and antihypertensive treatment of diabetic nephropathy. Nature Clinical Practice Nephrology 2:10, 562-567
CrossRef952
MARTIN GALLAGHER, VLADO PERKOVIC, JOHN CHALMERS. (2006) Diuretics: A modern day treatment option? (Review Article). Nephrology 11:5, 419-427
CrossRef953
Antonio Ceriello. (2006) Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes. Current Opinion in Lipidology 17:5, 510-518
CrossRef954
Daniel A Duprez, Daniel J Wilson. 2006. Arterial Hypertension. , 19-62.
CrossRef955
Rudy Bilous. (2006) The prevalence and management of cardiorenal risk factors in patients with diabetic nephropathy. Nature Clinical Practice Endocrinology & Metabolism 2:10, 548-549
CrossRef956
Michael Cuffe. (2006) The patient with cardiovascular disease: Treatment strategies for preventing major events. Clinical Cardiology 29:S2, 4-12
CrossRef957
David W. Gardner, Khurshid A. Khan, Gurushankar Govindarajan, John M. Palmer, James R. Sowers. 2006. Type 1 Diabetes Mellitus. , 147-186.
CrossRef958
Makoto Mizuno, Toshio Sada, Mikio Kato, Yasuo Fukushima, Hideki Terashima, Hiroyuki Koike. (2006) The Effect of Angiotensin II Receptor Blockade on an End-Stage Renal Failure Model of Type 2 Diabetes. Journal of Cardiovascular Pharmacology 48:4, 135-142
CrossRef959
Genjiro Kimura. (2006) Japanese subpopulation analysis of the RENAAL, the landmark trial, is welcomed by our society. Clinical and Experimental Nephrology 10:3, 226-227
CrossRef960
Kiyoshi Kurokawa, Juliana C.N. Chan, Mark E. Cooper, William F. Keane, Shahnaz Shahinfar, Zhongxin Zhang. (2006) Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clinical and Experimental Nephrology 10:3, 193-200
CrossRef961
H. Makino, M. Mukoyama, K. Mori, T. Suganami, M. Kasahara, K. Yahata, T. Nagae, H. Yokoi, K. Sawai, Y. Ogawa, S. Suga, Y. Yoshimasa, A. Sugawara, I. Tanaka, K. Nakao. (2006) Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. Diabetologia 49:10, 2514-2524
CrossRef962
C. Hasslacher. (2006) Metabolische Kontrolle bei diabetischer Nephropathie. Der Diabetologe 2:5, 410-418
CrossRef963
W. Hunger-Dathe, G. Wolf. (2006) Albuminurie bei Diabetes mellitus. Der Diabetologe 2:5, 400-409
CrossRef964
Lingyun Lai, Jing Chen, Chuan-Ming Hao, Shanyan Lin, Yong Gu. (2006) Aldosterone promotes fibronectin production through a Smad2-dependent TGF-β1 pathway in mesangial cells. Biochemical and Biophysical Research Communications 348:1, 70-75
CrossRef965
R. Kreutz. (2006) Hypertonietherapie. Clinical Research in Cardiology 95:S6, vi34-vi40
CrossRef966
Akira Mima, Takeshi Matsubara, Hidenori Arai, Hideharu Abe, Kojiro Nagai, Hiroshi Kanamori, Eriko Sumi, Toshikazu Takahashi, Noriyuki Iehara, Atsushi Fukatsu, Toru Kita, Toshio Doi. (2006) Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy. Laboratory Investigation 86:9, 927-939
CrossRef967
Karin Jandeleit-Dahm, Mark E. Cooper. (2006) Hypertension and Diabetes: Role of the Renin-Angiotensin System. Endocrinology & Metabolism Clinics of North America 35:3, 469-490
CrossRef968
, G. Breithardt. (2006) Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz. Clinical Research in Cardiology Supplements 1:1, 8-30
CrossRef969
(2006) Literature alert. Current Hypertension Reports 8:5, 353-355
CrossRef970
Kyung W Park. (2006) Angiotensin-Converting Enzyme Inhibitors, AG Receptor Blockers, and Aldosterone Receptor Antagonists. International Anesthesiology Clinics 43:2, 23-37
CrossRef971
Akinlolu O. Ojo. (2006) Cardiovascular Complications After Renal Transplantation and Their Prevention. Transplantation 82:5, 603-611
CrossRef972
William B. White, Henry A. Punzi, Debra Murwin, Stephen E. Koval, Giora Davidai, Joel M. Neutel. (2006) Effects of the Angiotensin II Receptor Blockers Telmisartan vs Valsartan in Combination With Hydrochlorothiazide 25 mg Once Daily for the Treatment of Hypertension. The Journal of Clinical Hypertension 8:9, 626-633
CrossRef973
M. Canales, P. Youssef, R. Spong, A. Ishani, K. Savik, M. Hertz, H. N. Ibrahim. (2006) Predictors of Chronic Kidney Disease in Long-Term Survivors of Lung and Heart-Lung Transplantation. American Journal of Transplantation 6:9, 2157-2163
CrossRef974
James B. Wetmore, Kirsten L. Johansen, Saunak Sen, Adriana M. Hung, David H. Lovett. (2006) An angiotensin converting enzyme haplotype predicts survival in patients with end stage renal disease. Human Genetics 120:2, 201-210
CrossRef975
G L Bakris, L Ruilope, F Locatelli, A Ptaszynska, B Pieske, I Raz, A A Voors, J Dechamplain, M A Weber. (2006) Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. Journal of Human Hypertension 20:9, 693-700
CrossRef976
Huifang Cheng, Raymond C Harris. (2006) Potential side effects of renin inhibitors – mechanisms based on comparison with other renin–angiotensin blockers. Expert Opinion on Drug Safety 5:5, 631-641
CrossRef977
N. R. ROBLES, B. CANCHO, S. BARROSO, M. V. MARTÍN, E. SÁNCHEZ CASADO. (2006) Untoward effects of chronic dual renin-angiotensin system blockade: influence of previous chronic renal failure. International Journal of Clinical Practice 60:9, 1035-1039
CrossRef978
Michel Azizi. (2006) Renin inhibition. Current Opinion in Nephrology and Hypertension 15:5, 505-510
CrossRef979
IGOR CODREANU, NORBERTO PERICO, SANJIB K SHARMA, ARRIGO SCHIEPPATI, GIUSEPPE REMUZZI. (2006) Prevention programmes of progressive renal disease in developing nations (Review Article). Nephrology 11:4, 321-328
CrossRef980
Aldo P. Maggioni. (2006) Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease. Cardiovascular Drugs and Therapy 20:4, 295-308
CrossRef981
Susan B. Gurley, Alicia Allred, Thu H. Le, Robert Griffiths, Lan Mao, Nisha Philip, Timothy A. Haystead, Mary Donoghue, Roger E. Breitbart, Susan L. Acton, Howard A. Rockman, Thomas M. Coffman. (2006) Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. Journal of Clinical Investigation 116:8, 2218-2225
CrossRef982
(2006) Letters to the Editor. The American Statistician 60:3, 295-297
CrossRef983
L. Ebony Boulware, Misty U. Troll, Bernard G. Jaar, Donna I. Myers, Neil R. Powe. (2006) Identification and Referral of Patients With Progressive CKD: A National Study. American Journal of Kidney Diseases 48:2, 192-204
CrossRef984
HIROSHI KAWACHI, NAOKO MIYAUCHI, KOICHI SUZUKI, GI DONG HAN, MICHIAKI ORIKASA, FUJIO SHIMIZU. (2006) Role of podocyte slit diaphragm as a filtration barrier (Review Article). Nephrology 11:4, 274-281
CrossRef985
Jerome Rossert, Marc Froissart. (2006) Role of Anemia in Progression of Chronic Kidney Disease. Seminars in Nephrology 26:4, 283-289
CrossRef986
K Katayama, S Nomura, H Ishikawa, T Murata, S Koyabu, T Nakano. (2006) Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney International 70:1, 151-156
CrossRef987
Teresa M Seccia, Anna S Belloni, Diego Guidolin, Daniele Sticchi, Gastone G Nussdorfer, Achille C Pessina, Gian Paolo Rossi. (2006) The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension. Journal of Hypertension 24:7, 1419-1427
CrossRef988
Marcia Murussi, Jorge Luiz Gross, Sandra Pinho Silveiro. (2006) Glomerular filtration rate changes in normoalbuminuric and microalbuminuric Type 2 diabetic patients and normal individuals. Journal of Diabetes and its Complications 20:4, 210-215
CrossRef989
Aysegul Atmaca, Olcay Gedik. (2006) Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes. Advances in Therapy 23:4, 615-622
CrossRef990
G Tonolo, M Velussi, E Brocco, C Abaterusso, A Carraro, G Morgia, A Satta, R Faedda, A Abhyankar, H Luthman, R Nosadini. (2006) Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney International 70:1, 177-186
CrossRef991
V R Sørensen, P M Hansen, J Heaf, B Feldt-Rasmussen. (2006) Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Kidney International 70:1, 187-191
CrossRef992
G. Cohuet, H. Struijker-Boudier. (2006) Mechanisms of target organ damage caused by hypertension: Therapeutic potential. Pharmacology & Therapeutics 111:1, 81-98
CrossRef993
Martin MacKinnon, Sabin Shurraw, Ayub Akbari, Greg A. Knoll, James Jaffey, Heather D. Clark. (2006) Combination Therapy With an Angiotensin Receptor Blocker and an ACE Inhibitor in Proteinuric Renal Disease: A Systematic Review of the Efficacy and Safety Data. American Journal of Kidney Diseases 48:1, 8-20
CrossRef994
K J Schjoedt, K Rossing, T R Juhl, F Boomsma, L Tarnow, P Rossing, H-H Parving. (2006) Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney International
CrossRef995
M Okumura, M Masada, Y Yoshida, H Shintaku, M Hosoi, N Okada, Y Konishi, T Morikawa, K Miura, M Imanishi. (2006) Decrease in tetrahydrobiopterin as a possible cause of nephropathy in type II diabetic rats. Kidney International
CrossRef996
D J Kelly, Y Zhang, A J Cox, R E Gilbert. (2006) Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model. Kidney International 69:11, 1954-1960
CrossRef997
PAUL E DE JONG, RON T GANSEVOORT. (2006) Prevention of chronic kidney disease: The next step forward! (Review Article). Nephrology 11:3, 240-244
CrossRef998
Bernard MY Cheung. (2006) Therapeutic potential of angiotensin receptor blockers in hypertension. Expert Opinion on Investigational Drugs 15:6, 625-635
CrossRef999
Gavin Y. Oudit, Andrew M. Herzenberg, Zamaneh Kassiri, Denise Wong, Heather Reich, Rama Khokha, Michael A. Crackower, Peter H. Backx, Josef M. Penninger, James W. Scholey. (2006) Loss of Angiotensin-Converting Enzyme-2 Leads to the Late Development of Angiotensin II-Dependent Glomerulosclerosis. The American Journal of Pathology 168:6, 1808-1820
CrossRef1000
Marcello Casaccia Bertoluci, Deise Uebel, Alexandre Schmidt, Fulvio Clemo Santos Thomazelli, Fábio Ramos Oliveira, Helena Schmid. (2006) Urinary TGF-β1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. Diabetes Research and Clinical Practice 72:3, 258-264
CrossRef1001
M. Lajer, K. J. Schjoedt, P. Jacobsen, L. Tarnow, H.-H. Parving. (2006) Aldosterone synthase (CYP11B2) -344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian Type 1 diabetic patients. Diabetic Medicine 23:6, 675-680
CrossRef1002
(2006) Journal club. Kidney International 69:11, 1932-1933
CrossRef1003
A. Cordero Fort, J. Moreno Arribas, A. Martín Arnau, E. Nasarre Lorite, E. Alegría Barrero, E. Alegría Ezquerra. (2006) Prevalencia de síndrome metabólico y asociación con la cardiopatía isquémica en pacientes cardiológicos ambulatorios. Revista Clínica Española 206:6, 259-265
CrossRef1004
Julie Kreyenbuhl, Faith B. Dickerson, Deborah R. Medoff, Clayton H. Brown, Richard W. Goldberg, LiJuan Fang, Karen Wohlheiter, Leena P. Mittal, Lisa B. Dixon. (2006) Extent and Management of Cardiovascular Risk Factors in Patients With Type 2 Diabetes and Serious Mental Illness. The Journal of Nervous and Mental Disease 194:6, 404-410
CrossRef1005
A. Roca-Cusachs. (2006) Tratamiento preventivo del ictus. Clínica e Investigación en Arteriosclerosis 18, 20-33
CrossRef1006
B R Hemmelgarn, J Zhang, B J Manns, M Tonelli, E Larsen, W A Ghali, D A Southern, K McLaughlin, G Mortis, B F Culleton. (2006) Progression of kidney dysfunction in the community-dwelling elderly. Kidney International 69:12, 2155-2161
CrossRef1007
Naohito Ishii, Hideki Ikenaga, Pamela K. Carmines, Nobukazu Takada, Toshio Okazaki, Tatsuo Nagai, Tadakazu Maeda, Yoshikazu Aoki, Takao Saruta, Masato Katagiri. (2006) Impact of angiotensin-converting enzyme inhibition on renal cortical nitrotyrosine content during increased extracellular glucose concentration. Clinical Biochemistry 39:6, 633-639
CrossRef1008
Matthew D Breyer, Zhonghua Qi, Elena Tchekneva. (2006) Diabetic nephropathy: leveraging mouse genetics. Current Opinion in Nephrology and Hypertension 15:3, 227-232
CrossRef1009
Philippe Gosse. (2006) Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection. Expert Review of Cardiovascular Therapy 4:3, 319-333
CrossRef1010
John H. Contois, Celia Hartigan, Lokinendi V. Rao, L. Michael Snyder, Michael J. Thompson. (2006) Analytical validation of an HPLC assay for urinary albumin. Clinica Chimica Acta 367:1-2, 150-155
CrossRef1011
Shant Der Sarkissian, Matthew J. Huentelman, Jillian Stewart, Michael J. Katovich, Mohan K. Raizada. (2006) ACE2: A novel therapeutic target for cardiovascular diseases. Progress in Biophysics and Molecular Biology 91:1-2, 163-198
CrossRef1012
Wilbert S. Aronow. (2006) Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure. Cardiology in Review 14:3, 108-124
CrossRef1013
P. C. Y. Tong, G. T. C. Ko, W.-B. Chan, R. C. W. Ma, W.-Y. So, M. K. W. Lo, K.-F. Lee, R. Ozaki, C.-C. Chow, C. S. Cockram, J. C. N. Chan. (2006) The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency. Diabetes, Obesity and Metabolism 8:3, 342-347
CrossRef1014
D de Zeeuw, D Ramjit, Z Zhang, A B Ribeiro, K Kurokawa, J P Lash, J Chan, G Remuzzi, B M Brenner, S Shahinfar. (2006) Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. Kidney International 69:9, 1675-1682
CrossRef1015
N. Seki, N. Hashimoto, Y. Suzuki, K. Yagui, Y. Saito. (2006) Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy. Diabetes Research and Clinical Practice 72:2, 135-141
CrossRef1016
Barbara J. Zarowitz, Eric G. Tangalos, Kelly Hollenack, Terry O’Shea. (2006) The Application of Evidence-Based Principles of Care in Older Persons (Issue 3): Management of Diabetes Mellitus. Journal of the American Medical Directors Association 7:4, 234-240
CrossRef1017
Mohan Shenoy, Carrie B. Chapman, M. Zaim Nawaz, NancyK. Sweitzer. (2006) Diagnosis and Management of Stage A Heart Failure. Congestive Heart Failure 12:3, 146-152
CrossRef1018
Allan Flyvbjerg. (2006) Inhibition and reversibility of renal changes: lessons from diabetic kidney disease. Acta Paediatrica 95, 83-92
CrossRef1019
Giuseppe Mancia. (2006) Total cardiovascular risk: a new treatment concept. Journal of Hypertension 24:Suppl 2, S17-S24
CrossRef1020
Gerald Schulman, Rajiv Agarwal, Muralidhar Acharya, Tomas Berl, Samuel Blumenthal, Nelson Kopyt. (2006) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of AST-120 (Kremezin) in Patients With Moderate to Severe CKD. American Journal of Kidney Diseases 47:4, 565-577
CrossRef1021
Elizabeth F. O. Kern, Miriam Maney, Donald R. Miller, Chin-Lin Tseng, Anjali Tiwari, Mangala Rajan, David Aron, Leonard Pogach. (2006) Failure of ICD-9-CM Codes to Identify Patients with Comorbid Chronic Kidney Disease in Diabetes. Health Services Research 41:2, 564-580
CrossRef1022
Roland E Schmieder. (2006) Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?. Journal of Hypertension 24:Suppl 2, S31-S35
CrossRef1023
Christine Z Guo, Smita Kherde, Gail K Adler. (2006) Role of mineralocorticoid receptor in diabetic vascular disease. Current Opinion in Endocrinology & Diabetes 13:2, 127-134
CrossRef1024
Kathy Nicholls. (2006) Angiotensin II antagonists. Nephrology 11, S92-S97
CrossRef1025
J Karalliedde, G Viberti. (2006) Evidence for renoprotection by blockade of the renin–angiotensin–aldosterone system in hypertension and diabetes. Journal of Human Hypertension 20:4, 239-253
CrossRef1026
Noriko Yamabe, Takako Yokozawa. (2006) Activity of the Chinese prescription Hachimi-jio-gan against renal damage in the Otsuka Long-Evans Tokushima Fatty rat: a model of human type 2 diabetes mellitus. Journal of Pharmacy and Pharmacology 58:4, 535-545
CrossRef1027
Allison B. Rosen. (2006) Indications for and Utilization of ACE Inhibitors in Older Individuals with Diabetes. Findings from the National Health and Nutrition Examination Survey 1999 to 2002. Journal of General Internal Medicine 21:4, 315-319
CrossRef1028
Kathy Nicholls. (2006) Antihypertensive therapy in diabetic nephropathy. Nephrology 11, S73-S78
CrossRef1029
Michael A Weber. (2006) Hypertension treatment and implications of recent cardiovascular outcome trials. Journal of Hypertension 24:Suppl 2, S37-S44
CrossRef1030
Piero Ruggenenti, Manuel Macia, Giuseppe Remuzzi. (2006) Angiotensin-receptor blockers for renal protection in Type 2 diabetes. Aging Health 2:2, 295-301
CrossRef1031
Shahnaz Shahinfar, Paulette A Lyle, Zhongxin Zhang, William F Keane, Barry M Brenner. (2006) Losartan: lessons learned from the RENAAL study. Expert Opinion on Pharmacotherapy 7:5, 623-630
CrossRef1032
Steven G. Chrysant, George S. Chrysant. (2006) The Pleiotropic Effects of Angiotensin Receptor Blockers. The Journal of Clinical Hypertension 8:4, 261-268
CrossRef1033
Kwang Kon Koh, Michael J Quon, Seung Hwan Han, Wook-Jin Chung, Jeong-a Kim, Eak Kyun Shin. (2006) Vascular and metabolic effects of candesartan: insights from therapeutic interventions. Journal of Hypertension 24:Suppl 1, S31-S38
CrossRef1034
R. Asmar. (2006) Targeting effective blood pressure control with angiotensin receptor blockers. International Journal of Clinical Practice 60:3, 315-320
CrossRef1035
Norman K Hollenberg. (2006) Diabetes, nephropathy, and the renin system. Journal of Hypertension 24:Suppl 1, S81-S87
CrossRef1036
S Suissa, T Hutchinson, J M Brophy, A Kezouh. (2006) ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney International 69:5, 913-919
CrossRef1037
Jens Gaedeke, Hans-H Neumayer, Harm Peters. (2006) Pharmacological management of renal fibrotic disease. Expert Opinion on Pharmacotherapy 7:4, 377-386
CrossRef1038
Allen Clermont, Sven-Erik Bursell, Edward P Feener. (2006) Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. Journal of Hypertension 24:Suppl 1, S73-S80
CrossRef1039
Wilbert S. Aronow. (2006) Drug Therapy of Older Persons With Hypertension. Journal of the American Medical Directors Association 7:3, 193-196
CrossRef1040
Christian W. Mende. (2006) Improving Antihypertensive Therapy in Patients with Diabetic Nephropathy. Southern Medical Journal 99:2, 150-157
CrossRef1041
Kei Endo, Yoh Miyashita, Hidehisa Sasaki, Masahiro Ohira, Atsuhito Saiki, Nobukiyo Koide, Masaki Otsuka, Tomokazu Oyama, Murano Takeyoshi, Yoshiaki Ito, Koji Shirai. (2006) Probucol delays progression of diabetic nephropathy. Diabetes Research and Clinical Practice 71:2, 156-163
CrossRef1042
Hermann Haller, Gian C Viberti, Albert Mimran, Giuseppe Remuzzi, Antonius J Rabelink, Eberhard Ritz, Lars C Rump, Luis M Ruilope, Shigehiro Katayama, Sadayoshi Ito, Joseph L Izzo, Andrzej Januszewicz. (2006) Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Journal of Hypertension 24:2, 403-408
CrossRef1043
AJ Palmer, R Chen, WJ Valentine, S Roze, B Bregman, N Mehin, S Gabriel. (2006) Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes. Diabetes & Metabolism 32:1, 69-76
CrossRef1044
J.M. Mostaza, C. Lahoz. (2006) Utilización combinada de fármacos para la prevención cardiovascular: más allá de una polipastilla. Clínica e Investigación en Arteriosclerosis 18:1, 35-39
CrossRef1045
Satoshi Morita, Shunichi Fukuhara, Tadao Akizawa, Yasushi Asano, Shozo Koshikawa, Keizo Koide, Kiyoshi Kurokawa. (2006) Prognostic Factors for a Composite End-Point of Renal Outcomes in Patients With Chronic Kidney Disease. Therapeutic Apheresis and Dialysis 10:1, 72-77
CrossRef1046
Michel Azizi, Randy Webb, Juerg Nussberger, Norman K Hollenberg. (2006) Renin inhibition with aliskiren: where are we now, and where are we going?. Journal of Hypertension 24:2, 243-256
CrossRef1047
M Mohsen Ibrahim. (2006) RAS inhibition in hypertension. Journal of Human Hypertension 20:2, 101-108
CrossRef1048
Christina M Wyatt, Michael C Kim, Jonathan A Winston. (2006) Therapy Insight: how changes in renal function with increasing age affect cardiovascular drug prescribing. Nature Clinical Practice Cardiovascular Medicine 3:2, 102-109
CrossRef1049
SREEDHAR MANDAYAM, WILLIAM E MITCH. (2006) Dietary protein restriction benefits patients with chronic kidney disease (Review Article). Nephrology 11:1, 53-57
CrossRef1050
C P Kovesdy, B K Trivedi, K Kalantar-Zadeh, J E Anderson. (2006) Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney International 69:3, 560-564
CrossRef1051
Ahmet M. Sengul, Yüksel Altuntas, Akın Kürklü, Levent Aydın. (2006) Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Research and Clinical Practice 71:2, 210-219
CrossRef1052
Matthew R. Weir. (2006) Providing End-Organ Protection With Renin?Angiotensin System Inhibition: The Evidence So Far. The Journal of Clinical Hypertension 8:2, 99-107
CrossRef1053
R. Düsing. (2006) Angiotensin II-receptor blocker dosages: How high should we go?. International Journal of Clinical Practice 60:2, 179-183
CrossRef1054
Joseph Vassalotti. 2006. Nutritional Strategies for the Patient with Diabetic Nephropathy. , 149-170.
CrossRef1055
W Y So, R C W Ma, R Ozaki, P C Y Tong, M C Y Ng, C S Ho, C W K Lam, C C Chow, W B Chan, A P S Kong, J C N Chan. (2006) Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients – interaction with ACE insertion/deletion polymorphism. Kidney International
CrossRef1056
Arya M. Sharma, Stefan Engeli. (2006) The Role of Renin?Angiotensin System Blockade in the Management of Hypertension Associated With the Cardiometabolic Syndrome. Journal of the CardioMetabolic Syndrome 1:1, 29-35
CrossRef1057
B M Y Cheung, G T Y Cheung, I J Lauder, C-P Lau, C R Kumana. (2006) Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. Journal of Human Hypertension 20:1, 37-43
CrossRef1058
Eiji Sugaru, Tsutomu Nakagawa, Michiko Ono-Kishino, Jun Nagamine, Teruhisa Tokunaga, Makoto Kitoh, W. Ewan Hume, Ryu Nagata, Mutsuo Taiji. (2006) Enhanced Effect of Combined Treatment with SMP-534 (Antifibrotic Agent) and Losartan in Diabetic Nephropathy. American Journal of Nephrology 26:1, 50-58
CrossRef1059
Cataldo Abaterusso, Giovanni Gambaro. (2006) The Role of Glycosaminoglycans and Sulodexide in the Treatment of Diabetic Nephropathy. Treatments in Endocrinology 5:4, 211-222
CrossRef1060
Cornelis Boersma, Jarir Atthobari, Ron T Gansevoort, Lolkje T W de Jong-Van den Berg, Paul E de Jong, Dick de Zeeuw, Lieven J P Annemans, Maarten J Postma. (2006) Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy. PharmacoEconomics 24:6, 523-535
CrossRef1061
Hiroshi Osawa, Norio Nakamura, Kenichi Shirato, Masayuki Nakamura, Michiko Shimada, Ryuichirou Kumasaka, Reiichi Murakami, Takeshi Fujita, Hideaki Yamabe, Ken Okumura. (2006) Losartan, an Angiotensin-II Receptor Antagonist, Retards the Progression of Advanced Renal Insufficiency. The Tohoku Journal of Experimental Medicine 209:1, 7-13
CrossRef1062
Camila M. Manrique, Guido Lastra, John Palmer, Craig S. Stump, James R. Sowers. (2006) Hypertension?A Treatable Component of the Cardiometabolic Syndrome: Challenges for the Primary Care Physician. The Journal of Clinical Hypertension 8:s1, 12-20
CrossRef1063
Lawrence A Frazee, Seyhoon Samandari, Natthavat Tanphaichitr, Claire C Bourguet, Eugene W Pfister. (2006) Screening for Nephropathy and Antiangiotensin Use Among Diabetic Patients in an Academic Community Medical Center. American Journal of Therapeutics 13:1, 18-23
CrossRef1064
Wilbert S. Aronow. (2006) Treatment of Systolic and Diastolic Heart Failure in the Elderly. Journal of the American Medical Directors Association 7:1, 29-36
CrossRef1065
Aslam H Anis, Huiying Sun, Sonia Singh, John Woolcott, Bohdan Nosyk, Marc Brisson. (2006) A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of??Hypertension with Left Ventricular Hypertrophy. PharmacoEconomics 24:4, 387-400
CrossRef1066
Artur Beltrame Ribeiro. (2006) Angiotensin II antagonists – therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy. Current Medical Research and Opinion 22:1, 1-16
CrossRef1067
Charlie Zhao, Sujata Vaidyanathan, Ching-Ming Yeh, Mojdeh Maboudian, Hans Armin Dieterich. (2006) Aliskiren Exhibits Similar Pharmacokinetics in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus. Clinical Pharmacokinetics 45:11, 1125-1134
CrossRef1068
Maurizio Cereda, Jiri Horak, Patrick Neligan. 2006. Renal Diseases. , 229-260.
CrossRef1069
P Thomson, M Fisher. (2006) Cardiovascular outcomes in diabetic nephropathy studies. Practical Diabetes International 23:1, 13-18
CrossRef1070
George W Carides, Shahnaz Shahinfar, Erik J Dasbach, William F Keane, William C Gerth, Charles M Alexander, William H Herman, Barry M Brenner, the RENAAL Investigators. (2006) The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy. PharmacoEconomics 24:6, 549-558
CrossRef1071
Ariela Benigni, Carla Zoja, Marco Campana, Daniela Corna, Fabio Sangalli, Daniela Rottoli, Elena Gagliardini, Sara Conti, Steve Ledbetter, Giuseppe Remuzzi. (2006) Beneficial Effect of TGFβ Antagonism in Treating Diabetic Nephropathy Depends on When Treatment Is Started. Nephron Experimental Nephrology 104:4, e158-e168
CrossRef1072
G Neil Thomas, Paul Chan, Brian Tomlinson. (2006) The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension. Drugs & Aging 23:2, 131-155
CrossRef1073
Marvin Moser. (2006) More Confusing Messages From the Hypertension Treatment Trials. The Journal of Clinical Hypertension 8:1, 8-11
CrossRef1074
Eisei Noiri, Nobuo Nagano, Kosuke Negishi, Kent Doi, Sonoe Miyata, Megumi Abe, Tamami Tanaka, Koji Okamoto, Norio Hanafusa, Yasushi Kondo, Nobukazu Ishizaka, Toshiro Fujita. (2006) Efficacy of Darbepoetin in Doxorubicin-Induced Cardiorenal Injury in Rats. Nephron Experimental Nephrology 104:1, e6-e14
CrossRef1075
Ingrid Fleming, Karin Kohlstedt, Rudi Busse. (2006) The tissue renin–angiotensin system and intracellular signalling. Current Opinion in Nephrology and Hypertension 15:1, 8-13
CrossRef1076
Michel Burnier, Anne Zanchi. (2006) Blockade of the renin–angiotensin–aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. Journal of Hypertension 24:1, 11-25
CrossRef1077
Dae Jung Kim, Jaiyong Kim, Hyeyoung Kim, Kyung Wan Min, Seok Won Park, Ie Byung Park, Jeong Hyun Park, Sei Hyun Baik, Hyun Shik Son, Chul Woo Ahn, Jee-Young Oh, Sunhee Lee, Juneyoung Lee, Choon Hee Chung, Kyung Mook Choi, Injeoung Choi, Hwayoung Kim. (2006) Current Status of Diabetic End-Stage Renal Disease Using Korean Health Insurance Database. The Journal of Korean Diabetes Association 30:5, 355
CrossRef1078
Kambiz Kalantarinia, Mark D. Okusa. (2006) The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease. Current Diabetes Reports 6:1, 8-16
CrossRef1079
Junko Shoda, Yoshihiko Kanno, Hiromichi Suzuki. (2006) A Fiveyear Comparison of the Renal Protective Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with NonDiabeticNephropathy. Internal Medicine 45:4, 193-198
CrossRef1080
W.J. Elliott. (2006) Effects of Different Blood Pressure-Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus: Results of Prospectively Designed Overviews of Randomized Trials. Yearbook of Cardiology 2006, 90-92
CrossRef1081
Tsutomu Yamazaki. (2006) Proposed New Score to Rate the Strength of Evidence and Its Application to Large-Scale Clinical Trials of Angiotensin-Receptor Blockers. Circulation Journal 70:9, 1155-1158
CrossRef1082
Keith C. Ferdinand, Elijah Sounders. (2006) Hypertension-Related Morbidity and Mortality in African Americans?Why We Need to Do Better. The Journal of Clinical Hypertension 8:s1, 21-30
CrossRef1083
Paul Komenda, Adeera Levin. (2006) Analysis of cardiovascular disease and kidney outcomes in multidisciplinary chronic kidney disease clinics: complex disease requires complex care models. Current Opinion in Nephrology and Hypertension 15:1, 61-66
CrossRef1084
Mark E Williams. (2006) New Potential Agents in Treating Diabetic Kidney Disease. Drugs 66:18, 2287-2298
CrossRef1085
Masanori Yoshizumi, Keisuke Ishizawa, Yuki Izawa, Toshiaki Tamaki. (2006) Folia Pharmacologica Japonica 128:3, 147-151
CrossRef1086
Patrick J. Flannery, Robert F. Spurney. (2006) Transactivation of the Epidermal Growth Factor Receptor by Angiotensin II in Glomerular Podocytes. Nephron Experimental Nephrology 103:3, e109-e118
CrossRef1087
Anna C Calkin, Terri J Allen. (2006) Diabetes Mellitus-Associated Atherosclerosis. American Journal of Cardiovascular Drugs 6:1, 15-40
CrossRef1088
Jean-Francois Marier, James Lee, Siva Rama Prasad Kambhampati, Lawrence Galitz, Ramon Vargas, James Moberly, Daniel E. Salazar. (2006) Effect of Repeated Oral Administrations of the Oral Adsorbent AST-120 on Serum Creatinine and Other Markers of Renal Function. American Journal of Nephrology 26:2, 136-141
CrossRef1089
Melvin R. Hayden, James R. Sowers. (2006) Hypertension in type 2 diabetes mellitus. Insulin 1:1, 22-37
CrossRef1090
B. Amann. (2006) Diabetische Nephropathie und ACE-Hemmer. Clinical Research in Cardiology 95:S1, i83-i87
CrossRef1091
Mustafa Gullulu, Ibrahim Akdag, Serdar Kahvecioglu, Gülaydan Filiz, Vahide Savci. (2006) Aldosterone Blockage in Proliferative Glomerulonephritis Prevents Not Only Fibrosis, but Proliferation as Well. Renal Failure 28:6, 509-514
CrossRef1092
Ja Wook Koo. (2006) Renal Interstitial Fibrosis and Angiotensin Inhibition. Electrolyte & Blood Pressure 4:1, 35
CrossRef1093
2006. Diuretics. , 1152-1169.
CrossRef1094
Héctor R. Martínez-Ramírez, Basilio Jalomo-Martínez, Laura Cortés-Sanabria, Enrique Rojas-Campos, Graciela Barragán, Gilberto Alfaro, Alfonso M. Cueto-Manzano. (2006) Renal Function Preservation in Type 2 Diabetes Mellitus Patients With Early Nephropathy: A Comparative Prospective Cohort Study Between Primary Health Care Doctors and a Nephrologist. American Journal of Kidney Diseases 47:1, 78-87
CrossRef1095
W.J. Elliott. (2006) Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Yearbook of Cardiology 2006, 64-66
CrossRef1096
Saad Hafidh, Neelavathi Senkottaiyan, Daniel Villarreal, Martin A. Alpert. (2005) Management of the Metabolic Syndrome. The American Journal of the Medical Sciences 330:6, 343-351
CrossRef1097
ALBERTO MARTÍNEZ-CASTELAO, FERNANDO DE ALVARO, JOSÉ LUIS GÓRRIZ. (2005) Epidemiology of diabetic nephropathy in Spain. Kidney International 68, S20-S24
CrossRef1098
GIUSEPPE REMUZZI, NORBERTO PERICO, MANUEL MACIA, PIERO RUGGENENTI. (2005) The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney International 68, S57-S65
CrossRef1099
J.F. Blicklé. (2005) Management of hypertension in elderly diabetic patients. Diabetes & Metabolism 31, 5S82-5S91
CrossRef1100
Pedro Aranda, Julian Segura, Luis M. Ruilope, Francisco J. Aranda, Miguel A. Frutos, Verónica López, Eduardo López de Novales. (2005) Long-Term Renoprotective Effects of Standard Versus High Doses of Telmisartan in Hypertensive Nondiabetic Nephropathies. American Journal of Kidney Diseases 46:6, 1074-1079
CrossRef1101
Rajiv Agarwal, Muralidhar Acharya, Jin Tian, Richard L. Hippensteel, Joel Z. Melnick, Ping Qiu, Laura Williams, Daniel Batlle. (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney International 68:6, 2823-2828
CrossRef1102
W. S. Aronow. (2005) Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:12, 1597-1605
CrossRef1103
Cristina Sierra, Alejandro de la Sierra. (2005) Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Current Opinion in Internal Medicine 4:6, 583-589
CrossRef1104
Massimo Volpe, Giuseppe Mancia, Bruno Trimarco. (2005) Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. Journal of Hypertension 23:12, 2113-2118
CrossRef1105
ADEERA LEVIN. (2005) The need for optimal and coordinated management of CKD. Kidney International 68, S7-S10
CrossRef1106
Peggy W.G. du Buf-Vereijken, Amanda J.W. Branten, Jack F.M. Wetzels. (2005) Idiopathic Membranous Nephropathy: Outline and Rationale of a Treatment Strategy. American Journal of Kidney Diseases 46:6, 1012-1029
CrossRef1107
Wolfgang C. Winkelmayer, Michael A. Fischer, Sebastian Schneeweiss, Philip S. Wang, Raisa Levin, Jerry Avorn. (2005) Underuse of ACE Inhibitors and Angiotensin II Receptor Blockers in Elderly Patients With Diabetes. American Journal of Kidney Diseases 46:6, 1080-1087
CrossRef1108
Kavitha M. Chinnaiyan, Daniel Alexander, Peter A. McCullough. (2005) Role of Angiotensin II in the Evolution of Diastolic Heart Failure. The Journal of Clinical Hypertension 7:12, 740-747
CrossRef1109
George Y.H. Chi. (2005) Some issues with composite endpoints in clinical trials. Fundamental and Clinical Pharmacology 19:6, 609-619
CrossRef1110
FRANCESCO LOCATELLI, LUCIA DEL VECCHIO, PIETRO POZZONI. (2005) Clinical benefits of slowing the progression of renal failure. Kidney International 68, S152-S156
CrossRef1111
Norman K. Hollenberg. (2005) Is there a pharmacologic basis for combination renin axis blockade?. Kidney International 68:6, 2901-2903
CrossRef1112
MANUEL PRAGA. (2005) Therapeutic measures in proteinuric nephropathy. Kidney International 68, S137-S141
CrossRef1113
Robert D. Toto. (2005) Heart Disease in Diabetic Patients. Seminars in Nephrology 25:6, 372-378
CrossRef1114
K. Rossing, P. K. Christensen, P. Hovind, H.-H. Parving. (2005) Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients. Diabetologia 48:11, 2241-2247
CrossRef1115
Vishal Bhatia, Ruchi Bhatia, Boban Mathew. (2005) Angiotensin Receptor Blockers in Congestive Heart Failure. Cardiology in Review 13:6, 297-303
CrossRef1116
E. N. Liberopoulos, D. P. Mikhailidis, M. S. Elisaf. (2005) Diagnosis and management of the metabolic syndrome in obesity. Obesity Reviews 6:4, 283-296
CrossRef1117
Alberto Cordero, Martín Laclaustra, Montse León, José A. Casasnovas, Alberto Grima, Mónica Nájar, Emilio Luengo, Alfonso del Río, Ignacio Ferreira, Eduardo Alegría. (2005) Factores de riesgo cardiovascular y síndrome metabólico asociados a la disfunción renal subclínica: subanálisis del Registro MESYAS. Medicina Clínica 125:17, 653-658
CrossRef1118
A. Sánchez Rodríguez, M. Sánchez Ledesma, I. Cruz González. (2005) Hipertensión arterial. Relevancia epidemiológica. Tratamiento farmacológico. Indicaciones. Criterios de respuesta. Asociaciones. Efectos secundarios. Interacciones. Situaciones de especial relevancia. Medicine - Programa de Formación Médica Continuada Acreditado 9:46, 3050-3061
CrossRef1119
David B. Hughes, Mark L. Britton. (2005) Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers for Prevention and Treatment of Nephropathy Associated with Type 2 Diabetes Mellitus. Pharmacotherapy 25:11, 1602-1620
CrossRef1120
Ann M. Borzecki, Dan R. Berlowitz. (2005) Management of hypertension and diabetes: Treatment goals, drug choices, current practice, and strategies for improving care. Current Hypertension Reports 7:6, 439-449
CrossRef1121
Liffert Vogt, Gerjan Navis, Jürgen Köster, Athanasios J Manolis, John L Reid, Dick de Zeeuw. (2005) The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. Journal of Hypertension 23:11, 2055-2061
CrossRef1122
Martin MacKinnon, Frans H. H. Leenen, Marcel Ruzicka. (2005) Does ALLHAT change the management of hypertension in chronic kidney disease?. Current Hypertension Reports 7:6, 474-483
CrossRef1123
Steven M Snapinn, Qi Jiang, Boris Iglewicz. (2005) Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator. The American Statistician 59:4, 301-307
CrossRef1124
Simona Bruno, Dario Cattaneo, Norberto Perico, Giuseppe Remuzzi. (2005) Emerging drugs for diabetic nephropathy. Expert Opinion on Emerging Drugs 10:4, 747-771
CrossRef1125
A.-N. Lasaridis, P.-A. Sarafidis. (2005) Néphropathie diabétique et traitement antihypertenseur : quelles sont les leçons des essais cliniques ?. EMC - Néphrologie 2:4, 182-193
CrossRef1126
A. Chacón García, J.F. Menárguez Puche, A. Alcántara Muñoz. (2005) Microalbuminuria y diabetes mellitus tipo 2. Áreas de incertidumbre. Atención Primaria 36:6, 324-327
CrossRef1127
Bernard Waeber. (2005) What can be learned from the experience with the fixed low-dose combination of perindopril/indapamide in the treatment of hypertension?. Expert Opinion on Pharmacotherapy 6:13, 2291-2299
CrossRef1128
Bertrand Dussol, Cecilia Iovanna, Denis Raccah, Patrice Darmon, Sophie Morange, Philippe Vague, Bernard Vialettes, Charles Oliver, Anderson Loundoun, Yvon Berland. (2005) A Randomized Trial of Low-Protein Diet in Type 1 and in Type 2 Diabetes Mellitus Patients With Incipient and Overt Nephropathy. Journal of Renal Nutrition 15:4, 398-406
CrossRef1129
Manuel Pérez-Maraver, Maria José Carrera, Teresa Micaló, Manuel Sahun, Cayetano Vinzia, Joan Soler, Eduard Montanya. (2005) Renoprotective effect of diltiazem in hypertensive type 2 diabetic patients with persistent microalbuminuria despite ACE inhibitor treatment. Diabetes Research and Clinical Practice 70:1, 13-19
CrossRef1130
Harjot K. Saini, Yan-Jun Xu, Amarjit S. Arneja, Paramjit S. Tappia, Naranjan S. Dhalla. (2005) Pharmacological basis of different targets for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine 9:4, 818-839
CrossRef1131
Johannes Pill, Bettina Kraenzlin, Julia Jander, Tim Sattelkau, Maliha Sadick, Hans-Martin Kloetzer, Carsten Deus, Uwe Kraemer, Norbert Gretz. (2005) Fluorescein-labeled sinistrin as marker of glomerular filtration rate. European Journal of Medicinal Chemistry 40:10, 1056-1061
CrossRef1132
RAKESH AMIN, CHARLES TURNER, SARA VAN AKEN, TERESA KONOPELSKA BAHU, ANGELA WATTS, DAVID R M LINDSELL, R NEIL DALTON, DAVID B DUNGER. (2005) The relationship between microalbuminuria and glomerular filtration rate in young type 1 diabetic subjects: The Oxford Regional Prospective Study. Kidney International 68:4, 1740-1749
CrossRef1133
V. Barrios Alonso, C. Escobar Cervantes, A. Calderón Montero. (2005) ARA II en insuficiencia cardíaca crónica. Coincidencias y divergencias. ¿Efecto de clase?. Revista Clínica Española 205:10, 499-506
CrossRef1134
NOBUE TANAKA, TETSUYA BABAZONO. (2005) Assessing genetic susceptibility to diabetic nephropathy. Nephrology 10:s2, S17-S21
CrossRef1135
KUNITOSHI ISEKI. (2005) Predictors of diabetic end-stage renal disease in Japan. Nephrology 10:s2, S2-S6
CrossRef1136
N. Ferreira-Maldent, F. Maillot, J.-L. Guilmot. (2005) Le pied du diabétique : attention, danger !. Annales de Dermatologie et de Vénéréologie 132:10, 797-814
CrossRef1137
MARK E COOPER, KARIN JANDELEIT-DAHM, MERLIN C THOMAS. (2005) Targets to retard the progression of diabetic nephropathy. Kidney International 68:4, 1439-1445
CrossRef1138
Cristina Sierra, Alejandro de la Sierra. (2005) Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Current Opinion in Internal Medicine 4:5, 469-475
CrossRef1139
Xiaoyan Zhou, Edward D Frohlich. (2005) Physiologic evidence of renoprotection by antihypertensive therapy. Current Opinion in Internal Medicine 4:5, 523-528
CrossRef1140
Anton C. Schoolwerth, Michael M. Engelgau, Thomas H. Hostetter. (2005) A Public Health Action Plan Is Needed for Chronic Kidney Disease. Advances in Chronic Kidney Disease 12:4, 418-423
CrossRef1141
WONG KOK SENG, SHANG-JYH HWANG, DONG CHEOL HAN, CHUA CHIN TEONG, JULIANA CHAN, THOMAS A BURKE, GEORGE W CARIDES, YON JONG CHOI. (2005) Losartan reduces the costs of diabetic end-stage renal disease: An Asian perspective. Nephrology 10:5, 520-524
CrossRef1142
, G. Boner, M. E. Cooper, K. McCarroll, B. M. Brenner, D. Zeeuw, P. R. Kowey, S. Shahinfar, T. Dickson, R. S. Crow, H.-H. Parving. (2005) Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia 48:10, 1980-1987
CrossRef1143
Kambiz Zandi-Nejad, Barry M Brenner. (2005) Primary and secondary prevention of chronic kidney disease. Journal of Hypertension 23:10, 1771-1776
CrossRef1144
Satoshi Morita, Shunichi Fukuhara, Tadao Akizawa, Yasushi Asano, Kiyoshi Kurokawa. (2005) Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD). Clinical and Experimental Nephrology 9:3, 219-227
CrossRef1145
Robert C. Atkins. (2005) The changing patterns of chronic kidney disease: The need to develop strategies for prevention relevant to different regions and countries. Kidney International 68:s98, S83-S85
CrossRef1146
Kenneth L. Choi, William J. Elliott. (2005) Antihypertensive, antiproteinuric therapy and myocardial infarction and stroke prevention. Current Hypertension Reports 7:5, 367-373
CrossRef1147
(2005) Combination Drug Treatment for Hypertension. Current Hypertension Reports 7:5, 358-359
CrossRef1148
Dick de Zeeuw, Hans L. Hillege, Paul E. de Jong. (2005) The kidney, a cardiovascular risk marker, and a new target for therapy. Kidney International 68:s98, S25-S29
CrossRef1149
Norberto Perico, Igor Codreanu, Arrigo Schieppati, Giuseppe Remuzzi. (2005) Prevention of progression and remission/regression strategies for chronic renal diseases: Can we do better now than five years ago?. Kidney International 68:s98, S21-S24
CrossRef1150
S.M. Thomas, G.C. Viberti. (2005) Cardiovascular risk in diabetic kidney disease: A model of chronic renal disease. Kidney International 68:s98, S18-S20
CrossRef1151
Cristina Sierra, Alejandro de la Sierra. (2005) Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Current Opinion in Nephrology and Hypertension 14:5, 435-441
CrossRef1152
Ricardo Correa-Rotter, Luis Gonzalez-Michaca. (2005) Early detection and prevention of diabetic nephropathy: A challenge calling for mandatory action for Mexico and the developing world. Kidney International 68:s98, S69-S75
CrossRef1153
Aneliya Parvanova, Carlos Chiurchiu, Piero Ruggenenti, Giuseppe Remuzzi. (2005) Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade. Expert Opinion on Pharmacotherapy 6:11, 1931-1942
CrossRef1154
Keith C. Norris, Lawrence Y. Agodoa. (2005) Unraveling the racial disparities associated with kidney disease1. Kidney International 68:3, 914-924
CrossRef1155
Kasper Rossing, Katrine J. Schjoedt, Berit R. Jensen, Frans Boomsma, Hans-Henrik Parving. (2005) Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney International 68:3, 1190-1198
CrossRef1156
Keecia D. King, Jocelyn D. Jones, Jessica Warthen. (2005) Microvascular and Macrovascular Complications of Diabetes Mellitus. American Journal of Pharmaceutical Education 69:5, 87
CrossRef1157
Antonios H. Tzamaloukas, Glen H. Murata. (2005) Prevention of Nephropathy in Patients with type 2 Diabetes Mellitus. International Urology and Nephrology 37:3, 655-663
CrossRef1158
Robert D. Toto. (2005) Proteinuria reduction: Mandatory consideration or option when selecting an antihypertensive agent?. Current Hypertension Reports 7:5, 374-378
CrossRef1159
Zhong Jian Cheng, Tina Grönholm, Marjut Louhelainen, Piet Finckenberg, Saara Merasto, Ilkka Tikkanen, Eero Mervaala. (2005) Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats. Journal of Hypertension 23:9, 1757-1770
CrossRef1160
Shiraz I. Mishra, Charlotte Jones-Burton, Jeffrey C. Fink, Jeanine Brown, George L. Bakris, Matthew R. Weir. (2005) Does dietary salt increase the risk for progression of kidney disease?. Current Hypertension Reports 7:5, 385-391
CrossRef1161
Sharon Ann Hunt. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Journal of the American College of Cardiology 46:6, e1-e82
CrossRef1162
José V. Lozano, Josep Redón, Luis Cea-Calvo, Cristina Fernández-Pérez, Jorge Navarro, Álvaro Bonet, Jorge González-Esteban. (2005) Evaluación del riesgo de un primer ictus en la población hipertensa española en atención primaria. Estudio ERIC-HTA. Medicina Clínica 125:7, 247-251
CrossRef1163
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article. Journal of the American College of Cardiology 46:6, 1116-1143
CrossRef1164
Karl Heinz Rahn. (2005) The role of calcium antagonists in patients with chronic renal failure. Pediatric Nephrology 20:9, 1208-1213
CrossRef1165
Takako Nakagawa, Takako Yokozawa, Noriko Yamabe, Hirozo Goto, Naotoshi Shibahara, Dong Young Rhyn, Yutaka Shimada. (2005) Long-term treatment with Hachimi-jio-gan attenuates kidney damage in spontaneously diabetic WBN/Kob rats. Journal of Pharmacy and Pharmacology 57:9, 1205-1212
CrossRef1166
Matthew F Yuyun, Amanda I Adler, Nicholas J Wareham. (2005) What is the evidence that microalbuminuria is a predictor of cardiovascular disease events?. Current Opinion in Internal Medicine 4:4, 375-380
CrossRef1167
OLIVER GROSS, MARIE-LOUISE KOEPKE, BOGDAN BEIROWSKI, ECKHARD SCHULZE-LOHOFF, STEPHAN SEGERER, MANFRED WEBER. (2005) Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688. Kidney International 68:2, 456-463
CrossRef1168
James B. Meigs. (2005) Prevention of coronary heart disease in diabetes. Current Treatment Options in Cardiovascular Medicine 7:4, 259-271
CrossRef1169
Rajiv Agarwal, Timothy M. Curley. (2005) The Role of Statins in Chronic Kidney Disease. The American Journal of the Medical Sciences 330:2, 69-81
CrossRef1170
Romana Ry??av??, Vladim??r Tesa??, Miroslav Merta. (2005) Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease. Blood Pressure Monitoring 10:4, 207-213
CrossRef1171
SYDNEY TANG, JOSEPH C K LEUNG, LORETTA Y Y CHAN, YUN HOI LUI, COLIN S O TANG, CHI HANG KAN, YIU WING HO, KAR NENG LAI. (2005) Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney International 68:2, 802-812
CrossRef1172
Lawrence Agodoa, Keith Norris, David Pugsley. (2005) The disproportionate burden of kidney disease in those who can least afford it. Kidney International 68:s97, S1-S3
CrossRef1173
ALLON N FRIEDMAN, LAWRENCE G HUNSICKER, JACOB SELHUB, ANDREW G BOSTOM. (2005) C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. Kidney International 68:2, 773-778
CrossRef1174
Susanne B. Nicholas, Naureen Tareen, Ashraf Zadshir, David Martins, Deyu Pan, Keith C. Norris. (2005) Management of early chronic kidney disease in indigenous populations and ethnic minorities. Kidney International 68:s97, S78-S81
CrossRef1175
Norberto Perico, Igor Codreanu, Arrigo Schieppati, Giuseppe Remuzzi. (2005) The future of renoprotection. Kidney International 68:s97, S95-S101
CrossRef1176
B. M. Y. Cheung, Y. L. Wong, C. P. Lau. (2005) Queen Mary Utilization of Antihypertensive Drugs Study: side-effects of antihypertensive drugs. Journal of Clinical Pharmacy and Therapeutics 30:4, 391-399
CrossRef1177
Jose Antonio García-Donaire, Julian Segura, Luis Miguel Ruilope. (2005) An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy. Expert Opinion on Pharmacotherapy 6:9, 1587-1596
CrossRef1178
Daniel T. Lackland. (2005) Population strategies to treat hypertension. Current Treatment Options in Cardiovascular Medicine 7:4, 253-258
CrossRef1179
Yuki Izawa, Masanori Yoshizumi, Yoshiko Fujita, Nermin Ali, Yasuhisa Kanematsu, Keisuke Ishizawa, Koichiro Tsuchiya, Toshiyuki Obata, Yousuke Ebina, Shuhei Tomita, Toshiaki Tamaki. (2005) ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells. Experimental Cell Research 308:2, 291-299
CrossRef1180
Franz H. Messerli, Ehud Grossman. (2005) Therapeutic Controversies in Hypertension. Seminars in Nephrology 25:4, 227-235
CrossRef1181
Bonnie B. Dean, Michelle Dylan, Anacleto Gano, Kevin Knight, Joshua J. Ofman, Barton S. Levine. (2005) Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Current Medical Research and Opinion 21:7, 981-987
CrossRef1182
José Miguel González-Clemente, Olga Giménez-Palop, Assumpta Caixàs, María José Barahona, David Subías, Carme Vilardell, Gabriel Giménez-Pérez, Dídac Mauricio. (2005) Escasa caracterización clínica de los pacientes con diabetes mellitus incluidos en los principales ensayos clínicos sobre hipertensión arterial. Medicina Clínica 125:5, 173-178
CrossRef1183
KASPER ROSSING, HARALD MISCHAK, HANS-HENRIK PARVING, PER K CHRISTENSEN, MICHAEL WALDEN, MEIKE HILLMANN, THORSTEN KAISER. (2005) Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney International 68:1, 193-205
CrossRef1184
Jacoba P. Greving, Petra Denig, Willem Jan van der Veen, Frank W. Beltman, Miriam C. J. M. Sturkenboom, Dick de Zeeuw, Flora M. Haaijer-Ruskamp. (2005) Uptake of angiotensin II receptor blockers in the treatment of hypertension. European Journal of Clinical Pharmacology 61:5-6, 461-466
CrossRef1185
RAJIV AGARWAL, CHANDAN SAHA, MEHER BATTIWALA, NINA VASAVADA, TIMOTHY CURLEY, SHAWN D CHASE, NADINE SACHS, MERFAKE H SEMRET. (2005) A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney International 68:1, 285-292
CrossRef1186
Kumar Sharma, SoHee Lee, Steven Han, Sungchun Lee, Barbara Francos, Peter McCue, Richard Wassell, M. Alexander Shaw, Satish P. RamachandraRao. (2005) Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. PROTEOMICS 5:10, 2648-2655
CrossRef1187
Michael Wiederkehr, Robert Toto, Andrew Z. Fenves, C. Venkata S. Ram. (2005) Hypertension and the Kidney. Seminars in Nephrology 25:4, 236-245
CrossRef1188
Shawna D. Nesbitt. (2005) Hypertension in Special Populations. Seminars in Nephrology 25:4, 210-214
CrossRef1189
Sanne de Vogel, Ewout J Hoorn, Vasilios Papademetriou. (2005) Losartan in cardiovascular disease. Future Cardiology 1:4, 433-446
CrossRef1190
Kenneth L. Choi, George L. Bakris. (2005) Hypertension Treatment Guidelines: Practical Implications. Seminars in Nephrology 25:4, 198-209
CrossRef1191
Stefano Bianchi, Roberto Bigazzi, Vito M. Campese. (2005) Antagonists of Aldosterone and Proteinuria in Patients With CKD: An Uncontrolled Pilot Study. American Journal of Kidney Diseases 46:1, 45-51
CrossRef1192
Ivan Tkáč. (2005) Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis. Diabetes Research and Clinical Practice 68, S2-S9
CrossRef1193
Alberto Zanchetti. (2005) Evidence-based medicine in hypertension: what type of evidence?. Journal of Hypertension 23:6, 1113-1120
CrossRef1194
M T Schram, F J van Ittersum, A Spoelstra-de Man, R A J M van Dijk, C G Schalkwijk, R G Ijzerman, J W R Twisk, C D A Stehouwer. (2005) Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. Journal of Human Hypertension 19:6, 429-437
CrossRef1195
William Bestermann, Mark C. Houston, Jan Basile, Brent Egan, Carlos M. Ferrario, Dan Lackland, Ralph G. Hawkins, James Reed, Philip Rogers, Daniel Wise, Michael A. Moore. (2005) Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome in the Southeastern United States, Part II: Treatment Recommendations for Management of the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome. The American Journal of the Medical Sciences 329:6, 292-305
CrossRef1196
M. Ravid, R. Rachmani. (2005) Cardiovascular protection in patients with type 2 diabetes mellitus: Considerations about the tightness of blood pressure control and the choice of treatment. European Journal of Internal Medicine 16:3, 154-159
CrossRef1197
C E Mogensen. (2005) New concepts in blood pressure-lowering management in diabetic patients: the case for early ACE inhibitor combination therapy with diuretics. Journal of Human Hypertension 19, S15-S20
CrossRef1198
William M. McClellan. (2005) Epidemiology and Risk Factors for Chronic Kidney Disease. Medical Clinics of North America 89:3, 419-445
CrossRef1199
Karima Zitouni, Diane D. Harry, Jaffar Nourooz-Zadeh, D. John Betteridge, Kenneth A. Earle. (2005) Circulating vitamin E, transforming growth factor beta1, and the association with renal disease susceptibility in two racial groups with type 2 diabetes. Kidney International 67:5, 1993-1998
CrossRef1200
Matthew F Yuyun, Amanda I Adler, Nicholas J Wareham. (2005) What is the evidence that microalbuminuria is a predictor of cardiovascular disease events?. Current Opinion in Nephrology and Hypertension 14:3, 271-276
CrossRef1201
Melanie L Praught, Michael G Shlipak. (2005) Are small changes in serum creatinine an important risk factor?. Current Opinion in Nephrology and Hypertension 14:3, 265-270
CrossRef1202
Rainer U Pliquett. (2005) Therapy of chronic renal insufficiency: from renal physiology to cardiovascular outcomes. Therapy 2:3, 425-437
CrossRef1203
Roland E Schmieder. (2005) Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers. Journal of Hypertension 23:5, 905-911
CrossRef1204
Scott G. Satko, Barry I. Freedman. (2005) The Familial Clustering of Renal Disease and Related Phenotypes. Medical Clinics of North America 89:3, 447-456
CrossRef1205
Kambiz Zandi-Nejad, Barry M. Brenner. (2005) Strategies to Retard the Progression of Chronic Kidney Disease. Medical Clinics of North America 89:3, 489-509
CrossRef1206
Bryan M. Curtis, Adeera Levin, Patrick S. Parfrey. (2005) Multiple Risk Factor Intervention in Chronic Kidney Disease: Management of Cardiac Disease in Chronic Kidney Disease Patients. Medical Clinics of North America 89:3, 511-523
CrossRef1207
V. Barrios Alonso, J.P. Tomás Zarlenga, A. Calderón Montero, C. Escobar Cervantes. (2005) Papel de los ARA-II en el tratamiento de la hipertensión arterial. De la evidencia a la práctica clínica. Clínica e Investigación en Arteriosclerosis 17, 70-82
CrossRef1208
Toshiyo Sonta, Toyoshi Inoguchi, Shingo Matsumoto, Keiji Yasukawa, Mieko Inuo, Hirotaka Tsubouchi, Noriyuki Sonoda, Kunihisa Kobayashi, Hideo Utsumi, Hajime Nawata. (2005) In vivo imaging of oxidative stress in the kidney of diabetic mice and its normalization by angiotensin II type 1 receptor blocker. Biochemical and Biophysical Research Communications 330:2, 415-422
CrossRef1209
M Volpe, L M Ruilope, G T McInnes, B Waeber, M A Weber. (2005) Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?. Journal of Human Hypertension 19:5, 331-339
CrossRef1210
H. Haller. (2005) Die neuen Richtlinien zur Behandlung der Hypertonie. Der Internist 46:5, 538-547
CrossRef1211
Camille A. Jones, Andrzej S. Krolewski, John Rogus, Jay L. Xue, Allan Collins, James H. Warram. (2005) Epidemic of end-stage renal disease in people with diabetes in the United States population: Do we know the cause?. Kidney International 67:5, 1684-1691
CrossRef1212
Clarice Kazue Fujihara, Mariliza Velho, Denise Maria Avancini Costa Malheiros, Roberto Zatz. (2005) An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney International 67:5, 1913-1924
CrossRef1213
Marc Maillard, Michel Burnier. (2005) Telmisartan/hydrochlorothiazide: a new fixed dose combination. Expert Review of Cardiovascular Therapy 3:3, 375-386
CrossRef1214
Kevin C. Abbott, Erin M. Bohen, Christina M. Yuan. (2005) Preservation of Renal Structure and Function at 2 Years without Calcineurin Inhibitor Use. American Journal of Transplantation 5:5, 1168-1168
CrossRef1215
Panagiotis T. Vlagopoulos, Mark J. Sarnak. (2005) Traditional and Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease. Medical Clinics of North America 89:3, 587-611
CrossRef1216
Vijay Viswanathan, C. Snehalatha, Mamtha B. Nair, R. Kumutha, A. Ramachandran. (2005) Levels of transforming growth factor beta 1 in south Indian type 2 diabetic subjects. Diabetes/Metabolism Research and Reviews 21:3, 276-280
CrossRef1217
Steven G Coca, Mark A Perazella. (2005) Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?. Expert Review of Cardiovascular Therapy 3:3, 497-512
CrossRef1218
Adeera Levin, Lesley A. Stevens. (2005) Executing Change in the Management of Chronic Kidney Disease: Perspectives on Guidelines and Practice. Medical Clinics of North America 89:3, 701-709
CrossRef1219
Martin J. Andersen, Rajiv Agarwal. (2005) Etiology and Management of Hypertension in Chronic Kidney Disease. Medical Clinics of North America 89:3, 525-547
CrossRef1220
J-L Mas. (2005) Atherothrombosis: management of patients at risk. International Journal of Clinical Practice 59:4, 407-414
CrossRef1221
Robert D. Toto. (2005) Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. The Journal of Clinical Hypertension 7, 15-20
CrossRef1222
Mark E. Williams, Katherine R. Tuttle. (2005) The next generation of diabetic nephropathy therapies: An update. Advances in Chronic Kidney Disease 12:2, 212-222
CrossRef1223
Gilberta Giacchetti, Leonardo A. Sechi, Silvia Rilli, Robert M. Carey. (2005) The renin–angiotensin–aldosterone system, glucose metabolism and diabetes. Trends in Endocrinology & Metabolism 16:3, 120-126
CrossRef1224
Norberto Perico, Igor Codreanu, Arrigo Schieppati, Giuseppe Remuzzi. (2005) The scientific care for prevention: An overview. Kidney International 67:s94, s8-s13
CrossRef1225
E. Schulze-Lohoff, T. Matth
us, M. Weber. (2005) Fr
CrossRef1226
Victor Dzau. (2005) The cardiovascular continuum and renin–angiotensin–aldosterone system blockade. Journal of Hypertension 23:Suppl 1, S9-S17
CrossRef1227
Piero Ruggenenti, Arrigo Schieppati, Norberto Perico, Igor Codreanu, Li Peng, Giuseppe Remuzzi. (2005) Kidney prevention recipes for your office practice. Kidney International 67:s94, s136-s141
CrossRef1228
Rebecca Pellicano, Peter G. Kerr, Robert C. Atkins. (2005) What have we learned from clinical trials on prevention?. Kidney International 67:s94, s101-s106
CrossRef1229
Philip Kam-Tao Li, Jan J. Weening, John Dirks, Sing Leung Lui, Cheuk Chun Szeto, Sydney Tang, Robert C. Atkins, William E. Mitch, Kai Ming Chow, Giuseppe D'Amico, Barry I. Freedman, David C. Harris, Lai-Seong Hooi, Paul E. de Jong, Priscilla Kincaid-Smith, Kar Neng Lai, Evan Lee, Fu-Keung Li, Shan-Yan Lin, Wai-Kei Lo, M.K. Mani, Timothy Mathew, Mutsumi Murakami, Jia-Qi Qian, Sylvia Ramirez, Thomas Reiser, Yasuhiko Tomino, Matthew K. Tong, Wai-Kay Tsang, Kriang Tungsanga, Haiyan Wang, Andrew K. Wong, Kim Ming Wong, Wu-Chang Yang, Dick de Zeeuw, Alex W. Yu, Giuseppe Remuzzi, . (2005) A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney International 67:s94, s2-s7
CrossRef1230
Gozewijn Dirk Laverman, Steen Andersen, Peter Rossing, Gerjan Navis, Dick de Zeeuw, Hans-Henrik Parving. (2005) Renoprotection with and without blood pressure reduction. Kidney International 67:s94, s54-s59
CrossRef1231
Nina Vasavada, Rajiv Agarwal. (2005) Role of oxidative stress in diabetic nephropathy. Advances in Chronic Kidney Disease 12:2, 146-154
CrossRef1232
Pascale H. Lane. (2005) Pediatric aspects of diabetic kidney disease. Advances in Chronic Kidney Disease 12:2, 230-235
CrossRef1233
Gordon T McInnes. (2005) Lowering blood pressure for cardiovascular risk reduction. Journal of Hypertension 23:Suppl 1, S3-S8
CrossRef1234
Michael A Weber. (2005) Managing the patient at risk for a second stroke. Journal of Hypertension 23:Suppl 1, S41-S47
CrossRef1235
Takashi Uzu, Tamaki Harada, Tomoko Namba, Ryohei Yamamoto, Ken Takahara, Atsushi Yamauchi, Genjiro Kimura. (2005) Thiazide diuretics enhance nocturnal blood pressure fall and reduce proteinuria in immunoglobulin A nephropathy treated with angiotensin II modulators. Journal of Hypertension 23:4, 861-865
CrossRef1236
Peter A. McCullough, Sandeep S. Soman. (2005) Contrast-Induced Nephropathy. Critical Care Clinics 21:2, 261-280
CrossRef1237
Ken W. Edmisson. (2005) Multidimensional Pharmacologic Strategies for Diabetes. Nursing Clinics of North America 40:1, 107-117
CrossRef1238
Gerd R. Hetzel, J??rg Plum, Andreas Fussh??ller, Adina Voiculescu, Wiebke Gr??nberg, Bernd Grabensee. (2005) Effects of Candesartan on Glomerular Hemodynamics and Permselectivity in Patients with Favorable Renal Allograft Function. Transplantation 79:6, 710-715
CrossRef1239
Zhong-Gao Xu, Tae-Hyun Yoo, Dong-Ryeol Ryu, Hyeong Cheon Park, Sung Kyu Ha, Dae Suk Han, Sharon G. Adler, Rama Natarajan, Shin-Wook Kang. (2005) Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli. Kidney International 67:3, 944-952
CrossRef1240
Nathaniel Winer, Amy Folker, Julie A. Murphy, Elena Hung, Mara Bard, Alexander Perkelvald, James R. Sowers, George L. Bakris. (2005) Effect of Fixed-Dose ACE-Inhibitor/Calcium Channel Blocker Combination Therapy vs. ACE-Inhibitor Monotherapy on Arterial Compliance in Hypertensive Patients With Type 2 Diabetes. Preventive Cardiology 8:2, 87-92
CrossRef1241
Gary T. C. Ko, Chiu-Chi Tsang, Hamish C. K. Chan. (2005) Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: A one-year randomized study of valsartan versus enalapril. Advances in Therapy 22:2, 155-162
CrossRef1242
John B. Standridge. (2005) Hypertension and atherosclerosis: Clinical implications from the ALLHAT trial. Current Atherosclerosis Reports 7:2, 132-139
CrossRef1243
Aldo Pietro Maggioni, Gianna Fabbri. (2005) VALIANT (VALsartan In Acute myocardial iNfarcTion) trial. Expert Opinion on Pharmacotherapy 6:3, 507-512
CrossRef1244
Rosario Scaglione, Christiano Argano, Salvatore Corrao, Tiziana Di Chiara, Anna Licata, Giuseppe Licata. (2005) Transforming growth factor β1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial. Journal of Hypertension 23:3, 657-664
CrossRef1245
J. D. Lee, J. R. Morrissey, D. P. Mikhailidis, V. Patel. (2005) CARDS on the table: should everybody with type 2 diabetes take a statin?. Current Medical Research and Opinion 21:3, 357-361
CrossRef1246
Gunter Wolf, Eberhard Ritz. (2005) Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney International 67:3, 799-812
CrossRef1247
Jacques Champlain. (2005) Do angiotensin II antagonists provide benefits beyond blood pressure reduction?. Advances in Therapy 22:2, 117-136
CrossRef1248
Kei Fukami, Mark E Cooper, Josephine M Forbes. (2005) Agents in development for the treatment of diabetic nephropathy. Expert Opinion on Investigational Drugs 14:3, 279-294
CrossRef1249
M. Hanefeld. (2005) Outcome studies in type 2 diabetes. Current Medical Research and Opinion 21:s1, S41-S48
CrossRef1250
Peter R. Kowey, Tania Z. Dickson, Zhongxin Zhang, Shahnaz Shahinfar, Barry M. Brenner. (2005) Losartan and end-organ protection-lessons from the renaal study. Clinical Cardiology 28:3, 136-142
CrossRef1251
Vikram Kalra, Sandeep Mahajan, Sanjay Kumar Agarwal, Suresh Chander Tiwari. (2005) Cardiorenal Disease: A Clinical Intersection. International Urology and Nephrology 37:1, 175-184
CrossRef1252
Bryan Williams. (2005) Recent hypertension trials. Journal of the American College of Cardiology 45:6, 813-827
CrossRef1253
M. Cecilia Lansang, Radomir Stevanovic, Deborah A. Price, Lori M. B. Laffel, Norman K. Hollenberg. (2005) ACE and non-ACE pathways in the renal vascular response to RAS interruption in type 1 diabetes mellitus. Kidney International 67:3, 1033-1037
CrossRef1254
(2005) Telmisartan vs. Enalapril in Type 2 Diabetes. New England Journal of Medicine 352:8, 835-836
Full Text1255
E. M. Stuveling. (2005) Biochemical risk markers: a novel area for better prediction of renal risk?. Nephrology Dialysis Transplantation 20:3, 497-508
CrossRef1256
P.R. Conlin. (2005) Redefining efficacy of antihypertensive therapies beyond blood pressure reduction - the role of angiotensin II antagonists. International Journal of Clinical Practice 59:2, 214-224
CrossRef1257
Giuseppe Remuzzi, Jan J Weening. (2005) Albuminuria as early test for vascular disease. The Lancet 365:9459, 556-557
CrossRef1258
Alan B Weder. (2005) The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a comparison of first-line combination therapies. Expert Opinion on Pharmacotherapy 6:2, 275-281
CrossRef1259
Robert C. Atkins, Esther M. Briganti, Julia B. Lewis, Lawrence G. Hunsicker, Gregory Braden, Paul J. Champion de Crespigny, Giacomo DeFerrari, Paul Drury, Francesco Locatelli, Thomas B. Wiegmann, Edmund J. Lewis. (2005) Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. American Journal of Kidney Diseases 45:2, 281-287
CrossRef1260
Paolo Palatini. (2005) Combination Therapy in the Management of Hypertension: Focus on Angiotensin Receptor Blockers Combined With Diuretics. The Journal of Clinical Hypertension 7:2, 96-101
CrossRef1261
Wael A Al Jaroudi, Nuha Nuwayri-Salti, Julnar A Usta, Darine S Zwainy, Chehade N Karam, Khalil M Bitar, Anwar B Bikhazi. (2005) Effect of insulin and angiotensin II receptor subtype-1 antagonist on myocardial remodelling in rats with insulin-dependent diabetes mellitus. Journal of Hypertension 23:2, 381-392
CrossRef1262
Jeanette M Wood, Christian R Schnell, Frederic Cumin, Jo??l Menard, Randy L Webb. (2005) Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. Journal of Hypertension 23:2, 417-426
CrossRef1263
M.-L. Gross, M. Adamczak, E. Ritz. (2005) Renal failure and ACE inhibition: how much is too much?. Zeitschrift f
CrossRef1264
Enrico Agabiti Rosei, Damiano Rizzoni, Maria Lorenza Muiesan, Intissar Sleiman, Massimo Salvetti, Cristina Monteduro, Enzo Porteri. (2005) Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. Journal of Hypertension 23:2, 435-444
CrossRef1265
H.-H. Parving. (2005) Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study. QJM 98:2, 119-126
CrossRef1266
Shahnaz Shahinfar, Tanya Dickson Zhongxin, William F. Keane, Barry M. Brenner, . (2005) Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: New lessons from the RENAAL Study. Kidney International 67:s93, S48-S51
CrossRef1267
Prakash C. Deedwania, Natalia Volkova. (2005) Current treatment options for the metabolic syndrome. Current Treatment Options in Cardiovascular Medicine 7:1, 61-74
CrossRef1268
Sverre E Kjeldsen, Ingrid Os, Aud H??ieggen, Kim Beckey, Gilbert W Gleim, Suzanne Oparil. (2005) Fixed-Dose Combinations in the Management of Hypertension. American Journal of Cardiovascular Drugs 5:1, 17-22
CrossRef1269
A. Y. T. Wu, N. C. T. Kong, F. A. Leon, C. Y. Pan, T. Y. Tai, V. T. F. Yeung, S. J. Yoo, A. Rouillon, M. R. Weir, . (2005) An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 48:1, 17-26
CrossRef1270
Ren?? R Wenzel. (2005) Renal Protection in Hypertensive Patients: Selection of Antihypertensive Therapy. Drugs 65:Suppl 2, 29???39
CrossRef1271
Matthew R Weir, Roland C Blantz. (2005) The clinical utilization of albuminuria as a surrogate measure of cardiovascular disease burden and risk for events: are we there yet?. Current Opinion in Nephrology and Hypertension 14:1, 39-41
CrossRef1272
Fernando de Alvaro, Olga Velasco, Jesus Honorato, Carlos Calvo, Inma Parrondo, . (2005) Microalbuminuria in hypertensive patients: Evaluation of one-year treatment with irbesartan. Kidney International 67:s93, S29-S34
CrossRef1273
Sabita S Soedamah-Muthu, Coen D A Stehouwer. (2005) Cardiovascular Disease Morbidity and Mortality in Patients with Type 1 Diabetes Mellitus. Treatments in Endocrinology 4:2, 75-86
CrossRef1274
William C. Knowler, Josef Coresh, Robert C. Elston, Barry I. Freedman, Sudha K. Iyengar, Paul L. Kimmel, Jane M. Olson, Rosemarie Plaetke, John R. Sedor, Michael F. Seldin. (2005) The Family Investigation of Nephropathy and Diabetes (FIND). Journal of Diabetes and its Complications 19:1, 1-9
CrossRef1275
B. Waeber. (2005) Position of fixed‐dose combinations containing an AT 1 ‐receptor blocker and a thiazide diuretic. Blood Pressure 14:6, 324-336
CrossRef1276
Luis M. Ruilope, Enrico Agabiti Rosei, George L. Bakris, Giuseppe Mancia, Neil R. Poulter, Stefano Taddei, Thomas Unger, Massimo Volpe, Bernard Waeber, Faiez Zannad. (2005) Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection. Blood Pressure 14:4, 196-209
CrossRef1277
Brian M. Murray, Krishna Malireddi, Venkat Vavilala. (2005) Delivery of Predialysis Care in an Academic Referral Nephrology Practice. Renal Failure 27:5, 571-580
CrossRef1278
Mark E. Williams. (2005) Diabetic Nephropathy: The Proteinuria Hypothesis. American Journal of Nephrology 25:2, 77-94
CrossRef1279
Alan J. Zillich, Joseph J. Saseen, Renee M. DeHart, Peter Dumo, Darren W. Grabe, Cheryl Gilmartin, David M. Hachey, Joanna Q. Hudson, Maria C. Pruchnicki, Melanie S. Joy. (2005) Caring for Patients with Chronic Kidney Disease: A Joint Opinion of the Ambulatory Care and the Nephrology Practice and Research Networks of the American College of Clinical Pharmacy. Pharmacotherapy 25:1, 123-143
CrossRef1280
Francesco Locatelli, Lucia Del Vecchio, Pietro Pozzoni, Marco D'Amico, Simeone Andrulli. (2005) Is it the agent or the blood pressure level that matters for renal and vascular protection in chronic nephropathies?. Kidney International 67:s93, S15-S19
CrossRef1281
Christopher Hassler, Michel Burnier. (2005) Circadian Variations in Blood Pressure. American Journal of Cardiovascular Drugs 5:1, 7-15
CrossRef1282
Tsuneo Takenaka, Taku Mimura, Yoshihiko Kanno, Hiromichi Suzuki. (2005) Qualification of Arterial Stiffness as a Risk Factor to the Progression of Chronic Kidney Diseases. American Journal of Nephrology 25:5, 417-424
CrossRef1283
Norihiko Sakai, Takashi Wada, Kengo Furuichi, Yasunori Iwata, Keiichi Yoshimoto, Kiyoki Kitagawa, Satoshi Kokubo, Motoo Kobayashi, Akinori Hara, Junya Yamahana, Toshiya Okumura, Kazuya Takasawa, Shin-Ichi Takeda, Mitsuhiro Yoshimura, Hiroshi Kida, Hitoshi Yokoyama. (2005) Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. American Journal of Kidney Diseases 45:1, 54-65
CrossRef1284
NOBUYOSHI TAKAHASHI, TOSHIAKI KAWAGUCHI, TADASHI SUZUKI. (2005) Therapeutic effects of long-term administration of an oral adsorbent in patients with chronic renal failure: two-year study. International Journal of Urology 12:1, 7-11
CrossRef1285
Niclás Roberto Robles, J Ocon, C F Gomez, M Manjon, L Pastor, J Herrera, J Villatoro, J Calls, J Torrijos, V I Rodríguez, M M. A Rodriguez, M L Mendez, A Morey, F I Martinez, J Marco, A Liebana, B Rincon, F Tornero. (2005) Lercanidipine in Patients with Chronic Renal Failure: The ZAFRA Study. Renal Failure 27:1, 73-80
CrossRef1286
Kikuo Nutahara, Eiji Higashihara, Shigeo Horie, Kouichi Kamura, Ken Tsuchiya, Toshio Mochizuki, Tatsuo Hosoya, Tomohiro Nakayama, Norio Yamamoto, Yoshio Higaki, Toshiko Shimizu. (2005) Calcium Channel Blocker versus Angiotensin II Receptor Blocker in Autosomal Dominant Polycystic Kidney Disease. Nephron Clinical Practice 99:1, c18-c23
CrossRef1287
Domenic A Sica, Todd W B Gehr, Siddhartha Ghosh. (2005) Clinical Pharmacokinetics of Losartan. Clinical Pharmacokinetics 44:8, 797-814
CrossRef1288
Thomas Unger, Michael Schupp. (2005) Telmisartan: from lowering blood pressure to end-organ protection. Future Cardiology 1:1, 7-15
CrossRef1289
Andrew J. Palmer, Lieven Annemans, Stephane Roze, Pablo Lapuerta, Roland Chen, Sylvie Gabriel, Paulo Carita, Roger A. Rodby, Dick de Zeeuw, Hans-Henrik Parving, Fernando De Alvaro. (2005) Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. Kidney International 67:s93, S52-S54
CrossRef1290
Peter A Meredith. (2005) Angiotensin II Receptor Antagonists Alone and Combined with Hydrochlorothiazide. American Journal of Cardiovascular Drugs 5:3, 171-183
CrossRef1291
Masahiko IGARASHI, Yumi JIMBU, Akihiko HIRATA, Makoto TOMINAGA. (2005) Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes. Endocrine Journal 52:3, 353-362
CrossRef1292
Hyeong Cheon Park, So Rae Choi, Beom Seok Kim, Tae Hee Lee, Byung Seung Kang, Kyu Hyun Choi, Ho Yung Lee, Dae Suk Han, Sung-Kyu Ha. (2005) Polymorphism of the ACE Gene in Dialysis Patients: Overexpression of DD Genotype in Type 2 Diabetic End-Stage Renal Failure Patients. Yonsei Medical Journal 46:6, 779
CrossRef1293
Maria R. Hansberry, William L. Whittier, Michelle W. Krause. (2005) The elderly patient with chronic kidney disease. Advances in Chronic Kidney Disease 12:1, 71-77
CrossRef1294
Masahiro Takeuchi. (2005) Iryo To Shakai 15:1, 17-24
CrossRef1295
Guillermo Burlando, Ramiro A S??nchez, Felipe H Ramos, Carl E Mogensen, Alberto Zanchetti. (2004) Latin American consensus on diabetes mellitus and hypertension. Journal of Hypertension 22:12, 2229-2241
CrossRef1296
F Harzallah, H Alberti, F Kanoun, F Elhouch, H Slimane. (2004) Quality of care of patients with type 2 diabetes in a Tunisian university hospital. Diabetes & Metabolism 30:6, 523-526
CrossRef1297
Brent Egan, Gilbert Gleim, Jessica Panish. (2004) Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL. Current Medical Research and Opinion 20:12, 1909-1917
CrossRef1298
Michael Weber, Jan Basile, Joseph Izzo, Suzanne Oparil. (2004) Blood Pressure Goal Attainment: Meeting the Challenge of the JNC 7's Blood Pressure Goals and the Role of Renin-Angiotensin-Aldosterone System Blockade. The Journal of Clinical Hypertension 6:12, 699-705
CrossRef1299
P. Cía Gómez, A. Martínez Berganza, J.I. Pérez Calvo. (2004) Tratamiento farmacológico de la hipertensión arterial. Medicine - Programa de Formación Médica Continuada Acreditado 9:23, 1481-1493
CrossRef1300
J.-M. Halimi. (2004) Rein et diabète. La Revue de Médecine Interne 25, S339-S341
CrossRef1301
Jean-Jacques Mourad, Bernard Waeber, Fa??ez Zannad, Maurice Laville, G??rard Duru, Michel Andr??jak. (2004) Comparison of different therapeutic strategies in hypertension. Journal of Hypertension 22:12, 2379-2386
CrossRef1302
Paul E. de Jong, Barry M. Brenner. (2004) From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria. Kidney International 66:6, 2109-2118
CrossRef1303
Kazunori Yoshida, Masahiro Kohzuki. (2004) Clinical and Experimental Aspects of Olmesartan Medoxomil, a New Angiotensin II Receptor Antagonist. Cardiovascular Drug Reviews 22:4, 285-308
CrossRef1304
Barnett, Anthony H., Bain, Stephen C., Bouter, Paul, Karlberg, Bengt, Madsbad, Sten, Jervell, Jak, Mustonen, Jukka, . (2004) Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy. New England Journal of Medicine 351:19, 1952-1961
Full Text1305
Ruggenenti, Piero, Fassi, Anna, Ilieva, Anelja Parvanova, Bruno, Simona, Iliev, Ilian Petrov, Brusegan, Varusca, Rubis, Nadia, Gherardi, Giulia, Arnoldi, Federica, Ganeva, Maria, Ene-Iordache, Bogdan, Gaspari, Flavio, Perna, Annalisa, Bossi, Antonio, Trevisan, Roberto, Dodesini, Alessandro R., Remuzzi, Giuseppe, . (2004) Preventing Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine 351:19, 1941-1951
Full Text1306
Mitch, William E., . (2004) Treating Diabetic Nephropathy — Are There Only Economic Issues?. New England Journal of Medicine 351:19, 1934-1936
Full Text1307
Peter Jacobsen, Hans-Henrik Parving. (2004) Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy. Kidney International 66:s92, S108-S110
CrossRef1308
Addison A. Taylor. (2004) Combination drug treatment of hypertension: Have we come full circle?. Current Cardiology Reports 6:6, 421-426
CrossRef1309
Ricardo Correa-Rotter, Sarala Naicker, Ivor J. Katz, Sanjay K. Agarwal, Raul Herrera Valdes, Dan Kaseje, Bernardo Rodriguez-Iturbe, Faissal Shaheen, Chitr Sitthi-Amorn, . (2004) Demographic and epidemiologic transition in the developing world: Role of albuminuria in the early diagnosis and prevention of renal and cardiovascular disease. Kidney International 66:s92, S32-S37
CrossRef1310
Ling Yu, Wayne A. Border, Ian Anderson, Matthew McCourt, Yufeng Huang, Nancy A. Noble. (2004) Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney International 66:5, 1774-1784
CrossRef1311
Richard B Devereux, Paulette A Lyle. (2004) Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Expert Opinion on Pharmacotherapy 5:11, 2311-2320
CrossRef1312
James P. Smith, Julia B. Lewis. (2004) Hypertension management: Special considerations in chronic kidney disease patients. Current Hypertension Reports 6:6, 462-468
CrossRef1313
Katherine R. Tuttle. (2004) Cardiovascular Implications of Albuminuria. The Journal of Clinical Hypertension 6:s11, 13-17
CrossRef1314
William E. Mitch, Shahnaz Shahinfar, Tania Z. Dickson, Dick de Zeeuw, Zhongxin Zhang. (2004) Detecting and managing patients with type 2 diabetic kidney disease: Proteinuria and cardiovascular disease. Kidney International 66:s92, S97-S98
CrossRef1315
Josephine M. Forbes, Merlin C. Thomas, Suzanne R. Thorpe, Nathan L. Alderson, Mark E. Cooper. (2004) The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney International 66:s92, S105-S107
CrossRef1316
Anjanette S. Tan, Saravanan Kuppuswamy, Adam T. Whaley-Connell, L Romayne Kurukulasuriya, James R. Sowers. (2004) Recommendations for Special Populations. The Endocrinologist 14:6, 368-381
CrossRef1317
George L. Bakris. (2004) Implications of Albuminuria on Kidney Disease Progression. The Journal of Clinical Hypertension 6:s11, 18-22
CrossRef1318
Ji-Guang Wang, Yan Li. (2004) Primary and secondary prevention of stroke by antihypertensive drug treatment. Expert Review of Neurotherapeutics 4:6, 1023-1031
CrossRef1319
Mitra K. Nadim, Renee Dua, Vito M. Campese. (2004) Antihypertensive drugs and the kidney. Current Cardiology Reports 6:6, 403-408
CrossRef1320
Ron T. Gansevoort, Bart van der Heij, Coen A. Stegeman, Frank T. de Charro, Martin G. Nieuwenhuizen, Dick de Zeeuw, Paul E. de Jong. (2004) Trends in the incidence of treated end-stage renal failure in The Netherlands: Hope for the future?. Kidney International 66:s92, S7-S10
CrossRef1321
Marcello Tonelli, Dorothea Collins, Sander Robins, Hanna Bloomfield, Gary C. Curhan. (2004) Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. American Journal of Kidney Diseases 44:5, 832-839
CrossRef1322
Bradford C. Berk, John D. Bisognano. (2004) Value in hypertension treatment. Current Hypertension Reports 6:6, 411-413
CrossRef1323
Errol D. Crook, Sejal R. Patel. (2004) Diabetic nephropathy in African-American patients. Current Diabetes Reports 4:6, 455-461
CrossRef1324
W. S. Aronow. (2004) Management of the Elderly Person After Myocardial Infarction. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59:11, 1173-1185
CrossRef1325
Peter A McCullough. (2004) Cardiovascular disease in chronic kidney disease from a cardiologistʼs perspective. Current Opinion in Nephrology and Hypertension 13:6, 591-600
CrossRef1326
Ronald D Smith, Carlos M Ferrario. (2004) Renal protective capacity of the angiotensin receptor antagonists. Therapy 1:2, 331-339
CrossRef1327
Tracy A. McGowan, Yanqing Zhu, Kumar Sharma. (2004) Transforming growth factor-beta: A clinical target for the treatment of diabetic nephropathy. Current Diabetes Reports 4:6, 447-454
CrossRef1328
Gonzalo Calvo, Fernando de Andres-Trelles. (2004) Albuminuria as a surrogate marker for drug development: A European Regulatory perspective. Kidney International 66:s92, S126-S127
CrossRef1329
Charles M. Alexander, Paulette A. Lyle, William F. Keane, George W. Carides, Zhongxin Zhang, Shahnaz Shahinfar. (2004) Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. Kidney International 66:s92, S115-S117
CrossRef1330
Sharon Adler. (2004) Diabetic nephropathy: Linking histology, cell biology, and genetics. Kidney International 66:5, 2095-2106
CrossRef1331
Dick de Zeeuw. (2004) Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?. Kidney International 66:s92, S2-S6
CrossRef1332
Robert C. Atkins, Kevan R. Polkinghorne, Esther M. Briganti, Jonathan E. Shaw, Paul Z. Zimmet, Steven J. Chadban. (2004) Prevalence of albuminuria in Australia: The AusDiab Kidney Study. Kidney International 66:s92, S22-S24
CrossRef1333
David G. Warnock. (2004) Inclusion of albumin as a target in therapy guidelines: Guidelines for chronic kidney disease. Kidney International 66:s92, S121-S123
CrossRef1334
Micha Maeder, Maja Klein, Thomas Fehr, Hans Rickli. (2004) Contrast nephropathy: Review focusing on prevention. Journal of the American College of Cardiology 44:9, 1763-1771
CrossRef1335
Valérie Tikhonoff, Alberto Mazza, Edoardo Casiglia, Achille C Pessina. (2004) Role of manidipine in the management of patients with hypertension. Expert Review of Cardiovascular Therapy 2:6, 815-827
CrossRef1336
Mark E. Williams. (2004) Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Current Diabetes Reports 4:6, 441-446
CrossRef1337
Atsuhiro Ichihara, Matsuhiko Hayashi, Yuki Kaneshiro, Fumiaki Suzuki, Tsutomu Nakagawa, Yuko Tada, Yukako Koura, Akira Nishiyama, Hirokazu Okada, M. Nasir Uddin, A.H.M. Nurun Nabi, Yuichi Ishida, Tadashi Inagami, Takao Saruta. (2004) Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin. Journal of Clinical Investigation 114:8, 1128-1135
CrossRef1338
K K. Venkat. (2004) Proteinuria and Microalbuminuria in Adults: Significance, Evaluation, and Treatment. Southern Medical Journal 97:10, 969-979
CrossRef1339
Marvin Moser. (2004) Update on the Management of Hypertension: Recent Clinical Trials and the JNC 7. The Journal of Clinical Hypertension 6:s10, 4-13
CrossRef1340
LS Levene, PG McNally, RC Fraser, AGJ Lowy. (2004) What characteristics are associated with screening positive for microalbuminuria in patients with diabetes in the community?. Practical Diabetes International 21:8, 287-292
CrossRef1341
Rajiv Gupta, Yochai Birnbaum, Barry F. Uretsky. (2004) The renal patient with coronary artery disease. Journal of the American College of Cardiology 44:7, 1343-1353
CrossRef1342
SANAE INOUE, YASUHIKO TOMINO. (2004) Effects of calcium antagonists in hypertensive patients with renal dysfunction: A prospective, randomized, parallel trial comparing benidipine and nifedipine. Nephrology 9:5, 265-271
CrossRef1343
DONALD W BOWDEN, CARLA J COLICIGNO, CARL D LANGEFELD, MICHÈLE M SALE, ADRIENNE WILLIAMS, PAMELA J ANDERSON, STEPHEN S RICH, BARRY I FREEDMAN. (2004) A genome scan for diabetic nephropathy in African Americans. Kidney International 66:4, 1517-1526
CrossRef1344
Masakazu Haneda, Ryuichi Kikkawa, Hideto Sakai, Ryuzo Kawamori. (2004) Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. Diabetes Research and Clinical Practice 66:1, 87-95
CrossRef1345
K. D. Flemming, R. D. Brown. (2004) Secondary Prevention Strategies in Ischemic Stroke: Identification and Optimal Management of Modifiable Risk Factors. Mayo Clinic Proceedings 79:10, 1330-1340
CrossRef1346
A. Ceriello, R. Assaloni, R. Ros, A. Maier, L. Quagliaro, L. Piconi, K. Esposito, D. Giugliano. (2004) Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients. Diabetologia 47:9, 1535-1540
CrossRef1347
Niels H. Andersen, Carl E. Mogensen. (2004) Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease. Current Hypertension Reports 6:5, 369-376
CrossRef1348
T Damci, H Kultursay, A Oguz, S Pehlivanoglu, L Tokgozoglu. (2004) Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey. Diabetes & Metabolism 30:4, 327-333
CrossRef1349
Alan H. Gradman. (2004) Managing High-Risk Patients With Hypertension: Focus on the Renin-Angiotensin System. The Journal of Clinical Hypertension 6:9, 501-508
CrossRef1350
Kathleen L. Wyne. (2004) Management of Type 2 Diabetes Mellitus: Is It Time for a Paradigm Shift?. Metabolic Syndrome and Related Disorders 2:4, 251-262
CrossRef1351
Peter Hovind, Lise Tarnow, Hans-Henrik Parving. (2004) Remission and regression of diabetic nephropathy. Current Hypertension Reports 6:5, 377-382
CrossRef1352
L.M. Ruilope, M. Volpe. (2004) The case for blood pressure control in risk groups. International Journal of Clinical Practice 58:9, 844-849
CrossRef1353
Anupama Mohanram, Zhongxin Zhang, Shahnaz Shahinfar, William F. Keane, Barry M. Brenner, Robert D. Toto. (2004) Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney International 66:3, 1131-1138
CrossRef1354
Jocelyn D. Jones, Keecia D. King, Frank S. Emanuel. (2004) Hypertension: A Clinical Pharmacist's Synopsis of JNC 7. American Journal of Pharmaceutical Education 68:3, 71
CrossRef1355
Stefan Schäfer, Hans-Ludwig Schmidts, Markus Bleich, Andreas E Busch, Wolfgang Linz. (2004) Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent. British Journal of Pharmacology 143:1, 27-32
CrossRef1356
Markus Lassila, Mark E. Cooper, Karin Jandeleit-Dahm. (2004) Antiproteinuric effect of RAS blockade: New mechanisms. Current Hypertension Reports 6:5, 383-392
CrossRef1357
Palmer, Biff F., . (2004) Managing Hyperkalemia Caused by Inhibitors of the Renin–Angiotensin–Aldosterone System. New England Journal of Medicine 351:6, 585-592
Full Text1358
SHUEI-LIONG LIN, YUNG-MING CHEN, WEN-CHIH CHIANG, TUN-JUN TSAI, WAN-YU CHEN. (2004) Review Article. Pentoxifylline: A potential therapy for chronic kidney disease. Nephrology 9:4, 198-204
CrossRef1359
Michel Marre, Juan Garcia Puig, Franciszek Kokot, Margarita Fernandez, Gy??rgy Jermendy, Lionel Opie, Valentin Moyseev, Andr?? Scheen, Constantin Ionescu-Tirgoviste, M Helena Saldanha, Aaron Halabe, Bryan Williams, Decio Mion, Maximino Ruiz, Kjeld Hermansen, Jaakko Tuomilehto, Bartolom?? Finizola, Yves Gallois, Philippe Amouyel, Jean-Pierre Ollivier, Roland Asmar. (2004) Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes. Journal of Hypertension 22:8, 1613-1622
CrossRef1360
BERNARDO RODRÍGUEZ-ITURBE, TADASHI SATO, YASMIR QUIROZ, NOSRATOLA D VAZIRI. (2004) AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat. Kidney International 66:2, 668-675
CrossRef1361
Hiromichi Suzuki, Yoshihiko Kanno, Keiko Kaneko, Masaharu Kaneko, Syuhei Kotaki, Taku Mimura, Hiroshi Takane. (2004) Comparison of the Effects of Angiotensin Receptor Antagonist, Angiotensin Converting Enzyme Inhibitor, and their Combination on Regression of Left Ventricular Hypertrophy of Diabetes Type 2 Patients on Recent Onset Hemodialysis Therapy. Therapeutic Apheresis and Dialysis 8:4, 320-327
CrossRef1362
C Sierra, Luis M Ruilope. (2004) Novel antihypertensive agents. Expert Opinion on Investigational Drugs 13:8, 987-998
CrossRef1363
David G. Warnock, Stephen C. Textor. (2004) Hypertension. American Journal of Kidney Diseases 44:2, 369-375
CrossRef1364
Steven G. Chrysant, George S. Chrysant. (2004) Clinical Experience With Angiotensin Receptor Blockers With Particular Reference to Valsartan. The Journal of Clinical Hypertension 6:8, 445-451
CrossRef1365
KIRSTEN DE GROOT, FERDINAND HERMANN BAHLMANN, JOHANNA SOWA, JANA KOENIG, JAN MENNE, HERMANN HALLER, DANILO FLISER. (2004) Uremia causes endothelial progenitor cell deficiency. Kidney International 66:2, 641-646
CrossRef1366
MASATO NISHIMURA, TETSUYA HASHIMOTO, HIROYUKI KOBAYASHI, TOYOFUMI FUKUDA, KOJI OKINO, NORIYUKI YAMAMOTO, HIROSHI FUJITA, NAOTO INOUE, TSUNEHIKO NISHIMURA, TOSHIHIKO ONO. (2004) Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease in hemodialysis patients. Kidney International 66:2, 811-819
CrossRef1367
W. Y. S. Leung. (2004) The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy. Nephrology Dialysis Transplantation 19:10, 2519-2525
CrossRef1368
Paresh Dandona, Ajay Chaudhuri, Ahmad Aljada. (2004) Endothelial dysfunction and hypertension in diabetes mellitus. Medical Clinics of North America 88:4, 911-931
CrossRef1369
Dominic A Sica. (2004) Angiotensin-receptor blockade in renal disease: the hard issues. Expert Review of Cardiovascular Therapy 2:4, 469-471
CrossRef1370
Seok Man Son, Matthew K. Whalin, David G. Harrison, W. Robert Taylor, Kathy K. Griendling. (2004) Oxidative stress and diabetic vascular complications. Current Diabetes Reports 4:4, 247-252
CrossRef1371
Michael A. Weber. (2004) Angiotensin II Receptor Blockers in Older Patients. The American Journal of Geriatric Cardiology 13:4, 197-205
CrossRef1372
Ali Jawa, Juanita Kcomt, Vivian A Fonseca. (2004) Diabetic nephropathy and retinopathy. Medical Clinics of North America 88:4, 1001-1036
CrossRef1373
Helmy M. Siragy. (2004) Clinical Trials Report. Current Hypertension Reports 6:4, 255-256
CrossRef1374
Eberhard Ritz, Ralf Dikow, Martin Zeier. (2004) Compelling drug indications in diabetic and nondiabetic nephropathy. Current Hypertension Reports 6:4, 293-299
CrossRef1375
Norberto Perico, Piero Ruggenenti, Giuseppe Remuzzi. (2004) Losartan in diabetic nephropathy. Expert Review of Cardiovascular Therapy 2:4, 473-483
CrossRef1376
W.H Wilson Tang, Anjli Maroo, James B Young. (2004) Ischemic heart disease and congestive heart failure in diabetic patients. Medical Clinics of North America 88:4, 1037-1061
CrossRef1377
Norman K. Hollenberg. (2004) Aldosterone in the development and progression of renal injury. Kidney International 66:1, 1-9
CrossRef1378
Joseph L Izzo. (2004) Arterial stiffness and the systolic hypertension syndrome. Current Opinion in Cardiology 19:4, 341-352
CrossRef1379
Sheerin Mathur, Cathy A. Brown, Ursula M. Dietrich, John S. Munday, Melvin A. Newell, Suzanne E. Sheldon, Leslie M. Cartier, Scott A. Brown. (2004) Evaluation of a technique of inducing hypertensive renal insufficiency in cats. American Journal of Veterinary Research 65:7, 1006-1013
CrossRef1380
Wladyslaw Sulowicz, Tomasz P. Stompor. (2004) Timely referral to the nephrologist: Essential to optimizing patient outcomes. Hemodialysis International 8:3, 233-243
CrossRef1381
John L Lin, Doris Armour. (2004) Selected medical management of the older rehabilitative patient. Archives of Physical Medicine and Rehabilitation 85, 76-82
CrossRef1382
Anthony L. McCall. (2004) Hypertension management in patients with diabetic nephropathy. Current Hypertension Reports 6:4, 272-279
CrossRef1383
Minoru Sasaki, Sayuri Uehara, Hisashi Ohta, Kazuhiro Taguchi, Masayuki Kemi, Masaru Nishikibe, Hiroyoshi Matsumoto. (2004) Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice. Life Sciences 75:7, 869-880
CrossRef1384
Jan Östergren. (2004) Candesartan for the treatment of hypertension and heart failure. Expert Opinion on Pharmacotherapy 5:7, 1589-1597
CrossRef1385
Peter A McCullough. (2004) Opportunities for improvement in the cardiovascular care of patients with end-stage renal disease. Advances in Chronic Kidney Disease 11:3, 294-303
CrossRef1386
Robert N. Foley. (2004) HYPERTENSION IN HEMODIALYSIS PATIENTS: Cardiac Disease in Chronic Uremia: Can it Explain the Reverse Epidemiology of Hypertension and Survival in Dialysis Patients?. Seminars in Dialysis 17:4, 275-278
CrossRef1387
O. Gross. (2004) Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrology Dialysis Transplantation 19:7, 1716-1723
CrossRef1388
C. R. Parikh. (2004) Rapid microalbuminuria screening in type 2 diabetes mellitus: simplified approach with Micral test strips and specific gravity. Nephrology Dialysis Transplantation 19:7, 1881-1885
CrossRef1389
Tsutomu Sanaka, Tadao Akizawa, Keizou Koide, Shozo Koshikawa. (2004) Protective Effect of an Oral Adsorbent on Renal Function in Chronic Renal Failure: Determinants of its Efficacy in Diabetic Nephropathy. Therapeutic Apheresis and Dialysis 8:3, 232-240
CrossRef1390
Matthew R. Weir. (2004) Angiotensin II Receptor Blockers: The Importance of Dose in Cardiovascular and Renal Risk Reduction. The Journal of Clinical Hypertension 6:6, 315-325
CrossRef1391
Dick de Zeeuw, Giuseppe Remuzzi, Hans-Henrik Parving, William F. Keane, Zhongxin Zhang, Shahnaz Shahinfar, Steve Snapinn, Mark E. Cooper, William E. Mitch, Barry M. Brenner. (2004) Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney International 65:6, 2309-2320
CrossRef1392
Jorge Eduardo Toblli, Graciela DeRosa, Gabriel Cao, Pablo Piorno, Patricia Pagano. (2004) ACE inhibitor and angiotensin type I receptor antagonist in combination reduce renal damage in obese Zucker rats. Kidney International 65:6, 2343-2359
CrossRef1393
Julie P. Sutherland, Benjamin McKinley, Robert H. Eckel. (2004) The Metabolic Syndrome and Inflammation. Metabolic Syndrome and Related Disorders 2:2, 82-104
CrossRef1394
Lawrence Baruch, Prabhakara Kunamneni. (2004) Beta-blockers in heart failure: Is more better?. Current Heart Failure Reports 1:2, 77-81
CrossRef1395
Allison B. Rosen, Andrew J. Karter, Jennifer Y. Liu, Joe V. Selby, Eric C. Schneider. (2004) Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in High-risk Clinical and Ethnic Groups with Diabetes. Journal of General Internal Medicine 19:6, 669-675
CrossRef1396
Yackoob Kassim Seedat. (2004) Correspondence. Journal of Hypertension 22:5, 1048
CrossRef1397
Louise M. Burrell, Colin I. Johnston, Christos Tikellis, Mark E. Cooper. (2004) ACE2, a new regulator of the renin–angiotensin system. Trends in Endocrinology & Metabolism 15:4, 166-169
CrossRef1398
Osamu Hotta. (2004) Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy. Seminars in Nephrology 24:3, 244-255
CrossRef1399
Luca De Nicola, Roberto Minutolo, Vincenzo Bellizzi, Carmine Zoccali, Bruno Cianciaruso, Vittorio E Andreucci, Giorgio Fuiano, Giuseppe Conte. (2004) Achievement of target blood pressure levels in chronic kidney disease: a salty question?1 1See Appendix for complete list of investigators in the TABLE in CKD Study Group.. American Journal of Kidney Diseases 43:5, 782-795
CrossRef1400
Lawrence Baruch. (2004) Hypertension and the Elderly: More Than Just Blood Pressure Control. The Journal of Clinical Hypertension 6:5, 249-255
CrossRef1401
Fadi El-Atat, Samy I. McFarlane, James R. Sowers. (2004) Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management. Current Hypertension Reports 6:3, 215-223
CrossRef1402
Benjamin J. Epstein, Kurt A. Wargo, Kenneth Chong, Evelyn C. Y. Chan. (2004) Elevations in Serum Creatinine Concentration: Concerning or Reassuring?. Pharmacotherapy 24:5, 697-703
CrossRef1403
(2004) References. American Journal of Kidney Diseases 43, 268-290
CrossRef1404
R. Rachmani, I. Slavachevsky, M. Amit, Z. Levi, Y. Kedar, M. Berla, M. Ravid. (2004) The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabetic Medicine 21:5, 471-475
CrossRef1405
Peter Jacobsen, Kasper Rossing, Hans-Henrik Parving. (2004) Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Current Opinion in Nephrology and Hypertension 13:3, 319-324
CrossRef1406
Nitin Khosla, Peter Hart, George L. Bakris. (2004) Management of hypertension in the cardiometabolic syndrome and diabetes. Current Diabetes Reports 4:3, 199-205
CrossRef1407
M. K. W. Lo, K.-F. Lee, N. N. Chan, W. Y. S. Leung, G. T. C. Ko, W.-B. Chan, W.-Y. So, M. C. Y. Ng, C.-S. Ho, J. S. L. Tam, C. W. K. Lam, P. C. Y. Tong, J. C. N. Chan. (2004) Effects of gender, Helicobacter pylori and hepatitis B virus serology status on cardiovascular and renal complications in Chinese type 2 diabetic patients with overt nephropathy. Diabetes, Obesity and Metabolism 6:3, 223-230
CrossRef1408
F. Locatelli. (2004) Hypertension and cardiovascular risk assessment in dialysis patients. Nephrology Dialysis Transplantation 19:5, 1058-1068
CrossRef1409
Stephen C. Jones, Sally M. Marshall, Rudy W. Bilous. 2004. Diabetic Nephropathy. .
CrossRef1410
Donna S. Hanes, Anita Nahar, Matthew R. Weir. (2004) The tissue renin-angiotensin-aldosterone system in diabetes mellitus. Current Hypertension Reports 6:2, 98-105
CrossRef1411
Norman K. Hollenberg, Radomir Stevanovic, Anupam Agarwal, M. Cecilia Lansang, Deborah A. Price, Lori M.B. Laffel, Gordon H. Williams, Naomi D.L. Fisher. (2004) Plasma aldosterone concentration in the patient with diabetes mellitus Rapid Communication. Kidney International 65:4, 1435-1439
CrossRef1412
Joel M. Neutel, David H.G. Smith, Micheal A. Weber, Antonia C. Wang, Harvey N. Masonson. (2004) Use of an Olmesartan Medoxomil-Based Treatment Algorithm for Hypertension Control. The Journal of Clinical Hypertension 6:4, 168-399
CrossRef1413
Karen A. Griffin, Anil K. Bidani. (2004) Hypertensive renal damage: Insights from animal models and clinical relevance. Current Hypertension Reports 6:2, 145-153
CrossRef1414
Matthew R Weir. (2004) Blood pressure management in the kidney transplant recipient. Advances in Chronic Kidney Disease 11:2, 172-183
CrossRef1415
B. Charbonnel, B. Bouhanick, C. Le Feuvre. (2004) Recommandations SFC/ALFEDIAM sur la prise en charge du patient diabétique vu par le cardiologue. Diabetes & Metabolism 30:2, 2S9-2S24
CrossRef1416
Peter A McCullough. (2004) Cardiovascular risk reduction and preservation of renal function in the early nephropathy patient. Advances in Chronic Kidney Disease 11:2, 184-191
CrossRef1417
Kamyar Kalantar-Zadeh, Denis Fouque, Joel D. Kopple. (2004) Outcome research, nutrition, and reverse epidemiology in maintenance dialysis patients. Journal of Renal Nutrition 14:2, 64-71
CrossRef1418
J. S. Zaltzman. (2004) The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. Nephrology Dialysis Transplantation 19:4, 940-944
CrossRef1419
N. Joss. (2004) Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. QJM 97:4, 219-227
CrossRef1420
Massimo Volpe. (2004) Hypertension therapy: Mixing, matching, and meeting targets. Advances in Therapy 21:2, 107-122
CrossRef1421
Kunihiro Yamagata, Hideto Takahashi, Soh Suzuki, Kaori Mase, Masahiro Hagiwara, Yoshio Shimizu, Kouichi Hirayama, Masaki Kobayashi, Mitsuharu Narita, Akio Koyama. (2004) Age distribution and yearly changes in the incidence of ESRD in Japan. American Journal of Kidney Diseases 43:3, 433-443
CrossRef1422
Reza Abdi, Barry M Brenner. (2004) Impact of renin angiotensin system blockade on renal function in health and disease: an end or a beginning?. Seminars in Nephrology 24:2, 141-146
CrossRef1423
Matthew R. Weir. (2004) Microalbuminuria in Type 2 Diabetics: An Important, Overlooked Cardiovascular Risk Factor. The Journal of Clinical Hypertension 6:3, 134-143
CrossRef1424
Ariela Benigni, Elena Gagliardini, Giuseppe Remuzzi. (2004) Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement. Seminars in Nephrology 24:2, 131-140
CrossRef1425
Gregory M. Caputo, Joel B. Braunstein, Roger S. Blumenthal. (2004) Evolving targets for risk reduction in diabetes. Clinical Cardiology 27:3, 125-128
CrossRef1426
Sheila A Doggrell. (2004) Candesartan for the prevention and treatment of stroke – results of the SCOPE and ACCESS trials. Expert Opinion on Pharmacotherapy 5:3, 687-690
CrossRef1427
Steven G Chrysant, George S Chrysant. (2004) Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opinion on Pharmacotherapy 5:3, 657-667
CrossRef1428
Stevo Julius, Michael H Alderman, Gareth Beevers, Björn Dahlöf, Richard B Devereux, Janice G Douglas, Jonathan M Edelman, Katherine E Harris, Sverre E Kjeldsen, Shawna Nesbitt, Otelio S Randall, Jackson T Wright. (2004) Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy. Journal of the American College of Cardiology 43:6, 1047-1055
CrossRef1429
Maristela Lika Onozato, Akihiro Tojo, Atsuo Goto, Toshiro Fujita. (2004) Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet. Kidney International 65:3, 951-960
CrossRef1430
Casey N Gashti, George L Bakris. (2004) The role of calcium antagonists in chronic kidney disease. Current Opinion in Nephrology and Hypertension 13:2, 155-161
CrossRef1431
Helmy M Siragy. (2004) AT1 and AT2 receptor in the kidney: role in health and disease. Seminars in Nephrology 24:2, 93-100
CrossRef1432
L. M. Ruilope. (2004) What is the impact of PRIME on real-life diabetic nephropathy?. International Journal of Clinical Practice 58:3, 268-276
CrossRef1433
Amy J Mangrum, George L Bakris. (2004) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Seminars in Nephrology 24:2, 168-175
CrossRef1434
&NA;. (2004) Screening for Type 2 Diabetes Mellitus in Adults: Recommendations and Rationale. AJN, American Journal of Nursing 104:3, 83-90
CrossRef1435
Hans-Henrik Parving, Steen Andersen, Peter Jacobsen, Per K Christensen, Kasper Rossing, Peter Hovind, Peter Rossing, Lise Tarnow. (2004) Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Seminars in Nephrology 24:2, 147-157
CrossRef1436
Donald Silverberg, Dov Wexler, Miriam Blum, Doron Schwartz, Adrian Iaina. (2004) The association between congestive heart failure and chronic renal disease. Current Opinion in Nephrology and Hypertension 13:2, 163-170
CrossRef1437
Arati Wagh, Neil J Stone. (2004) Treatment of metabolic syndrome. Expert Review of Cardiovascular Therapy 2:2, 213-228
CrossRef1438
Yoshihiko Kanno, Keiko Kaneko, Masaharu Kaneko, Syuhei Kotaki, Taku Mimura, Hiroshi Takane, Hiromichi Suzuki. (2004) Angiotensin Receptor Antagonist Regresses Left Ventricular Hypertrophy Associated with Diabetic Nephropathy in Dialysis Patients. Journal of Cardiovascular Pharmacology 43:3, 380-386
CrossRef1439
Tatsuo Yanagawa, Atsushi Araki, Kazuo Sasamoto, Shinichiro Shirabe, Toshikazu Yamanouchi. (2004) Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metabolism 53:3, 353-357
CrossRef1440
M. Praga. (2004) Reply. Nephrology Dialysis Transplantation 19:3, 747-a-748
CrossRef1441
Haiyan Wang, Jingzi Li, Ling Yu, Yani Zhao, Wei Ding. (2004) Antifibrotic effect of the Chinese herbs, Astragalus mongholicus and Angelica sinensis, in a rat model of chronic puromycin aminonucleoside nephrosis. Life Sciences 74:13, 1645-1658
CrossRef1442
S. T. Knudsen, T. Bek, P. L. Poulsen, M. N. Hove, M. Rehling, C. E. Mogensen. (2004) Effects of losartan on diabetic maculopathy in type 2 diabetic patients - reply. Journal of Internal Medicine 255:2, 306-307
CrossRef1443
Hirokazu Okada, Yusuke Watanabe, Tsutomu Inoue, Tatsuya Kobayashi, Tomohiro Kikuta, Yoshihiko Kanno, Shinichi Ban, Hiromichi Suzuki. (2004) Angiotensin II type 1 receptor blockade attenuates renal fibrogenesis in an immune-mediated nephritic kidney through counter-activation of angiotensin II type 2 receptor. Biochemical and Biophysical Research Communications 314:2, 403-408
CrossRef1444
Christos Chatziantoniou, Jean-Jacques Boffa, Pierre-Louis Tharaux, Martin Flamant, Pierre Ronco, Jean-Claude Dussaule. (2004) Progression and regression in renal vascular and glomerular fibrosis. International Journal of Experimental Pathology 85:1, 1-11
CrossRef1445
Reginald P. Sequeira, Khalid A. Jassim Al Khaja, Awatif H.H. Damanhori. (2004) Evaluating the treatment of hypertension in diabetes mellitus: a need for better control?. Journal of Evaluation in Clinical Practice 10:1, 107-116
CrossRef1446
Gilbert W. Gleim, Charles S. Tressler. (2004) Effects of losartan on diabetic maculopathy in type 2 diabetic patients. Journal of Internal Medicine 255:2, 304-305
CrossRef1447
Patricia J. Neafsey. (2004) Self-Medication Practices That Alter the Efficacy of Selected Cardiac Medications. Home Healthcare Nurse: The Journal for the Home Care and Hospice Professional 22:2, 88-98
CrossRef1448
Przemyslaw Rutkowski, Leszek Tylicki, Marcin Renke, Grzegorz Korejwo, Zbigniew Zdrojewski, Boleslaw Rutkowski. (2004) Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. American Journal of Kidney Diseases 43:2, 260-268
CrossRef1449
Martin C Michel, Herbert Bohner, J??rgen K??ster, Rafael Sch??fers, Uwe Heemann. (2004) Safety of Telmisartan in Patients with Arterial Hypertension. Drug Safety 27:5, 335-344
CrossRef1450
Ursula C Brewster, Mark A Perazella. (2004) Can dual blockade of the renin–angiotensin system reduce progression of kidney disease beyond monotherapy?. Expert Opinion on Drug Safety 3:1, 9-23
CrossRef1451
Shunichi KOJIMA, Mikio SHIDA, Hiroyuki YOKOYAMA. (2004) Comparison between Cilnidipine and Amlodipine Besilate with Respect to Proteinuria in Hypertensive Patients with Renal Diseases. Hypertension Research 27:6, 379-385
CrossRef1452
Hiroshi YAMAGUCHI, Masahiko IGARASHI, Akihiko HIRATA, Hiromi TSUCHIYA, Kazuhiko SUGIYAMA, Yoshihiro MORITA, Yumi JIMBU, Hiroshi OHNUMA, Makoto DAIMON, Makoto TOMINAGA, Takeo KATO. (2004) Progression of Diabetic Nephropathy Enhances the Plasma Osteopontin Level in Type 2 Diabetic Patients. Endocrine Journal 51:5, 499-504
CrossRef1453
C. E. Mogensen, M. E. Cooper. (2004) Diabetic renal disease: from recent studies to improved clinical practice. Diabetic Medicine 21:1, 4-17
CrossRef1454
Gérard M London, Roland G Asmar, Michaël F O'Rourke, Michel E Safar. (2004) Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/Indapamide in hypertensive subjects: comparison with atenolol. Journal of the American College of Cardiology 43:1, 92-99
CrossRef1455
M. Cooper, G. Boner. (2004) Dual blockade of the renin-angiotensin system in diabetic nephropathy. Diabetic Medicine 21:s1, 15-18
CrossRef1456
Gordon T McInnes. (2004) Reply. Journal of Hypertension 22:1, 226-227
CrossRef1457
Kevin C Abbott, George L Bakris. (2004) What have we learned from the current trials?. Medical Clinics of North America 88:1, 189-207
CrossRef1458
David M. Cocchetto. (2004) Regulatory Decision‐Making in the United States Based on a Single Pivotal Clinical Study: Principles and Precedents. Clinical Research and Regulatory Affairs 21:2, 101-143
CrossRef1459
H Lehnert, P Bramlage, D Pittrow, W Kirch. (2004) Regression of Microalbuminuria in???Type 2 Diabetics after Switch to???Irbesartan Treatment. Clinical Drug Investigation 24:4, 217-225
CrossRef1460
Jonathan D Rippin, Anthony H Barnett, Stephen C Bain. (2004) Cost-Effective Strategies in the Prevention of Diabetic Nephropathy. PharmacoEconomics 22:1, 9-28
CrossRef1461
Riccardo Sarzani, Paolo Dess??-Fulgheri, Alessandro Rappelli. (2004) Angiotensin Receptor Blockers and Target-Organ Protection Beyond Blood Pressure Control. High Blood Pressure & Cardiovascular Prevention 11:2, 65-73
CrossRef1462
A. Siebenhofer, J. Plank, K. Horvath, A. Berghold, A. J. Sutton, R. Sommer, T. R. Pieber. (2004) Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials. Diabetic Medicine 21:1, 18-25
CrossRef1463
Marvin Moser, John Setaro. (2004) Continued importance of diuretics and β-adrenergic blockers in the management of hypertension. Medical Clinics of North America 88:1, 167-187
CrossRef1464
Richard N Re. (2004) Tissue renin angiotensin systems. Medical Clinics of North America 88:1, 19-38
CrossRef1465
Brian Rayner. (2004) Advances in the treatment of diabetic renal disease: focus on losartan. Current Medical Research and Opinion 20:3, 333-340
CrossRef1466
Peter A Meredith, John L Reid. (2004) Efficacy and Tolerability of Long-Term Rilmenidine Treatment in Hypertensive Diabetic Patients. American Journal of Cardiovascular Drugs 4:3, 195-200
CrossRef1467
Naoyuki Nakao, Hachiro Seno, Hirotake Kasuga, Takanobu Toriyama, Hirohisa Kawahara, Masafumi Fukagawa. (2004) Effects of Combination Treatment with Losartan and Trandolapril on Office and Ambulatory Blood Pressures in Non-Diabetic Renal Disease: A COOPERATE-ABP Substudy. American Journal of Nephrology 24:5, 543-548
CrossRef1468
Massimo Volpe. (2004) Evidence-Based Indications in Hypertensive Patients. High Blood Pressure & Cardiovascular Prevention 11:1, 1-7
CrossRef1469
Thomas Unger, Gordon T McInnes, Joel M Neutel, Michael B??hm. (2004) The Role of Olmesartan Medoxomil in the Management of Hypertension. Drugs 64:24, 2731-2739
CrossRef1470
Edward D Frohlich. (2004) Target organ involvement in hypertension: a realistic promise of prevention and reversal. Medical Clinics of North America 88:1, 209-221
CrossRef1471
S. M. Marshall. (2004) Inhibition of the renin-angiotensin system: added value in reducing cardiovascular and renal risk?. Diabetic Medicine 21:1, 1-3
CrossRef1472
D. W. Johnson. (2004) Evidence-based guide to slowing the progression of early renal insufficiency. Internal Medicine Journal 34:1-2, 50-57
CrossRef1473
Katherine F Croom, Monique P Curran, Karen L Goa, Caroline M Perry. (2004) Irbesartan. Drugs 64:9, 999-1028
CrossRef1474
Maarten W Taal. (2004) Slowing the Progression of Adult Chronic Kidney Disease. Drugs 64:20, 2273-2289
CrossRef1475
Andr?? J Scheen. (2004) Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System. Drugs 64:22, 2537-2565
CrossRef1476
Nicholas L M Cruden, David E Newby. (2004) Angiotensin Antagonism in Patients with Heart Failure. American Journal of Cardiovascular Drugs 4:6, 345-353
CrossRef1477
Carlos Ferrario, Michael Moore. (2004) AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan. Current Medical Research and Opinion 20:3, 279-293
CrossRef1478
Alexander Tenenbaum, Enrique Z Fisman. (2004) Impaired Glucose Metabolism in Patients with Heart Failure. American Journal of Cardiovascular Drugs 4:5, 269-280
CrossRef1479
Yasuhiko IINO, Matsuhiko HAYASHI, Tetsuya KAWAMURA, Tatsuo SHIIGAI, Yasuhiko TOMINO, Kenichi YAMADA, Takeyuki KITAJIMA, Terukuni IDEURA, Akio KOYAMA, Tetsuzo SUGISAKI, Hiromichi SUZUKI, Satoshi UMEMURA, Yoshindo KAWAGUCHI, Shunya UCHIDA, Michio KUWAHARA, Tsutomu YAMAZAKI, JLIGHT Study Investigators. (2004) Renoprotective Effect of Losartan in Comparison to Amlodipine in Patients with Chronic Kidney Disease and Hypertension-a Report of the Japanese Losartan Therapy Intended for the Global Renal Protection Hypertensive Patients (JLIGHT) Study. Hypertension Research 27:1, 21-30
CrossRef1480
Arrigo Schieppati, Giuseppe Remuzzi. (2003) The future of renoprotection: Frustration and promises. Kidney International 64:6, 1947-1955
CrossRef1481
Lars Rothermund, Peter Kossmehl, Hans-H Neumayer, Martin Paul, Reinhold Kreutz. (2003) Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension. Journal of Hypertension 21:12, 2389-2397
CrossRef1482
Robert B. Toto. (2003) Hypertensive nephrosclerosis in African Americans. Kidney International 64:6, 2331-2341
CrossRef1483
(2003) Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines. Diabetic Medicine 20:12, 972-987
CrossRef1484
Guy De Backer, Ettore Ambrosioni, Knut Broch-Johnsen, Carlos Brotons, Renata Cifkova, Jean Dallongeville, Shah Ebrahim, Ole Faergeman, Ian Graham, Guiseppe Mancia, Volkert Manger Cats, Kristina Orth-Gom??r, Joep Perk, Kalevi Py??r??l??, Jos?? L. Rodicio, Susana Sans, Vedat Sansoy, Udo Sechtem, Sigmund Silber, Troels Thomsen, David Wood. (2003) European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European Journal of Cardiovascular Prevention and Rehabilitation 10:Supplement 1, S1-S78
CrossRef1485
Luis M. Ruilope, Julian Segura. (2003) Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: A review of the clinical trial evidence. Clinical Therapeutics 25:12, 3044-3064
CrossRef1486
Mann, Douglas L., Deswal, Anita, . (2003) Angiotensin-Receptor Blockade in Acute Myocardial Infarction — A Matter of Dose. New England Journal of Medicine 349:20, 1963-1965
Full Text1487
Juan M. Aranda, C. Richard Conti. (2003) Angiotensin II blockade: A therapeutic strategy with wide applications. Clinical Cardiology 26:11, 500-502
CrossRef1488
Sheldon Chen, Belinda Jim, Fuad N Ziyadeh. (2003) Diabetic nephropathy and transforming growth factor-β: transforming our view of glomerulosclerosis and fibrosis build-up. Seminars in Nephrology 23:6, 532-543
CrossRef1489
Antonio Alberto Lopes, Sherman A. James, Friedrich K. Port, Akinlolu O. Ojo, Lawrence Y. Agodoa, Kenneth A. Jamerson. (2003) Meeting the Challenge to Improve the Treatment of Hypertension in Blacks. The Journal of Clinical Hypertension 5:6, 393-401
CrossRef1490
Bruce A. Manzo, Mazen S. Matalka, Susan L. Ravnan. (2003) Evaluation of a Therapeutic Conversion from Amlodipine to Felodipine. Pharmacotherapy 23:11, 1508-1512
CrossRef1491
Joseph L. Izzo. (2003) Hypertension in the Metabolic Syndrome and Diabetes: Pathogenesis, Clinical Studies, and Treatment. The Journal of Clinical Hypertension 5:6, 3-10
CrossRef1492
Kelli L. Davis, Jean M. Nappi. (2003) The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist. Clinical Therapeutics 25:11, 2647-2668
CrossRef1493
JA Whitworth. (2003) Emerging drugs in the management of hypertension. Expert Opinion on Emerging Drugs 8:2, 377-388
CrossRef1494
Marvin Moser. (2003) Rationale for Combination Therapy in the Management of Hypertension. The Journal of Clinical Hypertension 5:6, 17-25
CrossRef1495
Johannes F.E. Mann, Hertzel C. Gerstein, Qi-Long Yi, Jörg Franke, Eva M. Lonn, Byron J. Hoogwerf, Andrew Rashkow, Salim Yusuf. (2003) Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. American Journal of Kidney Diseases 42:5, 936-942
CrossRef1496
(2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. The Lancet 362:9395, 1527-1535
CrossRef1497
Ruth C. Campbell, Piero Ruggenenti, Giuseppe Remuzzi. (2003) Proteinuria in diabetic nephropathy: Treatment and evolution. Current Diabetes Reports 3:6, 497-504
CrossRef1498
Domenic A. Sica. (2003) Combination Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Therapy: Its Role in Clinical Practice. The Journal of Clinical Hypertension 5:6, 414-420
CrossRef1499
Prabal K Chatterjee, Christoph Thiemermann. (2003) Emerging drugs for renal failure. Expert Opinion on Emerging Drugs 8:2, 389-435
CrossRef1500
Pierre-François Plouin. (2003) Stable patients with atherosclerotic renal artery stenosis should be treated first with medical management. American Journal of Kidney Diseases 42:5, 851-857
CrossRef1501
(2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. Journal of Hypertension 21:11, 1983-1992
CrossRef1502
S. Sanal, W. S. Aronow. (2003) Effect of an Educational Program on the Prevalence of Use of Antiplatelet Drugs, Beta Blockers, Angiotensin-Converting Enzyme Inhibitors, Lipid-Lowering Drugs, and Calcium Channel Blockers Prescribed During Hospitalization and at Hospital Discharge in Patients With Coronary Artery Disease. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 58:11, M1046-M1048
CrossRef1503
George L. Bakris, Nauman Tarif, Henry R. Black. 2003. Arterial Hypertension in Diabetes: Etiology and Treatment. .
CrossRef1504
Laura G. Sanchez-Lozada, Edilia Tapia, Richard J. Johnson, Bernardo Rodriguez-Iturbe, Jaime Herrera-Acosta. (2003) Glomerular hemodynamic changes associated with arteriolar lesions and tubulointerstitial inflammation. Kidney International 64:s86, 9-14
CrossRef1505
Kambiz Kalantarinia, Alaa S. Awad, Helmy M. Siragy. (2003) Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney International 64:4, 1208-1213
CrossRef1506
Steven G Chrysant. (2003) Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan®/HCT). Expert Review of Cardiovascular Therapy 1:3, 335-343
CrossRef1507
Marc S. Weinberg, Nicholas Kaperonis, George L. Bakris. (2003) How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?. Current Hypertension Reports 5:5, 418-425
CrossRef1508
Steven G Chrysant, George S Chrysant. (2003) Pharmacological profile and clinical use of moexipril. Expert Review of Cardiovascular Therapy 1:3, 345-352
CrossRef1509
Barry M. Brenner. (2003) AMGEN International Prize. The history and future of renoprotection. Kidney International 64:4, 1163-1168
CrossRef1510
Douglas A. Nigbor, Julia B. Lewis. (2003) Use of calcium antagonists in renal patients: Therapeutic benefit or medical malpractice?. Current Hypertension Reports 5:5, 430-436
CrossRef1511
Gozewÿn Laverman, Piero Ruggenenti, Giuseppe Remuzzi. (2003) Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics?. Current Hypertension Reports 5:5, 364-367
CrossRef1512
Matthew R. Weir. (2003) Chronic kidney disease: Blood pressure, treatment goals, and cardiovascular outcomes. Current Hypertension Reports 5:5, 405-407
CrossRef1513
Sergio Mezzano, Alejandra Droguett, M. Eugenia Burgos, Leopoldo G. Ardiles, Claudio A. Flores, Claudio A. Aros, Italo Caorsi, Carlos P. Vio, Marta Ruiz-Ortega, Jesus Egido. (2003) Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney International 64:s86, 64-70
CrossRef1514
Gozewijn D Laverman, Giuseppe Remuzzi. (2003) Antihypertensive therapy in chronic renal disease. Journal of Hypertension 21:9, 1625-1626
CrossRef1515
Katherine R Tuttle, Pamela W Anderson. (2003) A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C β inhibition. American Journal of Kidney Diseases 42:3, 456-465
CrossRef1516
Peter Sleight, Salim Yusuf. (2003) New evidence on the importance of the renin???angiotensin system in the treatment of higher-risk patients with hypertension. Journal of Hypertension 21:9, 1599-1608
CrossRef1517
Michael A. Weber, George L. Bakris, Joel M. Neutel, Giora Davidai, Thomas D. Giles. (2003) Quality of Life Measured in a Practice-Based Hypertension Trial of an Angiotensin Receptor Blocker. The Journal of Clinical Hypertension 5:5, 325-329
CrossRef1518
Marc A Pfeffer, Karl Swedberg, Christopher B Granger, Peter Held, John JV McMurray, Eric L Michelson, Bertil Olofsson, Jan Östergren, Salim Yusuf. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. The Lancet 362:9386, 759-766
CrossRef1519
John B. Kostis. (2003) Treatment of Hypertension in Older Patients: An Updated Look at the Role of Calcium Antagonists. The American Journal of Geriatric Cardiology 12:5, 319-327
CrossRef1520
Wendy P. Battisti, Joanne Palmisano, William F. Keane. (2003) Dyslipidemia in Patients with Type 2 Diabetes. Relationships between Lipids, Kidney Disease and Cardiovascular Disease. Clinical Chemistry and Laboratory Medicine 41:9, 1174-1181
CrossRef1521
Miles Fisher. (2003) Hypertension in diabetes: diuretic, ACE inhibitor or AIIRA?. Practical Diabetes International 20:7, 233-233a
CrossRef1522
L. Michael Prisant. (2003) Diabetes Mellitus and Hypertension: A Mandate for Intense Treatment According to New Guidelines. American Journal of Therapeutics 10:5, 363-369
CrossRef1523
K. Tryggvason, E. Pettersson. (2003) Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure. Journal of Internal Medicine 254:3, 216-224
CrossRef1524
CG Perry, AFB Kernohan, JR Petrie. (2003) Hypertension in diabetes: what's new, what's true, what's next?. Practical Diabetes International 20:7, 247-254
CrossRef1525
Richard J. MacIsaac, Mark E. Cooper. (2003) Microalbuminuria and diabetic cardiovascular disease. Current Atherosclerosis Reports 5:5, 350-357
CrossRef1526
Maarten J Postma, Hanneke Kruidhof, Lolkje TW de Jong-van den Berg, Dick de Zeeuw. (2003) Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy 4:9, 1543-1550
CrossRef1527
Amale A. Lteif, Kieren J. Mather, Charles M. Clark. (2003) Diabetes and Heart Disease. Cardiology in Review 11:5, 262-274
CrossRef1528
O Dupuy, X Chanudet, H Mayaudon, L Bordier, J Damiano, B Bauduceau. (2003) L'automesure de la pression artérielle chez le diabétique. Diabetes & Metabolism 29:4, 440-444
CrossRef1529
Thomas H Hostetter. (2003) Detecting early chronic kidney disease: are clinical laboratories a problem?. American Journal of Kidney Diseases 42:2, 392-394
CrossRef1530
Robert M. Carey, Helmy M. Siragy. (2003) The intrarenal renin–angiotensin system and diabetic nephropathy. Trends in Endocrinology & Metabolism 14:6, 274-281
CrossRef1531
Massimo Volpe, Beatrice Musumeci, Paola De Paolis, Carmine Savoia, Alberto Morganti. (2003) Angiotensin II AT2 receptor subtype. Journal of Hypertension 21:8, 1429-1443
CrossRef1532
Bruce L. Riser, Pedro Cortes, Mark Denichilo, Poornima V. Deshmukh, Parminder S. Chahal, Ali K. Mohammed, Jerry Yee, Dorothy Kahkonen. (2003) Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: Preliminary report. Kidney International 64:2, 451-458
CrossRef1533
R. E. Gilbert, H. Krum, J. Wilkinson-Berka, D. J. Kelly. (2003) The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabetic Medicine 20:8, 607-621
CrossRef1534
S. T. Knudsen, T. Bek, P. Logstrup Poulsen, M. Norgaard Hove, M. Rehling, C. E. Mogensen. (2003) Effects of losartan on diabetic maculopathy in type 2 diabetic patients: a randomized, double-masked study. Journal of Internal Medicine 254:2, 147-158
CrossRef1535
Norman RC Campbell, Finlay A McAlister, Rollin Brant, Mitch Levine, Denis Drouin, Ross Feldman, Robert Herman, Kelly Zarnke. (2003) Temporal trends in antihypertensive drug prescriptions in Canada before and after introduction of the Canadian Hypertension Education Program. Journal of Hypertension 21:8, 1591-1597
CrossRef1536
Wendy Weinstock Brown, Rosalind M Peters, Suzanne E Ohmit, William F Keane, Allan Collins, Shu-Chen Chen, Karren King, Michael J Klag, Donald A Molony, John M Flack. (2003) Early detection of kidney disease in community settings: the kidney early evaluation program (KEEP). American Journal of Kidney Diseases 42:1, 22-35
CrossRef1537
Domenic A. Sica. (2003) Renal handling of angiotensin receptor blockers: Clinical relevance. Current Hypertension Reports 5:4, 337-339
CrossRef1538
Li-Jun Ma, Agnes B. Fogo. (2003) Model of robust induction of glomerulosclerosis in mice: Importance of genetic background. Kidney International 64:1, 350-355
CrossRef1539
Luis M. Ruilope. (2003) Lessons from trials in hypertensive type 2 diabetic patients. Current Hypertension Reports 5:4, 322-328
CrossRef1540
Michael A. Weber. (2003) Creating a Combination Antihypertensive Regimen: What Does the Research Show?. The Journal of Clinical Hypertension 5:4, 12-20
CrossRef1541
Wilbert S. Aronow. (2003) Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure in Elderly Patients. Heart Disease 5:4, 279-294
CrossRef1542
Robert A. Hamilton, Michael P. Kane, Jason Demers. (2003) Angiotensin-Converting Enzyme Inhibitors and Type 2 Diabetic Nephropathy: A Meta-Analysis. Pharmacotherapy 23:7, 909-915
CrossRef1543
George L. Bakris. (2003) Who Should Be Treated With Combination Therapy as Initial Treatment for Hypertension?. The Journal of Clinical Hypertension 5:4, 21-28
CrossRef1544
Edward D. Frohlich, James R. Sowers. (2003) Management of diabetic and hypertensive cardiovascular disease. Current Hypertension Reports 5:4, 309-315
CrossRef1545
Barry M. Brenner. (2003) Retarding the progression of renal disease. Kidney International 64:1, 370-378
CrossRef1546
Giuseppe Derosa, Arrigo F.G. Cicero, Leonardina Ciccarelli, Roberto Fogari. (2003) A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clinical Therapeutics 25:7, 2006-2021
CrossRef1547
C. E. Mogensen. (2003) Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes*. Journal of Internal Medicine 254:1, 45-66
CrossRef1548
Rosaire P. Gray, John S. Yudkin. 2003. Clinical Features and Treatment of Coronary Heart Disease in Diabetes. .
CrossRef1549
Roger A. Rodby, Chion-Fang Chiou, Jeff Borenstein, Allison Smitten, Nishan Sengupta, Andrew J. Palmer, Stéphane Roze, Lieven Annemans, Teresa A. Simon, Roland S. Chen, Edmund J. Lewis. (2003) The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clinical Therapeutics 25:7, 2102-2119
CrossRef1550
Anne Zanchi, Marc Maillard, Michel Burnier. (2003) Recent clinical trials with omapatrilat: New developments. Current Hypertension Reports 5:4, 346-352
CrossRef1551
Ursula C. Brewster, John F. Setaro, Mark A. Perazella. (2003) The Renin-Angiotensin-Aldosterone System: Cardiorenal Effects and Implications for Renal and Cardiovascular Disease States. The American Journal of the Medical Sciences 326:1, 15-24
CrossRef1552
Massimo Volpe, Francesco Cosentino, Luis M Ruilope. (2003) Is it time to measure microalbuminuria in hypertension?. Journal of Hypertension 21:7, 1213-1220
CrossRef1553
Steven A. Baroletti, Steven Gabardi, Colm C. Magee, Edgar L. Milford. (2003) Calcium Channel Blockers as the Treatment of Choice for Hypertension in Renal Transplant Recipients: Fact or Fiction. Pharmacotherapy 23:6, 788-801
CrossRef1554
Samy I. McFarlane, Amal Farag, James Sowers. (2003) Calcium Antagonists in Patients with Type 2 Diabetes and Hypertension. Cardiovascular Drug Reviews 21:2, 105-118
CrossRef1555
Jan A Staessen, Ji-Guang Wang, Lutgarde Thijs. (2003) Cardiovascular prevention and blood pressure reduction. Journal of Hypertension 21:6, 1055-1076
CrossRef1556
N Goenka, S Panja, D James, S Shaikh, J Morrissey, V Patel. (2003) Ensuring the quality of diabetes care: Use of the QUAD-CAT model and Alphabet Strategy in clinical practice. Practical Diabetes International 20:5, 171-177
CrossRef1557
AH Barnett. (2003) Adopting more aggressive strategies for the management of renal disease in type 2 diabetes. Practical Diabetes International 20:5, 186-190
CrossRef1558
Jessup, Mariell, Brozena, Susan, . (2003) Heart Failure. New England Journal of Medicine 348:20, 2007-2018
Full Text1559
M Luiza Caramori, Michael Mauer. (2003) Diabetes and nephropathy. Current Opinion in Nephrology and Hypertension 12:3, 273-282
CrossRef1560
Errol D. Crook, Latha Velusamy. (2003) Are low target blood pressure goals justified in persons with diabetes mellitus?. Current Hypertension Reports 5:3, 231-238
CrossRef1561
Bernard Waeber, Michel Burnier. (2003) AT 1 receptor antagonism in hypertension: what has been learned with irbesartan?. Expert Review of Cardiovascular Therapy 1:1, 23-33
CrossRef1562
Rajiv Agarwal. (2003) Systolic Hypertension in Hemodialysis Patients. Seminars in Dialysis 16:3, 208-213
CrossRef1563
William C. Cushman. (2003) The Burden of Uncontrolled Hypertension: Morbidity and Mortality Associated With Disease Progression. The Journal of Clinical Hypertension 5:3, 14-22
CrossRef1564
Care California Healthcare FoundationAme. (2003) Guidelines for Improving the Care of the Older Person with Diabetes Mellitus. Journal of the American Geriatrics Society 51:5s, 265-280
CrossRef1565
Keith Norris, Charles Vaughn. (2003) The role of renin–angiotensin– aldosterone system inhibition in chronic kidney disease. Expert Review of Cardiovascular Therapy 1:1, 51-63
CrossRef1566
Marvin Moser. (2003) The JNC 7: Stepped Care Is Alive and Well. The Journal of Clinical Hypertension 5:3, 187-195
CrossRef1567
Arleen F. Brown, Amy G. Gross, Peter R. Gutierrez, Luohua Jiang, Martin F. Shapiro, Carol M. Mangione. (2003) Income-Related Differences in the Use of Evidence-Based Therapies in Older Persons with Diabetes Mellitus in For-Profit Managed Care. Journal of the American Geriatrics Society 51:5, 665-670
CrossRef1568
Adamasco Cupisti, Giovanni Manca Rizza, Claudia D’Alessandro, Ester Morelli, Giuliano Barsotti. (2003) Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients. Biomedicine & Pharmacotherapy 57:3-4, 169-172
CrossRef1569
Susan K. Maue, James H. Jackson, Bruce A. Weiss, Marc L. Rivo, Vishu Jhaveri, Barbara Lennert. (2003) The Hypertension Management Program: Identifying Opportunities for Improvement. The Journal of Clinical Hypertension 5:3, 33-40
CrossRef1570
Bernard Waeber. (2003) Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Review of Cardiovascular Therapy 1:1, 43-50
CrossRef1571
Wilbert S. Aronow. (2003) Treatment of Heart Failure in Older Persons.. Congestive Heart Failure 9:3, 142-147
CrossRef1572
Deborah A. Price, Naomi D. L. Fisher. (2003) The renin-angiotensin system in blacks: Active, passive, or what?. Current Hypertension Reports 5:3, 225-230
CrossRef1573
Anupama Mohanram, Robert D Toto. (2003) Outcome studies in diabetic nephropathy. Seminars in Nephrology 23:3, 255-271
CrossRef1574
Wei X. Lu, Jay Lakkis, Matthew R. Weir. (2003) Optimizing target-organ protection in patients with diabetes mellitus: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers?. Current Hypertension Reports 5:3, 192-198
CrossRef1575
Elisabetta Cerbai, Petra De Paoli, Laura Sartiani, Giuseppe Lonardo, Alessandro Mugelli. (2003) Treatment With Irbesartan Counteracts the Functional Remodeling of Ventricular Myocytes From Hypertensive Rats. Journal of Cardiovascular Pharmacology 41:5, 804-812
CrossRef1576
Jan A Staessen, Jiguang Wang, Giuseppe Bianchi, Willem H Birkenhäger. (2003) Essential hypertension. The Lancet 361:9369, 1629-1641
CrossRef1577
Wendy L St Peter, Anton C Schoolwerth, Tracy McGowan, William M McClellan. (2003) Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomes. American Journal of Kidney Diseases 41:5, 903-924
CrossRef1578
Allan J. Collins. (2003) Cardiovascular Mortality in End-Stage Renal Disease. The American Journal of the Medical Sciences 325:4, 163-167
CrossRef1579
Harm Peters, Matthias Rückert, Jens Gaedeke, Lutz Liefeldt, Markus Ketteler, Arya M Sharma, Hans-H. Neumayer. (2003) Angiotensin-converting enzyme inhibition but not β-adrenergic blockade limits transforming growth factor-β overexpression in acute normotensive anti-thy1 glomerulonephritis. Journal of Hypertension 21:4, 771-780
CrossRef1580
Merlin C Thomas, Mark E Cooper, Shahnaz Shahinfar, Barry M Brenner. (2003) Dialysis delayed is death prevented: A clinical perspective on the RENAAL study. Kidney International 63:4, 1577-1579
CrossRef1581
James W. Scholey. (2003) Angiotensin II and the glomerulus: Focus on diabetic kidney disease. Current Hypertension Reports 5:2, 172-180
CrossRef1582
Christine M. Logar, Charles A. Herzog, Srinivasan Beddhu. (2003) Diagnosis and Therapy of Coronary Artery Disease in Renal Failure, End-Stage Renal Disease, and Renal Transplant Populations. The American Journal of the Medical Sciences 325:4, 214-227
CrossRef1583
(2003) International Society of Hypertension (ISH). Journal of Hypertension 21:4, 651-663
CrossRef1584
Julie A. Brousil, John M. Burke. (2003) Olmesartan medoxomil: An angiotensin II-receptor blocker. Clinical Therapeutics 25:4, 1041-1055
CrossRef1585
William F Keane, Barry M Brenner, Dick De Zeeuw, Jean-Pierre Grunfeld, Janet Mcgill, William E Mitch, Artur B Ribeiro, Shahnaz Shahinfar, Roger L Simpson, Steven M Snapinn, Robert Toto. (2003) The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney International 63:4, 1499-1507
CrossRef1586
Kunitoshi Iseki, Yoshiharu Ikemiya, Chiho Iseki, Shuichi Takishita. (2003) Proteinuria and the risk of developing end-stage renal disease. Kidney International 63:4, 1468-1474
CrossRef1587
Hassan N. Ibrahim, Thomas H. Hostetter. (2003) Aldosterone in renal disease. Current Opinion in Nephrology and Hypertension 12:2, 159-164
CrossRef1588
Brendan J. Barrett. (2003) THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Applying Multiple Interventions in Chronic Kidney Disease. Seminars in Dialysis 16:2, 157-164
CrossRef1589
Alexandra Martin, Michael R. Komada, David C. Sane. (2003) Abnormal angiogenesis in diabetes mellitus. Medicinal Research Reviews 23:2, 117-145
CrossRef1590
Domenic A. Sica. (2003) Aldosterone Receptor Blockade: A Therapy Resurrected. Heart Disease 5:2, 85-88
CrossRef1591
M. Usta, A. Ersoy, K. Dilek, B. Ozdemir, M. Yavuz, M. Gullulu, M. Yurtkuran. (2003) Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment. Journal of Internal Medicine 253:3, 329-334
CrossRef1592
Hideharu Funatsu, Hidetoshi Yamashita, Tomohiro Ikeda, Tatsuya Mimura, Erika Shimizu, Sadao Hori. (2003) Relation of diabetic macular edema to cytokines and posterior vitreous detachment. American Journal of Ophthalmology 135:3, 321-327
CrossRef1593
Adeera Levin. (2003) THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Clinical Epidemiology of Cardiovascular Disease in Chronic Kidney Disease Prior to Dialysis. Seminars in Dialysis 16:2, 101-105
CrossRef1594
P. Jacobsen, P. Rossing, L. Tarnow, P. Hovind, H-H. Parving. (2003) Birth weight - a risk factor for progression in diabetic nephropathy?. Journal of Internal Medicine 253:3, 343-350
CrossRef1595
James H. O’Keefe, Jared T. Lurk, Ravindra C. Kahatapitiya, Janet A. Haskin. (2003) The renin-angiotensin-aldosterone system as a target in coronary disease. Current Atherosclerosis Reports 5:2, 124-130
CrossRef1596
Lawrence P. McMahon. (2003) THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Hemodynamic Cardiovascular Risk Factors in Chronic Kidney Disease: What are the Effects of Intervention?. Seminars in Dialysis 16:2, 128-139
CrossRef1597
Michael A. Moore. (2003) Drugs That Interrupt the Renin-Angiotensin System Should Be Among the Preferred Initial Drugs to Treat Hypertension. The Journal of Clinical Hypertension 5:2, 137-144
CrossRef1598
Giacomo Deferrari, Maura Ravera, Valeria Berruti. (2003) Treatment of diabetic nephropathy in its early stages. Diabetes/Metabolism Research and Reviews 19:2, 101-114
CrossRef1599
Leszek Tylicki, Antje Habicht, Bruno Watschinger, Walter H. Hörl. (2003) Treatment of hypertension in renal transplant recipients. Current Opinion in Urology 13:2, 91-98
CrossRef1600
Sheila A Doggrell. (2003) ACE inhibitors or AT-1 antagonists – which is OPTIMAAL after acute myocardial infarction?. Expert Opinion on Pharmacotherapy 4:3, 407-409
CrossRef1601
Katrin Uhlig, Andrew S. Levey, Mark J. Sarnak. (2003) THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Traditional Cardiac Risk Factors in Individuals with Chronic Kidney Disease. Seminars in Dialysis 16:2, 118-127
CrossRef1602
William B. White. (2003) Clinical trial experience around the globe: Focus on calcium-channel blockers. Clinical Cardiology 26:S2, 7-11
CrossRef1603
T Souchet, I Durand Zaleski, T Hannedouche, M Rodier, S Gaugris, P Passa. (2003) An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. Diabetes & Metabolism 29:1, 29-35
CrossRef1604
P. W. Leeuw, prof.dr. W.H. Birkenhäger. (2003) Secundaire en maligne hypertensiehypertensie. Bijblijven 19:2, 96-100
CrossRef1605
F Fagnani, T Souchet, D Labed, S Gaugris, T Hannedouche, A Grimaldi. (2003) Management of hypertension and screening of renal complications by GPs in diabetic type 2 patients (France — 2001). Diabetes & Metabolism 29:1, 58-64
CrossRef1606
J. Herbert Patterson. (2003) Angiotensin II Receptor Blockers in Heart Failure. Pharmacotherapy 23:2, 173-182
CrossRef1607
Wendy W. Brown, Allan Collins, Shu-Cheng Chen, Karren King, Donald Molony, Monica R. Gannon, Gigi Politoski, William F. Keane. (2003) Identification of persons at high risk for kidney disease via targeted screening: The NKF Kidney Early Evaluation Program. Kidney International 63:s83, 50-55
CrossRef1608
Liz Lightstone. (2003) Preventing renal disease: The ethnic challenge in the United Kingdom. Kidney International 63:s83, 135-138
CrossRef1609
Ernesto L Schiffrin. (2003) Effect of antihypertensive treatment on small artery remodeling in hypertension. Canadian Journal of Physiology and Pharmacology 81:2, 168-176
CrossRef1610
Barry M. Brenner, Joann Zagrobelny. (2003) Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors. Kidney International 63:s83, 77-85
CrossRef1611
Timothy P. Murphy. (2003) Renal Ischemia as a Predictor of Cardiovascular Morbidity. Journal of Vascular and Interventional Radiology 14:2, P159-P164
CrossRef1612
Ricardo Utimura, Clarice Kazue Fujihara, Ana Lúcia Mattar, Denise Maria Avancini Costa Malheiros, Irene De Lourdes Noronha, Roberto Zatz. (2003) Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes1. Kidney International 63:1, 209-216
CrossRef1613
Norman K Hollenberg, Deborah A Price, Naomi DL Fisher, M Cecilia Lansang, Bruce Perkins, Michael S Gordon, Gordon H Williams, Lori MB Laffel. (2003) Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney International 63:1, 172-178
CrossRef1614
Atsuko NOSE, Yasukiyo MORI, Yoko UCHIYAMA-TANAKA, Noriko KISHIMOTO, Katsuya MARUYAMA, Hiroaki MATSUBARA, Toshiji IWASAKA. (2003) Regulation of Glucose Transporter (GLUT1) Gene Expression by Angiotensin II in Mesangial Cells: Involvement of HB-EGF and EGF Receptor Transactivation.. Hypertension Research 26:1, 67-73
CrossRef1615
Reza Tabrizchi. (2003) Dual ACE and Neutral Endopeptidase Inhibitors. Drugs 63:20, 2185-2202
CrossRef1616
Joel Handler. (2003) Opportunity for JNC VII. The Journal of Clinical Hypertension 5:1, 15-16
CrossRef1617
M. Onuigbo, M. R. Weir. (2003) Evidence-based treatment of hypertension in patients with diabetes mellitus. Diabetes, Obesity and Metabolism 5:1, 13-26
CrossRef1618
Masayuki TANEMOTO, Takaaki ABE, Noriyuki OBARA, Michiaki ABE, Fumitoshi SATOH, Sadayoshi ITO. (2003) Successful Treatment of Severe Hypertension with the Combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker. Hypertension Research 26:10, 863-868
CrossRef1619
Michael A. Weber. (2003) The ALLHAT Report: A Case of Information and Misinformation. The Journal of Clinical Hypertension 5:1, 9-13
CrossRef1620
&NA;. (2003) Inhibition of the renin-angiotensin system provides renoprotective effects for patients with type 2 diabetes mellitus. Drugs & Therapy Perspectives 19:1, 18-21
CrossRef1621
Iris Feria, Israel Pichardo, Patricia Juárez, Victoria Ramírez, Marco A González, Norma Uribe, Romeo García-Torres, Fernando López-Casillas, Gerardo Gamba, Norma A Bobadilla. (2003) Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney International 63:1, 43-52
CrossRef1622
Odd E Johansen, K??re I Birkeland. (2003) Preventing Macrovascular Disease in Patients with Type 2 Diabetes Mellitus. American Journal of Cardiovascular Drugs 3:4, 283-297
CrossRef1623
Ji-Guang Wang, Jan A. Staessen. (2003) Benefits of Antihypertensive Pharmacologic Therapy and Blood Pressure Reduction in Outcome Trials. The Journal of Clinical Hypertension 5:1, 66-75
CrossRef1624
Christopher I. Carswell, Karen L. Goa. (2003) Losartan. Drugs 63:4, 407-414
CrossRef1625
Amanda I Adler, Richard J Stevens, Sue E Manley, Rudy W Bilous, Carole A Cull, Rury R Holman. (2003) Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney International 63:1, 225-232
CrossRef1626
Tsuguya FUKUI, Mahbubur RAHMAN, Koichi HAYASHI, Kazuo TAKEDA, Jitsuo HIGAKI, Tosiya SATO, Masanori FUKUSHIMA, Junichi SAKAMOTO, Satoshi MORITA, Toshio OGIHARA, Kohshiro FUKIYAMA, Masatoshi FUJISHIMA, Takao SARUTA. (2003) Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients: Rationale, Design, and Methods. Hypertension Research 26:12, 979-990
CrossRef1627
Hirofumi MAKINO, Yoshio NAKAMURA, Jun WADA. (2003) Remission and Regression of Diabetic Nephropathy. Hypertension Research 26:7, 515-519
CrossRef1628
Marvin Moser. (2003) Results of the ALLHAT Trial: Is the Debate About Initial Antihypertensive Drug Therapy Over?. The Journal of Clinical Hypertension 5:1, 5-8
CrossRef1629
G. V. Ramesh Prasad, Dushanthi Pinnaduwage, Robert K. Parkes, Julian Midgley, J. Williamson Balfe, Robert A. Hegele, Shelley B. Bull, Edward H. Cole, Alexander G. Logan. (2003) Angiotensinogen M235T genotype predicts progression in chronic renal allograft dysfunction1. Transplantation 75:2, 209-216
CrossRef1630
Eckart Jungmann. (2003) Prevention and Treatment of Diabetic Nephropathy in Older Patients. Drugs & Aging 20:6, 419-435
CrossRef1631
Sheldon Chen, M Carmen Iglesias-de la Cruz, Belinda Jim, Soon Won Hong, Motohide Isono, Fuad N Ziyadeh. (2003) Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db mice. Biochemical and Biophysical Research Communications 300:1, 16-22
CrossRef1632
Hiroshi HIROSE, Ikuo SAITO. (2003) Trends in Blood pressure Control in Hypertensive Patients with Diabetes Mellitus in Japan. Hypertension Research 26:9, 717-722
CrossRef1633
Satoru MURAYAMA, Tsutomu HIRANO, Taro SAKAUE, Kenta OKADA, Reiko IKEJIRI, Mitsuru ADACHI. (2003) Low-Dose Candesartan Cilexetil Prevents Early Kidney Damage in Type 2 Diabetic Patients with Mildly Elevated Blood Pressure.. Hypertension Research 26:6, 453-458
CrossRef1634
Hiroto MATSUDA, Koichi HAYASHI, Koichiro HOMMA, Kyoko YOSHIOKA, Takeshi KANDA, Ichiro TAKAMATSU, Satoru TATEMATSU, Shu WAKINO, Takao SARUTA. (2003) Differing Anti-Proteinuric Action of Candesartan and Losartan in Chronic Renal Disease. Hypertension Research 26:11, 875-880
CrossRef1635
Enzo Ragucci, Joel Zonszein, William H. Frishman. (2003) Pharmacotherapy of Diabetes Mellitus: Implications for the Prevention and Treatment of Cardiovascular Disease. Heart Disease 5:1, 18-33
CrossRef1636
Robert A. Phillips, Robert A. Kloner, Richard H. Grimm, Myron Weinberger. (2003) The Effects of Amlodipine Compared to Losartan in Patients With Mild to Moderately Severe Hypertension. The Journal of Clinical Hypertension 5:1, 17-30
CrossRef1637
Alice Stanton. (2003) Therapeutic Potential of Renin Inhibitors in the Management of Cardiovascular Disorders. American Journal of Cardiovascular Drugs 3:6, 389-394
CrossRef1638
Ulf Lennart Hulthén. (2003) Nephrin. Journal of Hypertension 21:1, 39-40
CrossRef1639
Fumihiko TAKAHASHI, Naoyuki HASEBE, Junko CHINDA, Motoi OKADA, Toshiharu TAKEUCHI, Tomoya HIRAYAMA, Chiiko IMAMOTO, Kenjiro KIKUCHI. (2003) A Case of Nephrotic Syndrome Associated with Renovascular Hypertension Successfully Treated with Candesartan.. Hypertension Research 26:1, 123-127
CrossRef1640
Barry M. Brenner. (2002) Remission of renal disease: recounting the challenge, acquiring the goal. Journal of Clinical Investigation 110:12, 1753-1758
CrossRef1641
William C. Gerth, Giuseppi Remuzzi, Giancarlo Viberti, Thierry Hannedouche, Alberto Martinez-Castelao, Shahnaz Shahinfar, George W. Carides, Barry Brenner. (2002) Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union. Kidney International 62:s82, 68-72
CrossRef1642
Shahnaz Shahinfar, Tania Z. Dickson, Tultul Ahmed, Zhonxin Zhang, Denise Ramjit, Ronald D. Smith, Barry M. Brenner, . (2002) Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study. Kidney International 62:s82, 64-67
CrossRef1643
Jose Luno, Vicente Barrio, Maria Angeles Goicoechea, Cesar Gonzalez, Soledad Garcia De Vinuesa, Francisco Gomez, Carmen Bernis, Mario Espinosa, Francisco Ahijado, Jose Gomez, Pedro Escalada. (2002) Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney International 62:s82, 47-52
CrossRef1644
C.H Goss, N Mayer-Hamblett, R.A Kronmal, B.W Ramsey. (2002) The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases. Advanced Drug Delivery Reviews 54:11, 1505-1528
CrossRef1645
Saulo Klahr, Jeremiah Morrissey. (2002) Comparative effects of ACE inhibition and angiotensin II receptor blockade in the prevention of renal damage. Kidney International 62:s82, 23-26
CrossRef1646
Luis Miguel Ruilope, Jose Luno. (2002) Angiotensin blockade in type 2 diabetic renal disease. Kidney International 62:s82, 61-63
CrossRef1647
D. J. Campbell. (2002) Renin-angiotensin system inhibition: how much is too much of a good thing?. Internal Medicine Journal 32:12, 616-620
CrossRef1648
Manuel Praga, Enrique Morales. (2002) Renal damage associated with proteinuria. Kidney International 62:s82, 42-46
CrossRef1649
T MURPHY, J RUNDBACK, C COOPER, M KIERNAN. (2002) Chronic Renal Ischemia: Implications for Cardiovascular Disease Risk. Journal of Vascular and Interventional Radiology 13:12, 1187-1198
CrossRef1650
J STANLEY, R SAMSON. (2002) Treatment of hypertension from volume to vasoconstriction: The ACE up your sleeve. Seminars in Vascular Surgery 15:4, 225-236
CrossRef1651
(2002) Renovascular Hypertension, Endothelial Function, and Oxidative Stress. New England Journal of Medicine 347:19, 1528-1530
Full Text1652
Mandeep R. Mehra, Patricia A. Uber, Srinivasa Potluri. (2002) Renin Angiotensin Aldosterone and Adrenergic Modulation in Chronic Heart Failure: Contemporary Concepts. The American Journal of the Medical Sciences 324:5, 267-275
CrossRef1653
Donn Hogan, Empar Lurbe, M. Reza Salabat, Josep Redon, Daniel Batlle. (2002) Circadian changes in blood pressure and their relationships to the development of microalbuminuria in type 1 diabetic patients. Current Diabetes Reports 2:6, 539-544
CrossRef1654
Debasish Banerjee, Barry J. Materson. (2002) Blood pressure-independent impact of antihypertensive agents on cardiovascular and renal disease. Current Hypertension Reports 4:6, 445-452
CrossRef1655
Sheila A Doggrell. (2002) Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?. Expert Opinion on Pharmacotherapy 3:11, 1543-1556
CrossRef1656
A. J. Nicholls. (2002) The impact of atherosclerotic renovascular disease on diabetic renal failure. Diabetic Medicine 19:11, 889-894
CrossRef1657
Thomas D. Giles. (2002) Update on the Management of Diabetes and Hypertension. The Journal of Clinical Hypertension 4, 3-10
CrossRef1658
Alberto Zanchetti, Luis M Ruilope. (2002) Antihypertensive treatment in patients with type-2 diabetes mellitus. Journal of Hypertension 20:11, 2099-2110
CrossRef1659
Robert N Foley, Charles A Herzog, Allan J Collins. (2002) Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study1. Kidney International 62:5, 1784-1790
CrossRef1660
Mark Greathouse. (2002) A Review of Olmesartan Medoxomil Monotherapy: Antihypertensive Efficacy Similar to That of Other Angiotensin II Receptor Blocker/Hydrochlorothiazide Combinations?. Congestive Heart Failure 8:6, 313-320
CrossRef1661
Eva M. Vivian, Gail Breen Rubinstein. (2002) Pharmacologic management of diabetic nephropathy. Clinical Therapeutics 24:11, 1741-1756
CrossRef1662
Christopher A. Newton, Philip Raskin. (2002) Blood pressure control—Effects on diabetic nephropathy progression: How low does blood pressure have to be?. Current Diabetes Reports 2:6, 530-538
CrossRef1663
William C. Gerth. (2002) Compliance and persistence with newer antihypertensive agents. Current Hypertension Reports 4:6, 424-433
CrossRef1664
Robert D. Toto. (2002) Appropriate drug therapy for improving outcomes in diabetic nephropathy. Current Diabetes Reports 2:6, 545-552
CrossRef1665
Marvin Moser. (2002) Update on the Management of Hypertension: Do Recent Clinical Trial Results Indicate a Change in National Recommendations for Therapy?. The Journal of Clinical Hypertension 4, 20-31
CrossRef1666
Joseph L. Izzo, Marvin Moser. (2002) Clinical Impact of Renin-Angiotensin System Blockade: Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Antagonists. The Journal of Clinical Hypertension 4, 11-31
CrossRef1667
Jasjeet Kaur, Parminder Singh, James R. Sowers. (2002) Diabetes and Cardiovascular Diseases. American Journal of Therapeutics 9:6, 510-515
CrossRef1668
Matthew R. Weir. (2002) Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers. Current Hypertension Reports 4:5, 333-335
CrossRef1669
Pedro de Pablos-Velasco, Francisco Javier Martínez-Martín, Fátima Rodríguez Pérez, Luis Miguel Ruilope Urioste, Rafael García Robles. (2002) Prevalence, awareness, treatment and control of hypertension in a Canarian population. Relationship with glucose tolerance categories. The Guía Study. Journal of Hypertension 20:10, 1965-1971
CrossRef1670
. (2002) Is nierfalen bij type-2- diabetes te voorkomen met angiotensine-II-receptorantagonisten?. Medisch-Farmaceutische Mededelingen 40:10, 287-288
CrossRef1671
Jens Gaedeke, Nancy A. Noble, Wayne A. Border. (2002) Angiotensin II and progressive renal insufficiency. Current Hypertension Reports 4:5, 403-407
CrossRef1672
Alan H. Gradman, Celso Acevedo. (2002) Evolving strategies for the use of combination therapy in hypertension. Current Hypertension Reports 4:5, 343-349
CrossRef1673
Jan A. Staessen, Jiguang Wang. (2002) Are the benefits of antihypertensive therapy only due to blood pressure reduction?. Journal of Hypertension 20:10, 2096-2097
CrossRef1674
Kambiz Kalantarinia, Helmy M. Siragy. (2002) The choice of antihypertensive drugs in patients with diabetes: Angiotensin II and beyond. Current Diabetes Reports 2:5, 423-430
CrossRef1675
Matthew R. Weir. (2002) Progressive renal and cardiovascular disease: Optimal treatment strategies. Kidney International 62:4, 1482-1492
CrossRef1676
(2002) Diabetic Nephropathy. New England Journal of Medicine 347:12, 947-948
Full Text1677
Kenneth Dickstein, John Kjekshus. (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. The Lancet 360:9335, 752-760
CrossRef1678
Eva Lonn. (2002) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Current Atherosclerosis Reports 4:5, 363-372
CrossRef1679
Laurence J. Hirsch. (2002) Conflicts of interest in drug development: The practices of Merck & Co., Inc.. Science and Engineering Ethics 8:3, 429-442
CrossRef1680
R. A. Malik. (2002) Commentary. Diabetic Medicine 19:s5, 7-8
CrossRef1681
Jeffrey B. Kopp. (2002) Renal dysfunction in HIV-1-infected patients. Current Infectious Disease Reports 4:5, 449-460
CrossRef1682
Arrigo Schieppati, Norberto Perico, Giuseppe Remuzzi. (2002) Conflict of interest as seen from a researcher’s perspective. Science and Engineering Ethics 8:3, 337-342
CrossRef1683
Katsunori Suzuki, Satoshi Souda, Tomoo Ikarashi, Susumu Kaneko, Osamu Nakagawa, Yoshifusa Aizawa. (2002) Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy. Diabetes Research and Clinical Practice 57:3, 179-183
CrossRef1684
Gozewijn D. Laverman, Gerjan Navis, Robert H. Henning, Paul E. De Jong, Dick De Zeeuw. (2002) Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney International 62:3, 1020-1025
CrossRef1685
Errol D. Crook, John M. Flack, Mahmoud Salem, Abdulla K. Salahudeen, John Hall. (2002) Primary Renal Disease as a Cardiovascular Risk Factor. The American Journal of the Medical Sciences 324:3, 138-145
CrossRef1686
Lars H. Lindholm, Hans Ibsen, Knut Borch-Johnsen, Michael Hecht Olsen, Kristian Wachtell, Björn Dahlöf, Richard B. Devereux, Gareth Beevers, Ulf de Faire, Frej Fyhrquist, Stevo Julius, Sverre E. Kjeldsen, Krister Kristianson, Ole Lederballe-Pedersen, Markku S. Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel, Peter Aurup, Jonathan M. Edelman, Steven Snapinn. (2002) Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension 20:9, 1879-1886
CrossRef1687
Paul R. Conlin. (2002) Critical Pathways. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 1:3, 184-193
CrossRef1688
Giovanna di Corcia, Daniela Trotta, Alberto Verrotti, Francesco Chiarelli. (2002) New trends in the treatment of diabetic nephropathy in children. Expert Opinion on Pharmacotherapy 3:8, 1169-1176
CrossRef1689
Annamaria T. Kausz, Andrew S. Levey. (2002) The Care of Patients with Chronic Kidney Disease. What Must We Do and Who Should Do It?. Journal of General Internal Medicine 17:8, 659-663
CrossRef1690
Giuseppe Mancia, Guido Grassi. (2002) Systolic and diastolic blood pressure control in antihypertensive drug trials. Journal of Hypertension 20:8, 1461-1464
CrossRef1691
Arthur J Matas, Abhinav Humar, Kristen J Gillingham, William D Payne, Rainer W G Gruessner, Raja Kandaswamy, David L Dunn, John S Najarian, David E R Sutherland. (2002) Five preventable causes of kidney graft loss in the 1990s: A single-center analysis1. Kidney International 62:2, 704-714
CrossRef1692
Sumeska Thavarajah, George A. Mansoor. (2002) Are clinical endpoint benefits of angiotensin converting enzyme inhibitors independent of their blood pressure effects?. Current Hypertension Reports 4:4, 290-297
CrossRef1693
Steven P Marso. (2002) Optimizing the diabetic formulary: beyond aspirin and insulin. Journal of the American College of Cardiology 40:4, 652-661
CrossRef1694
W. S. Aronow. (2002) Guest Editorial: What Is the Appropriate Treatment of Hypertension in Elders?. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57:8, M483-M486
CrossRef1695
Domenic A. Sica, Michael Weber. (2002) The Losartan Intervention for Endpoint Reduction (LIFE) Trial-Have Angiotensin-Receptor Blockers Come of Age?. The Journal of Clinical Hypertension 4:4, 301-305
CrossRef1696
Maria-Teresa Zanella, Artur B. Ribeiro. (2002) The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. Clinical Therapeutics 24:7, 1019-1034
CrossRef1697
Jean-Jacques Mourad, Michel E Safar, Michael F O'Rourke. (2002) Who is fooling us?. The Lancet 360:9326, 89
CrossRef1698
M. N. Kerstens, H. Buter, G. J. Navis, R. P. F. Dullaart. (2002) 11b-hydroxysteroid dehydrogenase activity in proteinuric patients and the effect of angiotensin-II receptor blockade. European Journal of Clinical Investigation 32:7, 513-518
CrossRef1699
Neil Shusterman. (2002) Risk-benefit assessment of angiotensin II receptor antagonists. Expert Opinion on Drug Safety 1:2, 137-152
CrossRef1700
Maarten W. Taal, Barry M. Brenner. (2002) Combination ACEI and ARB therapy: additional benefit in renoprotection?. Current Opinion in Nephrology and Hypertension 11:4, 377-381
CrossRef1701
Brian Kennon, Miles Fisher. (2002) ACE inhibitors and diabetes: from HOPE to PROGRESS. Practical Diabetes International 19:6, 176-179
CrossRef1702
Geoffrey Boner, Zemin Cao, Mark E. Cooper. (2002) Combination Antihypertensive Therapy in the Treatment of Diabetic Nephropathy. Diabetes Technology & Therapeutics 4:3, 313-321
CrossRef1703
Francesco Chiarelli, Daniela Trotta, Alberto Verrotti, Angelika Mohn. (2002) Treatment of hypertension and microalbuminuria in children and adolescents with type 1 diabetes mellitus. Pediatric Diabetes 3:2, 113-124
CrossRef1704
Kiyoshi Kurokawa, Masaomi Nangaku, Reiko Inagi, Toshio Miyata. (2002) Perspectives of chronic renal failure. Nephrology 7:s3, S145-S150
CrossRef1705
Howard D. Weinberger, Jennifer J. Weinberger. (2002) Use of Angiotensin-Converting Enzyme Inhibitors to Prevent Cardiovascular Disease. Primary Care Case Reviews 5:2, 61-67
CrossRef1706
Margo P. Cohen, Fuad N. Ziyadeh, Soon Won Hong, Clyde W. Shearman, Elizabeth Hud, Gregory T. Lautenslager, M. Carmen Iglesias-de la Cruz, Sheldon Chen. (2002) Inhibiting albumin glycation in vivo ameliorates glomerular overexpression of TGF-beta1. Kidney International 61:6, 2025-2032
CrossRef1707
Michael Bursztyn. (2002) Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study. The Lancet 359:9324, 2201
CrossRef1708
Marcin Adamczak, Martin Zeier, Ralf Dikow, Eberhard Ritz. (2002) Kidney and hypertension. Kidney International 61:s80, 62-67
CrossRef1709
Carlos M. Ferrario. (2002) Angiotensin I, angiotensin II and their biologically active peptides. Journal of Hypertension 20:5, 805-807
CrossRef1710
Meryem Tuncel, Robert Augustyniak, Weiguo Zhang, Robert D. Toto, Ronald G. Victor. (2002) Sympathetic nervous system function in renal hypertension. Current Hypertension Reports 4:3, 229-236
CrossRef1711
Kiyoshi KUROKAWA, Masaomi NANGAKU, Reiko INAGI, Toshio MIYATA. (2002) Perspectives of chronic renal failure. Nephrology 7, S145-S150
CrossRef1712
Sheldon Tobe, Murray Epstein. (2002) The use of calcium antagonists in the treatment of hypertensive persons with kidney disease. Current Hypertension Reports 4:3, 191-194
CrossRef1713
Sheila A Doggrell. (2002) Class benefits of AT 1 antagonists in Type 2 diabetes with nephropathy. Expert Opinion on Pharmacotherapy 3:5, 625-628
CrossRef1714
Mandeep R. Mehra, Patricia A. Uber, Srinivasa Potluri, Hector O. Ventura. (2002) Is heart failure with preserved systolic function an overlooked enigma?. Current Cardiology Reports 4:3, 187-193
CrossRef1715
Jay Garg, George L. Bakris. (2002) Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Current Hypertension Reports 4:3, 185-190
CrossRef1716
Norbert Lameire, Jean-Pierre Wauters, Jose Luis Gorriz Teruel, Wim Van Biesen, Raymond Vanholder. (2002) An update on the referral pattern of patients with end-stage renal disease. Kidney International 61:s80, 27-34
CrossRef1717
Chi-yuan Hsu. (2002) Does non-malignant hypertension cause renal insufficiency? Evidence-based perspective. Current Opinion in Nephrology and Hypertension 11:3, 267-272
CrossRef1718
Tamara B. Horwich, Gregg C. Fonarow. (2002) Prevention of heart failure. Current Cardiology Reports 4:3, 194-199
CrossRef1719
Remuzzi, Giuseppe, Schieppati, Arrigo, Ruggenenti, Piero, . (2002) Nephropathy in Patients with Type 2 Diabetes. New England Journal of Medicine 346:15, 1145-1151
Full Text1720
Pedro Luis de Pablos-Velasco, Fernando Pazos Toral, Juan E. Esmatjes, Francisco Fernandez-Vega, Martín Lopez de la Torre, Antonio Pozuelo, Luis M. Ruilope. (2002) Losartan titration versus diuretic combination in type 2 diabetic patients. Journal of Hypertension 20:4, 715-719
CrossRef1721
Herbert Thurston. (2002) Dual angiotensin II blockade: a promise of enhanced renal protection?. Journal of Hypertension 20:4, 607-609
CrossRef1722
Björn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, Stevo Julius, Gareth Beevers, Ulf de Faire, Frej Fyhrquist, Hans Ibsen, Krister Kristiansson, Ole Lederballe-Pedersen, Lars H Lindholm, Markku S Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet 359:9311, 995-1003
CrossRef1723
Karin Jandeleit-Dahm, Mark E. Cooper. (2002) Hypertension and diabetes. Current Opinion in Nephrology and Hypertension 11:2, 221-228
CrossRef1724
Lars H Lindholm, Hans Ibsen, Björn Dahlöf, Richard B Devereux, Gareth Beevers, Ulf de Faire, Frej Fyhrquist, Stevo Julius, Sverre E Kjeldsen, Krister Kristiansson, Ole Lederballe-Pedersen, Markku S Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel, Peter Aurup, Jonathan Edelman, Steven Snapinn. (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet 359:9311, 1004-1010
CrossRef1725
Hans R Brunner, Haralambos Gavras. (2002) Angiotensin blockade for hypertension: a promise fulfilled. The Lancet 359:9311, 990-992
CrossRef1726
Menno J.A. Kocks, Dick de Zeeuw, Gerjan J. Navis. (2002) Optimal blood pressure control and antihypertensive regimens in hypertensive renal disease: the potential of exploring the mechanisms of response variability. Current Opinion in Nephrology and Hypertension 11:2, 135-140
CrossRef1727
Ernesto L. Schiffrin. (2002) Good news for patients with type 2 diabetes: angiotensin receptor blocker treatment delays progression of diabetic nephropathy. Current Opinion in Nephrology and Hypertension 11:2, 173-175
CrossRef1728
(2002) Angiotensin-Receptor Blockers, Type 2 Diabetes, and Renoprotection. New England Journal of Medicine 346:9, 705-707
Full Text1729
Hiromichi SUZUKI, Yoshihiko KANNO, Naofumi IKEDA, Hidetomo NAKAMOTO, Hirokazu OKADA, Souichi SUGAHARA. (2002) Selection of the Dose of Angiotensin Converting Enzyme Inhibitor for Patients with Diabetic Nephropathy Depends on the Presence or Absence of Left Ventricular Hypertorphy.. Hypertension Research 25:6, 865-873
CrossRef1730
William B. Strawn. (2002) Implications physiopathologiques et cliniques des r??cepteurs AT1/AT2 de l??angiotensine II dans les pathologies m??taboliques. Drugs 62:Special Issue 1, 31-41
CrossRef1731
Makoto MIZUNO, Toshio SADA, Mikio KATO, Hiroyuki KOIKE. (2002) Renoprotective Effects of Blockade of Angiotensin II AT1 Receptors in an Animal Model of Type 2 Diabetes. Hypertension Research 25:2, 271-278
CrossRef1732
H. Y. How, B. M. Sibai. (2002) Use of angiotensin-converting enzyme inhibitors in patients with diabetic nephropathy. Journal of Maternal-Fetal and Neonatal Medicine 12:6, 402-407
CrossRef1733
Domenic A. Sica, George L. Bakris. (2002) Type 2 Diabetes: RENAAL and IDNT-The Emergence of New Treatment Options. The Journal of Clinical Hypertension 4:1, 52-57
CrossRef1734
Satoru KURIYAMA, Haruo TOMONARI, Goro TOKUDOME, Makoto HORIGUCHI, Hirofumi HAYASHI, Hideyuki KOBAYASHI, Masahiro ISHIKAWA, Tatsuo HOSOYA. (2002) Antiproteinuric Effects of Combined Antihypertensive Therapies in Patients with Overt Type 2 Diabetic Nephropathy.. Hypertension Research 25:6, 849-855
CrossRef1735
Kazuhiro HARADA, Masami OHMORI, Akio FUJIMURA. (2002) Vasoconstricting Effect of Angiotensin II in Human Hand Veins: Influence of Aging, Diabetes Mellitus and Hypertension.. Hypertension Research 25:5, 683-688
CrossRef1736
S DINNEEN. (2002) What's new in & Diabetes treatment. Medicine 30:1, iv-vi
CrossRef1737
Yasutaka YAMAMOTO, Kazuhiko SONOYAMA, Koichi MATSUBARA, Masako FURUSE, Toru YATSUHASHI, Toshihiro HAMADA, Kazuhide OGINO, Osamu IGAWA, Ichiro HISATOME, Chiaki SHIGEMASA. (2002) The Status of Hypertension Management in Japan in 2000.. Hypertension Research 25:5, 717-725
CrossRef1738
Daniel C. Cattran. (2002) Membranous nephropathy: Quo vadis?. Kidney International 61:1, 349-350
CrossRef1739
Thomas D. Giles, Gary E. Sander. (2002) Angiotensin II (AT 1 ) Redeptor Antagonists, Diabetes, and Nephropathy. The American Journal of Geriatric Cardiology 11:1, 62-65
CrossRef1740
H. McIntyre, F. V. Costa, R. Düsing, W. Gerth. (2002) The Role of Losartan in Cost-effective Hypertension Control. Current Medical Research and Opinion 18:3, 139-145
CrossRef1741
Pierre Corvol, Pierre-Francois Plouin. (2002) Antagonistes des r??cepteurs de l???angiotensine II. Drugs 62:Special Issue 1, 53-64
CrossRef1742
Michael A. Moore. (2002) Improving the Managed Care of Hypertension with Angiotensin II Antagonists. The American Journal of the Medical Sciences 323:1, 25-33
CrossRef1743
Kathryn C. B. Tan, Wing-Sun Chow, Victor H. G. Ai, Karen S. L. Lam. (2002) Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes/Metabolism Research and Reviews 18:1, 71-76
CrossRef1744
Anil K. Bidani, Karen A. Griffin. (2002) Long-term renal consequences of hypertension for normal and diseased kidneys. Current Opinion in Nephrology and Hypertension 11:1, 73-80
CrossRef1745
Carl Erik Mogensen. (2002) Diabetic Renal Disease in Patients with Type 2 Diabetes Mellitus. Treatments in Endocrinology 1:1, 3-11
CrossRef1746
Ikuo SAITO, Hiroshi KAWABE, Minako TSUJIOKA, Hiroshi HIROSE, Hirotaka SHIBATA. (2002) Trends in Pharmacologic Management of Hypertension in Japan One Year after the Publication of the JSH 2000 Guidelines. Hypertension Research 25:2, 175-178
CrossRef1747
George Jerums, Richard J. MacIsaac. (2002) Treatment of Microalbuminuria in Patients with Type 2 Diabetes Mellitus. Treatments in Endocrinology 1:3, 163-173
CrossRef1748
Michael A. Weber. (2002) Calcium Channel Antagonists in the Treatment of Hypertension. American Journal of Cardiovascular Drugs 2:6, 415-431
CrossRef1749
Richard E. Gilbert, Darren J. Kelly. (2001) Nephropathy in type 2 diabetes: current therapeutic strategies. Nephrology 6:6, 266-269
CrossRef1750
Deborah A. Price, Norman K. Hollenberg. (2001) Angiotensin receptor blockers in diabetic nephropathy. Current Diabetes Reports 1:3, 267-274
CrossRef1751
Radko Komers, Sharon Anderson. (2001) Treatment of hypertension in diabetic patients with nephropathy. Current Diabetes Reports 1:3, 251-260
CrossRef1752
LH Opie. (2001) Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension. The Lancet 358:9296, 1829-1831
CrossRef1753
Michel Burnier. (2001) Novel angiotensin II inhibitors in cardiovascular medicine. Expert Opinion on Investigational Drugs 10:11, 1957-1964
CrossRef1754
Sharon See. (2001) Angiotensin II receptor blockers for the treatment of hypertension. Expert Opinion on Pharmacotherapy 2:11, 1795-1804
CrossRef1755
Kenneth Cusi. (2001) Cardiovascular Risk Management in Type 2 Diabetes: From Clinical Trials to Clinical Practice. The Endocrinologist 11:6, 474-490
CrossRef1756
Norman M. Kaplan. (2001) Treatment of coexisting diabetes and hypertension. Current Cardiology Reports 3:6, 498-503
CrossRef1757
Domenic A. Sica, William J. Elliott. (2001) Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Combination: Theory and Practice. The Journal of Clinical Hypertension 3:6, 383-387
CrossRef1758
Huston, Patricia, Peterson, Robert, . (2001) Withholding Proven Treatment in Clinical Research. New England Journal of Medicine 345:12, 912-914
Full Text1759
Hostetter, Thomas H., . (2001) Prevention of End-Stage Renal Disease Due to Type 2 Diabetes. New England Journal of Medicine 345:12, 910-912
Full Text1760
&NA;. (2001) A sartan proposition for treating renal disease?. Inpharma Weekly &NA;:1307, 18
CrossRef1761
Daniel J. Cordonnier, Philippe Zaoui, Serge Halimi. (2001) Role of ACE Inhibitors in Patients with Diabetes Mellitus. Drugs 61:13, 1883-1892
CrossRef
